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ABSTRACT 
 
The use and availability of herbal preparations covered by food law is increasing in the Netherlands and 
in other European Member States. Correspondingly, safety concerns relating to herbal preparations are growing 
as well. The aim of the present PhD project was therefore to review the toxicity of selected herbal preparations, to 
investigate the presence and actual levels of selected naturally-occurring toxic substances and contaminants in 
herbal preparations on the Dutch market and to estimate the associated risks. 
First, an overview is provided of the Dutch and European legal provisions for food commodities with 
botanical ingredients, the nature and mechanism of action of various toxic botanical ingredients specifically 
covered by these provisions, and the health concerns defined by risk assessors related to several botanicals for 
which no specific legal provisions exist. Secondly, data are presented on the actual occurrence in traditional 
herbal preparations (THPs) of a group of phytotoxins, i.e. aristolochic acids, which were banned by the Dutch 
Commodities Act Decree ‘Herbal preparations’. Aristolochic acids and derivatives are nephrotoxic, genotoxic and 
carcinogenic and are present in several plants from the Aristolochiaceae family. Aristolochic acids were found in 
25 of 190 THPs used in Traditional Chinese Medicine (TCM) sampled on the Dutch market. This shows that 
testing for aristolochic acids of Chinese THPs at risk of contamination is essential in the framework of food safety. 
Thirdly, the presence of selected toxic contaminants in herbal preparations on the Dutch market was 
investigated. Lead, mercury and arsenic levels were analyzed in THPs used in several Asian traditional medicine 
systems, such as Ayurveda, TCM, and Traditional Tibetan Medicine (TTM). These metals and metalloids were 
present in 186 (64%) of 292 THPs and use at recommended dose levels of 59 THPs (20%) would result in 
intakes of these contaminants significantly above established toxicological safety limits. It was concluded that the 
mercury, arsenic and lead contents of these Asian THPs are cause for concern. Because metals such as mercury 
can exist in various defined chemical species with different toxic properties, a study was performed using 
selective acid extraction procedures to determine the presence or absence of the relatively non-toxic elemental 
form of mercury in 19 Ayurvedic THPs, which were shown in the previous study to result in mercury intakes 
above the safety limit for inorganic mercury when used at the recommended daily dose level. It was concluded 
that in these THPs the main part of the mercury content is not present in the elemental form, that the mercury 
detected in Ayurvedic THPs is likely to be present in the inorganic form and that therefore the estimation of the 
related risks based on the safety limits for inorganic mercury is justified. 
In the last study of this PhD thesis, polycyclic aromatic hydrocarbons (PAH) were determined in more 
than 1500 food supplements sampled on the Dutch market, many of which contained herbal ingredients. Herbal 
preparations can become contaminated with PAH through various processes including direct atmospheric 
deposition on plant surfaces and drying practices during manufacturing. Several PAH, such as benzo[a]pyrene 
are genotoxic and carcinogenic. Supplements containing herbal ingredients such as St. John’s wort and Ginkgo 
biloba, the phytochemical resveratrol and the bee product propolis showed the highest mean PAH levels. It was 
shown that individual food supplements can contribute significantly to PAH exposure, whereas on average PAH 
intake resulting from food supplement use will be at the lower end of the range of contributions of main food 
groups to PAH exposure. 
From the work described in this thesis it can be concluded that for herbal preparations ‘natural’ does not 
equal ‘safe’. Given that uncertainty exists whether additional European legal measures will be taken in the near 
future to restrict or prohibit the use of specific toxic herbal substances in foods and the fact that several herbal 
preparations for which specific provisions are absent in Dutch food safety law raise toxicological concern, would 
suggest that it is prudent to keep the Dutch Decree ‘Herbal preparations’ and other national legislation up to date 
in order to protect consumers from serious risks resulting from use of botanicals in food products such as herbal 
preparations. 
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Introduction 
 
This PhD thesis focuses on the safety of selected herbal preparations on the Dutch market. It concerns 
exclusively herbal preparations that are used orally and which are regulated by Dutch food law. Because a 
significant part of the research included in the project involves official controls by the Voedsel en Waren Autoriteit 
(VWA) – the Dutch Food and Consumer Safety Authority – safety concerns regarding herbal preparations are 
also approached from a legal perspective. The European Food Safety Authority (EFSA) recognized in 2004 that a 
large number of botanical materials and botanical preparations obtained from these materials by various 
processes were finding their way onto the food supplement market and that safety concerns existed for several of 
these products. The safety concerns related to botanicals and botanical preparations essentially relate to i) the 
presence of naturally-occurring toxic substances in plants, ii) the intentional addition or accidental occurrence of 
toxic contaminants and iii) interactions of botanical ingredients with active ingredients from medicinal products 
(herbal food-drug interactions) [1]. In the Netherlands, safety concerns related to specific herbal preparations 
including several issues referred to by EFSA such as the presence of toxic pyrrolizidine alkaloids or aristolochic 
acids in herbal preparations were addressed in 2001 by the Commodities Act Decree ‘Herbal preparations’ [1, 2]. 
Furthermore, the Decree prohibits the placing on the market of any herbal preparation that contains herbal 
substances in amounts that are detrimental to health [2].  
The aim of the present PhD project was to review the toxicity of selected herbal preparations, to 
investigate the presence and actual levels of selected contaminants and naturally-occurring toxic substances in 
herbal preparations on the Dutch market and to estimate the associated risks. 
 
Legal framework for herbal preparations and related botanical products  
The Dutch Commodities Act and its subordinate Decrees and Directives fall under the responsibility of 
the Ministry of Health. The Act regulates foods and a wide array of other commodities. The Commodities Act 
Decree ‘Herbal preparations’ (in Dutch: ‘het Warenwetbesluit Kruidenpreparaten’) covers herbal preparations that 
are brought on the market as foods and non-food products [2]. The Decree defines herbal preparations as ‘herbal 
substances, subjected to treatment or not, including herbal extracts, which are intended to be used by humans’. 
In addition, ‘herbal substances’ are defined as ‘substances that are composed of plant material’. According to 
EFSA, the term ‘botanical’ includes all botanical materials (e.g. whole, fragmented or cut plants, plant parts, 
algae, fungi and lichens) and the term ‘botanical preparation’ includes all preparations obtained from botanicals 
by various processes (e.g. pressing, squeezing, extraction, fractionation, distillation, concentration, drying up and 
fermentation) [3]. The terms ‘botanical material’ and ‘botanical preparation’ used by EFSA are essentially 
synonyms of respectively the terms ‘herbal substance’ and ‘herbal preparation’ as defined by the Decree ‘Herbal 
preparations’. However, the terms used by EFSA are not defined by law and are not linked to any legal category. 
In the current thesis the term ‘botanical’ can refer to either a botanical material or a botanical preparation as 
defined by EFSA without implying a certain legal category. Most botanicals for oral use on the Dutch market are 
herbal preparations covered by the Decree ‘Herbal preparations’ and the minority is regulated as medicinal 
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products or is covered by other legislation. Recent European legislation established traditional herbal medicinal 
products as a new category of medicinal products for human use [4]. This new Community legislation includes 
amongst others provisions for the establishment of the Committee for Herbal Medicinal Products (HMPC) of the 
European Medicines Agency (EMA; at that time the acronym EMEA was used) and this legislation has been 
reviewed elsewhere [5]. Products from this new category share several characteristics with herbal preparations 
such as botanical food supplements. An important difference is however that within European Member States, 
traditional herbal medicinal products can only be brought on the market after an authorization, whereas market 
introduction of botanical food supplements at present does not require a safety assessment and market 
authorization. 
 
European legislation applicable to food supplements with botanical ingredients 
Most herbal preparations covered by the present PhD project are food supplements with botanical 
ingredients. European Directive 2002/46/EC covers food supplements which, according to the preamble to this 
directive, can not only contain vitamins and minerals but also a wide range of other ingredients including various 
plants and herbal extracts [6]. The directive does however not specify which plants or herbal extracts can be used 
for the manufacture of food supplements. Moreover, European food law does not include any other specific 
legislation on the use of substances other than vitamins or minerals in food supplements similar to the Dutch 
Commodities Act Decree ‘Herbal preparations’, which only applies to the Netherlands. In the European legislative 
context, the use of plants or herbal extracts in food supplements is therefore subject to general rules relating to 
food safety [4]. Regulation (EC) No 178/2002, also called the General Food Law, which aims to harmonize food 
safety legislation in European Member States, includes such general rules. For example, the General Food Law 
explicitly forbids the placing of foods on the market, which are injurious to health or unfit for human consumption 
[7]. Furthermore, the General Food Law lays the primary legal responsibility for the safety of the food products on 
the business operators who placed these products on the market. The General Food Law does not provide any 
guidance on how the safety of foods should be assessed. To fill in this gap for botanical food supplements, EFSA 
developed a two-level tiered approach for the safety assessment of botanicals and botanical preparations 
intended for use as ingredients in food supplements [3], which was tested by an EFSA Scientific Cooperation 
(ESCO) Working Group composed of experts from Member States [8]. The final version of the resulting Guidance 
on safety assessment of botanicals and botanical preparations intended for use as ingredients in food 
supplements was published in 2009 [3]. Furthermore, a Compendium of botanicals reported to contain toxic, 
addictive, psychotropic, or other substances of concern was compiled by EFSA to be used as a preliminary tool 
for risk assessors. The Compendium was validated by the ESCO working group and the final version was 
published in 2009 together with the Guidance document [9]. The Compendium has no legal status, but aims at 
flagging plants or parts of plants or substances of possible concern for human heath naturally present in the listed 
botanicals. The Compendium is partly based on existing national lists of botanicals that are restricted or not 
admitted in food in several Member States [3]. 
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EFSA advised that priority for risk assessments should be given to those plants i) that are known to have 
an established history of food use and contain significant levels of substances of concern, ii) that are not allowed 
or recommended for food use in some European countries, iii) for which some adverse health effects have been 
reported, iv) for which consumption has significantly increased during recent years and for which the intended use 
levels are expected to be relatively high and v) for which there are both limited history of use and toxicity data 
available [3]. A more detailed overview of the current Dutch and European regulatory framework for selected food 
commodities with botanical ingredients is presented in Chapter 2 of this thesis. 
 
Plants with toxic constituents  
Plants do not only produce carbohydrates, fats or proteins, which are called primary metabolites. 
Another group called secondary metabolites includes a multitude of compounds such as alkaloids, polyphenols, 
coumarins, carotenoids, and other compounds that can exert a physiological effect in humans [10]. Any efficacy 
shown by botanical products is usually the result of the effects of one or more plant secondary metabolites and 
much effort is directed at identifying these compounds, which are also called active constituents [1, 11]. For many 
botanicals the active constituents have been identified but for others it has been proven hard to identify the 
compounds responsible for the effect [3]. In addition to their perceived beneficial effects on health, botanical 
constituents can also prove to be toxic causing adverse health effects. As a result, herbal preparations can be 
associated with direct and indirect health risks. An important example of an indirect health risk is interaction with 
conventional medicines, which will be discussed in some detail further on in this chapter. Furthermore, there are 
several types of direct toxic effects. De Smet [12] recognized the following categories of direct adverse reactions 
to herbal preparations: i) pharmacologically predictable and usually dose-dependent reactions, ii) idiosyncratic 
reactions, which are unpredictable and do not show a correlation between dose level and toxicological risk, iii) 
reactions that develop during long-term therapy and iv) delayed effects such as carcinogenicity and 
teratogenicity. In Chapter 3 of the present thesis, the nature and mechanism of action of several toxic botanical 
ingredients will be discussed. These botanicals are, or will probably be, specifically covered by Dutch or 
European legislation and are presently receiving increased attention in the field of food toxicology.  
Aristolochia spp. are an example of herbs with delayed toxic effects. It was determined that these effects 
were linked to naturally-occurring constituents of these plants called aristolochic acids. In Traditional Chinese 
Medicine (TCM), Aristolochia spp. are used in several traditional herbal preparations. Several species from the 
genera Aristolochia and Asarum, which belong to the family of the Aristolochaceae, contain aristolochic acids and 
related compounds. The kidney is an important target of aristolochic acids and their toxic action can result in renal 
failure. In the early 1990s, female patients of a Belgian slimming clinic were prescribed herbal preparations 
contaminated with aristolochic acids and subsequently developed rapidly progressing renal interstitial fibrosis, 
later referred to as aristolochic acid nephropathy (AAN). Furthermore, aristolochic acids and derivatives are both 
genotoxic and carcinogenic. Several of the Belgian patients diagnosed with AAN also developed urothelial cancer 
[13]. As a result, herbs with aristolochic acids were prohibited in the Netherlands in 2001 and other in countries 
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worldwide. The toxicity of aristolochic acids is discussed in Chapters 3 and 4 of this thesis and the occurrence of 
herbal preparations with aristolochic acids on the Dutch market is explored in Chapter 4 of this thesis.  
 
Contamination of herbal preparations  
Contamination is one of the safety issues recognized by EFSA to be relevant to herbal preparations [1]. 
This contamination can be either deliberate or unintentionally. Adulteration of herbal preparations with toxic herbs 
in Asian traditional medicine is a recognized problem. A cause of adulteration can be confusion over names. This 
has for example been reported to occur for plants that in Traditional Chinese Medicine (TCM) are used 
interchangeably with Aristolochia species (discussed in Chapter 4). Contamination of herbal preparations with a 
wide range of other substances than toxic plant material has been described. Contaminants include metals and 
metalloids such as lead, mercury and arsenic, synthetic drugs, polycyclic aromatic hydrocarbons (PAH) and other 
undesirable substances [1, 14, 15]. Synthetic drugs such as sibutramine or illegal analogs of sildenafil which is 
the active substance of Viagra® are relatively frequently found in botanical food supplements sampled by the 
VWA and other Dutch governmental services on the Dutch market. These adulterations are of major toxicological 
concern and the related health risks have increased in the last decade [14, 16, 17]. Especially botanical products 
originating from Asia are frequently contaminated with synthetic drugs, and therefore the growing volume of sales 
in the European Union for traditional herbal products (THPs) obtained from suppliers based in Asia and the 
increase in the number of outlets of products of traditional medicine are cause for concern [1]. Traditional 
medicine is defined by the World Health Organization (WHO) as: “the sum total of the knowledge, skills and 
practices based on the theories, beliefs and experiences indigenous to different cultures, whether explicable or 
not, used in the maintenance of health, as well as in the prevention, diagnosis, improvement or treatment of 
physical and mental illnesses”. The terms complementary-, alternative-, non-conventional medicine are used 
interchangeably with traditional medicine [18].  
Intentional addition of metals and metalloids to THPs has been described to occur in several Asian 
traditional medicine systems [14]. In the Indian traditional medicine system Ayurveda, Traditional Tibetan 
Medicine (TTM) and in TCM, the metals mercury and lead and the metalloid arsenic are deliberately added to 
THPs for therapeutic reasons. This practice has caused poisonings with Asian THPs worldwide. In Chapter 5 of 
this thesis the occurrence of these metals and metalloids in Asian THPs on the Dutch market is investigated and 
the related risks are assessed. Metals and metalloids can exist in different defined chemical species and the 
toxicity of these species can vary significantly (WHO, 2006). In order to estimate the risks related to exposure to 
metals and metalloids from food it is important to take into account the chemical species in which these metals 
and metalloids exist. This is illustrated in the example of mercury. The main types of mercury species are 
elemental mercury, inorganic and organic mercury compounds. Mercury is present in inorganic compounds as 
monovalent or divalent mercury. Organic mercury results from the combination of carbon and mercury and 
methylmercury is a highly toxic organic mercury species that can diffuse through phospholipid membranes [19, 
20]. Inorganic mercury is nephrotoxic and neurotoxic and long-term use of preparations with inorganic mercury 
compounds has resulted in poisonings worldwide [21]. In contrast, elemental mercury shows a low oral toxicity 
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when compared to organic and inorganic mercury compounds [19, 21]. This finding is especially relevant for 
mercury exposure from Ayurvedic THPs. In Ayurveda, elemental mercury is used as a starting material for 
mercury based ingredients that are an integral part of several Ayurvedic THPs. The elemental mercury is 
however extensively processed and mixed with sulfur and herbs before the resulting mercury based ingredient is 
added to Ayurvedic THPs. It is likely that during the preparation of Ayurvedic THPs the elemental mercury is 
completely transformed into inorganic mercury compounds, but conclusive analytical data supporting or rejecting 
this assumption is lacking. Because elemental mercury shows a low oral toxicity, a relative high elemental 
mercury level would require another type of safety limits than the safety limits for inorganic mercury used in 
Chapter 5. Thus, an important aspect in the risk assessment of mercury from the Ayurvedic THPs is whether 
mercury in these THPs is present as elemental mercury or not. A study into the presence or absence of the non-
toxic elemental form of mercury in Ayurvedic THPs was therefore conducted and the results of this study are 
presented in Chapter 6. 
As opposed to deliberate contamination of Asian herbal preparations with metals, metalloids or synthetic 
drugs, another group of contaminants are introduced unintentionally from the environment or through processing. 
Examples of this last group that are also found in herbal preparations are polycyclic aromatic hydrocarbons 
(PAH). These substances form a large class of organic compounds that are composed of two or more fused 
aromatic rings. PAH can occur in foods as a result from various processes. PAH can contaminate foods during 
smoking processes and heating and drying processes that allow combustion products to come into direct contact 
with the food. In addition, environmental pollution may cause contamination with PAH. These environmental PAH 
may be concentrated by the extraction steps applied in the production process of the botanical preparation, 
resulting in the past in for instance vitamin E samples that were highly PAH contaminated [15, 22-24]. Several 
PAH, such as benzo[a]pyrene are genotoxic and carcinogenic. PAH were evaluated by several risk assessment 
bodies such as the Dutch National Institute for Public Health and the Environment – het Rijksinstituut voor 
Volksgezondheid en Milieu (RIVM), the Scientific Committee on Food (SCF) of the European Union (EU) and the 
Joint FAO/WHO Expert Committee on Food Additives (JECFA) [25-27]. In 2008, the European Food Safety 
Authority (EFSA), which continued the work of the SCF, reviewed the available data on occurrence in food and 
toxicity of 16 priority PAH, 15 of which were identified by SCF and one, benzo[c]fluorene, by JECFA. EFSA 
concluded that 8 of these 16 ‘EFSA priority PAH’ for which oral carcinogenicity data are available (PAH8) could 
be used as indicator of the carcinogenic potency of PAH in food. EFSA concluded that the most suitable 
indicators of PAH in food with regards to both occurrence and toxicity were currently a combination of 4 
compounds of the PAH8 (referred to as PAH4) or PAH8 itself, with PAH8 not providing much added value 
compared to PAH4 [28]. The occurrence and connected risk assessment of PAH in herbal preparations on the 
Dutch market is explored in Chapter 7 of this thesis.  
 
Interactions of botanicals with medicinal products 
An indirect health risk of herbal preparations is the potential of certain herbs such as St. John’s wort 
(Hypericum perforatum L.) to interact with medicinal products [1]. The potential of St. John’s wort to interact with 
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certain medicines is stated in the package leaflets that accompany those medicines. EFSA noted however that 
contra-indications do not usually appear on the labels or any associated documentation when botanical food 
products are sold through supermarkets and other retail outlets. Furthermore, EFSA cited a study from 2001 by 
Izzo and Ernst who reviewed the seven top-selling herbal products (ginkgo, St. John’s wort, ginseng, garlic, 
echinacea, saw palmetto and kava) and recorded adverse drug interactions for Ginkgo, garlic, St. John’s wort, 
kava and ginseng but not for echinacea and saw palmetto [1, 29]. Interactions of herbal products with prescription 
drugs received increased attention in 1999 following a review published in the Lancet on the safety of St. John’s 
wort when used concomitantly with various prescribed drugs [30]. These prescribed drugs were drugs that are 
metabolized by hepatic cytochrome P450 (CYP) enzymes which activities could be doubled by St. John’s wort 
possibly leading to sub-therapeutic plasma concentrations of the drugs [30]. Subsequently, the EMA issued a 
warning for this potential effect of St. John’s wort in February 2000 [31]. HMPC of EMA adopted in November 
2009 a Community herbal monograph on Hypericum perforatum L., herba (well-established medicinal use)(St. 
John’s wort), in which it is established that concomitant use with cyclosporine, tacrolimus for systemic use, 
amprenavir, indinavir and other protease inhibitors, irinotecan and warfarin is contraindicated. The monograph 
also defines other cautions related to interactions with medicinal products including the warning that women using 
oral contraceptives should take additional contraceptive measures [32]. EMA also considered other possible 
herb-drug interactions, such as interactions between botanical laxative bulk producers as psyllium seed, 
ispaghula seed and husk and linseed, and certain medicines. EMA recommended to include a statement on the 
labeling of these botanical laxatives on the risk of interaction with medicinal products against diarrhea such as 
loperamide [33]. Because of the potential of St. John’s wort to interact with a wide range of drugs and the severity 
of several of these herb-drug interactions, the mechanism of action is discussed in more detail in Chapter 3 of this 
thesis. The topic of herb-drug interactions will however not be discussed further in this thesis. 
 
 
Objective and outline of this thesis 
 
The aim of the present PhD project was to review the toxicity of selected herbal preparations, to 
investigate the presence and actual levels of selected contaminants and naturally-occurring toxic substances in 
herbal preparations on the Dutch market and to estimate the associated risks. Three categories of safety issues 
related to herbal preparations have been identified by EFSA including i) the presence of naturally occurring toxic 
substances in plants, ii) contamination, and iii) interactions with medicinal products [1]. In this thesis mainly safety 
concerns of the first two categories were investigated.  
Chapter 1, the present chapter, provides a general introduction to safety concerns related to herbal 
preparations and other botanical products that are brought on the market as food commodities in the 
Netherlands. It also provides a short introduction on legislation and regulation relating to botanical products 
intended to be ingested by humans. Chapter 2 presents a synopsis of safety issues relating to botanicals that are 
addressed by Dutch and European food legislation with special emphasis on toxic constituents of plants and 
contaminants of herbal preparations. Furthermore, scientific opinions of European and national risk assessment 
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bodies on the risks of selected botanicals currently not covered by the Dutch Commodities Act are briefly 
discussed. Chapter 3 describes the nature and mechanism of action of several naturally occurring toxic 
substances in plants introduced in Chapter 2. Chapter 4 discusses the results of investigations into the 
occurrence of aristolochic acids in herbal preparations used in TCM sampled on the Dutch market and the risks 
associated with exposure to aristolochic acids from these specific Chinese traditional herbal preparations. 
Chapter 5 focuses on the contamination of herbal preparations on the Dutch market that are used in the Indian 
traditional medicine system Ayurveda, Traditional Tibetan Medicine (TTM) and TCM with mercury, lead and 
arsenic, and assesses the related risks by comparing the estimated heavy metal intake resulting from use at the 
proposed dose levels to established toxicological safety limits. In Chapter 6 it is investigated whether mercury 
found in Ayurvedic THPs was present as the non-toxic elemental mercury or not, in order to facilitate and further 
support the selection of established toxicological safety limits to be used for risk assessment providing the basis 
for subsequent market interventions. To this end, a method enabling detection of elemental mercury in the 
Ayurvedic THPs was established followed by detection of the possible presence of elemental mercury. Chapter 7 
presents data obtained in a survey into the occurrence of genotoxic and carcinogenic PAH in different food 
supplement categories. Because it was recognized from data obtained in 2003, the first year of the survey, that 
high benzo[a]pyrene levels are frequent in botanical food supplements special emphasis was placed on this 
category. Furthermore, the analytical method was expanded to include more of the 16 priority PAH defined by 
EFSA in 2008 in addition to benzo[a]pyrene. Finally, Chapter 8 presents a summary of the results obtained in this 
thesis and provides a discussion on how these results can be translated to the safety of herbal preparations 
currently on the Dutch market and what recommendations can be provided regarding the regulatory framework 
for herbal preparations on the basis of these findings. 
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Abstract 
 
In the Netherlands, the Commodities Act Decree ‘Herbal preparations’ regulates the use of toxic plants 
and fungi in herbal preparations. It includes limits for three types of phytotoxins in herbal preparations, which are 
toxic pyrrolizidine alkaloids, aristolochic acids and yohimbe alkaloids. Furthermore, the Decree currently prohibits 
the use in herbal preparations of 46 plants and fungi that are too toxic to be used in food or in other commodities. 
The constituents responsible for the toxic effects of these 46 plants are also found in plants not specifically 
regulated by the Decree. Within Europe, EFSA developed a new methodology for the safety assessment of 
botanicals used in food supplements and published a Compendium of botanicals that raise toxicological concern 
to be used as input for risk assessments. European and Dutch risk assessment bodies concluded that several 
botanicals pose health risks. The current paper presents an overview of the Dutch and European regulatory 
framework for selected food commodities with botanical ingredients as well as an overview of health concerns 
defined by risk assessors related to botanicals not specifically covered by these food safety laws. It is concluded 
that the current regulation and legislation in the Netherlands and Europe needs to be updated to address health 
risks relating to botanicals and botanical preparations that are identified to be of concern.   
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Introduction 
 
In the Netherlands, the Commodities Act and its subordinate Decrees and Directives regulate foods and 
a wide array of other commodities. The Dutch Commodities Act Decree ‘Herbal preparations’ (in Dutch: ‘het 
Warenwetbesluit Kruidenpreparaten’) covers herbal preparations that are brought on the market as foods (often 
as food supplements) and non-food commodities [1]. European food law does not include specific provisions that 
determine which botanicals can or cannot be used in food supplements. Within the European regulatory 
framework, the use of botanicals in food supplements is therefore subject to general rules in European food 
safety law including general rules established by Regulation (EC) No 178/2002. This Regulation is called the 
General Food Law and it explicitly forbids the placing of foods on the market, which are injurious to health or unfit 
for human consumption [2]. EFSA developed a two-level tiered approach for the safety assessment of botanicals 
and botanical preparations intended for use as ingredients in food supplements [3]. This method can then be 
used to assess whether a particular botanical is injurious to health or unfit for human consumption. Furthermore, 
a Compendium of botanicals reported to contain toxic, addictive, psychotropic, or other substances of concern 
was established by EFSA to be used as a preliminary tool for risk assessors. The Compendium is based in part 
on existing national lists of botanicals that are restricted or not admitted in food in several Member States [3]. A 
list of botanicals that are too toxic to be used in food or in other commodities included in the Dutch Decree ‘Herbal 
preparations’ was also used to compile the Compendium. European food safety legislation does contain 
provisions for several plant toxins in foods other than food supplements, and it also establishes maximum levels 
for certain contaminants of botanicals used in various categories of food products including food supplements. In 
the Netherlands, these European provisions have been transposed to the Dutch Commodities Act. 
The current Chapter will discuss selected safety issues relating to the use of botanicals in food, which 
are currently addressed by Dutch and European food legislation and which are of relevance to this PhD project. It 
is however not an in-depth review of the regulatory framework for botanical products that are intended to be 
consumed by humans. It will for instance only briefly touch upon legislation for medicinal products. The Chapter 
will focus on plants with toxic constituents regulated by the Dutch Commodities Act Decree ‘Herbal preparations’, 
but also on plants not regulated by the Decree but with identical or related toxic constituents. To this latter end, 
the scientific opinions of European and national risk assessment bodies on the risks of selected botanicals 
relevant to the Dutch market but currently not specifically covered by the Dutch Commodities Act will be 
discussed. The molecular mechanisms of toxicity of several of the phytotoxins for which legal provisions have 
been introduced in European and Dutch food law will then be discussed in more detail in Chapter 3 of this thesis. 
The present Chapter will also present information on the regulation and legislation for contaminants that may 
occur in botanical preparations, including toxic herbal adulterants, synthetic drugs, metals, mycotoxins and 
polycyclic aromatic hydrocarbons (PAH). Finally, the Chapter presents some considerations on products on the 
borderline with other legislation, notably the legislation for medicinal products and associated classification 
issues, and on the use of botanicals in the field of flavoring agents. 
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Toxic constituents of botanicals used in food supplements 
The Dutch Commodities Act Decree ‘Herbal preparations’ regulates the use of toxic plants and fungi in 
herbal preparations that are brought on the Dutch market [1]. The Decree defines herbal preparations as ‘herbal 
substances, subjected to treatment or not, including herbal extracts, which are intended to be used by humans. In 
addition, ‘herbal substances’ are defined as ‘substances that are composed of plant material’. 
 
Plants with toxic constituents regulated by the Decree ‘Herbal preparations’ 
The Dutch Commodities Act Decree ‘Herbal preparations’ defines limits to the occurrence of certain toxic 
constituents in herbal preparations or bans their presence altogether. The Decree includes limits for three types 
of phytotoxins in herbal preparations, namely toxic pyrrolizidine alkaloids, aristolochic acids and yohimbe 
alkaloids. The amount of toxic pyrrolizidine alkaloids in herbal preparations is limited to 1 µg/kg. Toxic 
pyrrolizidine alkaloids act principally on the liver where they can produce obstruction of hepatic veins resulting in 
veno-occlusive disease, which can be fatal. Several pyrrolizidine alkaloids are also genotoxic carcinogens. Plants 
known to contain pyrrolizidine alkaloids are widely used for medicinal purposes and some are even used as food 
(Chapter 3 of this thesis). Part I of the annex to the Decree ‘Herbal preparations’ lists plants that are known to 
contain toxic pyrrolizidine alkaloids such as comfrey (Symphytum officinale L.) and starflower or borage (Borago 
officinalis L.). However, the limit for toxic pyrrolizidine alkaloids extends to all plants with these constituents that 
are used in herbal preparations. Furthermore, the Decree forbids the presence of aristolochic acids and yohimbe 
alkaloids including yohimbine in herbal preparations. Aristolochic acids occur in several plants used medicinally in 
Traditional Chinese Medicine (TCM). Herbal preparations with Aristolochia spp. are carcinogenic to humans and 
naturally occurring mixtures of aristolochic acids are probably human carcinogens as well (Chapters 3 and 4 of 
this thesis).  
The presence of yohimbine and related alkaloids was prohibited in 2007 following a risk assessment by 
the Dutch National Institute for Public Health and the Environment (in Dutch: het Rijksinstituut voor 
Volksgezondheid en Milieu - RIVM) on request by the VWA [4, 5]. Yohimbine is a cyclic-indole alkaloid found in 
the bark of the West African yohimbe tree Pausinystalia johimbe (K. Schum.) Pierre ex Beille. The bark contains 
6% of related alkaloids, of which yohimbine is the principle alkaloid [6]. The alkaloids in this mixture are 
collectively called yohimbe alkaloids. Yohimbine has been used for the treatment of impotence. This alkaloid is a 
potent α2-adrenoreceptor (AR) antagonist. Inhibition of α2-ARs by yohimbine can result in an increase in blood 
pressure and heart rate. A wide array of clinical effects of yohimbine has been described including effects on the 
central nervous system (sleep disorders, anxiety, tremors), kidneys (dysuria and renal failure) and the 
gastrointestinal tract (anorexia, nausea and vomiting) [7, 8]. Adverse effects have been reported at daily doses of 
10 to 20 mg in several studies [5, 8]. In addition to the ban of yohimbe alkaloids, the use of plant material derived 
from the yohimbe tree in herbal preparations was also prohibited by inserting the herb on a list of plants in part II 
of the annex to the Decree ‘Herbal preparations’.  
Part II of the annex to the Decree ‘Herbal preparations’ defines plants that are too toxic to be used in 
food or in other commodities [1]. These plants are alphabetically listed and part II of the annex is currently 
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comprised of 46 toxic plants and fungi such as Aconitum napellus, Digitalis purpurea and Claviceps purpurea. 
The list was derived from a now repealed Decree (het Besluit U.A.-geneesmiddelen), which defined 
pharmaceutical substances including botanical preparations that only could be dispensed by pharmacies [1]. The 
list of toxic plants in part II and the list with plants containing pyrrolizidine alkaloids defined in part I of the annex 
also overlap to a considerable degree with the ‘CPMP list of herbal drugs with serious risks’ compiled by the 
Committee for Proprietary Medicinal Products (CPMP) and published by the European Commission in October 
1992 [9]. The Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA; at that 
time the acronym EMEA was used) considered the CPMP list a useful source of information on plants with 
intrinsic safety risks and effectively endorsed it by publishing it in its unrevised form in 2005 [10]. The Dutch 
repealed list of pharmaceutical substances that only could be dispensed by pharmacies and the CPMP ‘list of 
herbal drugs with serious risks’ indicate which parts of the plants are of toxicological concern. This information is 
however not provided for most of the banned plants that are defined in part II of the annex to the Decree ‘Herbal 
preparations’. Table 1 shows the plants and fungi banned in part II of the annex to the Decree and presents for 
each of these the constituent or constituents that are responsible for, or contribute to, the toxic effects of these 
botanicals [6, 8, 11-17]. It also shows which parts of the plants or fungi are of toxicological concern. Where 
possible, plants are grouped on the basis of the presence of related toxic constituents [8].  
EFSA recognized in its guidance on safety assessment of botanicals and botanical preparations that 
correct identification of the botanical source and botanical preparation is essential given that many species have 
been reclassified or renamed resulting in different scientific names for a single species. EFSA recommended 
therefore to follow as much as possible the nomenclature of the European Pharmacopoeia or additional sources 
such as Mansfeld’s World Database of Agricultural and Horticultural Crops, and the Germplasm Resources 
Information Network (GRIN) database by the United States Department of Agriculture [3, 11, 12]. Table 1 
includes in addition to the botanical names listed in part II of the annex to the Decree ‘Herbal preparations’, for 
each botanical the accepted botanical nomenclature including the author’s name as identified in Mansfeld’s 
database or the GRIN database. From Table 1 it can be derived that in several cases plant names in the list of 
part II of the annex have been misspelled, such as for instance Mandragora officinarum, which is incorrectly listed 
as Mandragora officinalis. Table 1 also includes Dutch and English common (vernacular) names. Common 
names may however not uniquely identify a species and are therefore not as reliable as scientific names [3]. In 
Traditional Chinese Medicine (TCM) use of common names is widespread and confusion over the identity of 
botanicals has resulted in poisonings due to the substitution of poisonous plants for innocuous species. In 
Belgium, 100 cases of rapidly progressing renal fibrosis were caused by substitution of Aristolochia fangchi for 
Stephania tetrandra. The substitution was probably caused by confusion over common names because both 
herbs can be identified in practice by the same traditional Chinese name, i.e. ‘Fang Ji’ (Chapter 4 of this thesis). 
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RIVM reviewed the toxicity of the plants and fungi currently defined in part II of the annex to the Decree 
and concluded that only for one herb (Convolvulus scammonia) on the list no evidence could be found supportive 
of maintaining its position on the list [8]. The resin of this botanical is however listed in the ‘CPMP list of herbal 
drugs with serious risks’ as a drastic laxative with irritant properties [9]. The herb has been included in lists of 
banned plants in other Member States too and is listed in the EFSA Compendium of botanicals that have been 
reported to contain toxic, addictive, psychotropic or other substances of concern [14]. The list of plants banned for 
use in herbal preparations established in part II of the annex to the Decree ‘Herbal preparations’ has been 
amended several times. To date, the herbs Magnolia officinalis, Stephania tetrandra and Lycium barbarum have 
been removed from the initial list by the Dutch Ministry of Health because of a risk assessment, which showed 
that these herbs were not toxic [18]. The risk assessment was conducted by RIVM on request by the VWA. While 
Stephania tetrandra in itself is not toxic, the potential for substitution with Aristolochia species poses a potential 
health risk and both VWA and RIVM advised therefore to maintain the ban on this botanical [19, 20].  
New additions to the list of banned herbs were kava kava (Piper methysticum G. Forst.) in 2003 and, 
already described, yohimbe in 2007. Kava kava was included on the list because of cases of liver toxicity reported 
in several countries. Risk assessments by governmental bodies from Germany and the UK were central to 
discussions whether kava kava should be removed from the Dutch market [21]. The German Federal Institute for 
Drugs and Medical Devices - Bundesinstitut fϋr Arzneimittel und Medizinprodukte (BfArM) in Bonn collected 39 
spontaneous reports where kava kava was linked to poor liver function, liver infections, necrosis and in three 
cases to fatal effects. In total 18 spontaneously reported cases were sufficiently documented in order to be 
assessed for causality. Based on these 18 cases and an additional 2 German cases reported in literature it was 
concluded that kava kava possesses the potential to cause severe liver toxicity showing a distinctive pattern of 
effects peaking at 3 to 4 months after the start of medication. In addition, the effects were likely to be more severe 
at higher doses [22]. BfArM repealed authorizations for kava kava products to treat nervous states such as 
anxiety, tension and restlessness in June 2002.  
In the UK, an expert group was established by the Medicines and Healthcare products Regulatory 
Agency (MHRA) to assess the safety of kava kava. The expert group determined in 2002 after reviewing 68 cases 
using a causality assessment method according to WHO criteria that this botanical was associated with an 
unacceptable risk of idiosyncratic hepatotoxicity. Kava kava products were subsequently removed from the UK 
market early 2003. All available data including details of an additional 42 cases were again reviewed in October 
2005. On a total of 110 received case reports, nine cases had a fatal outcome and in an additional nine cases 
patients received liver transplants and survived. The expert group concluded that the prohibition of kava kava 
remained justified and proportional. It was decided that none of other proposed risk minimization measures 
including label warnings would allow the safe use of kava kava [23]. 
It can be concluded that in the Netherlands the Decree ‘Herbal preparations’ includes limits for three 
types of phytotoxins in herbal preparations and prohibits the use in herbal preparations of 46 plants and fungi that 
are too toxic to be used in food or in other commodities. The constituents responsible for the toxic effects of these 
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46 plants are also found in plants not specifically regulated by the Decree. These plants not regulated by the 
Decree but containing identical or related toxic constituents are discussed in the next section. 
 
Plants not regulated by the Decree ‘Herbal preparations’ but with identical or related toxic constituents 
Where the Dutch list of banned botanicals contains only individual species, the ‘CPMP list of herbal 
drugs with serious risks’ also defines several genera in which all species possibly contain identical or related toxic 
constituents; examples are the genera Aconitum and Bryonia. The only Aconitum species banned in the 
Netherlands for use in herbal preparations is A. napellus, but botanical materials from other Aconitum species are 
also available as herbal preparations on the Dutch market. The roots of the species A. carmichaeli (Chuan Wu) 
and A. kusnezoffii (Cao Wu) are used in TCM for the treatment of musculoskeletal disorders and these species 
contain the potent neurotoxin and cardiotoxin aconitine, as does A. napellus (Table 1). Traditional Chinese herbal 
preparations are sold in the Netherlands in specialized shops where often therapists practice TCM as well. In 
Hong Kong several cases of herb-induced aconitine poisonings are treated in hospitals almost every year [24]. 
Certain preparation techniques are used in TCM in order to reduce aconitine and other toxic aconitine type 
alkaloids in Aconitum plant material, but levels of these aconitines can differ significantly between preparations 
[25]. Because many Aconitum species have been described, it is likely that several more of these species contain 
aconitines and that use of herbal preparations based on these plants can result in adverse effects. RIVM 
suggested to consider imposing a limit for, or a ban on the presence of aconitine and related aconitines in herbal 
preparations, analogous to the ban on aristolochic acids in herbal preparations already in place in the Decree [8]. 
A ban on the presence of aconitine and related aconitines in herbal preparations would be, in effect, in agreement 
with the CPMP position that all parts of all Aconitum spp. are herbal drugs with serious risks without any accepted 
benefit [26].  
In the review of all plants from part II of the annex to the Decree “Herbal preparations’, RIVM suggested 
to follow a similar strategy for several other categories of toxic constituents that could be found in plants included 
in the Dutch list of herbs that are banned from being used in herbal preparations (Table 2) [8]. Exposure to these 
constituents at typical dose levels can result in severe toxic effects. RIVM suggested that other botanicals with 
these constituents can also be cause for concern and that these botanicals were likely candidates for risk 
assessments. For example, strychnine is also found in other Strychnos species than S. nux-vomica, which is the 
only Strychnos species currently banned in the Netherlands, and these other toxic Strychnos species are used in 
Asia and Africa for several complaints [14, 27]. However, other categories of highly toxic constituents of 
botanicals exist and the toxic constituents presented in Table 2 cover only a certain part of the botanicals on the 
Dutch market for which possible health concerns exist. For a more extended overview, the reader is referred to 
the Compendium published by EFSA [14]. 
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Table 2 Categories (a) of constituents of banned herbal preparations in part II of the annex to the Commodities Act 
Decree ‘Herbal preparations’ that can result in severe toxic effects 
Constituents Examples of herbs with constituent 
Cardiac (cardenolide) glycosides Adonis vernalis L., Convallaria majalis L., Digitalis lanata Ehrh. 
Tropane alkaloids (hyoscamine, atropine or 
scopolamine) 
Atropa belladonna L., Datura stramonium L. 
Thujone Tanacetum vulgare L., Artemisia absinthium L. 
Genotoxic and carcinogenic constituents Juglans regia L. 
Aconitine and closely related aconitines Aconitum napellus L. 
Colchicine Colchicum autumnale L. 
Ergotamine, ergometrine and other ergot alkaloids Claviceps purpurea (Fr.) Tul. 
Yohimbe alkaloids Pausinystalia johimbe (K. Schum.) Pierre ex Beille 
Podophyllotoxin Podophyllum peltatum L. 
Protoanemonin Anemone pulsatilla L 
Ricin Ricinus communis L. 
Sparteine Sarothamnus scoparius (L.) Wimmer ex Koch 
Strychnine Strychnos nux-vomica L. 
a) As indicated by the Dutch National Institute for Public Health and the Environment (RIVM) [8] 
 
It can be concluded that there are several plants not regulated by the Dutch Decree ‘Herbal preparations’ 
but containing identical or related toxic constituents, which also give reason for concern. The current regulation 
and legislation in the Netherlands and Europe needs to be updated to address these possible health risks. This 
also holds for another class of botanicals, which are used in herbal preparations and not specifically regulated, 
but flagged by risk assessors because of health concerns. Examples of this class of botanicals are presented in 
the next section. 
 
Botanicals used in food supplements not specifically regulated but flagged by risk assessors due to health 
concerns 
In 2006, the HMPC of EMA (then known as the EMEA) published a statement on a potential connection 
between Cimicifugae racemosae rhizoma (black cohosh root) and cases of hepatotoxicity. EMA advised patients 
to stop taking the root of black cohosh (Cimicifuga racemosa (L.) Nutt., which is the synonym of Actaea racemosa 
L. [12]), upon signs and symptoms suggestive of liver injury and subsequently consult their doctor. Healthcare 
professionals were also asked to report suspected hepatic reactions [26]. In 2007, the HMPC published an 
update of the assessment of the case reports connected to black cohosh root use [28]. Overall, all discussed 
cases of literature and pharmacovigilance reports were poorly documented. Of the 18 cases that could be scored 
using a standardized causality assessment method (RUCAM), three cases could be classified as possible and 
two as probable. Since then discussions on the hepatotoxicity of black cohosh have been ongoing. One group 
reviewed 69, in general poorly documented, cases of which only one involved a possible causal relationship with 
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liver disease resulting in the conclusion that these cases did not, or only to a limited extent, support the 
hepatotoxicity of black cohosh [29]. Another group contested this conclusion and proposed that a label caution for 
black cohosh products should be made mandatory following similar proposals by British, Canadian and Australian 
governmental agencies due to growing evidence supporting the hepatotoxic potential of this botanical [30]. In 
Australia, medicines containing Cimicifuga racemosa are required since 2008 to list the following warning: ‘In very 
rare cases, Black cohosh has been associated with liver failure’ [31]. 
Another herb linked to liver toxicity is greater celandine (Chelidonium majus L.). Greater celandine 
contains at least 20 alkaloids including chelidonine, protopine and berberine, which belong in total to three groups 
of alkaloids. The herb is included in the EFSA Compendium and the benzophenantridine alkaloids chelidonine 
and others are listed as the chemicals of concern. Several Member States banned the sale of this botanical as 
food [14]. An ethanolic greater celandine extract was orally administered for 2 or 4 weeks to 48 Wistar rats in 
doses corresponding to 1.5 and 3 g/kg bw/day of herbal drug, equivalent to 5.5 and 11 mg/kg bw/day of total 
alkaloids. According to the authors, the botanical drug did not alter hepatic function but GSH levels and SOD 
activity were significantly reduced after 4 weeks of treatment. It was advised that long-term use should be avoided 
[32]. In Germany, BfArM limited in 2005 the intake of alkaloids from greater celandine to 2.5 µg per day based on 
an in vitro assay with rat hepatocytes. In 2008, this limit was expanded to 2.5 mg of total alkaloids per day 
(equivalent to 0.04 mg/kg bw/day for a 60 kg person) based on a NOAEL of > 3.69 mg/kg bw/day obtained in a 6 
month toxicity study in rats [33]. BfArM also assessed 48 cases of liver toxicity linked to herbal medicinal products 
containing greater celandine. In total, for 17 cases the causality was rated as probable, for 26 cases as possible 
and for one case as absent. Another 4 cases could not be assessed [33, 34]. One case report of toxic liver failure 
had a fatal outcome and the causality with greater celandine use was assessed as possible [34]. In the 
Netherlands, several botanical food supplements are on the market that contain greater celandine. 
In the ‘CPMP list of herbal drugs with serious risks’, Angelica archangelica L. is listed because of the 
presence of phototoxic furanocoumarins (or furocoumarins) [9]. A review of the available data by the HMPC of 
EMA showed that several furocoumarins, such as 8-methoxypsoralen, combined with UV-light pose a genotoxic 
and carcinogenic hazard to humans. 8-Methoxypsoralen is found in Angelica archangelica L. and in the fruits of 
Ammi majus L. This substance is used, followed by UVA light exposure, to treat vitiligo or psoriasis [6, 35]. 
Intakes of furocoumarins through botanical herbal medicinal products or herbal preparations (food supplements) 
will add to an already considerable exposure from various foods, such as celery. HMPC concluded that the health 
risk to humans associated with the exposure to furocoumarins from herbal preparations should be assessed [35]. 
Interestingly, the plant is not included in the EFSA Compendium but two other Angelica species are due to the 
presence of furocoumarins [14]. 
In 2006, following a rapid alert, RIVM assessed on request by the VWA the risks presented by 
cyanogenic glycosides in bitter almonds (Prunus dulcis (Mill.) D.A. Webb var. amara (DC.) Buchheim) and kernels 
of apricots (P. armeniaca L.). In the United States, apricot kernels, also referred to as apricot pits, are sold in 
health food stores and are believed by some to act as anticancer agents, although efficacy has not been 
demonstrated [6]. Apricot kernels and bitter almonds are sold in the Netherlands in food retail shops, health food 
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stores and via Internet as well. RIVM concluded that a dose of 0.6 mg cyanide/kg bw/day could possibly be fatal 
for adults and that 30 g of kernels could represent a lethal dose, assuming that the cyanogenic glycosides present 
in the kernels could release 1000 mg of cyanide/kg kernels. However, cyanide levels of up to 3000 mg/kg kernels 
have been reported [36]. At these higher concentrations, lower doses than 30 g of kernels could also be lethal. 
RIVM was not able to derive an acute oral reference dose due to the limited availability of data on the acute 
toxicity of cyanide via the oral route [37]. 
Botanicals with laxative properties are relatively popular. A number of glycosides with aglycones related 
to anthracene are present in botanicals such as cascara sagrada (Frangula purshiana (DC.) J. G. Cooper), 
frangula (Frangula alnus Mill.), aloe (Aloe vera (L.) Burm. f. (syn. A. barbadensis Mill.); Aloe ferox Mill.), rhubarb 
(Rheum palmatum L.) and senna (Senna alexandrina Mill.) [6, 12]. All of these plants are listed in the EFSA 
Compendium because of health concerns raised by the presence of anthracene derivatives. In addition, warning 
labels are mandatory for several of these botanicals in Belgium [14]. The anthracene derivatives found in these 
plants include anthraquinones, anthrones, dianthrones and related compounds that are mostly present as 
glycosides [6, 38]. These anthracene derivatives are also called anthranoids [38]. Anthranoid compounds are 
stimulant cathartics and exert their action by increasing the tone of the smooth muscle in the wall of the colon and 
stimulate the secretion of water and electrolytes into the large intestine [6].  
Anthranoid containing herbal drugs are recommended for short-term treatment (one to two weeks) of 
constipation [39]. Long-term use of herbal preparations with anthranoid compounds may however lead to watery 
diarrhea resulting in excess loss of electrolytes and water. Stimulant laxatives are habit-forming and long-term 
use may result in laxative dependence and loss of normal bowel function [6]. Abnormalities such as melanosis 
coli, enteric changes and neoplastic changes have been linked to anthranoid compounds [39, 40]. The 
association between colorectal neoplasm in humans and the use of herbs with these compounds remains 
however inconclusive [40]. HMPC assessed cascara, frangula bark, aloe, rhubarb and senna (pods and leaves) 
and concluded that use of herbal medicinal products based on these botanicals for more than one to two weeks 
requires medical supervision. HMPC also warned against impaired function of the intestine and dependence on 
these laxatives linked to long-term use and defined other warnings and precautions for use [41-46]. It can be 
concluded that it would be prudent not to use these stimulant laxatives for prolonged periods without medical 
supervision. 
 
Use of plants with flavoring properties in conventional foods and herbal preparations  
In addition to the use of botanicals to improve health or treat disease, many plants are used traditionally 
to enhance the flavor or aroma of foods. The use of plants for flavorings and food ingredients with flavoring 
properties in foods is regulated by European food legislation, which is the basis of provisions for these products in 
the Dutch Commodities Act. Recently, the European Union updated the current legislation on flavorings (Directive 
88/388/EEC) resulting in Regulation No 1334/2008, which shall apply from 20 January 2011 [47, 48]. Flavoring 
substances are defined chemical substances, including natural flavoring substances. The Committee of Experts 
on Flavouring Substances of the Council of Europe concluded that a number of substances occurring naturally in 
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botanical source materials for flavorings and food ingredients with flavoring properties, raise toxicological 
concern. In those cases where the Scientific Committee on Food (SCF) - or EFSA - confirmed that the substance 
in question raised toxicological concern, the substance was regarded as an undesirable substance and 
consequently prohibited by Regulation No 1334/2008 to be added to food in the form of the pure, chemically 
defined substance. These undesirable substances can also be present in flavoring preparations and food 
ingredients with flavoring properties due to their natural occurrence in plants that are used as source materials for 
these flavoring preparations and ingredients. Maximum levels for these undesirable substances have therefore 
been established for foods that contribute most to the human intake of these substances [48]. Table 3 presents 
these substances that in effect are toxic principles of which the addition to foods will be prohibited by Regulation 
No 1334/2008. Also shown in Table 3 are examples of botanicals that contain these toxic principles as well as the 
most important toxic effects of these substances [49-55]. The effects of several of these compounds are 
discussed in more detail in Chapter 3 of this thesis.  
Currently, Directive 88/388/EEC still applies and this directive also includes a list of compounds that are 
banned from being added to food in a pure, chemically defined form. The list in Directive 88/388/EEC is 
composed of substances that, except for santonin and isosafrole, are also prohibited by Regulation No 1334/2008 
from being used in food in a pure form [48]. Santonin is found in the plants Artemisia cina and A. maritima, which 
are banned for use in herbal preparations in the Netherlands (Table 1). Isosafrole is a weak rodent 
hepatocarcinogen. It occurs sporadically and then only together with safrole. SCF concluded that any measure to 
restrict exposure to safrole in food would cover isosafrole as well [56]. As well as the substances banned by 
Directive 88/388/EEC (with the exception of santonin and isosafrole), Regulation No 1334/2008 additionally 
prohibits the use of capsaicin, estragole, menthofuran, methyleugenol and teucrin A as pure substances in food 
[47, 48].  
One of the substances banned both by Directive 88/388/EEC and Regulation No 1334/2008 from being 
added in its pure form to food is the carcinogen beta-asarone [47, 48]. In addition to beta-asarone, its isomer 
alpha-asarone is also a mammalian carcinogen, but the addition of alpha-asarone to food as a pure substance is 
not prohibited. It is a constituent of several botanicals such as Asarum europaeum L., Asarum arifolium Michx and 
Daucus carota L. Asarones have also been reported to occur in Sassafras albidum (Nutt.) Nees and Acorus 
gramineus Ait. The HMPC of EMA advised that the concentration of both asarones in herbal medicinal products 
should be reduced to a minimum. Following the setting of maximum levels for beta-asarone in European food 
legislation, HMPC proposed a provisional limit of exposure from herbal medicinal products of 115 µg/day, 
equivalent to 2 µg/kg bw/day for a 60 kg person [57]. 
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Table 3 Substances effectively prohibited from 20 January 2011 by Regulation No 1334/2008 (annex III) from being 
added as such to food [48]  
Toxic substance  Toxic action/ effect Examples of herbs with constituent 
Agaric acid Highly irritating effect on intestinal 
mucosa 
Dried white agaric mushroom (Fomes officinalis (Vill:Fr) 
Ames) 
Aloin Laxative Aloe vera (L.) Burm. F., (= A. barbadensis), Aloe ferox 
Mill. 
Beta-asarone Carcinogenic in rodents, suspected 
genotoxic carcinogen 
Rhizome of calamus (Acorus calamus L.) 
Capsaicin Local irritant, increased risk for gastric 
cancer observed at doses above 200 mg 
per day 
Fruits of peppers (Capsicum annuum L. and C. 
frutescens L.) 
Coumarin (1,2-benzopyrone)  Hepatotoxicity  Cinnamon (Cinnamomum verum J. Presl) and tonka 
beans (Dipteryx odorata (Aubl.) Willd.) 
Estragole (1-allyl-4-
methoxybenzene)  
Genotoxic carcinogen Sweet basil (Ocimum basilicum L.) and tarragon 
(Artemisia dracunculus L.) 
Hydrocyanic acid Acute cyanide poisoning, chronic effects 
on nervous system and thyroid 
Present as cyanogenic glycosides at least in 2000 
plants, including bitter almonds and apricots (Prunus 
dulcis (Mill.) D.A. Webb var. amara (DC.) Buchheim, P. 
armeniaca L., respectively) 
Hypericine Enhanced photosensitivity St. John's wort (Hypericum perforatum L.) 
Menthofuran Hepatotoxicity, nephrotoxicity Peppermint oil (Mentha x piperita L. var. piperita) and 
pennyroyal oil (Mentha pulegium L.), buchu leaf oil 
(Agathosma betulina (P. J. Bergius) Pillans) 
Methyleugenol (4-allyl-1,2-
dimethoxybenzene) 
Genotoxic carcinogen Nutmeg (Myristica fragans Houtt.), tarragon, basil, star 
anise (Illicium verum Hook. F.)  
Pulegone Hepatotoxicity, nephrotoxicity Peppermint oil and pennyroyal oil 
Quassin Possible reproductive toxicity Quassia (Quassia amara L. or Picrasma excelsa (Sw.) 
Planch) 
Safrole (1-allyl-3,4-
methylene dioxy benzene)  
Genotoxic carcinogen Nutmeg and mace (Myristica fragans Houtt.), cinnamon, 
black pepper (Piper nigrum L.) and sweet basil 
Teucrin A Hepatotoxicity Germander (Teucrium chamaedrys L.) 
Thujone (alpha and beta) Neurotoxicity Sage (Salvia officinalis L.) and several Artemisia 
species such as wormwood (A. absinthium L.) 
References: [49-55] 
 
Furthermore, HMPC reviewed the SCF opinion on pulegone and menthofuran (Table 3) in relation to 
herbal medicinal products containing peppermint oil (Mentha piperita L.), mint oil (M. canadensis L., syn. M. 
arvensis var piperascens Malinv. Ex Holmes) and pennyroyal oil (M. pulegium L. or Hedeoma pulegoides (L.) 
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Pers) [58, 59]. Following the SCF, HMPC also concluded that pulegone is a hepatotoxin. Daily pulegone doses 
exceeding the TDI for food are commonly encountered in herbal medicinal products in Europe but no certain 
cases of liver toxicity in humans have been reported. HMPC concluded that the use of pennyroyal oil in 
unlicensed products should be discouraged [58]. HMPC also considered another toxic substance from Table 3, 
estragole, which is also found in a wide range of aromatic plants. It was concluded that estragole is a naturally 
occurring genotoxic carcinogen, but that it does not represent a significant cancer risk to users of herbal medicinal 
products given the low levels of exposure resulting from consumption of these products (short time use in adults 
at recommended posology) [60]. HMPC derived similar conclusions for methyleugenol, another alkenylbenzene 
included in Table 3 [61].  
The use of the Margin of exposure (MOE) approach developed by EFSA [62] has been advocated for the 
risk assessment of constituents of botanicals which are genotoxic and carcinogenic [63]. The MOE can be 
obtained by dividing the Benchmark Dose Lower Confidence Limit associated with an extra 10% cancer risk 
relative to background incidence (BMDL10) by the estimated dietary intake of a compound. EFSA proposed that 
MOEs of 10,000 or higher - taking into account certain criteria - would be of low concern from a public health point 
of view and might be considered as a low priority for risk management actions [62]. For example, for the intake of 
methyleugenol from spices MOEs of 15,400-158,000 for females and MOEs of 4,400-64,000 for males were 
calculated indicating that the use of these spices should be considered as a low priority for risk management [63]. 
However, for specific botanicals, MOEs might prove to be lower than 10,000 as was shown for estragole from 
infusions of bitter fennel fruits as tea for which MOEs in the range of 34 to 1000 could be calculated [64]. 
Glycyrrhizinic acid is a triterpenoid saponin compound extracted from the roots and rhizomes of the 
liquorice plant (Glycyrrhiza glabra L.) that is used for its sweetness in a range of foodstuffs such as liquorice 
confectionery. This active principle can cause water and sodium retention and increased excretion of potassium, 
which over a prolonged period may result in hypokalaemia, hypernatraemia, edema, hypertension and cardiac 
disorders (Chapter 3 of this thesis). Both EFSA and SCF evaluated the safety of this constituent and its 
ammonium salt and considered it prudent that regular ingestion should not exceed 100 mg/day [65, 66]. Directive 
2008/5/EC defines compulsory indications on confectionery and beverages in case these foods contain 
glycyrrhizinic acid above certain levels. At relatively low levels it is sufficient to include ‘contains liquorice’ into the 
labeling but at higher levels the following statement is to be included: ‘contains liquorice – people suffering from 
hypertension should avoid excessive consumption [67]. This obligation has been transposed to the Dutch 
Commodities Act Decree ‘Labeling of foods’. The rule does not apply to botanical food supplements with 
Glycyrrhiza glabra, however. 
 
Contaminants of botanical food supplements  
Botanical food supplements can become adulterated with other botanicals than the intended botanical 
ingredients. In 1997, the US Food and Drug Administration (FDA) investigated a case of a patient presenting with 
a toxic serum digoxin level after using a botanical preparation. It was shown that an ingredient of the preparation 
listed as ‘plantain’ was adulterated by Digitalis lanata Ehrh., which contains cardiac glycosides. Plantain (not to be 
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confused with the fruit of the banana plant of the genus Musa) is an herb of the genus Plantago. The potentially 
contaminated plantain powder had been distributed to at least 150 manufacturers, distributors, and retailers [68]. 
If this botanical would be found as an adulterant of herbal preparations on the Dutch market, specific provisions 
would already be in place to enforce food safety because Digitalis lanata Ehrh. is banned for use in herbal 
preparations in the Netherlands (Table 1).  
In the next example herbal preparations were found on the Dutch market that were adulterated by a 
botanical that was not specifically banned from use in food. In 2001, a series of reports were received by the 
VWA of adverse effects linked to a herbal tea mixture with star anise and other herbs. Investigation by the VWA 
showed that the tea contained fruits of an unknown star anise species lacking the anise flavor that is 
characteristic for Chinese star anise (Illicium verum Hook. f.), which is the star anise species used in food. The 
unidentified species was shown to contain the neurotoxin anisatine, which can cause epileptic seizures [69]. The 
absence of specific legal provisions seriously complicated enforcement actions. Measures to protect consumers 
were therefore taken by the VWA on the basis of the ban of placing foods on the market that are injurious to 
health or unfit for human consumption. Furthermore, it was interesting to note that VWA inspectors were informed 
that there existed at that time a shortage of Chinese star anise and that as a result star anise of inferior quality 
was used in food, which normally would not have been used for this purpose. It is likely that the toxic star anise 
fruits found in the tea were collected in the wild. This case illustrates that, as EFSA recognized in 2004, 
misidentification of plants harvested from the wild is an important problem regarding the safety of herbal 
preparations [70]. 
Contamination of herbal preparations with a wide range of other substances than toxic plant material has 
been described. Contaminants included heavy metals, synthetic drugs and other undesirable substances [70, 71]. 
Botanical food supplements are frequently adulterated with synthetic drugs such as sibutramine or illegal analogs 
of sildenafil, which is the active substance of Viagra®. Synthetic drugs are also found relatively often in botanical 
food supplements sampled by the VWA and other Dutch governmental services. These adulterations are of major 
toxicological concern and the related health risks have increased in the last decade [71-73]. The presence of 
synthetic drugs in food supplements can result in the classification of the product as medicinal product and this 
topic will be discussed further in the next section of this chapter, which focuses on borderline products.  
Recent reports of high levels of lead, cadmium and mercury in certain food supplements suggest that 
use of these products can contribute significantly to human exposure to these metals. The European Commission 
introduced therefore maximum levels for these metals in food supplements in Regulation (EC) No 1881/2006, 
which apply since July 2009 [74, 75]. No limit has yet been proposed for arsenic. In the Netherlands, Regulation 
(EC) No 1881/2006 is linked to the Dutch Commodities Act, but its provisions directly apply to foods on the Dutch 
market. In Chapter 5 the presence of lead, mercury and arsenic is investigated in herbal preparations used in 
Asian traditional medicine systems, which were sampled on the Dutch market. 
Mycotoxins are another important group of contaminants that can be found in botanical food 
supplements. These mycotoxins are in most cases produced by fungi that contaminated the botanical material. 
Regulation (EC) No 1881/2006 sets maximum levels for certain contaminants in foodstuffs including a limit for the 
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mycotoxin ochratoxin A on liquorice root used as an ingredient of herbal infusions [74, 76]. In some cases 
mycotoxins are the product of a fungal ingredient of a herbal preparation such as for instance the fungus 
Monascus purpureus that is used to produce red yeast rice. This herbal preparation is used for healthy blood lipid 
levels. An important active constituent of red yeast rice is monacolin K (the effects of this constituent will be 
discussed in the next section on borderline products) [77]. Moreover, the fungus Monascus purpureus also 
produces a secondary metabolite called citrinin. This hepato-nephrotoxin was found in each of 12 commercial 
‘Monascus red mould rice’ products that originated from China and were obtained from several European 
companies [78].  
Regulation (EC) No 1881/2006 also defines limits for benzo[a]pyrene in several foods, but not for food 
supplements. Benzo[a]pyrene is a polycyclic aromatic hydrocarbon (PAH) and several of these, including 
benzo[a]pyrene, are genotoxic and carcinogenic. The Dutch Commodities Act includes since January 2006 a 
maximum level of 10 µg/kg benzo[a]pyrene for food supplements with botanical ingredients and a maximum of 2 
µg/kg benzo[a]pyrene for supplements without these ingredients [79]. Chapter 7 of this thesis presents data 
obtained on the occurrence of genotoxic and carcinogenic PAH in different food supplement categories with 
special emphasis on botanical food supplements. 
 
Borderline products 
Certain borderline cases exist regarding the classification of products with substances, notably herbal 
extracts, that are used both in food supplements and for manufacturing proprietary medicinal products, in 
particular traditional herbal medicinal products [80]. The classification of products as medicinal products or as 
food products is an important matter that can significantly influence the availability of a product on the market. For 
instance, there used to be several herbal preparations on the Dutch market that contained ephedrine. These 
alkaloids are found in several species of the genus Ephedra. Herbal preparations regulated by food law with 
ephedrine alkaloids were predominantly sold as weight-loss supplements or as ‘herbal ecstacy’. In 2004, the 
Dutch Minister of Health concluded however that because of concerns regarding the toxicity of ephedrine 
alkaloids (see Chapter 3 of this thesis), products with these substances could only be allowed on the market as 
medicinal products for which a market approval is mandatory [81]. Because the registration procedure for 
medicinal products is costly, none of the food supplements with ephedrine alkaloids are now being sold as 
medicinal products. Other botanical products with stimulant activity have been brought on the market as an 
alternative to products with Ephedra spp. that contain synephrine as an active substance, which is chemically 
related to ephedrine (Chapter 3 of this thesis). This compound can be found in significant quantities in the peel of 
the immature fruit of the bitter orange (Citrus aurantium L. ssp. aurantium L.) but also in the whole mature fruit. 
Extracts used in many food supplements contain synephrine levels that are often much higher than the 
synephrine concentrations reported for traditional extracts of the dried fruit or peel [64]. It has been debated 
whether synephrine is a medicinal product or a food due to its similarities to ephedrine alkaloids in activity and 
toxicity. No official position has been issued by the Dutch competent authorities yet.  
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Discussions on the legal status of another botanical, red yeast rice, culminated in influential case law by 
the European Court of Justice which further refined the criteria for the classification of products as medicinal 
products (case C-140/07 ‘Hecht-Pharma GmbH’ of January 2009) [82]. Red yeast rice contains monacolin K, 
which is synonymous with lovastatin, an inhibitor of cholesterol synthesis contained in a number of prescription 
medicinal products. The recommended dose of the product under consideration in the court case amounted to a 
daily consumption of 1.33 to 4 mg of monacolin K, which is low in comparison with the daily consumption of 10 to 
80 mg recommended for lovastatin [82]. Red yeast rice is steamed rice fermented by the fungus Monascus 
purpureus [77, 78]. Adverse effects such as hepatotoxicity and myopathy have been linked to red yeast rice and 
monacolin K and other monacolins present in this preparation [77, 83]. From the judgment of the European Court 
of Justice in case C-140/07 it can be concluded that for a product to be classified as a medicinal product on the 
basis of its pharmacological effect, it must be able to significantly affect physiological functions in human beings. 
And when a classification as medicinal product is considered for a (botanical) product it is up to the competent 
authority to prove that this particular product appreciably affects physiological functions by conducting an 
scientific assessment of the specific pharmacological, immunological or metabolic properties taking into account 
its composition – including its content in active substances – and intended use levels.  
 
 
Conclusions 
 
In the Netherlands, the use of botanical ingredients in food supplements is covered by national 
legislation: the Commodities Act Decree ‘Herbal preparations’. In absence of European legislation for this 
category of products it is pertinent to keep the Decree up to date in order to deal with emerging health risks posed 
by changes in the market for food supplements with botanical ingredients. Recent work by RIVM, EMA and EFSA 
has shown that in addition to the three toxic herbal constituents (toxic pyrrolizidine alkaloids, yohimbe alkaloids 
and aristolochic acids) defined in the Decree, other groups of substances found in several food supplements with 
botanical ingredients are also of present concern. EFSA developed a new methodology for the safety assessment 
of botanicals used in food supplements and published a Compendium of botanicals that raise toxicological 
concern to be used as input for risk assessments. The tools developed by EFSA can then be used to assess the 
risks of botanicals not yet specifically covered by European and Dutch food safety legislation. European and 
Dutch risk assessment bodies concluded that several botanicals not specifically regulated by the Decree pose 
health risks. Opinions of these risk assessment bodies should be considered when a review of Decree ‘Herbal 
preparations’ is conducted. In several of these risk assessments label warnings are advocated for specific 
botanicals. It should be discussed whether label warnings are desired on food commodities including herbal 
preparations because foods are not expected by consumers to cause adverse effects. Altogether, it is concluded 
that the current regulation and legislation in the Netherlands and Europe needs to be updated to address health 
risks relating to botanicals and botanical preparations that are identified to be of concern. 
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Abstract 
  
At present there is an increasing interest for plant ingredients and their use in drugs, for teas or in food 
supplements. The present review describes the nature and mechanism of action of the phytochemicals presently 
receiving increased attention in the field of food toxicology. This relates to compounds including aristolochic 
acids, pyrrolizidine alkaloids, beta-carotene, coumarin, the alkenylbenzenes safrole, methyleugenol and 
estragole, ephedrine alkaloids and synephrine, kavalactones, anisatin, St. John’s wort ingredients, cyanogenic 
glycosides, solanine and chaconine, thujone, and glycyrrhizinic acid. It can be concluded that several of these 
phytotoxins cause concern, because of their bioactivation to reactive alkylating intermediates that are able to 
react with cellular macromolecules causing cellular toxicity, and, upon their reaction with DNA, genotoxicity 
resulting in tumors. Another group of the phytotoxins presented is active without the requirement for bioactivation 
and, in most cases these compounds appear to act as neurotoxins interacting with one of the neurotransmitter 
systems. Altogether the examples presented illustrate that natural does not equal safe and that in modern society 
adverse health effects, upon either acute or chronic exposure to phytochemicals, can occur as a result of use of 
plant- or herb-based foods, teas or other extracts. 
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Introduction 
 
Plants and their constituents have been used for ages as a source of bioactive ingredients for hunting, 
medical, warfare and assassination purposes. The Ebers papyrus (circa 1500 BC) already described a variety of 
poisons based on plant ingredients [1]. The ancient Greek and Roman literature gives several references to the 
use of poisons. Hemlock, which contains the nicotinic acid agonist alkaloids coniine and γ-conicine as its major 
toxic ingredients, was the official Greek state poison used for the execution of Socrates (470-399 BC) [1]. The 
use of plants and their ingredients for beneficial health purposes continues from these ancient times, through the 
Middle Ages, when botanical gardens were established and maintained as a source of medical plants, till modern 
time. At present there is an increasing interest for plant ingredients and their use in drugs, for teas or in food 
supplements. Many consumers equate “natural” with “safe” when considering plant-based food supplements or 
drug preparations. Unfortunately, the assumption that natural products are safe is false. Scientific literature 
describes a wide variety of plant-derived toxins, known as phytotoxins, which can be present in the fruit and 
vegetable components of our diet. These bioactive ingredients are generally regarded as safe (GRAS) at the 
current levels of exposure. However, in spite of a long history of safe use, botanical or herb-based food items 
may contain individual ingredients known to be toxic and even genotoxic and carcinogenic, and they may become 
of concern upon increased exposure. The present review describes the nature and mechanism of action of the 
phytochemicals presently receiving increased attention in the field of plant and herb-based food items. This 
relates to the mechanism of action and toxic effects of compounds including aristolochic acids, pyrrolizidine 
alkaloids, beta-carotene, coumarin, the alkenylbenzenes safrole, methyleugenol and estragole, ephedrine 
alkaloids and synephrine, kavalactones, anisatin, St. John’s wort ingredients, cyanogenic glycosides, solanine 
and chaconine, thujone and glycyrrhizinic acid.  
 
 
Review 
 
In the following sections the molecular mechanisms of toxicity of a series of phytotoxins of present 
interest in the field of food toxicology are summarized. Emphasis is on the molecular mechanisms underlying the 
toxicity. Compounds discussed have been selected because of their impact in the field of food toxicology during 
the past decade.  
 
 
Aristolochic acids 
 
Major characteristics, occurrence and intake   
Aristolociaceae have been used since ancient times in herb-based medicine. In 1991, a unique form of 
nephropathy was reported in Belgium. Over 100 young women suffered from kidney damage, developing in 
several patients into cancer of the kidneys and the urinary tract [2, 3]. This adverse effect was associated with the 
prolonged intake of a Chinese herb-based weight loss preparation in which Stephania tetranda was accidentally 
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replaced by Aristolochia fanchi, because both plants are used under the same name ‘Fangji’ in Chinese folk 
medicine [2]. Aristolochic acids occur throughout the plants and appear in roots, stem, leaves and fruit of 
Aristolochia fanchi. Levels in the crude drug can range between 0.1% and 0.6% dry weight [4, 5]. The clinical 
symptoms observed were named Chinese Herb Nephropathy (CHN) [3], and when it became clear that they were 
caused by aristolochic acids the disease was also named Aristolochic Acid Nephropathy (AAN) [6]. The ingested 
dose of aristolochic acids by patients with CHN has been estimated to be in the range of a few µg/kg bw/day [7]. 
 
Mechanism of toxic action  
Aristolochic acids I and II (Figure 1) are the major type of aristolochic acids and are know to be 
nephrotoxic, genotoxic and carcinogenic [8-13]. The first symptoms of AAN are the excretion of low molecular 
weight proteins in urine, indicating a toxic effect on the proximal tubules [14]. Reductive metabolic activation of 
aristolochic acids by cytochromes P450 (CYP) 1A1 or 1A2, and/or by other enzymes including NADPH:P450 
reductase, xanthine oxidase, NAD(P)H: quinone oxidoreductase (= DT-diaphorase), and peroxidases has been 
reported and results in formation of a cyclic reactive nitrenium ion (Figure 2) able to form covalent DNA adducts 
at the exocyclic amino groups of guanine and adenosine [8, 9, 15-20]. The adduct detected with highest 
frequency is the adenine adduct leading to an AT to TA transversion. The human tumor suppressor gene p53 
was shown to be a hot spot for this type of mutation by aristolochic acid metabolites [9]. Furthermore, in rodents 
the activation of the Ha-ras gene by a specific AT to TA transversion mutation was reported [21, 22].  
Studying 39 women with CHN, Nortier et al. [23] demonstrated aristolochic acid related DNA adducts in 
specimens of renal tissue, and concluded that a cumulative dose of 201 g or more of a compound labeled as 
containing Stephania tetrandia but actually containing Aristolochia fangchi increases the risk for developing 
urothelial carcinomas. This was concluded based on the observation that among the 24 patients with CHN that 
consumed a total dose of 200 or less, 8 cases of urethelial cancer were detected, whereas among 15 patients 
who had ingested 201 g or more 10 cases were found, which was significantly higher (P=0.05). Since the first 
reports of CHN in Belgium, similar cases have been described in several other countries including Spain, Japan, 
France, the UK and China [9 and references therein]. 
 
 
 
Figure 1 Structural formula of aristolochic acids [8-13]; with R=OCH3 in aristolochic acid I (8-methoxy-6-nitro-phenanthro-
(3,4-d)-1,3-dioxolo-5-carboxylic acid, and R= H in aristolochic acid II (6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid 
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Figure 2 Metabolic activation of aristolochic acids to a cyclic reactive nitrenium ion and its subsequent covalent adduct 
formation with deoxyadenosine (dA-N6-AA) and deoxyguanosine (dG-N2-AA); reductive activation of aristolochic acids in the 
first step can be catalyzed by CYP1A1 or CYP1A2, and/or by other enzymes including NADPH:P450 reductase, xanthine 
oxidase, NAD(P)H: quinone oxidoredutase (= DT-diaphorase), and peroxidases [8, 9, 15-20] 
 
Polymorphisms of influence  
To date, only a few percent of the patients treated with the slimming regimen are reported to have 
suffered from nephropathy [20]. A possible explanation for this observation may be differences in the enzymes 
involved in bioactivation/ detoxification of the aristolochic acids. Genetic polymorphisms in the enzymes 
catalyzing reductive activation, including CYP1A1 or CYP1A2, but also NADPH:P450 reductase, xanthine 
oxidase, NAD(P)H:quinone oxidoreductase (= DT-diaphorase), and peroxidases may be of influence. Thus, 
lifestyle factors like smoking, which induces CYP1A, and genetic polymorphisms for CYP1A2 and for 
NAD(P)H:quinone oxidoreductase leading to poor metabolizer phenotypes, may influence the risk posed by 
aristolochic acid consumption. 
 
Concluding remarks  
Following the reports of Aristolochia-related nephrotoxicity many countries have taken regulatory actions 
to protect the public by taking Aristolochia species from the supply chain. The European Agency for the 
Evaluation of Medicinal products even suggested to consider the prohibition of species at risk of being confused 
with Aristolochia species, unless appropriate quality control procedures are in place [7]. Such species include 
Akebia quinata, Akebia trifoliata, Clematis armandii, Clematis montana, Cocculus orbiculatus, Cocculus 
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laurifolius, Cocculus trilobus and Stephania tetrandra [7]. It can also be concluded that further identification of the 
enzymes principally involved in the bioactivation of aristolochic acids, and the screening of CHN patients for 
genetic polymorphisms in the major enzymes involved, seem important future steps to allow elucidation of 
possible relationships between genotypes and CHN, and to define the groups within the human population at 
increased risk. 
 
 
Pyrrolizidine alkaloids (PAs)  
 
Major characteristics, occurrence and intake  
Plants known to contain pyrrolizidine alkaloids (PAs) are widely used for medicinal purposes as home 
remedies all over the world, and some are even used as food. Human poisoning and even deaths from PAs have 
been reported in several countries including South Africa, Jamaica, Ecuador, Hong Kong, India, the former 
central Asian republics of the USSR, the UK and the US [24, 25]. PAs are present in plants of the families 
Boraginaceae (all genera), Asteraceae (Senecioneae and Eupatorieae), and Fabaceae (genus Crotalaria) [24]. 
PAs were known to be a hazard towards livestock for many decades. Human consumption of PAs occurs, for 
example, from consumption of Symphytum and Senecio species present in herbal preparations, such as “comfrey 
tea” or “groundsel tea”. Over 200 PAs have been identified, about half of them estimated to be toxic.  
Figure 3 presents the structures of some important pyrrolizidine alkaloids including echimidine, the most 
toxic PA in Symphytum officinale; jacobine, the major toxic alkaloid in Senecio jacobaea, and retrorsine, the major 
toxic alkaloid in Senecio vulgaris. Symphytum officinale, commonly called comfrey, contains in addition to 
echimidine also other alkaloids, including intermedine, lycopsamine, symphytine, and symglandine. The total 
content of PAs is nearly 0.5% in Symphytum caucasicum, but lower in S. officinale (leaves: 0.02-0.18%; roots: 
0.25-0.29%) and S. peregrinum was found to contain about 0.2% alkaloids in the tops [26]. Aside from ingesting 
the plants directly, PAs can be consumed by eating honey collected by bees that visit PA-containing plants 
(mainly species of Senecio) and by drinking milk or eating eggs produced by animals that have consumed PA-
containing plants [26-29]. In honey originating from species of Senecio, the total concentration of PAs was 0.3-3.2 
µg/kg. PAs could be detected in the concentration range of 30-70 µg/kg in honey from the Alpine foothills of 
Switzerland [26, 27]. The range of toxic doses in humans is about 0.1-10 mg/kg bw/day [26, 29]. However, the 
World Health Organization (WHO) suggested that the lowest intake of PAs that caused adverse effects in a 
human was just 0.015 mg/kg bw/day, corresponding to 1 mg/day for a 70 kg adult, based on the use of comfrey 
[24, 26]. Exposure to PAs can vary since PA content of comfrey roots and leaves have been reported to vary 
between 450 – 8300 mg/kg for roots and between 15-55 mg/kg for leaves [26, 30]. 
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Figure 3 Schematic presentation of the general structure of pyrrolizidine alkaloids (PAs), and structural formula of some 
important PAs including echimidine, the most toxic PA in Symphytum, retrorsine, the major toxic alkaloid in Senecio vulgaris 
and jacobine, the major toxic alkaloid in Senecio jacobaea; the hepatotoxic alkaloids have a 1,2-double bond in the 
pyrrolizidine ring and branched side chains, in which the 9-hydroxyl and preferably also the 7-hydroxyl substituent are 
esterified [24] 
 
Mechanism of toxic action  
The toxic effects of PAs in humans are principally on the liver. Here they can produce veno-occlusive 
disease (VOD), the major lesion being the occlusion of the central and sublobular hepatic veins [24]. The PAs are 
also known to cause liver damage in experimental and farm animals [24]. Furthermore, PAs are known to be 
mutagenic, carcinogenic and teratogenic [24]. The mechanism of toxic action has been related to the formation of 
pyrrole-type metabolites [24, 31, 32]. These pyrrolizidine pyrroles are pyrrolic dehydro-alkaloids, formed by 
dehydrogenation of the pyrrolizidine alkaloids by hepatic monooxygenases, especially CYPs (Figure 4) [24, 32]. 
The formation of the pyrrolic metabolites results from an initial hydroxylation of the unsaturated pyrrolizidine ring 
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adjacent to the nitrogen atom, leading to an unstable intermediate that decomposes to give the pyrrolic product 
[33]. The pyrrolic dehydro-alkaloid metabolites are reactive alkylating agents able to react with cellular 
nucleophiles (Figure 4), thereby causing DNA alkylation, DNA crosslinking and liver cell necrosis [24 and 
references therein]. The carcinogenic activity of PAs appears to parallel their mutagenic behavior but not their 
hepatotoxicity [24]. In addition, upon release from the liver the pyrroles may also affect the endothelium of blood 
vessels in the liver or lungs. Hydrolysis of the ester groups of PAs by esterases and formation and excretion of 
water soluble N-oxides are detoxification mechanisms, although for some PAs N-oxidation may represent a 
bioactivation pathway [32-34]. Conjugation by cellular nucleophiles including especially glutathione is an 
important detoxification pathway for the pyrrolic dehydro-alkaloid metabolites [32, 33 and references therein]. 
 
 
Figure 4 Metabolic activation of pyrrolizidine alkaloids to pyrrolic dehydro-alkaloids, proceeding by an initial hydroxylation of 
the unsaturated pyrrolizidine ring adjacent to the nitrogen atom by cytochromes P450, leading to an unstable intermediate 
that decomposes to give the pyrrolic dehydro-alkaloid product that reacts further to an alkylating intermediate [24]  
 
Polymorphisms of influence  
Sheep, guinea pigs, gerbils, rabbits, hamsters and Japanese quail are highly resistant to pyrrolizidine 
alkaloid toxicity, whereas rats, cattle, horses and chickens are highly susceptible [32]. These species dependent 
differences in sensitivity towards pyrrolizidine alkaloids have been related to species dependent differences in the 
conversion of the PAs to their pyrrole metabolites, although species dependent differences in detoxification 
mechanisms may also play a role [32, 34]. Metabolism of PAs to dehydropyrrolizidines is catalyzed by especially 
CYP3A and CYP2B6 isoenzymes [34]. Life style factors and genetic polymorphisms known to occur in the 
CYP3A family may play a role in interindividual differences in sensitivity towards PAs. This includes for example 
induction of CYP3A4, the most important drug-metabolizing CYP in human liver, by drugs like rifampicin, 
dexamethasone and phenobarbital.  
Detoxification of the PAs to the corresponding N-oxides is catalyzed by CYPs, including CYP3A, and 
flavin containing monooxygenase [34], and detoxification of the pyrrolic metabolites by glutathione conjugation is 
catalyzed by glutathione S-transferases (GSTs). The human CYP and GST isoenzymes involved in these 
detoxification pathways largely remain to be elucidated. Elucidation of the CYPs and of the GST isoenzymes 
involved in the detoxification pathways of PAs is required to conclude what other life style factors and genetic 
polymorphisms are likely to influence the interindividual differences in sensitivity. 
 CHAPTER 3  |  53
 53 
 
Concluding remarks  
An intake of 1 mg PAs /day, the lowest dose reported to cause veno-occlusive disease in a human, 
would be reached upon intake of 0.7 grams of a herb-based preparation that contains 1520 mg/kg. This is an 
amount that may be found in capsules on the market, indicating that such a product would be too toxic to 
consume on a regular basis. On the other hand products with no detectable PAs are also encountered. Together 
this indicates that regulatory actions are required until appropriate quality control procedures are in place.  
 
 
Beta-carotene 
 
Major characteristics, occurrence and intake  
In industrialized countries, fruits and vegetables provide an estimated 1.7-3 mg/day of pro-vitamin A 
carotenoids, of which beta-carotene is the principal component [35]. Other sources of beta-carotene include food 
additives (1-2 mg/person/day) and supplements [35]. Carotenoids, including beta-carotene and others, possess 
antioxidant and radical scavenging ability [36-39]. However, experimental studies with beta-carotene, at present 
provide perhaps the best example of unexpected health risks related to increased intake levels of a bioactive 
plant ingredient. Observational epidemiologic studies indicate that diets high in carotenoid-rich fruits and 
vegetables as well as increased serum levels of beta-carotene are associated with a decreased risk of lung 
cancer [40-42]. Based on these observations large human intervention trials with heavy smokers receiving beta-
carotene supplements were undertaken [43, 44]. The studies reported increased, instead of decreased levels of 
lung cancer incidence in the population of heavy smokers receiving beta-carotene supplements for several years. 
Similar to the effects of beta-carotene on lung cancer risk in heavy smokers, an increased lung cancer risk due to 
beta-carotene supplementation in asbestos-exposed workers was also reported [43]. More recently, Baron et al. 
[45] reported increased risk on colon cancer in cigarette smokers with a high intake of beta-carotene. 
 
Mechanism of toxic action  
The mechanism by which beta-carotene increases lung cancer risk in both heavy smokers and asbestos 
workers is at present unclear, although some hypotheses and initial results have been reported. One possible 
mechanism is a co-carcinogenic effect of beta-carotene mediated through a stimulating effect of beta-carotene on 
phase I bioactivating enzymes. Induction of CYP activity by beta-carotene, in particular of CYP1A1 and CYP1A2 
(activating aromatic amines, polychlorinated biphenyls, dioxins and PAHs), CYP2A (activating butadiene, 
hexamethyl phosphoramide and nitrosamines), CYP2B1 (activating olefins and halogenated hydrocarbons) and 
CYP3A (activating aflatoxins, 1-nitropyrene and PAHs), may result in increased formation of genotoxic 
metabolites of, amongst others, cigarette smoke constituents [35]. Another possible explanation suggests that 
high dose beta-carotene supplementation may enhance lung tumorigenesis in smokers by altering retinoid 
signaling. This may proceed through the formation of reactive oxidative cleavage products of beta-carotene that 
are able to interfere with normal retinoid signaling. The high oxygen pressure in the lungs may favor this oxidative 
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degradation of beta-carotene [46]. In addition, the interaction between reactive oxygen species, derived from 
tobacco smoke or induced in the lung upon asbestos exposure, may result in beta-carotene oxidation, which 
could lead to these toxic beta-carotene metabolites [47-50]. Reduction of retinoid signaling could also occur after 
induction of CYPs, CYP1A1 or CYP1A2 in particular, by cigarette smoke and high doses of beta-carotene, 
resulting in enhanced retinoic acid catabolism in the lung [51]. A hypothesis explaining how disturbed retinoid 
signaling may result in the increased lung tumor risk is presented in Figure 5. Alterations in retinoid signaling 
could result in reduced retinoid levels and suppression of RARß gene expression, the latter representing a tumor 
suppressor gene [35, 48-51]. Furthermore the whole process may induce increased expression of c-jun and c-fos 
genes resulting in higher levels of activator protein-1 (AP-1). Increased expression of c-Jun and c-Fos proteins 
has been reported for several mitogenic stimuli and tumor-promoting agents, and has been observed in tobacco-
smoke exposed ferrets supplemented with high-dose beta-carotene [50, 51].  
Of importance to note is that these tumor-promoting effects of beta-carotene are especially observed 
upon high dose supplementation in heavy smokers. Beta-carotene does not exert this tumor risk enhancing effect 
in former smokers [43]. In asbestos workers beta-carotene oxidation may be stimulated by the inflammatory 
process known to be induced in asbestos-exposed lungs [47]. Inflammatory cells isolated from nonsmokers with 
asbestosis are known to release significantly increased amounts of reactive oxygen species compared to cells 
recovered from control individuals [52]. 
 
Polymorphisms of influence  
Depending on the actual mechanism underlying the adverse effect of beta-carotene in heavy smokers, 
different polymorphisms may be of influence. When the induction of CYPs involved in bioactivation of pro-
carcinogens proves to be an important mechanism underlying the adverse effect in smokers, genetic 
polymorphisms in CYP1A1, CYP1A2, CYP2A, CYP2B1 and CYP3A may be of relevance. A role for increased 
retinoid acid catabolism has been related to the activity of especially CYP1A1 or CYP1A2. This implies that 
genetic polymorphisms modifying the activity of these two CYPs may influence the sensitivity of heavy smokers to 
the adverse effects of beta-carotene. 
 
Concluding remarks  
Recently the SCF concluded that there might be a very small difference between the levels of beta-
carotene that may confer health benefits (up to 10 mg/day from especially natural sources), and those that may 
produce adverse effects in smokers (20 mg/day) [35]. Therefore, beta-carotene suppletion should be regarded 
with caution. Furthermore, the role of other carotenoids in the reported association between reduced incidence of 
lung cancer and increased intake of vegetables and fruits rich in carotenoids remains to be elucidated [35]. The 
SCF also concluded that the possibility that some of the oxidative cleavage products of beta-carotene could 
interfere with retinoic acid homeostasis requires further investigation [35]. 
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Figure 5 Hypotheses for the oxidative mechanism for tumor enhancement by beta-carotene [46-51] 
 
The possible role of reduced retinoid acid levels in the mechanism of beta-carotene-mediated 
enhancement of cigarette smoke-induced lung cancer, has led some investigators to the conclusion that perhaps 
restoration of lung retinoic acid homeostasis by retinoic acid supplementation or by inhibition of CYP-enhanced 
retinoid acid catabolism can have chemopreventive effects against lung carcinogenesis [51]. This is an interesting 
hypothesis that needs further study. 
 
 
Coumarin 
 
Major characteristics, occurrence and intake  
Coumarin is a constituent of cinnamon, an important food flavor. Coumarin is naturally found at high 
levels in some essential oils, such as cinnamon bark oil (7000 mg/kg), cinnamon leaf oil (40,600 mg/kg), cassia 
leaf oil (up to 83,300 mg/kg), and lavender and peppermint oil (20 mg/kg) [53]. It is also found in some fruits 
(bilberry; 0.0005 mg/kg), green tea (1.2-1.7 mg/kg) [53] and other foods, such as chicory, honey cinnamon cake 
and in ‘speculaas’, a Dutch sweet spicy biscuit (35 mg/kg) [54]. The average human exposure to coumarin from 
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the diet and from fragrance use in cosmetic products is about 0.06 (i.e. 0.02 + 0.04) mg/kg bw/day [54, 55]. The 
use of coumarin as a food flavor was discontinued as a result of the finding of hepatotoxic effects in rats and dogs 
fed with coumarin in the diet [54-56]. Coumarin was banned in the USA in 1954 based on reports of 
hepatotoxicity in rats, prior to the existence of any carcinogenicity and mutagenicity data, and was recommended 
for withdrawal from use in the UK in 1965. In 1999, the EU Scientific Committee on Food (EU-SCF) listed 
coumarin as an ‘active principle’ and set the maximum permitted concentration for coumarin in food and alcoholic 
beverages at 2 mg/kg [54]. Enforcement of this concentration means the withdrawal of many products from the 
market. 
 
Mechanism of toxic action  
Pharmacokinetic studies in humans have demonstrated that coumarin is completely absorbed from the 
gastrointestinal tract after oral administration and extensively converted by first pass metabolism in the liver, with 
only between 2 and 6% reaching the systemic circulation intact [55]. In the rat, a relatively large amount is 
excreted via the bile. Thus, an appreciable proportion of the dose is excreted in the feces. The urine appears to 
be the major route of excretion in humans. Based on animal data the EU-SCF [54] concluded that coumarin is a 
carcinogen via the oral route, resulting in adenomas and carcinomas of the liver and bile ducts and adenomas of 
the kidney in rats, and in adenomas and carcinomas of the lung and adenomas of the liver in mice.  
The major characteristics of coumarin metabolism are presented in Figure 6. The pathway leading to 7-
hydroxylation is considered a detoxification pathway and the pathway leading to formation of a coumarin 3,4-
epoxide intermediate is the toxic bioactivating route. A number of studies have demonstrated that both acute and 
chronic coumarin-induced liver injury in the rat appears to be due to the presence of the 3,4-double bond and that 
the first step in coumarin bioactivation involves the CYP-dependent formation of a 3,4-epoxide intermediate [54-
56]. A key issue in the recent risk assessment of coumarin has been the question of whether or not coumarin is 
genotoxic. Recently, the European Food Safety Authority (EFSA) reevaluated coumarin and concluded that data 
on the absence of DNA adduct formation in kidney and liver of coumarin-exposed rats indicate that coumarin 
does not bind covalently to DNA in vivo. These results suggest that coumarin induces tumors via a mechanism of 
action that is preceded by toxicity in the target organ and that this will be reflected in a dose-response curve with 
a threshold reflecting a no adverse effect level [53]. This conclusion was corroborated by the facts that coumarin 
does not induce unscheduled DNA synthesis in male SD rat hepatocytes [57] and that coumarin was negative in 
an in vivo micronucleus assay in mice [58]. Based on this threshold type dose-response curve for tumor 
formation, EFSA suggested a TDI (Tolerable Daily Intake) for coumarin of 0-0.1 mg/kg bw/day [53]. The 
mechanism of this coumarin toxicity remains to be established, but metabolites down the 3,4-epoxidation pathway 
could play a role [53-56, 59]. Coumarin 3,4-epoxide can either rearrange spontaneously to  
o-hydroxyphenylacetaldehyde (o-HPA) or conjugate with glutathione, the latter either chemically or catalyzed by 
GST-alpha or GST-mu, but not GST-pi enzymes (Figure 6) [59].  
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Figure 6 Biotransformation reactions of coumarin leading to detoxification (7-hydroxylation and 3-hydroxylation) or metabolic 
activation via the coumarin 3,4-epoxide pathway [55]; formation of coumarin 3,4-epoxide is catalyzed by especially CYP2E1, 
and, to a lower extent, by CYP1A1 and CYP1A2 [62]; 7-Hydroxylation is catalyzed by CYP2A6 [55]; coumarin 3,4-epoxide 
can either rearrange spontaneously to o-hydroxyphenylacetaldehyde (o-HPA) or conjugate with glutathione, the latter either 
chemically or catalyzed by GST-alpha or GST-mu, but not GST-pi enzymes [57]; o-HPA is hepatotoxic [60] and is further 
converted by oxidation to o-hydroxyphenylacetic acid (o-HPAA) or by reduction to o- hydroxyphenylethanol (o-HPE) 
 
o-HPA is hepatotoxic [60] and is further converted by oxidation to o-hydroxyphenylacetic acid (o-HPAA) 
or by reduction to o-hydroxyphenylethanol (o-HPE) (Figure 6) [55, 59]. Oxidation to o-HPAA is considered a 
detoxification step coupled to urinary excretion, whereas reduction to o-HPE is followed by oxidation back to o-
HPA thereby contributing to slower hepatic clearance of the hepatotoxic o-HPA [59]. Detoxification of o-HPA to o-
HPAA may even be the major determinant of species differences in coumarin-induced hepatotoxicity [59]. 
 
Polymorphisms of influence  
The extent of coumarin 7-hydroxylation appears to be species rather than dose dependent [55]. The 
major pathway of coumarin metabolism in the rat is 3,4-epoxidation, 7-hydroxylation being a minor route. The 3,4-
epoxidation is also the major route of coumarin metabolism in the mouse, although major sex and strain 
differences exist. It was demonstrated that coumarin was more toxic for C3H/HeJ than for DBA/2J mice [61]. This 
might be explained by the fact that DBA/2J strain mice have higher hepatic coumarin 7-hydroxylation than 
C3H/HeJ strain mice.  
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Unlike the rat and the mouse, where the 3,4-epoxidation pathway predominates, the major pathway of 
coumarin metabolism in humans is 7-hydroxylation. This might explain why there is little evidence of coumarin-
induced toxicity in humans given therapeutic doses of coumarin that are up to 1900 times higher than those 
obtained from dietary sources and from fragrances used in cosmetic products. In the majority of human subjects 
studied, coumarin is extensively metabolized in the liver to 7-hydroxycoumarin by CYP2A6, although humans can 
also metabolize coumarin by 3,4-epoxidation [54-56, 62]. Studies using rat and human recombinant CYP 
enzymes have pointed at the formation of coumarin 3,4-epoxide by especially CYP2E1, and, to a lower extent, by 
CYP1A1 and CYP1A2 in both species [62].  
There appears to be a marked interindividual variation in coumarin metabolism to 7-hydroxycoumarin in 
humans due to a genetic polymorphism that exists in human CYP2A6 [55, 63, 64]. The role of CYP2A6 
polymorphism in human risk profiles for coumarin remains to be elucidated. At present it is still unknown which 
pathway takes over the metabolism of coumarin in individuals with the CYP2A6 deficiency. It cannot be ruled out 
that the pathway taking over is 3,4-epoxidation, also because CYPs other than CYP2A6, such as CYP2A13, have 
been reported to be able to catalyze both coumarin 7-hydroxylation but also the formation of metabolites 
representative for the 3,4-epoxide route, both to a comparable extent [65].   
Recently, the CYP2A6 genotype and development of hepatotoxicity in patients who were dosed with 90 
mg coumarin/day have been evaluated. From 231 patients 16 appeared to be defective for the CYP2A6 
genotype, being heterozygous for the CYP2A6*2 allele that leads to an inactive protein. Of the nine patients 
showing evidence of hepatotoxicity only one had the variant allele, eight being wild-type homozygotes [66]. This 
result indicates that a single copy of a variant CYP2A6 allele does not confer susceptibility to liver dysfunction in 
patients treated with coumarin [66]. Since the conversion of o-HPA to o-HPAA is catalyzed by aldehyde 
dehydrogenase, polymorphisms known to occur in this enzyme could contribute to interindividual differences in 
sensitivity toward coumarin induced toxicity, although this remains to be demonstrated. 
 
Concluding remarks  
Recently, the European Food Safety Authority (EFSA) reevaluated coumarin and concluded that 
coumarin induces tumors via a mechanism of action that is preceded by toxicity in the target organ [53]. Based on 
this, EFSA suggested a TDI (Tolerable Daily Intake) for coumarin of 0.1 mg/kg bw/day [53]. The estimated 
theoretical maximum daily intake of coumarin via food is 4.085 mg/day (0.07 mg/kg bw/day) or lower (1.3-1.5 
mg/day which equals 0.02 mg/kg bw/day), given a more realistic intake scenario [53, 55]. These intake scenarios 
are below the TDI, suggesting that withdrawal of products from the market would no longer be an issue.   
 
 
Alkenylbezenes: safrole, methyleugenol and estragole 
 
The group of alkenylbenzenes includes compounds like safrole, methyleugenol and estragole (Figure 7), 
which are important constituents of herbs like nutmeg, cinnamon, anise star, tarragon, sweet basil, sweet fennel 
and anise vert. The EU-SCF has launched scientific evaluations on these three alkenylbenzenes [67-69]. The 
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EU-SCF concluded that safrole, methyleugenol and estragole are genotoxic and carcinogenic, and indicated 
restrictions in use. Recently, however, an industrial expert panel from the Flavor and Extract Manufacturers 
Association (FEMA) published that exposure to methyleugenol and estragole, resulting from spice consumption, 
does not pose a significant cancer risk for humans [70]. The mechanistic argument underlying this conclusion 
relates to insight in the toxicokinetics and the mechanism of genotoxicity of the alkenylbenzenes.  
 
 
Figure 7 Structure of the alkenylbenzenes safrole, methyleugenol and estragole 
 
 
Alkenylbezenes: estragole 
 
Major characteristics, occurrence and intake  
Estragole occurs naturally in a variety of foods including tarragon (60-70% of essential oil), sweet basil 
(20-43% of essential oil), sweet fennel (5-20% of essential oil), anis vert (1% of essential oil), and anis star (5-6% 
of essential oil [69]. There are several food categories to which estragole could be added. For alcoholic 
beverages, canned fish, and fats and oils, estragol levels may amount to 100 mg/kg (approximately 4% of the 
market share), 50 mg/kg (approximately 30% of the market share) and 250 mg/kg (approximately 1% of the 
market share), respectively [69]. Based on these assumptions, the average daily intake from food was estimated 
to amount to 4.3 mg/person/day and the 97th percentile to 8.7 mg/person/day [69]. 
 
Mechanism of toxic action  
Figure 8 presents an overview of the relevant metabolic pathways of estragole, which is also 
representative for the metabolic profiles of methyleugenol and safrole. The CYP-derived metabolite 1'-
hydroxyestragole is the putative proximate carcinogen of estragole. It has been found in the urine of men dosed 
with 1 µg estragole/kg bw [71]. The ultimate electrophilic and carcinogenic metabolite of estragole is formed as a 
result of sulfotransferases converting 1'-hydroxyestragole to 1'-sulfooxyestragole [72]. Another major metabolic 
pathway of estragole in rats, mice and humans includes O-demethylation. At higher doses the proportion of O-
demethylation falls and the pathway leading to formation of 1'-hydroxyestragole increases (from 1.3-5.4% of the 
dose in the range of 0.05-50 mg/kg bw to 11.4-13.7% in the dose range of 500-1000 mg/kg bw for rats and mice) 
[73, 74]. Thus, it appears that the 1’-hydroxylation pathway is more prominent at higher levels of exposure.  
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Figure 8 Metabolic pathways for bioactivation and detoxification of estragole (also relevant for methyleugenol and safrole) 
[67-69] 
 
The FEMA USA Expert Panel even concluded that at low dose (100 µg/person which amounts to 1.5 µg/kg bw), 
human production of the 1’-hydroxy metabolite is expected to be very low given that urinary excretion of the 1’-
hydroxy metabolite is below 0.5% of the dose administered. This relative decrease in conversion to the proximate 
carcinogenic metabolite at lower doses, was an important argument for the FEMA USA Expert Panel to conclude 
that exposure to methyleugenol and estragole resulting from spice consumption does not pose a significant 
cancer risk for humans [70].  
In addition to formation of 1’-hydroxyestragole, formation of estragole-2',3'-oxide and 1'-
hydroxyestragole-2',3'-oxide (Figure 8) provide possible additional bioactivation pathways of estragole [75]. The 
estragole metabolites estragole-2',3'-oxide and 1'-hydroxyestragole-2',3'-oxide have been shown to be 
hepatocarcinogenic [72, 76] and to produce DNA adducts in vitro [77-79]. However, adducts of these 2’,3’-oxides 
were not among the major adducts found in mouse liver following in vivo administration of estragole [79]. 
Therefore it is concluded that they do not contribute significantly to the genotoxicity of estragole. The apparent 
absence of a role for estragole epoxidation in the genotoxicity of estragole has been ascribed to very rapid and 
efficient detoxification of the 2’,3’-oxides in the cell by a combination of epoxide hydrolases and glutathione S-
transferases [75]. 
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Polymorphisms of influence  
Human CYPs involved in the bioactivation of estragole to 1'-hydroxyestragole have not been identified. 
They may be in line with CYPs found to be involved in bioactivation of the related alkenylbenzenes 
methyleugenol and safrole, discussed below. Glucuronidation of 1’-hydroxyestragole catalyzed by uridine 
diphosphate glucuronosyltransferase (UGT) isoenzymes is a detoxification pathway and was recently shown to 
be catalyzed by human UGT2B7, UGT1A9 and UGT2B15 [80]. The UGT2B7 polymorphisms, leading to slow 
glucuronidators, may potentially lead to differences in toxicity of estragole. Life style factors, like concomitant 
chronic intake of therapeutic drugs and dietary components which increase the levels of UGT2B7 expression or 
which are substrates for UGT2B1 or UGT1A9, might also modify the relative risk [80]. Human CYPs of relevance 
for the detoxification pathways, and the type of sulfotransferases involved in the bioactivation to the ultimate 
electrophilic and carcinogenic metabolite 1'-sulfooxyestragole remain to be elucidated. 
 
Concluding remarks  
The EU-SCF concluded that estragole is genotoxic and carcinogenic, and indicated restrictions in use 
[74]. This will result in restrictions in use for the compound itself, but not for estragole containing herb extracts. 
Improved risk extrapolation from high dose animal experiments to low dose carcinogenic risks in man, taking into 
account the toxicokinetics of the CYPs responsible for the different biotransformation pathways, seems to be a 
prerequisite for future improvement of risk estimates for this alkenylbenzene.  
 
 
Alkenylbezenes: methyleugenol 
 
Major characteristics, occurrence and intake  
Methyleugenol is a natural constituent of a number of plants including nutmeg, pimento, lemongrass, 
tarragon, basil, star anise and fennel [68]. The compound is also used as a flavoring agent in jellies, baked 
goods, non-alcoholic beverages, chewing gums, relish and ice cream, and as a fragrance in several cosmetic 
products [68]. Intake estimates may vary widely because of lack of data about the concentration of the chemical 
in foodstuffs [68]. Intake estimates reported by the EU-SCF amount to an average intake for consumers of 13 
mg/person/day and a 97th percentile of 36 mg/person/day [68]. 
 
Mechanism of toxic action  
The metabolism and metabolic activation of methyleugenol proceeds similar to that depicted in Figure 8 
for estragole. Methyleugenol and its proximate carcinogenic metabolite 1'-hydroxymethyleugenol induce liver 
tumors in mice and rats [76, 81]. In addition, especially at higher doses, neuroendocrine tumors of the glandular 
stomach, as well as renal tube hyperplasia and adenomas were observed. In vitro, methyleugenol as well as its 
metabolites 1'-hydroxymethyleugenol and methyleugenol-2',3'-oxide induce unscheduled DNA synthesis (UDS) in 
cultured rat hepatocytes [82]. Howes et al. [83] reported an excellent correlation between UDS induction in rat 
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hepatocytes and results from rodent carcinogenicity studies for methyleugenol and also for related 
alkenylbenzenes like estragole and safrole. 
In addition, methyleugenol has been shown to form adducts with DNA and protein in human fibroblasts 
V79 cells transfected with human genes expressing sulfotransferases and in the mouse liver in vivo [84-86]. The 
adduct formation with methyleugenol (72.7 pmol/mg DNA) was higher than that induced by estragole (30.0 
pmol/mg DNA) or safrole (14.7 pmol/mg DNA)[86]. This order is in line with the relative differences in dose 
regimens required to induce tumors in animal studies, known to decrease in the order safrole > estragole > 
methyleugenol [67-69]. These observations, together with the fact that estimated daily intakes of methyleugenol 
(13 mg/person/day) [68] are higher than those estimated for estragole (4.3 mg/person/day) [69] and safrole (0.3 
mg/person/day) [67], seem to put the priority for risk management on methyleugenol. 
 
Polymorphisms of influence  
Recent studies revealed human CYP1A2 and CYP2C9 to be important isoenzymes in the conversion of 
methyleugenol to 1'-hydroxymethyleugenol, with CYP2D6 and CYP2C19 perhaps also involved in methyleugenol 
1ʹ′-hydroxylation [87]. The interindividual differences found in fifteen human liver microsomes were larger (5-fold 
difference) than the interspecies and sex differences found in the incubations with microsomes prepared from 
pooled livers of male and female rats, mice, and humans (2-fold difference) [87]. Therefore, interindividual 
differences in methyleugenol 1ʹ′-hydroxylation seem to be at least as important as interspecies differences 
between rodents and humans. In particular people that smoke (induction of CYP1A2), use barbiturates (induction 
of 2C9), or have polymorphisms especially in the CYP2D6 gene leading to ultra rapid metabolizer phenotypes 
might have a higher methyleugenol 1ʹ′-hydroxylation rate. These groups of people might be at higher risk of the 
adverse effects of exposure to methyleugenol. Polymorphisms in CYP2C9 and CYP2D6 leading to poor 
metabolizer phenotypes may reduce the relative risk. 
 
Concluding remarks.  
As for estragole, methyleugenol may be converted to a variety of metabolites with different toxicological 
impact. Identification of the biotransformation enzymes involved in the various bioactivation and detoxification 
pathways and the implementation of their toxicokinetics into risk assessment models seems to be required for 
improved methods for extrapolation from high dose animal experiments to low dose carcinogenic risks in man.   
 
 
Alkenylbezenes: safrole 
 
Major characteristics, occurrence and intake  
Similar to estragole and methyleugenol, safrole is a natural constituent of a number of spices such as 
nutmeg, mace, cinnamon, anise, black pepper and sweet basil. The most important dietary sources are nutmeg, 
mace and their essential oils. Safrole is also present in cola drinks. Safrole was the first of the class of 
alkenylbenzenes shown to have carcinogenic properties [88]. An exposure assessment was made based on a 
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selection of 28 food categories assuming a concentration of 0.5 mg safrole/kg for food in general, a concentration 
of 2 mg/kg for food containing cinnamon and of 5 mg/kg for food containing nutmeg. For beverages, canned fish 
and chewing gum the following concentrations were specified: beverages 5 mg/kg (4% of the market share), 
canned fish 20 mg/kg (30% of the market share), and chewing gum 10 mg/kg (2% of the market share). Using 
these assumptions the estimated average intake for consumers was calculated to amount to 0.3 mg/person/day 
and the 97th percentile to 0.5 mg/person/day [67]. 
 
Mechanism of toxic action  
Chronic administration of safrole in the diet at 0.5-1.0% for a year or more caused liver tumors in adult 
mice and rats [72, 76, 89, 90]. The carcinogenicity of safrole metabolites, namely 1'-hydroxysafrole, safrole-2',3'-
oxide and 1'-hydroxysafrole-2',3'-oxide was also clearly demonstrated [72, 76]. The main metabolic pathways are 
allylic hydroxylation to 1'-hydroxysafrole and oxidation and O-dealkylation, the latter leading to 4-allylcatechol that 
is easily oxidized to 4-allyl-o-quinone (Figure 9), and epoxidation of the allylic side chain or the aromatic ring. 1’-
Hydroxysafrole and 4-allylcatechol represent the main metabolites. 1’-Hydroxysafrole can be conjugated by 
sulfotransferases giving rise to a conjugate that can easily split producing the ultimate carcinogenic electrophilic 
carbonium ion (Figure 8). In addition, oxidation of 4-allylcatechol to 4-allyl-o-quinone may also generate an 
electrophilic toxic metabolite [91](Figure 9). Safrole-DNA adducts were identified in livers of mice given cola 
beverages instead of drinking water [92]. Inhibition of both DNA adduct formation and carcinogenicity of 1'-
hydroxysafrole was shown in the liver of mice deficient in synthesis of PAPS the cofactor required for 
sulfotransferase reactions, or mice treated with pentachlorophenol, a strong inhibitor of sulfotransferases [93]. 
 
 
 
Figure 9 Alternative bioactivation pathway for safrol leading to formation of catechol and quinone-type metabolites [91] 
 
Polymorphisms of influence  
The CYP enzymes involved in the bioactivation of safrole to its proximate carcinogen 1ʹ′-hydroxysafrole 
in man were identified to be CYP2C9, CYP2A6, CYP2D6 and CYP2E1 [94, 95]. Data from Gentest microsomes 
in which the activities towards enzyme-selective substrates are considered to be in the same order as the mean 
activities found in human liver microsomes, reveal CYP2A6 to contribute about two times more than the other 
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CYPs that are active in safrole 1’-hydroxyation [94]. Because CYP2C9, CYP2A6 and CYP2D6 are polymorphic 
[96], the bioactivation of safrole to 1’-hydroxysafrole in man is expected to be influenced by polymorphisms in 
these CYPs. Polymorphisms in CYP2C9, CYP2A6 and CYP2D6, leading to poor metabolizer phenotypes, may 
reduce the relative risk on the harmful effects of safrole, whereas life style factors like the use of alcohol, an 
inducer of CYP2E1 and barbiturates, inducers of CYP2C9 and polymorphisms in CYP2D6 and CYP2A6 leading 
to ultra rapid metabolizer phenotypes, may increase the relative risk. 
 
Concluding remarks  
As for estragole and methyleugenol, safrole may be converted to a variety of metabolites with different 
toxicological impact. Identification of the biotransformation enzymes involved in the various bioactivation and 
detoxification pathways and the implementation of their toxicokinetics into risk assessment models seem to be 
required for improved methods for extrapolation from high dose animal experiments to low dose carcinogenic 
risks in man.   
 
 
Ephedrine alkaloids 
 
Major characteristics, occurrence and intake  
Herbs like Ephedra sinica, Ephedra intermedia and Ephedra equisetina, also known by their Chinese 
name “Ma Huang”, contain so-called ephedrine alkaloids, among which ephedrine (Figure 10) is the dominant 
one. Other ephedrine alkaloids present include pseudo-ephedrine, nor-ephedrine, methylephedrine, 
methylpseudo-ephedrine and norpseudo-ephedrine. Certain dietary supplements also include ephedra, with the 
most popular uses being for improvement of weight loss and athletic performance [97]. Ephedrine, pseudo-
ephedrine, and related alkaloids are found in the herb Ma Huang at levels usually up to around 0.5 to 2.5 percent 
in total [98]. In Ma Huang sold as a powdered herb as well as in standardized extracts, total alkaloid levels may 
range from 6 to 8 percent, with one product even containing 12 percent [99]. Of the products tested by FDA, the 
mean contained 21.4 mg per dose [99]. 
 
Mechanism of toxic action  
The chemical structure of ephedrine resembles that of the neurotransmitter adrenalin (= epinephrine) 
(Figure 10). The mechanism of action of ephedrine alkaloids is based on this structural similarity. As adrenalin 
agonists, these alkaloids produce a sympathomimetic response, characterized by increased heart rhythm, 
hypertension (elevated blood pressure) and central nervous system stimulation [100-102]. 
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Figure 10 Structure of ephedrine, the major ephedrine alkaloid in ephedra, of adrenalin, the neurotransmitter towards which 
ephedrine acts an an agonist, and of synephrine, another adrenalin agonist 
 
Doses higher than 50 mg/day/adult may cause heart palpitations, nausea, dizziness, headache, 
sweating, neuropathy (nerve damage) and tremors. The stimulating effect on the central nervous system can also 
result in loss of appetite, insomnia, nervousness, seizures and euphoria. At doses above 500 to 1000 mg 
ephedrine the effects observed are nausea, vomiting, fever, psychoses, spasms, convulsions, respiratory 
disorders, coma, heart attack and death. A dose of 2000 mg/adult is considered lethal. Chronic exposure to 
ephedrines may cause behavioral disturbances and psychoses. Several case reports on the toxicity of ephedrine-
containing herb preparations have been described, some of them with fatal outcome [97].  
Exposure to ephedrine, which is an adrenaline agonist, in combination with drugs known to inhibit mono-
amine oxidase (MAO) can cause an increased risk on adverse effects. This because the MAO inhibitors block the 
degradation of adrenalin by MAO, thereby increasing the adrenalin concentration and stimulating the adrenergic 
neurotransmitter system. Likewise, coexposure with caffeine also has a synergistic effect on the action of 
ephedrine. Caffeine inhibits phosphodiesterase, the enzyme that hydrolyses cAMP, the second messenger of 
adrenalin mediated signal transduction. This also stimulates cholinergic neurotransmission. 
 
Polymorphisms of influence  
Biodegradation of ephedrine alkaloids may proceed similar to that of adrenalin, by oxidative deamination 
catalyzed by MAO. Genetic polymorphisms of influence on ephedrine alkaloid toxicity may thus be found at the 
level of this biodegradation enzyme and/or at the level of the adrenergic receptors for which polymorphisms have 
been described [103]. 
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Concluding remarks  
Recently most countries installed a ban on the use of ephedrine alkaloids in food supplements or other 
foods. This rule seems to reflect the scientific evidence showing that ephedra poses an unreasonable risk to 
consumer health. 
 
 
Synephrine 
 
Major characteristics, occurrence and intake  
Synephrine is the main active principle found in the fruit of several Citrus species including Citrus 
aurantium and Citrus reticulata [104]. In Traditional Chinese Medicine (TCM) the fruit is also known as Chih-shih. 
Synephrine occurs in all citrus products in very low concentrations (0.1-2.0%) with 0.25% representing an 
average value [105]. It is consumed by humans through a citrus fruit containing diet. 
 
Mechanism of toxic action  
Synephrine is chemically very similar to ephedrine (Figure 10). Both compounds act on the nervous 
system in a similar way [106, 107]. Synephrine is a drug in Europe (oxedrine; Sympatol) produced for use as a 
sympathomimeticum. It acts as a cardiac performance enhancer [108].  
 
Polymorphisms of influence  
See remarks made for ephedrine alkaloids. 
 
Concluding remarks  
After the FDA banned ephedra, diet-pill companies tried to find a possibly safer alternative turning to 
synephrine. Whether synephrine may act with potentially fewer side effects, like high blood pressure and 
increased heart rate, remains to be established. Consumers having high blood pressure or other heart problems 
should better not use any of these substances. 
 
 
Kavalactones 
 
Major characteristics, occurrence and intake  
The rootstock of the kava (Piper methysticum) plant contains a mixture of lipid soluble alpha-pyrones, 
also called kavapyrones or kavalactones. Pharmacologic activity of kava-kava has been related to six important 
kavalactones, kawain, 7,8-dihydrokawain, 5,6-dehydrokawain, methysticin, dihydromethysticin and yangonin 
(Figure 11). High quality kava rhizomes contain 5.5-8.3% kavalactones. Medicinal extracts used in Europe 
contain 30-70% kavalactones.  
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Figure 11 Structures of the major kavalactones from kava-kava 
 
Mechanism of toxic action  
Extracts containing high concentrations of kavalactones, at three times 100 mg doses of kava extract 
standardized to 70% kavalactone content a day, are used for the treatment of anxiety and depression and are 
claimed to have a calming effect and induce a state of happiness [109, 110]. Through their action on the nervous 
system they exert sedative, analgesic, anticonvulsant and muscle relaxant effects. The exact mechanism of 
action for this beneficial effect is not exactly known. Results from animal experiments suggest mechanisms that 
include inhibition of MAO activity, inhibition of noradrenalin reuptake in the presynaptic neuron and/or action as a 
dopamine antagonist [111, 112].  
The major toxic side effects of kava-kava are dermopathy [113-115] and liver toxicity [116-123]. Since 
1999, cases of severe hepatic toxicity in people using kava-containing herbal products have been reported in 
Europe and the United States [120, 124], including several cases in which patients required liver transplantation 
following the use of kava-containing products [124]. Liver damage has been reported at intake levels of 60-120 
mg kavalactones/day for as short as 14 days. Potential mechanisms underlying the liver toxicity have been 
related to glutathione depletion or quinone formation [125, 126]. Glutathione was reported to bind irreversibly with 
kavalactones by a Michael type addition, resulting in opening of the lactone ring (Figure 12A) [125], and high 
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doses of kavalactones may lead to rapid depletion of GSH followed by toxicity of the lactones to the GSH 
depleted liver cells [125].  
 
 
Figure 12 Reactions underlying possible mechanisms for kavalactone induced liver toxicity, including A) glutathione 
depletion and B) electrophilic quinone formation [125, 126] 
 
For kavalactones containing a methylenedioxyphenyl moiety, such as methysticin and 
dehydromethysticin, another mechanism may become relevant. CYP catalyzed O-dealkylation of the 
methylenedioxyphenyl moiety may generate a catechol moiety that may subsequently be oxidized to the 
corresponding electrophilic o-quinone (Figure 12B) [126]. The CYP isoenzyme(s) catalyzing this bioactivation 
have not been identified. Alternatively, it has been suggested that kava alkaloids, rather than kavalactones may 
be responsible for the hepatotoxicty [127]. 
 
Polymorphisms of influence  
Phenotyping of CYP2D6 activity with debrisoquine in two patients who developed clinical symptoms 
upon kavalactone ingestion revealed that both were poor metabolizers of debrisoquine. Since the local 
prevalence of CYP2D6 deficiency was 9%, the probability that two consecutive patients would be deficient was 
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reported to be less than 0.01% and it was concluded that these data suggest that CYP2D6 deficiency is a risk 
factor for hepatotoxicity due to kavalactones [128]. 
 
Concluding remarks  
Several case studies linking kava-kava to liver damage prompted several governments to remove kava-
kava extracts from the market. Although it seems generally accepted that kava-kava can be an effective 
symptomatic treatment option for anxiety [110, 129] the present advices are that these herbal preparations should 
not be used until the mechanism for hepatotoxicity is clearly ascertained [129]. 
 
 
Anisatin 
 
Major characteristics, occurrence and intake  
The spice Chinese star anise (Illicium verum) is used in many cultures, mostly for preparing tea. In 
Southern European countries (France, Spain) star anise is also used against intestinal complaints in children. 
Recently health problems have been observed due to the use of herb tea containing star anise [130]. In 
September 2001, in the Netherlands, more than 60 persons showed nausea and vomiting, after drinking a herbal 
tea called starmix tea, 22 persons were hospitalized due to tonic-clonic insults [131]. EEGs showed epileptiform 
abnormalities indicating a diffuse cerebral disease [132]. The complaints were ascribed to a toxic star anise 
species comparable to Japanese star anise (Illicium anisatum), which was accidentally exchanged for the non-
toxic Chinese staranise (Illicium verum) [131]. NMR analysis of this star anise species revealed the presence of 
anisatin. Anisatin is a sesquiterpenoid (Figure 13) causing numerous other symptoms like lower heartbeat and 
hallucinations. Because of the latter the Japanese star anise is also called Illicium religiosum. 
 
 
Figure 13 Structure of anisatin and of the neurotransmitter gamma-aminobutyric acid (GABA) for which anisatin is a 
competitive antagonist 
 
Mechanism of toxic action  
Anisatin acts as a non-competitive gamma-amino butyric acid (GABA)-antagonist that can cause tonic-
clonic insults [133]. GABA (Figure 13) is the most common message-altering neurotransmitter in the brain and 
produces stop-signals. It is known that abnormal levels of GABA unbalance the brain's message delivery system 
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causing a seizure or epileptic attack. Most of the new developments of epilepsy drugs stem from the discovery of 
GABA.  
 
Polymorphisms of influence  
There is no information available. 
 
Concluding remarks  
Illicium verum has been considered safe for consumption but it contains veranisatins in very low 
concentrations [134]. Taken the fact that relatively small quantities in infants may be sufficient to produce adverse 
neurologic reactions and the chances on possible adulteration of Illicium verum with Illicium anisatum, one could 
recommend against administering star anise to children [135].   
 
 
St. John’s wort  
 
Major characteristics, occurrence and intake  
The herbaceous plant St. John’s wort (Hypericum perforatum) is a member of the Hypericaceae family. 
The fresh plant contains up to 0.3% naphthodianthrones, including up to 0.09% hypericin and 0.23% 
pseudohypericin (Figure 14). The content of the phloroglucinol compound hyperforin (Figure 14) ranges from 2.0-
4.5% of the fresh plant. Adhyperforin (Figure 14), another phloroglucinol compound, comprises 0.2-1.8% of the 
plant. Phloroglucinols are structurally related to the bitter substances in hops. The phloroglucinols and 
naphthodianthrones are mainly localized in the flowers and buds. Other constituents include flavonols (e.g. 
kaempferol, quercetin), flavonoid glycosides (hyperoside, rutin) and biflavonoids (biapigenin) [136-139].   
 
 
Figure 14 Structures of the major active ingredients from St. John’s wort 
 
St. John’s wort is widely used as a treatment for depression. In the United States most St. John’s wort is 
used without medical supervision. Results of a meta-analysis study in 1996 suggested that hydroalcoholic  
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extracts of St. John’s wort were superior to placebo for treatment of mild to moderate depression [140]. 
Subsequent studies suggested that St. John’s wort is comparable to amitryptiline, imipramine, and fluoxetine. 
However, questions have been raised about methodological limitations of these studies. A double blind, 
randomized, placebo-controlled trial showed no efficacy of St. John’s wort in moderately severe major 
depression. In this 8-week parallel-group study 340 patients received daily doses of 900-1500 mg of the 
standardized St. John’s wort extract LI-160, 50-100 mg of sertraline or placebo. Neither agent was superior to 
placebo on the 2 primary outcome measures for which the HAM-D total score and a combination of the HAM-D 
total score and the CGI score were used. Sertraline performed better than placebo on the secondary measure 
CGI- improvement scale [141]. Several studies indicate that St. John’s wort extracts inhibit synaptosomal uptake 
of serotonin, dopamine and noradrenalin. Results of an in vitro study suggested that hyperforin is responsible for 
the inhibition of serotonin uptake [142]. 
 
Mechanism of toxic action  
Side effects of treatment with St. John’s wort tend to be mild and include swelling, anorgasmia and 
frequent urination [141]. Several cases of increased sensitivity to sunlight following use of St. John’s wort were 
reported. These reactions however are rare and may be encountered following prolonged exposure at high or 
very high doses [139]. In a study on the antiviral effects of hypericin, in patients with chronic hepatitis C virus 
infections, 5 of 12 subjects receiving 0.05 mg/kg bw/day orally for 8 weeks and 6 of 7 subjects receiving 0.10 
mg/kg bw/day developed phototoxic reactions. In both groups paresthesias were the most common reactions 
followed by dermatitis. In the high dose group darkened coloration and pruritic nodules were also reported. Apart 
from these effects no other serious adverse events were reported [143]. Similar phototoxic reactions were found 
in a study when intravenous hypericin was given to HIV-infected patients [144]. One could hypothesize that 
individuals with certain virus infections are more prone to develop phototoxic reactions to hypericin. 
Of concern is the capability of St. John’s wort to interact with certain drugs. In 1999, a review of available 
literature published in the Lancet [145] raised questions regarding the safety of St. John’s wort when used 
concomitantly with various prescribed drugs. This review discussed 8 cases of interactions between St. John’s 
wort and concomitant medications. The drugs for which interactions of St. John’s wort are of concern are drugs 
that are metabolized by hepatic CYP enzymes. This is because ingredients in St. John’s wort induce specific CYP 
activities involved in drug inactivation. Because of CYP induction plasma concentrations of certain drugs can 
become subtherapeutic [145]. Subsequently, the European Agency for the Evaluation of Medicinal products 
issued a warning for this potential effect of St. John’s wort [146].   
 
Polymorphisms of influence  
Recently, the effect of St. John’s wort on the activity of different CYP2C19 genotypes was studied by 
investigating mephenytoin pharmacokinetics in 12 healthy subjects by administering a single dose of the drug 
after two weeks of St. John’s wort treatment [147]. Mephenytoin is almost exclusively metabolized by CYP2C19. 
Treatment with St. John’s wort significantly increased mephenytoin metabolism in 6 wild-genotype CYP2C19*1/*1 
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subjects. The other 6 subjects which were homozygous for CYP2C19*2 or heterozygous for CYP2C19*2/*3 were 
found to be poor metabolizers of mephenytoin. In the poor metabolizers, St. John’s wort exerted no significant 
effect on mephenytoin metabolism. St. John’s wort administration did not significantly alter CYP1A2 activity 
determined by measuring caffeine metabolism [147]. When the effect of St. John’s wort on the metabolism of 
amitriptyline and its metabolites was studied no correlation between CYP2D6, 2C9 or 2C19 genotype and 
amitriptyline pharmacokinetics could be observed [148]. 
In humans, one case of reduced plasma concentrations of theophylline, a drug metabolized by CYP1A2 
and combined use of St. Johns wort was reported. However, a study of 12 healthy subjects taking a single dose 
of theophylline after two weeks of St. John’s wort use failed to show significant changes in theophylline plasma 
concentrations compared to theophylline plasma concentrations without treatment with St. John’s wort [149]. CYP 
3A4 and CYP 3A5, members of the CYP 3A subfamily, are the most abundantly expressed CYP enzymes in the 
liver and gastrointestinal tract of humans. They metabolize more than 120 frequently prescribed drugs [150]. A 
study in mice showed that St. John’s wort induced the CYP3A subfamily and that hyperforin played an important 
role in this effect [151]. When human hepatocytes were treated in vitro with hyperforin and St. John’s wort, 
expression of CYP3A4 was markedly increased by either treatment. Hyperforin accounted for much of the effect 
of St. John’s wort in this study [152]. By contrast, treatment of rats for 10 days with St. John’s wort failed to show 
an increased expression of hepatic CYP3A. Amounts of CYP1A2, multidrug resistance protein 2 (MRP2) and 
glutathione S-transferase-pi (GST-pi) however were increased up to respectively 357%, 304% and 252% of 
controls in the liver of rats exposed for 10 days to 400 mg St. John’s wort suspension/kg bw/day estimated to be 
an antidepressant effective dose in rats [153].   
A systemic review of clinical trials concerning interactions of St. John’s wort with prescribed drugs 
revealed that of 19 trials for which drug plasma data were available, 17 found a decrease in the systemic 
bioavailability of the drug upon coadministration with St. John’s wort [154]. Cotreatment with St. John’s wort was 
shown to reduce plasma concentrations of the antineoplastic agent irinotecan by 42% [155]. In healthy volunteers 
St. John’s wort reduced the area under the curve in plasma of the HIV-1 protease inhibitor indinavir by 57% [156]. 
Two cases of acute rejection in heart transplant patients were reported where St. John’s wort was used 
concomitantly with the immunosuppressive agent cyclosporin [157]. Other drugs affected by St. John’s wort are 
the tricyclic antidepressants amitriptyline and it’s metabolite nortriptyline, digoxin, ethinylestradiol and warfarin 
[145, 148, 158-160]. Table 1 presents an overview of examples of interactions of St. John’s wort with drugs [145, 
147, 148, 155-165]. There have been reports on pharmacodynamic interactions of St. John’s wort with drugs. 
Combined use of St. John’s wort with serotonin reuptake inhibitors, antidepressant drugs by 5 elderly patients 
resulted in symptoms characteristic of central serotonin excess. These symptoms include changes in mental 
status, tremor, gastrointestinal upset, headache, myalgia and restlessness [145].   
 
Concluding remarks  
Evidence of interactions of St. John’s wort with an increasing number of commonly used medicines is 
growing and more attention is required to prevent adverse effects of concomitant use of St. John’s wort and 
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drugs. When used properly this drug can be used safely. Medical staff should routinely ask patients for self-
medication with St. John’s wort and other herbs. Governmental bodies need to focus on prevention measures 
including communication of risks of interactions of certain food supplements with medicines to the general public. 
 
Table 1 Examples of interactions of St. John’s wort with drugs 
Drug Drug type Result of interaction Possible mechanism Ref. 
Cyclosporine Immunosuppressant Reduced plasma 
concentration 
Induction of CYP3A4 or P-
glycoprotein 
[157,158, 
161]   
Tacrolimus Immunosuppressant Decreased tacrolimus 
AUC 
Induction of CYP3A or P-
glycoprotein 
[162] 
Digoxin Cardiovascular drug Reduction of digoxin 
AUC 
Induction of CYP3A or P-
glycoprotein 
[160] 
Ethinyl oestradiol/ 
dienogesterol and 
other 
contraceptives 
Oral contraceptive Unexpected pregnancy, 
intermenstrual bleedings 
Induction of CYP3A4 [159, 163] 
 
Indinavir HIV-1 protease inhibitor Reduced plasma 
concentration 
Induction of CYP3A4 [156] 
Irinotecan Antineoplastic agent Reduced plasma 
concentration 
Induction of CYP3A4 [155] 
Mephenytoin Anticonvulsant Increased urine 
clearance of metabolite 
Induction of CYP2C19 [147] 
Warfarin Anticoagulant Reduced anticoagulant 
effect 
Induction of CYP2C9 [159] 
Amitriptyline, 
Nortriptyline 
Tricyclic antidepressants Reduced plasma 
concentration 
Induction of cytochrome P-
450, mainly CYP3A4 or P-
glycoprotein 
[148] 
Buspirone Anti anxiety drug Serotonin syndrome Overstimulation of 5-HT 
receptors 
[164] 
Nefazodon, 
Sertraline 
Selective serotonin reuptake 
inhibitor antidepressants 
Manic episodes, central 
serotonin excess 
Overstimulation of 5-HT 
receptors 
[145, 165] 
 
 
Cyanogenic glycosides 
 
Major characteristics, occurrence and intake  
Cyanogenic glycosides are present in a number of food plants and seeds and include compounds like 
amygdalin, dhurrin, linamarin, linustatin, lotaustralin, neolinustatin, prunasin, sambunigrin and toxiphyllin. Figure 
15 presents some relevant cyanogenic glycosides including linamarin, present in the roots of cassava (Manihot 
esculenta) at levels of 10-1120 mg HCN (free and bound)/kg, as well as in Lima bean seeds (Phaseolus lunatus) 
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at levels of 100-3000 mg HCN (free and bound)/kg, dhurrin from sorghum, and amygdalin, a natural substance 
found in seeds of apples and pears, as well as in the leaves, fruit and seeds of black cherry, almond, cherry, 
plum, peach and apricot trees at levels that may be as high as 300-4000 mg HCN (free and bound)/kg [166]. 
Holzbecher et al. [167] report that apricot seeds contain 2.92 mg/g HCN and peach seeds contain 2.60 mg/g 
HCN, while apple seeds contain only 0.61 mg/g HCN. The mean and 97th percentile overall daily intake of HCN 
have been estimated to be about 46-95 and 214-372 µg/person which corresponds to 0.7-1.4 and 3.3-5.4 µg/kg 
bw/day [166]. Food products containing relatively high levels of HCN (free and bound) are almonds and/or 
marzipan containing confectionery and baked goods, that may contain levels up to 40 mg/kg, with raw marzipan 
paste containing the highest level of 50 mg HCN (free and bound)/kg [166]. 
 
 
Figure 15 Examples of three important cyanogenic glycosides, linamarin from cassava, dhurrin from sorghum and amygdalin 
from, for example, apricot kernels and apple kernels 
 
Mechanism of toxic action  
Cyanogenic glycosides are a cause of concern, because once ingested they are metabolized to 
hydrogen cyanide (HCN). Hydrogen cyanide is released from the cyanogenic glycosides by plant beta-
glucosidases, which come into contact with the cyanogenic glycosides when fresh plant material is macerated as 
in chewing, or by beta-glucosidases present in the gut flora. Figure 16A presents the hydrolysis of amygdalin to 
HCN in the gastrointestinal tract. It is a two-step process catalyzed by the enzymes beta-glucosidase (produced 
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by intestinal bacteria) and hydroxynitrile lyase [168]. The cyanogenic glycosides, linamarin and lotaustralin from 
cassava are converted to HCN in the presence of linamarase, a naturally occurring enzyme in cassava. 
Linamarase acts on the glycosides when the cells are ruptured. Cassava is an important source of carbohydrate 
for people in Africa and South America. The toxic ingredients are detoxified by hydrolysis through chopping and 
grinding in running water prior to preparation [169].  
 
Figure 16 Enzymatic conversion of amygdalin to cyanide (A), and conversion of cyanide by rhodenese generating 
thiocyanate (B) 
 
Cyanide causes toxic effects by binding to cytochrome oxidase the terminal enzyme in the mitochondrial 
electron transport chain. By hampering the generation of ATP and oxygen utilization, a histotoxic anoxia is 
produced. In small doses, the body can detoxify cyanide. In man, cyanide (CN-) is detoxified by conversion in the 
liver to thiocyanate by rhodanese (Figure 16B), by direct chemical combination with sulphur containing amino 
acids or by combination with hydroxycobalamine. Methaemoglobin effectively competes with cytochrome oxidase 
for cyanide and the formation of methaemoglobin from hemoglobin by therapeutically added nitrite or amylnitrite 
is used in the treatment of cyanide poisoning. If untreated, large doses of cyanide are fatal [170-173]. The acute 
lethal oral dose of cyanide for humans is reported to vary between 0.5 to 3.5 mg CN-/kg bw [171-173] and the 
sensitivity to cyanide may be highly variable depending on age, body mass and health status of the individual 
[174].  
Holzbecher et al. [167] report that apricot seeds contain 2.92 mg/g HCN and peach seeds contain 2.60 
mg/g HCN, while apple seeds contain only 0.61 mg/g HCN. Accordingly, these authors conclude that a person 
can easily consume a lethal quantity of apricot or peach seeds, but is unlikely to eat a lethal amount of apple 
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seeds. The consumption of 60 bitter almonds, containing an average cyanide content of 6.2 mg HCN/ bitter 
almond [175] (leading to an intake of 6.2 mg HCN/kg bw which is above the acute lethal oral dose of 0.5 –3.5 
mg/kg bw), has been reported to be deadly for an adult [176]. Several case studies with fatal outcome upon 
ingestion of high levels of amygdalin have been reported [175, 177-179]. Acute cyanide toxicity at small doses 
can cause headache, tightness in throat and chest, and muscle weakness.  
The effects of chronic (long-term) exposure to cyanide are less well known. Chronic exposure to 
linamarin from cassavas, has been reported to cause malnutrition, diabetes, congenital malformations, 
neurological disorder and myelopathy [180, 181]. It has been proposed as the cause of epidemics of Konzo, a 
form of tropical myelinopathy with sudden onset of spastic paralysis [182, 183]. Degeneration of the corticospinal 
motor pathway in affected individuals may be the result of the production of thiocyanate from linamarin and the 
stimulation of neuronal glutamate receptors by thiocyanate [25, 184]. Thiocyanate is formed from HCN by the 
mitochondrial enzyme rhodanese (Figure 16B), a reaction that is generally considered a detoxification pathway of 
cyanide. The less toxic thiocyanate is excreted in the urine [176, 185]. In countries with low iodine uptake, 
thiocyanate exposure after cassava consumption might be a risk factor for goiter [186]. Goiter is thought to occur 
when cyanogenic glycosides are present at a level of 10-50 mg/kg in food. This thyrotoxic effect of cyanide 
results from the action of thiocyanate as an iodine antagonist. In the 1970's and early 1980's, amygdalin was 
proposed as an anticancer drug (also named laetrile and vitamin B17). However, the dangers and ineffectiveness 
of laetrile were soon recognized. The American Cancer Society has since then indicated that laetrile is a ‘toxic 
drug that is not effective as a cancer treatment’. And in recent years products containing amygdalin, including 
apricot kernels, were banned as over-the-counter products in many countries.   
 
Polymorphisms of influence 
There is no information available. 
 
Concluding remarks 
Several regulatory agencies have evaluated the toxicological and epidemiological data in order to 
establish a safe level of intake of cyanogenic glycosides. A numerical value for safe intake levels, i.e. a TDI, has 
not been derived, and it is generally concluded that application of limits for the presence of HCN in foods and 
beverages should be continued. 
 
 
Solanine and chaconine 
 
Major characteristics, occurrence and intake  
 Alpha-solanine and alpha-chaconine (Figure 17) are toxic saponin-like alkaloids. They exist as beta-
D-glycosides, and are present in potatoes (Solanum tuberosum). The total glycoalkaloid content in potatoes 
normally varies between 2-10 mg/100 g and in chips between 2 and 60 mg/100 g, the latter due to the fact that 
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processing of the potato in order to make chips may increase the amounts of glycoalkaloids [187]. FDA 
regulations limit the solanine content in potatoes to no more than 20 mg/100 g.  
 
 
 
 
Figure 17 Structures of alpha-solanine, alpha-chaconine and solanidine from potatoes 
 
Mechanism of toxic action 
The compounds inhibit cholinesterase enzymes: butyrylcholinesterase (BuChE), that is concentrated in 
the liver and lungs, and acetylcholinesterase (AChE), that is required to hydrolyze and inactivate the 
neurotransmitter acetylcholine [188, 189]. The mechanism of this inhibition was shown to be reversible and at a 
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concentration of 2.88 x10-5 M alpha-chaconine and alpha-solanine were shown to inhibit BuChE by about 70% 
and 50% respectively [190]. Changes in the glycoalkaloid content of potatoes may occur during storage, under 
the influence of light and radiation, following mechanical damage and as a result of food processing. Solanine is 
heat stable and insoluble in water; therefore cooking does not remove the toxicant. Human toxicity from ingestion 
of green potatoes with a high solanum glycoalkaloid content is associated with gastric pain, weakness, nausea 
and vomiting. The potential for teratogenic effects has been a significant public concern in populations consuming 
large amounts of potatoes. The concern arises from studies with Syrian hamsters. Animals treated orally with 
potato sprouts containing solanidine (Figure 17), the common aglycon of alpha-solanine and alpha-chaconine, 
had offspring with craniofacial malformations [191]. A 1972 report of Renwick [192] suggesting certain birth 
(neural tube) defects in humans in areas with higher consumption of potatoes infested with Phytophthora 
infestans, an infectious potato disease inducing the amount of solanine, could not be supported in animal 
experimental and human studies [193, 194]. The 2-week and 90-day NOAEL’s (No Observed Adverse Effect 
levels) for solanine are 35 and 22.5 mg/kg bw respectively.  
 
Polymorphisms of influence  
There is no information available. 
 
Concluding remarks  
There is a long history of human consumption of plants containing glycoalkaloids, and the consumption 
of potatoes with normal glycoalkaloid levels found in properly grown and handled tubers are not of concern.  
 
 
Thujone  
 
Major characteristics, occurrence and intake  
The terpenoids alpha- and beta-thujone (Figure 18) occur together in the essential oils and parts of the 
plants of Artemisia absinthium (wormwood), Salvia officinalis (sage), Salvia sclarea (clary), Tanacetum vulgare 
(tansy) and in Juniperus spp. The ratio of alpha- to beta-thujone varies with the source [195]. Synthetic alpha-
thujone is also available commercially. Thujone is present in food ingredients with flavoring properties. Estimates 
of intakes of thujone have been made in France and the United Kingdom. In France, the mean and the 97.5th 
percentile daily intakes were estimated to be 15.6 and 44.3 µg/kg bw/day respectively. The intakes in the United 
Kingdom were estimated to be somewhat lower at 3.9 and 14.2 µg/kg bw/day respectively. The major dietary 
contribution to intake appeared to derive from sage and sage-flavored products and alcoholic beverages including 
absinthe [195]. Absinthe is an emerald-green liquor that was very popular at the end of the 19th century. It was 
associated with the Bohemian lifestyle and was coupled to the inspiration of famous artists and poets. Because of 
its widespread abuse and the associated toxicity of its content of oil of wormwood, absinthe was made illegal in 
most countries in the 1910s. 
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Figure 18 The active principles from absinthe; alpha- and beta-thujone 
 
Mechanism of toxic action  
The most likely ingredient responsible for the toxicity is believed to be alpha-thujone. The content of 
beta-thujone often exceeds that of alpha-thujone, but the beta-stereo isomer is generally considered to be of 
lower toxicity than alpha-thujone [195-197]. The thujone content of old absinthe was about 260 ppm. Already by 
the end of the 19th century it was recognized that absinthe could cause convulsions, hyperactivity, excitability, 
hallucinations, and psychotic behavior, including suicide [196]. Other reported side effects of thujone and 
wormwood are nausea, vomiting, insomnia, restlessness, vertigo, tremors and seizures. Large doses of thujone 
have been found to cause delirium, convulsions, seizures, paralysis, brain damage, renal failure and death. 
The mechanism of neurotoxicity of alpha-thujone has been ascribed to the fact that it blocks the receptors for 
gamma-aminobutyric acid (GABA) in the brain [196]. Without access to GABA, a natural inhibitor of nerve 
impulses, neurons fire too easily and their signaling goes out of control. Thus, the mechanism underlying the 
adverse effect of alpha-thujone is comparable to that of anisatin (section 2.9).  
 
Polymorphisms of influence 
There is no information available. 
 
Concluding remarks  
In the 1990s absinthe has become popular again. Its newly fashionable image, combined with 
possibilities for global purchase through the Internet has helped initiate its revival. The currently available 
versions of absinthe have levels of thujone of about 10 ppm. This is below the current upper limit set in Annex II 
of Directive 88/388 EEC of 35 mg/kg (ppm) in bitters. The EU-SCF considered the available data inadequate to 
establish a TDI (Tolerable Daily Intake) but noted that some of the deficiencies in the database were being 
addressed in ongoing studies and they recommended that the results of these should be reviewed when available 
[195]. Current levels of alpha- and beta-thujone in absinthe are however judged to be of less toxicological 
concern than its ethanol content [198]. 
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Glycyrrhizinic acid  
 
Major characteristics, occurrence and intake  
Glycyrrhizinic acid (Figure 19) is a food flavoring substance extracted from the roots and rhizomes of the 
liquorice plant (Glycyrrhiza glabra). Because of its sweetness this triterpenoid saponin compound (33-200 times 
as sweet as sucrose) is an important component of a range of foodstuffs such as liquorice confectionery, tooth 
paste, cough drops, herbal teas, chewing gum, chewing tobacco and several alcoholic beverages (e.g. pastis). 
Herbal liquorice teas can contribute significantly to the intake of glycyrrhizinic acid. A Dutch study found for 
prepared herbal liquorice teas a mean concentration of 149 mg/l glycyrrhizinic acid (range 25-450 mg/l). The 
mean concentration of glycyrrhizinic acid in liquorice was 0.15% [199]. 
In the Netherlands, liquorice confectionery is consumed in relatively high quantities. In 1998, 0.4% of the 
Dutch population consumed 50 g of liquorice per day and 0.1% consumed more than 100 g per day leading to 
intakes of glycyrrhizinic acid of more than 75 mg and 150 mg per day, respectively [200]. The average daily 
consumption among regular consumers was 11.5 g/person [201]. In herbal medicine the root is used as Liquiritiae 
radix for treating cough, inflammation of the upper respiratory tract, gastritis and gastric ulcers. Glycyrrhizinic acid 
is present in the liquorice root as ammonium and calcium salts. When hydrolyzed glycyrrhizinic acid yields di-
glucuronic acid and glycyrrhetic acid (Figure 19). Other constituents of liquorice root are triterpenoid saponins 
(e.g. 24-hydroxyglycyrrhizin, glabranin A and B), flavonoids (e.g. the isoflavan glabridin) and coumarins [202].  
 
Mechanism of toxic action   
An essential step for absorption in the gastro-intestinal tract is the hydrolysis of glycyrrhizinic acid by 
intestinal bacteria into glycyrrhetic acid, which is the ultimate biologically active molecule (Figure 19).  
 
 
Figure 19 Structural formula of glycyrrhizinic acid and its conversion to the biologically active metabolite glycyrrhetic acid 
 
Absorption of glycyrrhyzinic acid, in the form of glycyrrhetic acid, from solutions or from liquorice is 
comparable and virtually complete. Due to its lipophilic nature excretion of glycyrrhetic acid by the kidney is very 
low. After a slow uptake by the liver the substance is subject to entero-hepatic circulation. Glycyrrhetic acid is the 
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biologically active metabolite, which inhibits the enzyme 11-beta-hydroxysteroid dehydrogenase-2 (11-BOHD-2). 
This enzyme is found in the distal kidney tubules and converts the steroid hormone cortisol to cortisone. Cortisol 
binds to the mineralocorticoid receptor but cortisone does not. A decreased activity of 11-BOHD-2 leads to an 
excess of cortisol and an overstimulation of this mineralocorticoid receptor. This causes water and sodium 
retention and an increased excretion of potassium. When exposed to large doses of glycyrrhizinic acid over a 
prolonged period, this electrolyte imbalance and the water retention can cause hypokalaemia, hypernatraemia, 
edema, hypertension and cardiac disorders [201, 203].  
 
Polymorphisms of influence  
An in vitro study showed that liquorice root extract and its major flavonoid glabridin inhibited human 
CYP3A4. Furthermore, glabridin inhibited CYP2B6, which is responsible for the metabolism of roughly 3% of 
prescribed drugs such as ketamine, phenobarbital and rifampin [204]. Glycyrrhizinic acid was found to increase 
plasma concentrations of prednisolone in humans [205]. In a repeated dose-response study in human volunteers 
a NOAEL of 2 mg/kg bw/day glycyrrhizinic acid was derived. 
  
Concluding remarks  
Because of limited data the EU-SCF [201] could not derive an ADI for glycyrrhizinic acid. The Committee 
was however of the opinion that ingestion of glycyrrhizinic acid should not exceed 100 mg/day which should 
protect the majority of the population. Yet certain subgroups with a decreased 11-BOHD-2 activity or 
hypertension might not be sufficiently protected [201]. 
 
 
Conclusions 
 
The present review describes the nature and mechanism of action of the phytochemicals nowadays 
receiving increased attention in the field of plant and herb-based food items, and Table 2 gives an overview of the 
data presented. From this it can be concluded that a variety of phytotoxins may cause concern, because of their 
bioactivation to reactive alkylating intermediates that are able to react with cellular macromolcules causing 
cellular toxicity, and, upon their reaction with DNA, genotoxicity resulting in tumors. Another group of phytotoxins 
of present concern is active without the requirement for bioactivation and, in most cases, appear to act as 
neurotoxins interacting with one of the neurotransmitter systems.  
For most compounds regulatory agents are aware of the problems encountered and have taken or are 
considering appropriate regulatory actions to protect the public. These regulatory actions may vary from setting 
TDIs (such as for example for coumarin), application of limits for the presence of a compound in foods and 
beverages (such as for HCN, thujone and glycoalkaloids), trying to define safe upper limits (such as for beta-
carotene), advising on a strategy aiming at restrictions in use (such as for estragole, methyleugenol and safrole), 
informing the public to be cautious and aware of possible adverse side effects, (as for St. John’s wort, 
glycyrrhizinic acid and kava-kava), or taking specific plant varieties and/or their ingredients from the market (such 
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as for aristolochic acids, pyrrolizidine alkaloids and kava-kava). In spite of this regulatory awareness, and 
previous and recent regulatory actions taken, it cannot be excluded that specific developments may still result in 
problems. This includes i) phenomena such as overconsumption by particular groups, sometimes stimulated by 
companies making illegal claims on their websites or in their literature, ii) the fact that many consumers equate 
“natural” with “safe” when considering plant-based food supplements or drug preparations, iii) the over-the-
counter selling of food supplements through Internet sites from countries where regulations are not in place, and 
iv) the fact that there is yet no system in place to guarantee the safety and quality of botanical supplements. 
 
Table 2 Overview of the food-borne phytochemicals of present concern in food toxicology and the mechanism of 
their toxic effect as discussed in the present paper 
Compound(s) Requires 
bioactivation 
Mechanism of action 
Aristolochic acids + Formation of reactive nitrenium ion causing Chinese Herb Nephropathy and 
urothelial cancers 
Pyrrolizidine alkaloids + Formation of pyrrolic dehydro-alkaloid metabolites alkylating DNA and other 
macromolcules, causing liver cell necrosis and liver cancer 
Beta-carotene + Oxidation products resemble retinal, disturbing retinal homeostasis leading, 
in combination with cigarette smoke, to (lung) tumor promotion 
Coumarin + Formation of toxic tumor inducing metabolites in the coumarin-3,4-oxide 
pathway 
Alkenylbenzenes: safrole, 
methyleugenol, estragole 
+ Formation of genotoxic, carcinogenic 1’- sulfooxymetabolites 
Ephedrine alkaloids - Adrenalin agonist 
Synephrine  - Adrenalin agonist 
Kavalactones +/- Glutathione depletion and/or quinone formation 
Anisatin - GABA antagonist 
St. John’s wort ingredients - Interfere with CYP-mediated biotransformation resulting in drug interactions 
Cyanogenic glycosides + Release of cyanide, inhibits cytochrome c oxidase   
Solanine - Cholinesterase inhibition 
Thujone - GABA antagonist 
Glycyrrhizinic acid + Hydrolysis generates glycyrrhetic acid that inhibits 11-beta-hydroxysteroid 
dehydrogenase-2 (11-BOHD-2), leading to an excess cortisol and 
overstimulation of the mineralocorticoid receptor, causing water and sodium 
retention and increased potassium excretion 
 
The latter is especially worrying as products on the market are known be of variable quality with high variation in 
the content of the active but also of the toxic principles, and the fact that already several examples of replacement 
of a harmless variety with a toxic alternative have occurred, either intentionally or accidentally. Misidentification of 
 CHAPTER 3  |  83 83 
plants harvested from the wild may add to the problem. The growing volume of products and sales call for a more 
formal pre-marketing assessment and better and stricter controls than presently available. 
Altogether the examples above illustrate that “natural” does not equal “safe” and that in modern society 
adverse health effects, upon either acute or chronic exposure to phytochemicals, can occur as a result of 
(mis)use of plant- or herb-based foods, botanicals or botanical preparations intended for human consumption as 
food supplements, teas or other extracts. At present regulatory bodies have become more aware of the problem 
and are increasing their efforts to ensure the safety of botanical supplements [206, 207].  
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Abstract  
 
In Traditional Chinese Medicine (TCM) several Aristolochia species are used. Aristolochia spp. contain a 
mixture of aristolochic acids (AAs) mainly AA I and AA II, which are nephrotoxicants and carcinogens. After AA 
related nephropathy (AAN) and urothelial cancer were described in female patients in Belgium following intake of 
AA contaminated herbal preparations, herbs with AAs were prohibited worldwide. Confusing nomenclature can 
cause AA contamination of certain Chinese traditional herbal preparations (THPs). Here we report the results of 
investigations by the Dutch Food and Consumer Product Safety Authority (VWA) into the presence of AAs in 
THPs sampled on the Dutch market using an LC-MS method. Between 2002 and 2006 we sampled 190 Chinese 
THPs using recent information on Chinese THPs potentially containing AAs. AA I was found in 25 samples up to 
a concentration of 1676 mg/kg. AA II was also found in 13 of these samples up to 444 mg/kg. All 25 positive 
samples including Mu Tong, Fang Ji, Tian Xian Teng and Xi Xin were part of a group of 68 THPs identified as 
possibly containing AAs. In a worst-case scenario use of a sample of Mu Tong with the highest AA content over a 
7-day period would result in the same intake levels of AAs, which significantly raised the cancer risk in the Belgian 
AAN cases. Our results show that contaminated THPs still can be found on the market following worldwide 
publicity. Therefore it can be concluded that testing of possibly AA contaminated THPs is still essential.  
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Introduction 
 
In Traditional Chinese Medicine (TCM) Aristolochia species such as A. fangchi and A. manshuriensis 
and others are used to treat snake and insect bites, promote lactation or urination and reduce edema [1]. 
Aristolochia spp. are used for medicinal purposes worldwide. Many herbs from the genus Aristolochia and several 
species of the genus Asarum, both belonging to the family of the Aristolochaceae, contain several aristolochic 
acids (AAs) often accompanied by aristolactams [2-4]. Literature on the toxicity of the Aristolochiaceae and 
related analytical papers mostly focus on a naturally occurring mixture of AAs mainly consisting of aristolochic 
acid I (AA I) and aristolochic acid (AA II) (Figure 1) [5].  
AAs were shown to be nephrotoxic and carcinogenic in animal studies with rodents [5,6]. It has been 
shown in rat studies that the renal proximal tubule is an important target of AA toxicity, which can result in renal 
failure [7,8]. AAs have been suggested to play a role in the Balkan endemic nephropathy (BEN) characterized by 
renal interstitial fibrosis. Seeds of Aristolochia clematitis, which is endemic to BEN affected areas, may have 
contaminated grain [9]. The International Agency for Research on Cancer (IARC) concluded that herbal 
preparations with Aristolochia spp. are carcinogenic to humans and that naturally occurring mixtures of AAs 
probably are human carcinogens as well [10]. In humans, the hepatic and renal activation of AAs is attributed to 
reductive metabolic activation by cytochrome P450 (CYP) 1A1, CYP1A2, NAD(P)H:quinone oxidoreductase and 
others. The resulting ultimate carcinogenic species is able to form adducts with DNA which in turn can cause 
mutations and neoplastic changes [5, 11]. We recently reviewed the toxic action of AA in some detail [12]. 
TCM is gaining popularity in Western countries but certain safety issues of Chinese traditional herbal 
preparations (THPs) such as the deliberate use of high amounts of heavy metals [13] and the presence of AAs 
invariably require attention. In the US and the Netherlands Chinese THPs are regarded as foods. In Dutch food 
law THPs are regulated as herbal preparations in the Commodities Act Decree ‘Herbal preparations’. Since it 
came into force early 2001, this Decree has prohibited the presence of AAs and their derivatives in herbal 
preparations with Aristolochia spp. This ban was recently extended to all herbal preparations irrespective of the 
plant species present. Several other countries such as the UK, the USA, Canada, Australia and New Zeeland 
have since 2000 significantly limited or prohibited the sale of AA containing herbs and issued warnings [14-18]. 
These measures were inspired by a steadily expanding insight into the nature of the causative agent of 
poisonings with Chinese THPs in Belgium in the early 1990s. 
 
 
 
 
 
 
 
Figure 1 Structures of AA I (R = OCH3) and AA II (R = H) 
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replaced by Aristolochia fanchi, b cause both plants are used under the ame name ‘Fangji’ i  Chinese folk 
medicine [2]. Aristolochic acids occur throughout the plants and appear n roots, stem, leaves and fruit of 
Aristolochia fanchi. Lev ls in the crude drug can range bet een 0.1% and 0.6% dry w ight [4, 5]. The cli ical 
symptoms observ d were named Chinese Herb Nephropathy (CHN) [3], and when it b came clear that they were 
caused by aristolochic acids the disease was also named Aristolochic Acid Nephropath (AAN) [6]. The ingested 
dose of aristolochic cids by patients with CHN has been estimated to be in the range of  few µg/kg bw/day [7]. 
 
Mechanism of toxic action  
Aristolochic acids I and II (Figure 1) are the m jor type of ristol chic acids and are know to be 
nephrotoxic, genotoxic and carcinogenic [8-13]. The first symptoms of AAN are the excretion of low molecular 
weight proteins in urine, indicating a toxic effect on the proximal tubules [14]. Reductive metabolic activation of 
aristolochic acids by cytochromes P450 (CYP) 1A1 or 1A2, and/or by other enzymes including NADPH:P450 
reductase, xanthine oxidase, NAD(P)H: quinone oxidoreductase (= DT-diaphorase), and peroxidases has been 
reported and results in formation of a cyclic reactive nitrenium ion (Figure 2) able to form covalent DNA adducts 
at the exocyclic amino groups of guanine and adenosine [8, 9, 15-20]. The adduct detected with highest 
frequency is the adenine adduct leading to an AT to TA transversion. The human tumor suppressor gene p53 
was shown to be a hot spot for this type of mutation by aristolochic acid metabolites [9]. Furthermore, in rodents 
the activation of the Ha-ras gene by a specific AT to TA transversion mutation was reported [21, 22].  
Studying 39 women with CHN, Nortier et al. [23] demonstrated aristolochic acid related DNA adducts in 
specimens of renal tissue, and concluded that a cumulative dose of 201 g or more of a compound labeled as 
containing Stephania tetrandia but actually containing Aristolochia fangchi increases the risk for developing 
urothelial carcinomas. This was concluded based on the observation that among the 24 patients with CHN that 
consumed a total dose of 200 or less, 8 cases of urethelial cancer were detected, whereas among 15 patients 
who had ingested 201 g or more 10 cases were found, which was significantly higher (P=0.05). Since the first 
reports of CHN in Belgium, similar cases have been described in several other countries including Spain, Japan, 
France, the UK and China [9 and references therein]. 
 
 
 
Figure 1 Structural formula of aristolochic acids [8-13]; with R=OCH3 in aristolochic acid I (8-methoxy-6-nitro-phenanthro-
(3,4-d)-1,3-dioxolo-5-carboxylic acid, and R= H in aristolochic acid II (6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid 
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Introduction 
 
In Traditional Chinese Medicine (TCM) Aristolochia species such as A. fangchi and A. manshuriensis 
and others are used to treat snake and insect bites, promote lactation or urination and reduce edema [1]. 
Aristolochia spp. are used for medicinal purposes worldwide. Many herbs from the genus Aristolochia and several 
species of the genus Asarum, both belonging to the family of the Aristolochaceae, contain several aristolochic 
acids (AAs) often accompanied by aristolactams [2-4]. Literature on the toxicity of the Aristolochiaceae and 
related analytical papers mostly focus on a naturally occurring mixture of AAs mainly consisting of aristolochic 
acid I (AA I) and aristolochic acid (AA II) (Figure 1) [5].  
AAs were shown to be nephrotoxic and carcinogenic in animal studies with rodents [5,6]. It has been 
shown in rat studies that the renal proximal tubule is an important target of AA toxicity, which can result in renal 
failure [7,8]. AAs have been suggested to play a role in the Balkan endemic nephropathy (BEN) characterized by 
renal interstitial fibrosis. Seeds of Aristolochia clematitis, which is endemic to BEN affected areas, may have 
contaminated grain [9]. The International Agency for Research on Cancer (IARC) concluded that herbal 
preparations with Aristolochia spp. are carcinogenic to humans and that naturally occurring mixtures of AAs 
probably are human carcinogens as well [10]. In humans, the hepatic and renal activation of AAs is attributed to 
reductive metabolic activation by cytochrome P450 (CYP) 1A1, CYP1A2, NAD(P)H:quinone oxidoreductase and 
others. The resulting ultimate carcinogenic species is able to form adducts with DNA which in turn can cause 
mutations and neoplastic changes [5, 11]. We recently reviewed the toxic action of AA in some detail [12]. 
TCM is gaining popularity in Western countries but certain safety issues of Chinese traditional herbal 
preparations (THPs) such as the deliberate use of high amounts of heavy metals [13] and the presence of AAs 
invariably require attention. In the US and the Netherlands Chinese THPs are regarded as foods. In Dutch food 
law THPs are regulated as herbal preparations in the Commodities Act Decree ‘Herbal preparations’. Since it 
came into force early 2001, this Decree has prohibited the presence of AAs and their derivatives in herbal 
preparations with Aristolochia spp. This ban was recently extended to all herbal preparations irrespective of the 
plant species present. Several other countries such as the UK, the USA, Canada, Australia and New Zeeland 
have since 2000 significantly limited or prohibited the sale of AA containing herbs and issued warnings [14-18]. 
These measures were inspired by a steadily expanding insight into the nature of the causative agent of 
poisonings with Chinese THPs in Belgium in the early 1990s. 
 
 
 
 
 
 
 
Figure 1 Structures of AA I (R = OCH3) and AA II (R = H) 
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In 1992, a cluster of 9 similar cases of renal interstitial fibrosis in female patients was identified in 
Brussels. All these patients were treated between 1990 and 1992 in a slimming clinic with a regimen consisting of 
a diet, injections and capsules containing pharmaceuticals such as fenfluramine, herbal preparations and a 
pancreas extract. Early 1990, the clinic had altered the THP formulation by introducing the Chinese herbs 
Magnolia officinalis and Stephania tetrandra to the capsules replacing other herbs. It was suggested that S. 
tetrandra was inadvertently replaced by Aristolochia fangchi. TLC detection of AAs in these herbal preparations 
failed however [19]. Afterwards, AAs were found in 11 of the 12 batches of S. tetrandra powder delivered to 
Belgian pharmacies during the treatment period [20]. The disease became known as Chinese herb nephropathy 
(CHN). After the initial report, more than 100 cases of rapidly progressing renal fibrosis associated with exposure 
to AAs were identified in Belgium and approximately 170 cases of AA associated CHN were described in other 
European countries, the USA and in Asia [5, and references therein].  
In renal tissue of 39 patients who were treated with the Belgian slimming regimen and who were followed 
for CHN related end stage renal failure, 18 cases of urothelial cancer were identified. All examined tissue samples 
contained AA related DNA adducts [21]. It was found that a total intake of more than 200 g S. tetrandra (probably 
mostly replaced by A. fangchi) was associated with a higher risk of urothelial carcinoma [21]. A statistical analysis 
of the prescriptions and medical files of 71 CHN patients showed that of all administered drugs only the 
cumulative dose of the contaminated S. tetrandra preparation could predict the renal failure progression rate [22]. 
The typical chronic interstitial lesions of CHN were reproduced in a rats injected with 10 mg/kg/day of a mixture of 
40% AA I and 60% AA II for 35 days [7]. Nowadays, many authors prefer to use the more accurate term 
‘aristolochic acid nephropathy’ (AAN) to the term CHN.  
As a result of the Belgian CHN cases it became better known why certain Chinese THPs are 
contaminated with AAs and what the effects of exposure to AAs can amount to. Confusion over the Chinese 
common name ‘Fang Ji’, which can refer both to the roots of S. tetrandra and A. fangchi, could have caused the 
contamination with AAs [19, 20]. In the trade of Chinese herbs, the substitution of one plant species for another is 
established practice [23]. Besides the THPs known to contain Aristolochia species, some THPs derived of certain 
plant species can be identified that can be replaced by Aristolochia species in practice.  
Several international Food and Medicine Authorities have published lists of THPs suspected to contain 
AA. The Dutch Food and Consumer Product Safety Authority (VWA) has implemented these lists in its sampling 
strategies of Chinese THPs and analyzed AAs in market samples. Reports providing quantitative data on AA 
levels of commercial THPs possibly containing AAs are scarce. This data could however be useful to validate the 
existing lists of suspected THPs and could help authorities to pinpoint their efforts to protect the consumer against 
exposure to AAs. In the present paper our results in this field over the past 4 years are presented and compared 
with recent scientific and regulatory data.  
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Materials and methods 
 
Sampling 
VWA inspectors sampled 190 Chinese THPs on the Dutch market in the period from November 2002 to 
June 2006. Samples were selected by using a list of single herb THPs and multi-ingredient THPs probably and 
possibly containing AAs, which was based on a list compiled by the FDA in 2001 [24]. The FDA list was 
supplemented and regularly updated in house with data on the nomenclature of AA containing herbal material 
from books on TCM, commercial TCM databases on the Internet, warnings of other inspection agencies and 
literature [1, 15, 23-28, 38, 40, 42].  
 
Table 1 Examples of single herb THPs possibly containing AAs 
Pin Yin name part used botanical name Latin pharmaceutical name incl. synonyms 
THPs with Aristolochia species  
Guang Fang Ji root A. fangchi Radix Aristolochia fangchi/ Aristolochiae Fangchi 
Ma Dou Ling  fruit A. contorta and A. debilis Fructus Aristolochiae 
Tian Xian Teng herb A. contorta and A. debilis Herba Aristolochiae/ Caulis Aristolochiae 
Guan Mu Tong  stem A. manshuriensis Caulis Aristolochia manshuriensis/ Aristolochiae 
Manshuriensis 
Qing Mu Xiang root A. debilis Radix Aristolochiae 
Xun Gu Feng, Bai Mao Teng herb A. mollissima Herba Aristolochiae Mollissimae 
THPs possibly contaminated with Aristolochia species  
Han Fang Ji root Stephania tetrandra Radix Stephania tetrandra 
Mu Fang Ji root Cocculus trilobus and  
C. orbiculatus 
Radix Cocculi Trilobi/ Radix Cocculus trilobus/ 
Radix Cocculi 
Chuan Mu Tong  stem Clematis armandii Caulis Clematis armandii/ Clematidis armandii 
Chuan Mu Tong stem Clematis montana Caulis Clematidis/ Clematis montana/ Clematis 
armandii  
Bai Mu Tong stem  Akebia quinata Caulis Akebia quinata 
Bai Mu Tong stem  Akebia trifoliata Caulis Akebia trifoliata 
Bai Mao Teng, Bai Ying herb Solanum lyratum Herba Solani Lyrati 
References: [1, 23, 24, 27, 42] 
 
Table 1 presents an extract of our sampling list defining the most pertinent Aristolochia species in use in 
TCM and several plant species with which they could be exchanged. The Chinese common names in the table 
refer to plants and the parts used and are given in Pin Yin, which is a phonetic representation of Chinese 
characters. The corresponding Latin pharmaceutical name also presented, is a combination of the part of the 
plant and often its binomial botanical name. Both types of nomenclature are seen in the market. Table 2 presents 
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examples of formulas, which can be potentially contaminated with AAs through the presence of Mu Tong, Fang Ji 
or Xi Xin. For sampling, products were selected by formula name or by screening the ingredient list for suspected 
herbs. Along with THPs known or suspected to contain AAs, THPs were sampled at random as well. THP names 
were copied as labeled and are presented in this paper without alterations. Generally no authentication of the 
herb was performed. 
 
Table 2 Examples of multi ingredient THPs possibly containing AAs 
Formula name in Pin Yin, in alphabetical order 
Formulas with Mu Tong or Fang Ji 
Anyang Jingzhi Gao  Fang Ji Huang Qi Tang Quell Fire  
Ba Zheng Wan Fenqing Wulin Wan  Shang Zhong Xia Tong Yong Tong Feng Fang 
Chi Kuan Yen Wan Fu Ke Fen Qing Wan  Shi Xiang Fan Shen Wan 
Chu Shi Wei Ling Tang Gan Lu Xiao Du Dan Shu Feng Huo Xue Tang 
Chun Yang Zheng Ji Wan Guan Xin Su He Wan Shu Jing Huo Xue Tang 
Da Huang Qing Wei Wan Guo Qi Yin Tienchi Hugu Wan 
Da Qiang Huo Tang Ji Jiao Li Huang Wan Xiao’er Jindan tablets 
Dang Gui Si Ni Tang Ji Sheng Ju He Wan Xiao Feng San 
Dang Gui Si Ni Wan Jia Wei Wu Lin San Xiao Huo Luo Dan 
Dao Chi San  Ju He Wan Xiao Xu Ming Tang 
Dao Chi Wan Kat Kit Wan Xin Yi Wan 
Dieda Wan Kuanhsin Suhowan Xuan Bi Tang 
Er Jia Jian Zheng Qi San Long Dan Xie Gan Tang Zhisou Huatan Wan 
Ershiwuwei Songshi Wan Long Dan Xie Gan Wan Zhu Ling Tang 
Fang Ji Fu Ling Tang Mu Fang Ji Tang  
Formulas with Xi Xin 
Chuan Xiong Cha Tiao San Du Huo Ji Sheng Tang San Bi Tang 
Chuan Xiong Cha Tiao Wan Jiu Wei Qiang Hou Tang She Gan Ma Huang Tang 
Da Huang Fu Zi Tang Ling Gan Wu Wei Jiang Xin Tang Tong Guan San 
Da Qin Jiao Tang Ma Huang Fu Zi Xi Xin Tang Wu Mei Wan 
Dang Gui Si Ni Tang Qu Feng Zhi Bao Dan Xiao Qing Long Tang 
References: [15, 24, 25, 27, 38, 40, 42] 
 
THPs were collected in TCM stores, oriental food stores, wholesale dealers, importers or TCM 
practitioners throughout the Netherlands. Sampling inspections were held at least each year. Locations were 
selected from the VWA-inspection database. During inspections of these locations new suppliers and stores were 
also identified and visited. THPs were sampled in pre-packaged form in capsules or tablets or in many cases in 
the form of coarse herbal material from glass containers sometimes with limited or no labeling. Samples were 
taken on the basis of quantities supplied to consumers, which is one unit (e.g. bottle, package or container) or in 
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case of coarse herbal material in amounts higher than 10 gram. Mixtures of the coarse materials are assembled 
in TCM shops according to a formula prescribed by an in house TCM practitioner. This THP mixture is then 
prepared at home as a decoction for which the herbs are boiled in water or other liquids. The strained liquid is 
then consumed [1]. 
 
Experimental 
The method used to quantify AA I and AA II was based on the method described by Flurer et al. [29]. 
The entire sample was homogenized or in case of capsules the contents of all the capsules was taken and 
homogenized, and from this a laboratory sample was taken for further analysis. After homogenization, 25 ml of 
extraction solution was added to 1 gram of sample. The extraction solution existed of 80% methanol, 18% water 
and 2% formic acid. The samples were shaken for 90 minutes in a shaking machine (Gerhardt LS-20, position 9). 
Then they were allowed to precipitate for about 1 hour. An aliquot of 1 ml was then centrifuged at a minimum of 
10000 g. The supernatant was transferred to a vial and hermetically sealed for LC-MS analysis. No concentration 
step was needed. 
 
Table 3 LC conditions for the determination of AA I and AA II 
Parameters Conditions 
Analytical column: Alltima C-18 column (150 x 3.2 mm i.d. – 5µm particle size) 
Precolumn: Alltima C-18 (7.5 x 3.0 mm i.d. – 5µm particle size) 
Column Temperature: 30°C 
Injection Volume: 20 µl (Full loop injection) 
Flow rate: 0.30 ml/min 
Mobile Phase: Eluent A: 10 mmol ammonium formate in 1% formic acid 
 Eluent B: Methanol 
  
LC Gradient Time (min) Eluent A (%) Eluent B (%) 
 0.00 50 50 
 10.00 20 80 
 21.00 20 80 
 22.00 0 100 
 25.00 0 100 
 26.00 50 50 
 34.00 50 50 
 
An Ion Trap LC-MS system of Thermofinnigan (LCQ Advantage) equipped with a quaternary pump, an 
autosampler with a column oven, a PDA-detector and an integration system together with LC-MS software was 
used for analysis. The separation was performed on an Alltima C-18 column (150 x 3.2 mm i.d. – 5µm particle 
size) with an Alltima C-18 precolumn (7.5 x 3.0 mm i.d. – 5µm particle size) using gradient elution. LC conditions 
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are listed in Table 3. The MS detection was performed by electrospray ionization (ESI) using the positive mode. 
The MS conditions are listed in Table 4. Before injection of samples, the system was equilibrated using 50% 
eluent A en 50% eluent B. Quantification of AA I and AA II was based on a standard mixture obtained from 
Sigma-Aldrich (Zwijndrecht, The Netherlands) containing 43% AA I and 54% AA II. 
 
Table 4 MS conditions for the determination of AA I and AA II 
Parameters Conditions 
Capillary temp: 250°C 
Sheath gas: 45% 
Aux/ sweep: 10 
Source voltage: 5.00 KV 
Source current:  80.00 µA 
Capillary voltage:  9.00 V 
Tube Lens offset:  15.00 V 
Scan:  100.00 – 400.00 m/z 
Parent ion AA I:  359.0 -> first daughter ion 298.0; second daughter ion 341.7 m/z 
Parent ion AA II: 329.1 -> first daughter ion 267.9; second daughter ion 294.0 m/z 
 
For every series of samples several quality checks were performed, including a check of validity of 
calibration, a check on the ratio of the first to the second daughter ion and the analysis of quality control samples 
(QC: 2 standardized control materials (SCM) containing both AA I or AA II). For this QC material the mean and a 
95% confidence interval were established. Each measurement of this QC material had to comply with this 95% 
confidence interval. AA was only quantified when all quality checks for a series of samples were in line with the 
desired performance characteristics. 
 
 
Results and discussion 
 
Characteristics of the analytical method  
For the in-house validation of the method for quantifying AA I and AA II, the limits of detection and 
quantification (LOD and LOQ) were determined. The LOD was defined as the concentration, which is three times 
higher than the range of the chromatographic background of the second daughter ion. The limit of detection 
determined in this way was 1.0 mg/kg for AA I and 1.6 mg/kg for AA II. The LOQ was defined as twice the LOD 
and was 2.0 mg/kg for AA I and 3.2 mg/kg for AA II. Two calibration curves were used, which both were linear 
with correlation coefficients of at least 0.97. The linearity for the low level AA ranges was determined between 86 
- 430 ng/ml for AA I and 108 - 540 ng/ml for AA II. The range of application for preparations containing high levels 
of AAs was determined at 430-6450 ng/ml for AA I and 540 - 8100 ng/ml for AA II. The calibration curves for the 
high concentration range were established by quadratic regression. Preparations containing even higher amounts 
of AAs were diluted with the extraction solution.  
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The validity of the calibration curve, retention times and LOD were checked with each series of samples. 
Quantification of both AA I and AA II was based on the first daughter ions. However, amounts were only 
quantified when the relative intensity of the second daughter ion in proportion to the first daughter ion was within 
specific limits. For this the peak surface of the second daughter ion was calculated as a percentage of the peak 
surface of the first daughter ion. For AA I the relative intensity of the second daughter ion (m/z 341.7) had to be 
44.0% ± 11.0% of the first daughter ion (m/z 298.0). Similarly for AA II the relative intensity of the second 
daughter ion (m/z 294.0) had to be 53.5% ±10.7% of the first daughter ion (m/z 267.9).  
For the recovery studies a blank THP sampled from the market (labeled as Mu Tong and Clematis 
armandii and analytically shown to be free of AA I and AA II) was spiked at levels between 2 and 11 mg/kg. As 
Mu Tong samples were expected to be frequently contaminated, this blanc Mu Tong sample without AAs was 
considered to be a relevant model for our research and the recovery studies were therefore performed on this 
sample. The recoveries determined from six replicate measurements under repeatability conditions were 87% 
and 82% respectively for AAI and AAII with relative standard deviations (RSD) of 3.7 and 3.5% respectively. The 
reproducibility was defined as 2.8 times the standard deviation obtained from results determined by different 
operators and at different times using standardized control materials (SCM).  
For AA I a SCM, a Xi Xin THP sampled from the market containing 4.75 mg/kg AA I, was used to 
determine the reproducibility which amounted to 0.94 mg/kg. For AA II a SCM was prepared from a mixture of a 
Guan Mu Tong THP sampled from the market (an Aristolochia sp. with a high level of AA II) and the blanc Mu 
Tong sample without any AAs which was used for the recovery studies. This mixture contained 3.76 mg/kg AA II 
and the reproducibility was 0.47 mg/kg. Both SCMs were analyzed each series. These performance 
characteristics of the method are in agreement with results published by Trujillo et al. [30].  
 
Confusion of herbs in TCM and sampling of AA containing THPs 
Besides a sensitive analytical method, an effective sampling protocol needed to be developed for 
enforcement of the ban on AAs. Central to this protocol was information on which Chinese herbs can possibly be 
replaced by herbs that contain AAs. In TCM confusion of herbs occurs frequently and can result from similarities 
in appearance, mistakes in (ancient) textbooks, counterfeits and in many cases ambiguous nomenclature [31]. 
Contamination of THPs with AAs can often be traced back to confusion over nomenclature. Common or 
vernacular names of plants are, as opposed to binomial botanical names, not very reliable for unambiguous 
identification of the particular species as, for instance, the interpretation of common names can even differ 
between geographical regions.  
In TCM, several plant species share a Chinese common name with an Aristolochia sp. and this common 
name could be seen as a group name for the species concerned. When a prefix is added to the group name, the 
common name refers to only one or two plant species of the group; in many cases however only the group name 
is used. The prefix can point at a region where the plant is grown, for example the prefix Chuan refers to the 
Sichuan province [1]. The common name Fang Ji refers to at least 4 plant species but in combination with the 
prefix ‘Guang’ it is exclusively used for the root of Aristolochia fangchi. There is also the possibility that a herb has 
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more than one common name which can lead to confusion as well. For instance, it was recently reported that 
Aristolochia mollissima is not only called Xun Gu Feng but Bai Mao Teng as well. This last common name is also 
used for Solanum lyratum, which confusingly has an alternate name as well, namely Bai Ying [32]. Substitution of 
S. lyratum by A. mollissima can occur when only the common name Bai Mao Teng is used when the THP is 
prescribed, self medicated, traded etc. Such a case has been reported in Hong Kong recently where a 60-year-
old man was diagnosed with renal failure and urethral cancer after he had erroneously been using Herba 
Aristolochia mollissimae instead of the desired Solanum species [31]. The authors indicated that confusion keeps 
recurring between the names Xun Gu Feng, Bai Mao Teng and Bai Ying [31]. Although A. mollissima is entered in 
the FDA list, the plant’s common name is not mentioned nor is S. lyratum [24]. Information of this nature might 
prove valuable when sampling THPs for AA analysis.  
Tables 1 and 2 present respectively an extract of our sampling list defining the most pertinent single herb 
THPs derived from Aristolochia spp. in use in TCM, several plant species which could be replaced by Aristolochia 
spp. and a list of possibly contaminated formulas. This list was proven useful for sampling 190 Chinese THPs on 
the Dutch market in the period from November 2002 to June 2006. 
 
Analytical results 
The Chinese common names and Latin pharmaceutical names of all 190 THPs were examined for 
indications that AA containing herbs might be present. We identified 68 THPs as products that could possibly 
contain AAs and this subgroup contained all 25 positive samples. The analytical results of the 68 potentially AA 
containing THPs are presented in Table 5 grouped by the Chinese common name. AA I was found in all 25 
samples positive for AA, the AA I level of 4 THPs was below the LOQ and AA I contents of the remaining samples 
ranged between 2 mg/kg and 1676 mg/kg. Together with AA I, AA II was detected in 13 samples with the AA II 
content of 1 sample below the LOQ and that of the other samples between 4 mg/kg and 444 mg/kg. When THPs 
contained more than the relevant LOQ action was taken to remove the products from the market.  
In 3 of 5 samples of single herb THPs (Guan Mu Tong (2x), Qing Mu Xian, Guang Fang Ji and Tian Xian 
Teng) labeled with names exclusively referring to Aristolochia species, significant amounts of AA I were found 
ranging between 74 and >1000 mg/kg implying that these samples contained indeed Aristolochia spp. The 
remaining 2 of these Aristolochia samples surprisingly contained no detectable levels of AAs. The identity of the 
samples was generally not authenticated however. In 11 of 12 samples of THPs with herbs from the genus 
Asarum, which also belongs to the Aristolochiaceae and in which AAs can be expected, low levels of AAs were 
detected. The remaining 11 positive samples were THPs that contained herbs, which can be substituted by 
Aristolochia spp. and belonged to the Fang Ji and Mu Tong groups of Table 5. Of these, 4 products were 
incorrectly labeled with names that identified the herbs as AA free counterparts of Aristolochia species. This 
shows that the problem in TCM of substitution of innocuous herbs with Aristolochia spp. is not yet resolved. 
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The problem of substitution of Chinese herbs with toxic counterparts is not limited to Aristolochia spp. In 
2001 the Dutch Health authorities including the VWA were faced with more than 60 poisonings with symptoms 
including epileptic seizures due to consumption of a herbal tea where the spice Chinese star anise (Illicium 
verum) was replaced by an unidentified Illicium sp. imported from China and which was shown to contain the 
neurotoxin anisatin [33]. 
We found no AAs in THPs which to our knowledge were not likely to be contaminated with AAs and 
could therefore be considered as randomly sampled. These THPs are presented in Table 6.  
 
Table 6 Randomly sampled Chinese THPs negative for Aristolochic acids (AAs) as determined with LC-MS 
Chinese common name, as labeled Latin Pharmaceutical name, as labeled 
Ba Zhen Wan --- 
Ba Zheng Ke Li Octo Form granules 
Bai Hua She She Cao Herba Hedyoti Diffusae 
Bai Qui Feng --- 
Bao He Wan --- 
Bi Xie Rhizoma Dioscorea Hypoglaucae 
Bian Dou Semen Lablab Album 
Bing Lang --- 
Cang Zhu Rhizoma Atracttylodi 
Che Qian Cao (2x) Plantago Asiatica/ Herba Plantagaginis 
Chuan Wu/ Chuang Mu/ --- R. A. Carmichaeli (2x)/ Aconit Carmichaeli Preparata 
Da Huang (2x) --- 
Dang Gui Chinese Angelica 
Dao Chi Pian Scarlet Form 
Ding Chuan Wan --- 
Du Zhong Bu Yao Granules --- 
Fan Xie Ye Folium Sennae 
Fang Feng Radix Sapashnikovae S 
Fu Ling (3x)/ --- (2x) Sclerotium Poriae Cocos (5x) 
Fu Ping --- 
Gui Fu Di Huang Wan --- 
Guo Teng Rumulus Unicare Cum Uncis 
He Shou Wu (2x)/ --- Radix Polygoni Multiflori (3x) 
Hong Hua Flos Carthami Tinctorii 
Huai Hua Flos Sophorae 
Huang Jing Rhizoma Polygonati, Polygonum officinale 
Huang Lian Tang Granules --- 
Huo Xiang Zheng Qi Wan --- 
Je Yiao Teng Caulis Polygoni Multiflori 
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Table 6 (continued)  
Chinese common name, as labeled Latin Pharmaceutical name, as labeled 
Jian Pi Wan --- 
Jinkuishenqiwan --- 
Ku Shen Pian --- 
Kuan Dong Hua (3x)/ --- (2x) / Dong Hua Flos Tussilagi Farfarae (6x) 
Lei Gong Teng Herba Polygoni Perfoliali 
Li Zhong Ke Li Midrif Form granules 
Ma Chi Xian Herba Portulacae 
Mai Wei Di Huang Wan --- 
Mi Niao Ning Ke Li --- 
Mi niao ning ke li --- 
Qing Fei Ping Chuan Tang Granules --- 
Qing Qi Hua Tan Pian --- 
Quang Huo Rhizoma Radix Notop Tergii 
Ren Shen Ye Folium Ginseng 
Sang Ju Yin Ke Li Chrysanth Form 
Sang Zhi --- 
Shenzhi Jiaonang --- 
Shu Gan Wan --- 
Shugawan --- 
Su Mu Lignum Sappan 
Te Xiao Yao Tong Ling --- 
Tiang Huang --- 
Wu ji bai fe --- 
Wu ji bai feng wan --- 
Wu Yao R. L. Strychnifoliae 
Xi Zhi Ren Black Cardamom 
Xia Sang Ju Chong Ji --- 
Xiang Yuan Flos C. Mediae 
Xiao Feng Ke Li Lay Wind Form 
Xiao Ji --- 
Xiao Yao San Tangkuei & Bupleurum Formula 
Ya Dan Zi Fructus Brucae Jav 
Yan Fu Mu --- 
Yang Xue Sheng Fa Jiao Nang --- 
Ye Jiae Tang --- 
Yin Chen Herba Artemisiae Scopariae (2x) 
Yu Mi Xu Stigma Maydis 
Yu Zhu (2x)/--- Rhizoma Polygonati/ Polygonati Odorati (2x) 
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Table 6 (continued)  
Chinese common name, as labeled Latin Pharmaceutical name, as labeled 
Ze Lan/ --- Herba Lycopi (2x) 
Zi Cao Radix Arnebiae S. Lithosspermi (2x) 
Zi Cao (2x) Radix Arnebiae (2x) 
Zi Hua Di Ding Herba Violae 
Zuo Gui Wan --- 
--- Aconite Ginseng & Ginger Combination 
--- Artemisia Scoparia 
--- Astragalus extract tablets 
--- Beautifying and slimming tea 
--- Bupleurum & Dragon Bone Combination 
--- Flos Chrysanthemi (3x) 
--- Herba Artemisiae Annuae 
--- Herba Eupatorii Fortunei (2x) 
--- Herba Lobeliae Chinensis Cum Radice (2x) 
--- Plantaginia Semen extract 
--- Radix Phytolaccae 
--- Radix Pulsatilae Chinenses 
--- Radix Rubiae 
--- Rehmannia Eight Formulas 
--- Rhizoma Dryopteria Crassihizomae (2x) 
--- Taraxaci Herbs 
 
Though AAs were absent, some of these products could pose a health risk to the user because they 
may contain other natural toxins. For example, we sampled 2 THPs labeled as Chuan Wu and Radix Aconiti 
Carmichaeli, which is the root of Aconitum carmichaeli. This plant and the related A. kusnezoffii (Cao Wu) are 
used in TCM for the treatment of musculoskeletal disorders and contain the potent neurotoxin and cardiotoxin 
aconitine. In Hong Kong cases of herb-induced aconitine poisonings are treated almost every year [34]. Also 
several herbs were sampled known to contain pyrrolizidine alkaloids (PAs), which are mutagenic and 
carcinogenic hepatotoxicants (for a review see [12]). The PA containing herbs are Zi Cao (Arnebia euchroma and 
Lithospermum erythrorhizon), Kuang Dong Hua (Tussilago farfara) and Pei Lan (Eupatorium fortunei) [35]. 
Altogether, based on our results it can be concluded that especially single herb THPs under the Chinese common 
names of Mu Tong, Fang Ji, Tian Xian Teng and Xi Xin could be contaminated with AAs. Besides single herb 
THPs, certain multi-ingredient THPs can be at risk of adulteration as well (Table 5). In the following paragraphs 
we will expand on the possible reasons of contamination of these particular THPs with AAs. 
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Mu Tong 
We found AAs in 7 out of 14 single herb THPs with the pharmaceutical names Caulis Akebia or Caulis 
Clematis armandii or Mu Tong with or without the prefixes Guan or Chuan. The common Chinese name Guan Mu 
Tong exclusively refers to the stem of Aristolochia manshuriensis [23] and 2 samples exclusively labeled as 
“Guang Mu Tong” [sic] contained an AA I level of 919 mg/kg and 1000 mg/kg or higher and the AA II contents 
were 82 mg/kg and > 100 mg/kg respectively. Hashimoto et al. [3] report AA I contents of A. manshuriensis (Kan-
mokutsu in Japanese) ranging between 0.169 - 0.882 %, which is more than 1.5 - 8.8 times higher than the levels 
we found. Trujillo et al. [30] reported an AA content of 2830 mg/kg in a sample of A. manshuriensis stem. In our 
study another sample verbally indicated to be “Guang Mu Tong” [sic], but labeled as “Caulis Clematidis Armandii”, 
contained no AAs. The stem of Clematis armandii is called Chuan Mu Tong, however. We therefore conclude that 
the prefix Guang was mistaken for Chuan, which would explain the absence of AAs. A further 5 samples labeled 
as Caulis Clematidis Armandii with or without Mu Tong, did as expected not contain AAs. Of the positive samples, 
3 were labeled as a Chuan Mu Tong and Caulis Akebia (stem of A. quinata or A. trifoliata), which to our 
knowledge is not a common combination. The common Chinese name of Caulis Akebia is Bai Mu Tong and not 
Chuan Mu Tong, which refers to the stem of Clematis armandii, and C. montana [1, 23]. Furthermore, 2 THPs 
labeled as Mu Tong, one of which also labeled as Caulis Akebiae, contained high levels of both AA I and AA II. 
These findings strongly underline that the nomenclature of THPs cannot to be relied upon in some cases. Also 
the fact that AAs were found in half of the Mu Tong samples indicates that this group of THPs needs constant 
monitoring. Bensky & Gamble note that in premodern China Akebia was used as Mu Tong but that at present 
Aristolochia manshuriensis is used most often [1]. 
The formula Long Dan Xie Gan Wan is included in the FDA list of potential AA containing herbs and 
formulas [24]. The suffix “Wan” in the formula name refers to pill in Pin Yin [1]. The formula Long Dan Xie Gan 
Tang is reported to contain 10 ingredients among which Caulis Mu Tong [25] for which either Aristolochia 
manshuriensis or the known Akebia spp. and Clematis spp. can be used [1]. In our study, we sampled Long Dan 
Xie Gan and related products with the suffixes “Pian” (tablet) and “Tang” (decoction) [1, 25] and found 41-59 
mg/kg AA I in 3 of 8 related samples. Health authorities such as Health Canada and the MHRA in the UK issued 
warnings against the use of this product in 2002 and 2003 [15, 16]. Synonyms are “Quell fire” and “Lung Tan Xie 
Gan pills” [36]. Quell fire tablets were taken of the market in 2000 and reformulated as requested by the FDA after 
the detection of AAs [37]. We found no AAs in one sample of Quell fire, which had a different lot number and 
expiry date than the earlier recalled lots [37]. A case of end stage renal failure and recurrent carcinomas in the 
bladder due to the 5-year use of Longdan Xieganwan manufactured in China, was reported in the UK [38]. The 
formulas Dao Chi San and Xiao Feng San were sampled each once and were found to be negative for AAs in our 
study. Both formulas contain Caulis Mu Tong but some of the classical sources describe Xiao Feng San without 
this herb however [25]. Xiao Feng San has been found to contain AAs in Australia [17]. The FDA included the 
formula Dao Chi Wan in the listing of THPs suspected to contain AAs [24]. This formula has probably the same 
composition as Dao Chi San except that the latter is a powder (San) instead of a pill (Wan) [25]. It is prudent to 
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include the formulas Long Dan Xie Gan, Dao Chi San and Xiao Feng San in a sampling protocol because of a 
possible inclusion of A. manshuriensis.  
 
Mu Xiang and Tian Xian Teng  
No AAs were detected in 4 related Mu Xiang samples. This common name can refer to the roots of 
Aristolochia debilis, Aucklandii lappa, Saussurea lappa, Inula helenium, I. racemosa and Vladimiria souliei [23]. 
Qing Mu Xian exclusively refers to the root of Aristolochia debilis (see Table 1) but a sample of this THP 
contained contrary to expectations no AAs. Although our samples of Mu Xian, Guang Mu Xian (the root of 
Saussurea lappa) and Vladimiria (Chuan Mu Xian is the root of V. souliei [1]) could potentially be substituted by 
A. debilis we did not detect AAs. This is in agreement with information of the European Agency for the Evaluation 
of Medicinal products (EMEA) [23]. More research is needed however to evaluate the likelihood of this particular 
substitution. Another single herb THP originating from an Aristolochia sp. is Tian Xian Teng, which according to 
the Chinese Pharmacopoeia is Herba Aristolochiae, derived of A. contorta and A. debilis. A sample of this THP 
was found to contain 74 mg/kg of AA I and 33 mg/kg of AA II. Although Tian Xian Teng was sampled once and 
might not be very common on the market it should be included in sampling protocols. 
 
Fang Ji 
In TCM the common name Fang Ji generally refers to several different herbs, namely Cocculus trilobus, 
C. orbiculatus, Stephania tetrandra and Aristolochia fangchi. Guang Fang Ji refers exclusively to Aristolochia 
fangchi and is the only of these species to contain AAs [1, 23]. We sampled 1 THP verbally indicated as Guang 
Fang Ji, which contained no AA however. A low concentration of AA was detected in a sample labeled as Fanji 
and Sclerotium Poriae Cocos. In a THP called Niu Ru Shiu, unknown to us, but also labeled as Cocculi Sarm. 
Rad. traces of AA I were detected. Obviously Rad. stands for Radix and in the FDA list the herbs Cocculus 
sarmentosus and C. trilobus are included as synonyms of Cocculus orbiculatus [24]. The root of C. orbiculatus as 
well as C. trilobus is called Mu Fang Ji in several sources [1, 39] and might therefore be substituted with Guang 
Fang Ji (Aristolochia fangchi) (Table 1) [24]. We found a relatively high AA I concentration of 523 mg/kg and 21 
mg/kg of AA II in the multi ingredient THP Mu Fang Ji Tang, which contains Radix Cocculi Trilobi (Mu Fang Ji) or 
Radix Stephania tetrandra (Han Fang Ji) according to some sources [40, 41] or Radix Aristolochiae fangchi to 
another source [42]. We found no AAs in 3 single herb THP samples labeled as Radix Stephania tetrandra and/or 
Fang Ji. This does not indicate however that Fang Ji requires less attention. An AA contaminated THP labeled as 
Stephania tetrandra was the cause of the Belgian AAN incident [20-22]. In a Swiss survey of AA I in commercial 
samples of slimming regimens consisting of Chinese plant mixtures, 4 out of 42 were tested positive. AA I was 
found in a sample Han Fang Ji declared to be Stephania tetrandra radix and traces were found in Han Fang Ji 
derived of Sinomenium acutum [28]. Both species are listed in the FDA list [24]. Another multi-ingredient THP 
analyzed by the Swiss researchers called Fang Ji Huang Qi Tang contained traces of AA I but a second sample 
did not [28]. We could not detect AAs either in Fang Ji Qi Tang, which could be a related formula. More attention 
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should be focused on multi ingredient THPs and the lists of these THPs potentially containing herbs with AAs 
should be expanded.  
 
Xi Xin 
We found low levels of AA I ranging between the LOQ and 31 mg/kg in 10 out of 11 samples labeled as 
Xi Xin, Xi Xin (Bei) and Herba Asarum or Herba Asarum (North), Herba Asarum cum Radice samples. No AA II 
was found. Xi Xin refers to Asarum sieboldii; the genus Asarum belongs to the Aristolochiaceae and could be 
expected to contain AAs. Hashimoto et al. [3] analyzed the Chinese Asarum spp. A. heterotropoides, A. sieboldii, 
A. splendens and A. himalaicum and A. forbesii and found only traces of AA I in A. splendens and A. himalaicum. 
Schaneberg et al. [4] found up to 370 mg/kg AA I but no AA II in the North American Asarum species A. 
canadense. Although the AA levels found in this study are low, batches of Xi Xin should be routinely screened for 
AAs before they are brought on the market. 
 
Wei Ling Xian and Ba Yue Zha: likelihood of substitution by Aristolochia spp. 
In the FDA list Wei Ling Xian or the root of Clematis chinensis is included as a THP, which may be 
adulterated with AA [24]. The Latin pharmaceutical name is Radix Clematidis and also refers to the roots of C. 
hexapetala and C. uncinata. Substitution of these herbs by the stem of Clematis armandii or C. montana (Chuan 
Mu Tong which can be replaced by the stem of Aristolochia manshuriensis, Guan Mu Tong) (seems not likely 
because the root of these last Clematis spp. is not reported to be in use for Wei Ling Xian [1, 43]. Another 
hypothetical option is confusion between the Wei Ling Xian and Qing Mu Xian (the root of Aristolochia debilis) but 
we found no reports of this substitution. We analyzed 10 samples of Wei Ling Xian/ Radix Clematidis (Chinensis), 
5 samples of Radix Clematidis and a formula containing this herb [25] but no AAs were found. Our results might 
indicate that Radix Clematidis or Wei Ling Xian is not likely to be replaced by Aristolochia spp. Nevertheless the 
FDA reported in 2001 the contamination of a Clematis chinensis extract with AAs [44], more research into this 
substitution is therefore warranted.  
Another herb where substitution by Aristolochia spp. seems unlikely is Fructus Akebiae or Ba Yue Zha. 
According to Bensky & Gamble [1] both names refer to the fruit of Akebia quinata and A. trifoliata. The fruit of 
these plants has also been reported to be referred to as Yu Zhi Zhi in the Pharmacopoeia of the People's 
Republic of China and is entered as such in the FDA list [24, 45]. We found no AAs in 2 samples labeled as 
Fructus Akebiae and Ba Yue Zha. As the common Chinese name of Fructus Akebiae bears no resemblance to a 
common name of any Aristolochia sp. confusion would not seem likely. This has to be supported by additional 
results however, before this specific THP may be considered for removal from the list of suspected materials. It 
might be possible that the fruit of Aristolochia debilis or A. contorta (Ma Dou Ling) and Fructus Akebiae are used 
interchangeably but we are not aware of reports of such a substitution.  
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Exposure data 
The batches of Stephania tetrandra powder which were replaced by Aristolochia spp. in the Belgian AAN 
incident were reported to contain AA levels up to 1.56 g/kg with a mean of 0.65 g/kg [20]. Interestingly only in 2 of 
the 12 investigated batches tetrandrine, the characteristic alkaloid of S. tetrandra, was found and in 1 of these in 
combination with AAs. This would indicate that the rest of the batches consisted of 100% Aristolochia spp. 
replacing S. tetrandra [20]. It was estimated that the cumulative consumption of more than 200 g of these 
powders raised the risk of urothelial carcinoma [21]. This corresponds to a cumulative chronic intake of 130 mg of 
AAs when using the mean AA content reported by Vanhaelen et al. [20]. We sampled a THP labeled as Chuan 
Mu Tong and C. Akebia on the Dutch market with an AA content of 2.1 g/kg consisting of a natural mixture of 1.7 
g/kg of AA I and 0.44 g/kg of AA II (Table 5). In a worst-case scenario 62 g of this THP with the highest AA 
content would supply more than 130 mg of AAs that, considering the Belgian data, could significantly raise the 
risk for cancer. According to Bensky & Gamble the recommended dosage of Mu Tong is 3-9 g, probably per day 
[1]. The authors warn against overdose with reference to a case of acute renal failure following a dose of 60 g. No 
limitation in the duration of use is given. When in our worst case scenario the preparation with the highest AA 
content would be used following the highest dosing regimen, exposure to more than 130 mg of AAs would be 
achieved in 7 days assuming that all AA is released from the matrix. In the Belgian cases of urothelial carcinoma, 
the mean exposure duration was 15 months and generally end-stage renal failure occurred 3 to 85 months after 
cessation of the herbal regimen [21]. In Belgium, the Fang Ji was consumed as a powder, which might have 
increased the exposure to AAs. In China however, Chinese THPs are mostly used as decoctions, which might 
reduce the toxicity of Aristolochia spp. However in Chinese literature 2 cases of acute renal failure after 
consuming a decoction made of 70 g and 175 g of Mu Tong, probably Guan Mu Tong and 4 deaths of renal 
failure after consuming decoctions of 50-120 g of Mu Tong were reported [46, and the references therein]. In the 
UK, 2 cases were reported of end stage renal failure following the use of Mu Tong containing AA I and AA II. Mu 
Tong was consumed by one patient as a tea for 6 years and the other patient used a preparation for 2 years in an 
undisclosed way [47].  
 
 
Conclusion 
 
Our finding that AAs were detected in 25 of 68 THPs sampled on the Dutch market, which could include 
AA containing herbs, indicates that several years after the ban the risk of inadvertent exposure to AAs remains 
significant for those who use these particular THPs. In 1999, the MCA, now the MHRA, found AAs in 40% of the 
samples with Fang Ji and Mu Tong on the UK market [23]. Although the number of samples is relatively small we 
found a similar percentage of samples containing AAs namely 37 % of the suspected samples, which indicates 
that the situation has not improved since. In the UK the use of Mu Tong, Fang Ji, Ma Dou Ling or Qing Mu Xiang 
is prohibited since 2001. Amongst these are also species such as Stephania tetrandra, Clematis spp. and Akebia 
spp., which do not belong to the Aristolochiaceae and do not contain AAs [15]. The Dutch Commodities Act 
Decree ‘Herbal preparations’ used to prohibit the sale of Magnolia officinalis and Stephania tetrandra as well. 
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After a re-evaluation of the literature it was concluded that these herbs in themselves pose little risk and 
subsequently the prohibition of these herbs was discontinued but it was recognized that a risk of substitution of S. 
tetrandra by Aristolochia fangchi remained [48].  
Internationally, the problem of AA contaminated THPs still requires attention several years after 
measures by regulatory authorities in countries as Great Britain, New Zeeland, Canada and Australia and 
publicity generated by this [14-18]. The Belgian AAN tragedy clearly illustrates that contamination of THPs with 
AAs can have very serious consequences. Continued enforcement of the ban of AAs in the Netherlands will show 
if the problem of AA contamination of Chinese THPs is addressed more actively in the field of trade and if stricter 
regulatory measures are warranted. When identified, contaminated products will be removed from the Dutch 
market. The VWA will also in collaboration with customs direct its enforcement at the import of herbal material in 
order to prevent AA containing THPs from entering the market. More research into possible contamination of 
THPs will help to safeguard the quality of Chinese THPs. As contamination is unnecessary TCM practitioners, 
manufacturers, vendors and importers of Chinese THPs should structurally direct efforts to the avoidance of AAs 
in THPs known to have the potential of contamination with AAs. Certification of THPs might aid to prevent the 
import of AA-contaminated products but such a system needs close monitoring. It can be concluded that testing 
of the imported herbs for AA contamination is still essential. 
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Abstract 
 
Traditional herbal preparations (THPs) used in Ayurveda, Traditional Chinese Medicine (TCM), 
Traditional Tibetan Medicine (TTM) and other Asian traditional medicine systems may contain significant amounts 
of mercury, arsenic or lead. Though deliberately incorporated in Asian THPs for therapeutic purposes, these 
constituents have caused intoxications worldwide. The aim of this study was therefore to determine mercury, 
arsenic and lead levels in Asian THPs on the Dutch market. 292 THPs used in Ayurveda, TCM and TTM were 
sampled between 2004 and 2007. Samples were mostly multi ingredient THPs containing herbs and minerals. 
The labeling of less than 20% of the THPs suggested the presence of mercury, arsenic or lead. These elements 
were shown by ICP-MS in 186 (64%) of 292 THPs. Estimated weekly mercury, arsenic and lead intake levels 
were calculated for each THP from the analytically determined concentrations and the recommended dose. 59 
THPs (20%) were likely to result in intakes of these elements significantly exceeding safety limits. Of these 59 
THPs, intake estimates for 50 THPs significantly exceeded the safety limit for mercury (range 1.4-1747 mg/week); 
intake estimates for 26 THPs significantly exceeded the safety limit for arsenic (range 0.53-427 mg/week) and 
intake estimates for 8 THPs were significantly above the safety limit for lead (range 2.6-192 mg/week). It is 
concluded that the mercury, arsenic and lead contents of THPs used in Ayurveda, TCM and TTM remain a cause 
for concern and require strict control. 
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Introduction 
 
In Asian traditional medicine systems such as Traditional Chinese Medicine (TCM), Traditional Tibetan 
Medicine (TTM) and the Indian traditional medicine systems Ayurveda, Unani-Tibb and Siddha, traditional herbal 
preparations (THPs) play an important role [1-4]. In the Netherlands, Asian THPs can be brought on the market 
as food supplements, which do not require prior safety evaluation. Asian THPs have been reported to contain 
herbal toxic principles, undeclared synthetic drugs and significant amounts of mercury, arsenic and lead [5-14]. 
Use of Indian, Tibetan and Chinese THPs has resulted in lead poisonings worldwide and several mercury and 
arsenic intoxications as well [15-31]. In Ayurveda, Siddha, Unani-Tibb, TTM and TCM, ingredients high in the 
metals mercury and lead or the metalloid arsenic are added to THPs for therapeutic purposes [1, 2, 4, 16, 18]. In 
TCM tranquilizing and detoxifying effects are attributed to mercury [16] and nearly 10% of the formulas in the 
Pharmacopoeia of China incorporate the mercury containing mineral cinnabar [32, 33]. In 25% of the 634 
formulas for Ayurvedic THPs in the official Ayurvedic Formulary of India, mercury, lead and arsenic compounds 
are listed as ingredients [34, 35]. An Ayurvedic discipline called ‘Rasa shastra’ is dedicated to the study of the 
therapeutic use of mercury and other metals or metalloids [36]. In most cases high levels of metals or metalloids 
in Ayurvedic THPs result from intentional incorporation of certain metallic preparations called ‘bhasmas’ in the 
products. The metals and metalloids in bhasmas are claimed to be detoxified by elaborate processing steps 
including many cycles of heating and subsequent cooling in herbal mixtures and animal products such as cow’s 
urine or ghee [18, 34, 35, 37, 38]. Comparable preparations called kushtas and parpams are in use in Unani-Tibb 
and Siddha, respectively [1, 2].  
Metals and metalloids can exist in different defined chemical species and the toxicity of these species 
can vary significantly [39]. Available reports consistently point to the presence of inorganic metal or metalloid 
compounds in Chinese, Tibetan and Indian THPs including Ayurvedic THPs. Naga bhasma, a widely used 
Ayurvedic lead preparation [34], contains lead sulfide (PbS); other lead preparations contain lead oxide (PbO) or 
lead sulfate (PbSO4) [37, 38]. In TCM, lithargyrum or ‘mi tuo seng’ (PbO) is used [40]. Important Ayurvedic 
mercury preparations are ‘parada’ (purified mercury), ‘hingula’ (cinnabar, HgS), ‘kajjali’ (HgS) and ‘makaradhvaja’ 
(HgS) [38,41]. In TTM, processed mercury preparations (tsothel) are used as well, which mainly consist of 
mercuric sulfide (HgS) and smaller amounts of mercuric sulfite (HgSO3) and mercuric sulfate (HgSO4) [4]. In 
TCM, mercury is used as cinnabar (zu sha) and as calomel (qing fen, Hg2Cl2) [10, 16, 40, 42, 43]. In both Chinese 
and Ayurvedic THPs, realgar (As4S4), orpiment (As2S3) and arsenolite (As2O3) are used but in Ayurveda these 
minerals are processed before use [10, 40, 42-44]. In certain kushtas (used in Unani-Tibb) As2O3 was found, but 
kusthas can contain other inorganic arsenicals as well [2, 17, 45].  
In 2004, the Dutch Food and Consumer Product Safety Authority (VWA) received reports of two cases of 
lead poisoning linked to the use of Ayurvedic THPs from, respectively, India and Nepal [46, 47]. These cases 
prompted the VWA to intensify investigations into metal and metalloid contents of Asian THPs. The objective of 
this investigation was to study the metal and metalloid contents of Asian THPs on the Dutch market and assess 
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the related risks by comparing the estimated metal and metalloid intake resulting from use at the proposed dose 
levels to established toxicological safety limits. The current report presents the results of this study. 
 
 
Material and methods 
 
Sampling 
VWA inspectors sampled 292 Asian THPs for oral use on the Dutch market between December 2004 
and June 2007. The aim of the sampling plan was to collect commercially available Asian THPs that could 
potentially contain significant amounts of mercury, arsenic or lead. Samples were of Ayurvedic, Chinese and 
Tibetan origin and were directly collected from importers, producers and vendors throughout the Netherlands. The 
locations were selected from the VWA inspection database or identified by an Internet search. No THPs were 
purchased via Internet.  
Per product, one or more units of at least 20 g were sampled. Criteria for inclusion were an apparent 
relation to Ayurveda, TCM or other traditional Asian medicine systems and the presence of ingredients used 
traditionally in these medicine systems. THPs lacking such features were excluded. For instance, a food 
supplement made in China with the contemporary ingredient spirulina or an American supplement with the 
traditional ingredient gingseng but lacking a link with TCM, would be excluded.  
Sampling was aimed at multi ingredient THPs with herbs and minerals but some single herb preparations 
were also included. The labeling of each potential sample was scanned for ingredients listed in Table 1 reported 
to contain mercury, arsenic or lead [7, 16, 34, 35, 42, 44, 48]. We also compared the product name to a list of 
names of classical formulas for Ayurvedic THPs (Table 2) and a list of classical formulas for Chinese THPs (Table 
3) that are reported to include mercury, arsenic or lead compounds. Table 2 was compiled from the official 
Ayurvedic Formulary published by the Indian government [34, 35] by selecting from this source the names of 
formulas for THPs for oral use that included ingredients with lead, mercury or arsenic.  
Table 3 was compiled from the Pharmacopoeia of the People’s Republic of China (English edition of 
1997) by the British Medicine Control Agency supplemented with names of formulas for Chinese THPs which 
were described in a TCM handbook to contain ingredients with lead, mercury and arsenic [40, 48]. Also included 
in Table 3 were Chinese THPs reported to contain mercury, arsenic or lead [5, 10, 16, 25, 33, 44]. THPs with 
ingredients listed in Table 1 or product names listed in Tables 2 or 3 were sampled preferentially, but other THPs 
were sampled as well. 
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Table 1 Traditional names of lead, mercury and arsenic preparations used as ingredients of Asian THPs 
Element  Pharmaceutical or traditional names of 
preparation 
Synonyms and related preparations or compounds 
Lead Lithargyrum (lead monoxide) A: girisindura, litharge, mrddara srnga, mrddarasrnga, 
muddarasankha, sindura 
C: mi tuo seng 
 A: Naga bhasma A: ahi, bhujagalauha, sisaka, 
   
Mercury A: Parada (purified mercury) A: chapala, haraja; isa, mrtasuta, rasa, rasa sindura, rasaraja 
rasendra, rasesa, rasesvara, rasottama, suddhasuta, suta, 
sutaka, 
 Cinnabar (red mercury sulfide) A: aruna, caliya, hingula, hingulotthaparada, hingula 
sambhava suta, suddha hingula 
C: zhu sha, chen sha, dan sha 
 Calomel (mercurous chloride) C: qing fen, shui yin fen, gong fen, chen fen 
 Hydrargyri oxydum rubrum (red mercury oxide)  
   
Arsenic Orpiment (arsenic trisulfide) A: ala, haratala, haritala, tala, talaka 
C: cihuang 
 Realgar (arsenic sulfide or arsenic disulfide) A: manahsila, manayola, sila, 
C: xiong huang, xiong jing, yao huang 
 Arsenolite (white arsenic or arsenic trioxide) A: gauripasana, malla, svetamalla 
C: pishi 
A: traditional name used in Ayurveda 
C: traditional name used in TCM  
References: [7, 16, 34, 35, 42, 44, 48] 
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Table 2 Formulas for Ayurvedic THPs for oral use 
possibly containing mercury, arsenic or lead 
Ayurvedic THP Synonyms 
Agnitundivati Angitundi Vati  
Ajirna Kantaka Rasa  
Amavatari Rasa Amavatari Ras; Amvatari 
Ras 
Amlapittantaka Rasa Amlapittantka Rasa  
Anandabhairava Rasa Anand Bhairav Ras; 
Anandbhairav Ras  
Arogyavardhini Gutika  
Arsakuthara Rasa Arsh Kuthar Ras; Arsha 
Kuthar Rasa 
Astaksari Gutika  
Asvakancuki Rasa Ashwakanchuki Ras  
Balarka Rasa Balark Rasa  
Bola Parpati Bol Parpati 
Brhadagnikumara Rasa  
Brhanmaricadya Taila  
Brhat Candrodaya 
Makaradhvaja 
 
Brhat Garbhacintamani 
Rasa 
Brihat Garbhachintamani 
Rasa; Garbha Chintamani 
Ras Vrihat   
Brhat Kasturibhairava 
Rasa 
Brihat Kasturi Bhairav Rasa 
Brhat Nrpavallabha Rasa  
Brhat Purnacandra Rasa Brihat Purnachandra Rasa 
Brhat Sarvajvarahara 
Lauha 
Sarvajwarhar Loha Br.  
Brhat Vangesvara Rasa Bangeshwar Ras Brihat  
Brhat Vatacintamani Rasa Brihat Vata Chintamani; 
Brihat Vatchintamani Rasa 
Brhat Vidyadharabhra 
Rasa  
 
Brhat Visamajvarantaka 
Lauha 
 
Brhatcchrngarabhra Rasa  
Candrakala Rasa Chandrakala Ras (Tamra 
Yukta)  
Table 2 (Continued)  
Ayurvedic THP Synonyms 
Candramrta Rasa Chandramrit Ras  
Candramsu Rasa  
Caturbhuja Rasa Chaturbhuj Rasa  
Caturmukha Rasa Chaturmukh Ras  
Cintamanicaturmukha 
Rasa 
 
Ekangavira Rasa Kangveer Ras; Ekangvir 
Ras  
Gaganasundara Rasa  
Gandamala Kandana Rasa  
Gandhaka Vati Gandhak Bati (Raj Bati) 
Garbha Cintamani Rasa  
Garbhapala Rasa Garbhapal Ras  
Gorocanadi Vati Gorochandi Vati  
Grahani Kapata Rasa Grahani Kapat Ras  
Guducyadi Modaka  
Gulma Kalanala Rasa Gulma Kalanal Ras  
Haritala Bhasma Harital Bhasma 
Hemagarbha Pottali Rasa  
Hemanatha Rasa Hemnath Ras 
Hingulesvara Rasa  
Hiranya Garbha Pottali 
Rasa 
 
Hrdanyarnava Rasa Hridayarnava Ras  
Icchabhedi Rasa Ichhabhedi Ras (Jaypal 
Yukta)  
Jalodarari Rasa  
Jvaraghni Gutika  
Jvarankusa Rasa (Ka)  
Jvararyabhra  
Kalakuta Rasa  
Kanakasundara Rasa  
Kancanabhra Rasa  
Kantavallabha Rasa Khantavallabha Rasa 
Karpura Rasa Karpur Ras 
Kasisadi Ghrta  
Kasturi Bhairava Rasa Kastoori Bhairav Ras 
Kasturyadi Vayu Gutika  
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Table 2 (Continued)  
Ayurvedic THP Synonyms 
Kravyada Rasa  
Krmi Kuthara Rasa Krimi Kuthar Rasa 
Krmimudgara Rasa Krimimudgar Ras  
Kumarakalyana Rasa Kumarkalyan Rasa  
Laghvananda Rasa  
Lakanatha Rasa  
Laksminarayana Rasa Laxminarayan Rasa 
Laksmivilasa Rasa Laxmivilas Ras; Laxmi 
Vilas Rasa 
Lauha Parpati  
Lila Vilasa Rasa Lilavilas Rasa 
Mahagandhaka Vati  
Maha Jvarankusa Rasa Mahajwarankush Ras; 
Mahajvarankush Rasa 
Maha Laksmivilasa Rasa Mahalaxmi Vilas Rasa; 
Mahalaxmivilas Ras; 
Mahalakshmi Vilas Ras 
Mahatarunarka Rasa  
Maha Vata Vidhvamsana 
Rasa 
Mahavatvidhvasan Ras; 
Mahavatvidhvansan Rasa; 
Mahavat Vidhwans Ras  
Maha Vatagajankus A 
Rasa 
 
Maha Yogaraja Guggulu Maha Yograj Guggul 
Makara Dhvaja Makardhwaj; Makardhvaj 
Rasa  
Mallasindura Mallasindur  
Manikya Rasa  
Manmathabhra Rasa  
Maricadya Taila  
Mrtyunjaya Rasa Mrityunjai Ras 
Muktapancamrta Rasa Mukta Panchamrit Ras; 
Moti Yukt  
Naga Bhasma Nag Bhasma 
Naraca Rasa  
Navaratnarajamrganka 
Rasa 
 
Nidrodaya Rasa  
Table 2 (Continued)  
Ayurvedic THP Synonyms 
Nityananda Rasa  
Nrpativallabha Rasa Nripatiballabha Ras 
Pancamrta Lauha Guggulu  
Pancamrta Parpati Panchmrita Parpati  
Pancanana Rasa  
Piyusavalli Rasa Piyushvali Ras  
Prabhakara Rasa  
Pradarantaka Lauha Pradarantak Lauh 
Pradarantaka Rasa Pradarantak Rasa  
Pratapalankesvara Rasa Prataplankeshwar 
Purnacandra Rasa Purnachandra Ras  
Puspadhanva Rasa Pushpadhanwa 
Putapakva Visama 
Jvarantaka Lauha  
 
Rajamrganka Rasa  
Rajata Bhasma  
Rasa Parpati Ras Parpati 
Rasakarpura  
Rasamanikya Rasa Manikya 
Rasapuspa  
Rasaraja Rasa Ras Raj Ras; Rasraj Rasa 
Rasasindura Rasa Sindur  
Ratnagiri Rasa  
Samirapannaga Rasa Samirpannag Rasa  
Sankha Vati Shankhavati;  
Shankh Vati 
Saubhagya Vati Saubhagya Bati 
Siddhapranes Vara Rasa Siddhapraneshwar Rasa 
Sirah Suladi Vajra Rasa Shirahsuladrivajara Ras  
Smrti Sagara Rasa Smritisagar Ras; Smriti 
Sagar Rasa 
Sri Jayamangala Rasa  
Sri Ramabana Rasa  
Srinrpativallabha Rasa  
Srngarabhra Rasa Shringarabhra Ras 
Sucikabharana Rasa  
Sukramatrka Vati Shukramatrika Vati 
Sulavajrini Vatika Shoolvarjini Vati 
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Table 2 (Continued)  
Ayurvedic THP Synonyms 
Sutasekhara Rasa Soothashekara; 
Sutshekhar Rasa; 
Sutsjekhar Rasa  
Sutikabharana Rasa Sutikabharan Ras  
Svacchanda Bhairava 
Rasa 
 
Svalpanayika Curna  
Svarna Bhasma Swarna Bhasma 
Svarna Parpati Swarna Parpati 
Svarnabhupati Rasa  
Svarnasindura  
Svarnavanga  
Svasa Kasa Cintamani 
Rasa 
Shawsa Kasa Chintamani; 
Swasakas Chintamani 
Rasa  
Svasakuthara Rasa Swas Kuthar Ras; Swasa 
Kuthara Ras; Shwas 
Kuthar Rasa 
Tamra Bhasma  
Tamra Parpati  
Tarakesvara Rasa  
Tarunarka Rasa  
Tribhuvanakirti Rasa Tribhuvankirti  
Trivanga Bhasma Tribanga Bhasma 
Trivikrama Rasa  
Unmadagajakesari Rasa  
Vajrakapata Rasa  
Vanga Bhasma  
Varisosana Rasa  
Varja Bhasma  
Vasanta Malati Rasa  
Vasanta Tilaka Rasa  
Vasantakusumakara Rasa Vasant Kusumakar Rasa  
Vata Gajankusa Rasa Vatagajankush Ras; 
Vatgajankush Rasa 
Vatagnikumara Rasa  
Vatakulantaka Rasa Vatkulantak Ras; 
Vatakulantak Ras 
Table 2 (Continued)  
Ayurvedic THP Synonyms 
Vataraktantaka Rasa  
Vatari Rasa Vatari Ras 
Vatavidhavamsana Rasa  
Vidanga Lauha  
Yakrdari Lauha  
Yakrtplihari Lauha Yakritplihari Loha 
Yogendra Rasa  
References: [34, 35] 
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ICP-MS determination of metals and metalloids 
A routine method for the determination of metals and metalloids in herbal preparations with Inductively 
Coupled Plasma Mass Spectrometry (ICP-MS) was developed and validated for several elements including 
arsenic, lead, and mercury. Routinely cadmium, zinc, copper, nickel, chromium and aluminum were monitored as 
well. Samples were completely homogenized by grinding them to powder with a grinder (Retsch). To 20 - 100 mg 
(depending on the elements to be measured) of the powdered sample 3 ml nitric acid (HNO3, 65%) and 1 ml 
hydrogen peroxide (H2O2, 30%) were added. A destruction step was then performed using a microwave oven 
(Ethos Plus Microwave Labstation, Milestone) in which the samples were treated for 25 minutes at 200ºC. The 
solution produced by the destruction process was then quantitatively transferred with de-ionized water from the 
destruction vessel to a 50 ml volumetric flask. Before filling the flask to the 50 ml mark with de-ionized water, 500 
µl aureumchloride (AuCl, 100 mg/L) solution was added. Throughout the analysis Milli-Q grade de-ionized water 
was used. The sample solutions were diluted (up to 10000 times) when necessary to fit within the calibration 
curve and measured with ICP-MS (Thermo Electron PQ Excell) using the ‘Collision Cell Technology mode’ (CCT-
mode) with a helium/hydrogen flow (95/5%). Using this gas mixture in the CCT-mode most interferences were 
reduced [49].  
In order to test if each destruction vessel was clean prior to use, test runs were performed on each 
vessel with only 3 ml HNO3 (65%) and 1 ml H2O2 (30%) before each series of samples. This was repeated after 
each series in order to confirm that no metals or metalloids were left in the vessels. For the in house validation of 
the method, first the limits of detection and quantification (LOD and LOQ) were determined. The LOD was defined 
as three times the residual standard deviation of the standard calibration curve. The LOQ was defined as twice 
the LOD. The range of the calibration curve was used to calculate the range of application. Samples were diluted 
and reanalyzed when concentrations appeared to exceed the highest concentration of the calibration curve. The 
accuracy of the method was determined by analysis of a Certified Reference Material (CRM)(IRMM; BCR 482: 
trace elements in Lichen). The analytes of this CRM had to be within the 95% confidence interval of the certified 
values.  
Furthermore, the relative standard deviation (RSDr) was measured by replicate analysis (n=6) of the 
CRM under repeatability conditions. The RSDr is a measure of the degree of agreement of results obtained by the 
same analyst with identical reagents, equipment and instruments within a short period of time under conditions 
kept as constant as possible. The CRM was also used as quality control sample in each series of measurements. 
The expanded measurement uncertainty (in mg/kg) was determined as the reproducibility from measurements 
(n>10) of this CRM, analyzed by different persons on different days.  
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Table 3 Formulas for Chinese THPs for oral use 
possibly containing mercury, arsenic or lead 
Product Name Toxic substance 
Ailing Yihao (a) Arsenolite 
Angong Niuhuang San, -Wan (b, 
c, d) 
Cinnabar, Realgar 
An Shen Bu Nao Pian  
(Ansenpunaw tablets) (c) 
Cinnabar 
Bai Zi Yang Xin Wan (c) Cinnabar 
Baochi San Cinnabar 
Baochiwanying-san (e) Cinnabar 
Baolong Wan Cinnabar 
Bao Ning Dan (f)  
Bao Ying Dan (c) Cinnabar 
Bingpen San Cinnabar 
Biwen San Cinnabar 
Bushen Yinao Pian Cinnabar 
Chunyang Zhengqi Wan Cinnabar, Realgar (+ 
Aristolochia Radix) 
Ci Zhu Wan (b, c) Cinnabar 
Da Huo Luo Wan (d) high mercury content 
reported (d) 
Da qili San Cinnabar (g) 
Dendrobium Moniliforme Night 
Sight Pills (d) 
high mercury content 
reported (d) 
Ding Xian Wan (b) Cinnabar 
Ershiwuwei Shanhu Wan Cinnabar 
Ershiwuwei Songshi Wan Cinnabar 
Feierwanyaopian (e)  
Geng Yi Wan (b) Cinnabar 
Hongling San Cinnabar, Realgar 
Hua Chong Wan Red lead oxide 
Hui Chun Dan (b) Cinnabar 
Hu Po Bao Long Wan (Po Lung 
Yuen Med. Pills) (c) 
Cinnabar 
Jian Nao Wan (healthy brain 
pills) (c) 
Cinnabar 
Jierezhenluesan (e) Cinnabar 
Jiusheng San Calomel, Hydrargyri 
Oxydum Rubrum 
Table 3 (continued)  
Product Name Toxic substance 
Jiuyi San Hydrargyri Oxydum 
Rubrum 
Jufangniuhuang-qingxinwan (e) Cinnabar, Realgar 
Jufang Zhibao San Cinnabar, Realgar 
Liushenwan(e)/ Liu Shen Wan (b) Realgar 
Meihua Dianshe Wan Cinnabar, Realgar 
Niuhuang Baolong Wan Cinnabar, Realgar 
Niu Huang Cheng Qi Tang (b) Cinnabar, Realgar 
Niu Huang Chiang Ya Wan high mercury and arsenic 
contents reported (d) 
Niu Huang Ching Hsin Wan high mercury and arsenic 
contents reported (d) 
Niuhuang Jiedu Pian Realgar 
Niuhuang Jiedu Wan Realgar 
Niuhuang Qianjin San Cinnabar 
Niuhuangqingfei-san (e) Cinnabar, Realgar 
Niu Huang Qing Xin Wan (b) Cinnabar, Realgar 
Niuhuang Zhenjing Wan Cinnabar, Realgar 
Peaceful (c) Cinnabar 
Pinggan Shuluo Wan Cinnabar 
Po Lung Yuen Med. Pills (c) Cinnabar 
Qianjinsan (e) Cinnabar 
Qi Li San (b, c) Cinnabar 
Qizhen Wan Cinnabar, Realgar 
Renqing Changjue Cinnabar 
Renqing Mangjue Cinnabar 
San Li Hui Chun Dan (c) Cinnabar 
Shayao Cinnabar, Realgar 
She Dan Chen Pi San (c) Cinnabar 
Sheng Tie Luo Yin  
Shixiang Fansheng Wan Cinnabar (+ Aristolochia 
Radix) 
Shugan Wan Cinnabar 
Shuzheng Pian Cinnabar, Realgar 
Suhexiang Wan/ Su He Xian 
Wan (b, c) 
Realgar 
Ta Huo Lo Tan (d) high mercury and arsenic 
contents reported (d) 
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Table 3 (continued)  
Product Name Toxic substance 
Tianwang Buxin Wan Cinnabar 
Tiewadan (e) Cinnabar 
Tse Koo Choy (c) Calomel 
Tsai Tsao Wan (d) high mercury and arsenic 
contents reported (d) 
Tzuhsueh Tan (Zi Xue Dan) (c) Cinnabar 
Wanshi Niuhuang Qingxin Wan/ 
Wan Shi Niu Huang Qing Xin 
Wan (c) 
Cinnabar 
Watermelon frost (Xi Gua 
Shuang) (c) 
Cinnabar 
Xiangsu Zhengwei Wan Cinnabar 
Xiao’er Baishou Wan Cinnabar 
Xiao’er Huadu San Realgar 
Xiao’er Jindan Pian Cinnabar (+ Aristolochia 
manshuriensis) 
Xiao’er Jingfeng San Cinnabar, Realgar 
Xiaoerqifengsan Cinnabar 
Xiao’er Qingre Pian Cinnabar, Realgar 
Xiaoerqiyingwan (e) Cinnabar (arsenic also 
detected) (e)  
Xiao’er Zhibao Wan Cinnabar, Realgar 
Xi Gua Shuang (Watermelon 
frost) 
Cinnabar 
Yatong Yili Wan Cinnabar, Realgar 
Yinianjin Cinnabar 
Yingerbaofeining (e) Cinnabar 
Yingerle (e) Cinnabar 
Yixian Wan Cinnabar, Realgar 
Yi Yuan San (b) Cinnabar 
Zaizao Wan Cinnabar  
Zhi Bao Dan Cinnabar, Realgar 
Zhou Che Wang (b) Calomel 
Zhuhuang Chuihou San Realgar 
Zhu Sha An Shen Wan (b, c) 
(Cinnabar sedative pill) 
Cinnabar 
Zijin Ding/ Zi Jin Ding (c) Cinnabar, Realgar 
Table 3 (continued)  
Product Name Toxic substance 
Zixue Cinnabar 
Zi Xue Dan (b,c) (Tzuhsueh Tan) 
(c) 
Cinnabar 
Based on [48]. Additional references: a) [44]; b) [40]; c) [16];  
d) [5]; e) [10]; f) [25]; g) [33] 
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Table 4 lists the method performance characteristics as the LOD, LOQ, range of application, accuracy, 
RSDr and the measurement uncertainty (in mg/kg). According to the AOAC guidelines for single laboratory 
validation of chemical methods for botanicals and dietary supplements, the accuracy has to be between 75 and 
120% at the measured concentrations [50]. The values for the accuracy of the method for mercury, arsenic and 
lead as listed in Table 4 fitted well within these limits as did the other elements that can be analyzed with this 
method. The RSDr for all elements was found to be below 10% with mercury displaying the highest value of 9.5%. 
These values are also in accordance with this AOAC program that requires the RSDr to be below 10% at the 
measured concentrations. For the elements Al, Ni, Cu and Zn the limits of detection and quantification were about 
10 times higher than that of mercury, which has an LOD of 0.03 mg/kg. Addition of AuCl to the sample and flush 
solutions helped to overcome initial problems with persistent mercury residues in the system because of the 
capacity of mercury to complex with gold [51].  
 
Table 4 Characteristics (limit of detection (LOD), limit of quantification (LOQ), range of application, accuracy and 
expanded measurement uncertainty) of the analytical method for Pb, As and Hg determined by in house 
validation 
Element LOD 
(mg/kg) 
LOQ 
(mg/kg) 
Range of 
application 
(mg/kg) 
Accuracy (a) 
(%) 
RSDr (b) 
(%) 
 Expanded Measurement Uncertainty (c) 
(mg/kg) 
Pb 0.18 0.36 0.25 – 12.5 103 5.1 3.4 (at level of 37.3 mg/kg) 
Hg 0.03 0.06 0.25 – 12.5 99 9.5 0.047 (at level of 0.549 mg/kg) 
As 0.06 0.13 0.25 – 12.5 96 2.1 0.09 (at level of 0.89 mg/kg) 
a) Accuracy has to be between 75 and 120% [50] 
b) Relative Standard Deviation (RSDr) may not exceed 10% [50] 
c) The expanded measurement uncertainty (mg/kg) was calculated as the reproducibility at the concentration level of the 
CRM. 
 
Estimation of the weekly mercury, arsenic or lead intake and selection of safety limits 
At the time of completion of this study neither Dutch nor European food law contained maximum levels 
for mercury, arsenic or lead in food supplements. We based our enforcement actions therefore on the legal 
requirement that only safe foods are to be placed on the market. In order to assess the safety of a THP we 
estimated the associated intake of mercury, lead and arsenic and subsequently compared the estimated intakes 
of these elements to established safety limits. The estimated mercury, arsenic or lead intake per week was 
calculated from the analytically determined concentrations of these elements, the unit dose weight and the 
highest recommended daily dose stated on the label of the THP. In a few cases where no recommended dose 
could be identified on the label or from other sources a default value was used of, depending on the dose form, 
one pill or 1 g of powder per day. We did not consider background exposure from other sources such as foods, 
water or ambient air in our risk assessment. For each of these three elements we selected an established safety 
limit by reviewing risk assessments by international and national bodies. We preferentially considered safety limits 
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for inorganic mercury, arsenic and lead compounds because available sources on the speciation of these 
elements in Chinese, Ayurvedic and other Asian THPs consistently indicated that mercury, arsenic and lead are 
present as inorganic compounds [2, 4, 10, 16, 17, 34, 35, 37, 38, 40-43, 45, 52, 53]. Examples of the risk 
assessments by international and national bodies reviewed are shown in Table 5 [9, 54-61].  
 
Table 5 Safety limits for lead, mercury and arsenic 
Element Safety limit  Safety limit set by Safety limit set for Tolerable weekly intake 
(mg/week) (a) 
Lead 4.5 µg/day  US Pharmacopoeia-
specification (b) 
Lead from a daily dose of 
calcium carbonate  
0.0315 
 25 µg/kg bw/week  
 
JECFA-PTWI (c) Lead from all food sources 1.5 
Mercury 0.3 µg/kg bw/day  US EPA-RfD (d) Mercuric chloride 0.126 
 5 µg/kg bw/week JECFA-PTWI  (e) Total mercury from diets high 
in methylmercury 
0.3 
 2 µg/kg bw/day 
 
IPCS-TDI (f) /RIVM-TDI (g) Inorganic mercury 0.84 
Arsenic 0.3 µg/kg bw/day  US EPA-RfD (h) Inorganic arsenic 0.126 
 1.0 µg/kg bw/day RIVM-TDI (g) Inorganic arsenic 0.42 
 15 µg/kg bw/week JECFA-PTWI (i) Inorganic arsenic 0.90 
 3 µg/kg bw/day ANZFA-TDI (j) Inorganic arsenic 1.26 
a) Calculated for a 60 kg adult 
References: b) [9]; c) [54]; d) [55]; e) [56]; f) [57]; g) [58]; h) [59]; i) [60]; j) [61] 
 
From the selected safety limit we calculated a tolerable weekly intake (TWI) limit for a 60 kg adult. For 
mercury we selected the TDI for inorganic mercury of 2 µg/kg bw/day set independently by the Dutch National 
Institute for Public Health and the Environment (RIVM) and the International Program on Chemical Safety (IPCS) 
[57, 58]. This TDI is equivalent to a TWI limit of 0.84 mg per week for a 60 kg adult (Table 5). For arsenic we 
selected the TDI for inorganic arsenic set by RIVM of 1.0 µg/kg bw/day, equivalent to a TWI limit of 0.42 mg per 
week for a 60 kg adult (Table 5) [58]. For lead we selected the provisional tolerable weekly intake (PTWI) limit for 
lead from all sources of 25 µg/kg bw/week established by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA), equivalent to a TWI limit of 1.5 mg per week for a 60 kg adult (Table 5) [54, 62]. 
In agreement with European Regulation (EC) No. 333/2007 we established for enforcement purposes for 
mercury, arsenic or lead each, the estimated weekly intake level at which the TWI limit is exceeded beyond 
reasonable doubt [63]. We derived these VWA action limits by adding to the selected TWI limit for the element, 
the analytically obtained expanded measurement uncertainty for the estimated weekly intake (in mg/week). For 
the estimated lead intake of a THP, a VWA action limit of 1.85 mg per week was derived. The VWA action limit for 
the estimated weekly intake of mercury was 1.31 mg per week and for arsenic the VWA action limit was a 
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maximum estimated weekly intake of 0.510 mg per week. Recently the European Commission established for 
food supplements maximum product levels of 0.10 mg/kg for mercury and 3.0 mg/kg for lead, which will enter into 
force on the 1st of July 2009 [64]. No limit has yet been proposed for arsenic in food supplements. We also 
applied these EU maximum levels to our data to estimate the effect of this new legislation on the availability of 
Asian THPs with mercury or lead on the Dutch market. Furthermore, we applied safety limits used in several 
pertinent studies on mercury, arsenic or lead in Asian THPs to our data in order to explore how the selection of 
other relevant limits would have affected the outcome of the study. 
 
 
Results 
 
Mercury, arsenic or lead contents of THPs 
In total 186 (64%) of 292 THPs used in Ayurveda, TCM and TTM contained arsenic, mercury or lead. 
Figure 1 shows for lead, mercury and arsenic separately, how the THPs were distributed over increasing 
concentration ranges of these elements. The labeling of less than 20% of the THPs did contain indications that 
matched an entry of Tables 1, 2 or 3, which would suggest the presence of ingredients with mercury, arsenic or 
lead levels. The remaining THPs were sampled according the general criteria of the defined sampling protocol to 
test the presence of mercury, arsenic or lead in Asian THPs prevalent on the Dutch market.  
 
 
 
 
Figure 1 Concentrations of lead, mercury and arsenic in THPs; nd: not detected 
 
 nd 0 1 10 102  103  104 105  106 
Metal or metalloid concentration (mg/kg) 
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Lead was present in 123 (42%) THPs and levels ranged from 0.5 to a maximum of 60 000 mg/kg that 
was found in the Ayurvedic THP Vasant Yog. The average lead level in the positive samples was 1,000 mg/kg; 
the median level was 13 mg/kg and the 95th percentile 573 mg/kg. Mercury was found in 131 (45%) THPs in 
levels from 0.2 up to 171 000 mg/kg and the highest concentration was found in the Ayurvedic THP Yogendra 
Ras. The average mercury level in the positive samples was 11 800 mg/kg, the median level was 50 mg/kg and 
the 95th percentile was 86 000 mg/kg. In 105 (36 %) of the 292 collected THPs arsenic was present in levels 
ranging from 0.2 up to 89 800 mg/kg, the latter in the Ayurvedic THP Swashanti Yog. The average arsenic level in 
the positive samples was 2300 mg/kg; the median level was 7.6 mg/kg and the 95th percentile for arsenic of 7600 
mg/kg. In a few cases low levels of cadmium were found but the associated estimated intakes were not above 
international safety limits (data not shown). Table 6 shows for lead, arsenic and mercury separately the number of 
Ayurvedic, Chinese and Tibetan THPs in which these elements were detected above the LOQ. 
 
Table 6 Number of Ayurvedic, Chinese and Tibetan THPs with lead, mercury or arsenic above the limit of 
quantification 
 No. of Ayurvedic THPs No. of Chinese THPs No. of Tibetan THPs 
Total of the THP type sampled 242 42 8 
Lead above LOQ (a) 105 13 5 
Mercury above LOQ 117 8 6 
Arsenic above LOQ 85 15 5 
Total of THPs with at least one element 
above LOQ 
161 19 7 
a) LOQ: Limit of quantification 
 
Estimated weekly metal or metalloid intakes in relation to the selected safety limits 
In total 64 (22%) of 292 THPs were likely to result in weekly intakes of lead, arsenic or mercury, 
separately or in combination, above the selected TWI limits when used according to recommendations. Levels of 
these elements in 59 of these 64 THPs would result in intakes that also exceeded the VWA action limits; this 
signified that in total for 59 (20%) of the 292 THPs the estimated intakes of lead, arsenic or mercury would 
exceed the selected TWI limits beyond reasonable doubt (Table 7). In total 25 THPs from Table 7 carried 
indications that according to Table 1, 2 and 3 suggested that ingredients high in mercury, arsenic or lead could be 
present. Use according recommendations of the Ayurvedic THPs ‘Raja Parvatini’, ‘Vasant Yog’ and ‘Nature Slim’ 
would result in daily doses of lead, mercury and arsenic above all 3 VWA action limits simultaneously. 
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Table 7 Asian THPs resulting in estimated lead, mercury or arsenic intakes significantly above one or more TWI 
limits 
Arsenic Mercury Lead Asian THP Type of Asian 
THP (a)  mg/week  
Abhrak Bashma A 0.82 nd 1.3 
Abhrak Bhasma A 1.0 nd 1.6 
Agni Vati A nd 72 nd 
Amrit Prash A 0.1 5.1 0.04 
Amrit Ras A 1.8 377 0.27 
Arjuna Hepatone A nd 198 1,0 
Arogya Vardhini Vati A nd 338 nd 
Arogyavardhini Vishisht A 0.04 1.9 0.21 
Ayfer A 0.05 0.12 4.0 
Ayu-Hirakam A 0.21 2.6 0.14 
Bat Chintamani A 2.2 471 0.26 
Bo Zi Yang Xin Wan C nd 1473 nd 
Chandraprabha A 0.07 nd 15 
Diabetomed A 1.4 3.5 0.41 
Ding Xin Wan C 0.44 430 1.3 
Ere Forte A nd 12 0.34 
Femi-Smilin A 7.5 0.73 0.33 
Gandhadi Yog A nd 11 nd 
Ghandramsu Ras A nd 132 0.14 
Guggulu A 0.38 7.9 3.1 
Gurgum-8 T 2.9 317 0.04 
Guyu Depak T 0.47 192 0.1 
Guyu Depak T 0.94 239 0.15 
Heartina A 262 340 nd 
Herba Figura A 0.07 2.3 0.07 
Herbo Gastrol A nd 14 0.33 
Herbogastrol A nd 12 0.23 
Herbogastrol A nd 27 nd 
Hridaya Chintamani A 2.6 396 nd 
Jeevani Vati A 0.22 173 nd 
Kamachudamani Ras A 7.7 22 0.27 
Liv.52 A nd nd 2.6 
Luxmi Vilas Classic A 0.02 138 0.05 
Maha Manjishtadi Ghan Vati A 0.04 4.2 0.09 
Maha Ras Guggul A 1.0 1.2 0.03 
Mahabatbiddhonsan Ras A 0.08 69 78 
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Table 7 (continued)     
Arsenic Mercury Lead 
Asian THP 
Type of Asian 
THP (a)  mg/week  
Makar Wazra A 5.0 903 nd 
Mutik-25 T 0.53 146 nd 
Natureslim A 79 111 192 
Pesin A 0.9 923 0.07 
Raja Parvartini A 2.2 7.2 5.4 
Ras Yog A 0.04 92 nd 
Ru Pi Xiao Pian C 1.1 nd nd 
Sanjiwani A 427 nd nd 
Shatavari A 1.3 2.4 0.14 
Shingorabrak A nd 162 nd 
Shringrabhra A 0.8 20 0.12 
Shringrabhra A nd 26 1.2 
Sirshool Vajraras A 0.05 299 1.1 
Swas Kuthar Ras A 66 65 0.11 
Swashanti Yog A 200 118 nd 
Sworna Yog A 1.5 70 nd 
Tianwang Buxin Wan (b) C nd 24 0.17 
Triyog Misran A nd 71 nd 
Ulceromed A 0.03 22 0.10 
Vasant Yog A 0.60 57 105 
Yogendra Ras A 0.06 274 0.18 
Yograj Guggulu A 0.08 1.4 1.6 
Zhui Feng Tou Gu C 5.1 1747 0.67 
Estimated element intake values in bold are above the VWA action limit for that element at the proposed use level; values in 
italics are between the TWI limit and the VWA action limit.  
nd: not detected. 
a) THP types sampled: ‘A’ for Ayurvedic THPs, ‘C’ for Chinese THPs, ‘T’ for Tibetan THPs 
b) The daily dose assumed to be 1 pill (0.195 g) 
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Figure 2 shows for lead, mercury, and arsenic, respectively, the distribution of THPs over increasing 
ranges of weekly intake estimates in relation to the individual TWI limits for these elements. The median intake of 
lead with THPs positive for this metal was 0.11 mg/week, the median intake of mercury with THPs containing this 
metal was 0.52 mg/week and the median arsenic intake with THPs positive for this metalloid was 0.08 mg/week. 
The lead intake estimates at proposed dose levels for 10 THPs exceeded the TWI limit of 1.5 mg lead per week 
(range 1.6-192 mg/week) (Figure 2) and the lead intake estimates for 8 of these also exceeded the VWA action 
limit of 1.85 mg/week. Of these 10 THPs, 8 THPs would at their proposed dose levels also result in intakes above 
TWI limits for arsenic or mercury or both as well. 
 
 
Figure 2 Estimated weekly intake of lead, mercury and arsenic resulting from intake of THPs at their proposed use levels; 
‘TWI’ refers to the tolerable weekly intake limit for each element; for lead the TWI is 1.5 mg/week, for mercury 0.84 mg/week 
and for arsenic 0.42 mg/week; nd: not detected 
 
The estimated mercury intake at the proposed dose level of 55 THPs would be above the TWI limit of 
0.84 mg inorganic mercury per week (range 0.92-1747 mg/week) (Figure 2) and mercury intake estimates of 50 of 
these were also above the VWA action limit of 1.31 mg/week. Of 26 of these 55 THPs, the intake of arsenic or 
lead resulting from their proposed dose levels, would also be in excess of the TWI limits for one or both of these 
two elements. We found 29 THPs where the proposed dose levels would result in arsenic intakes above the TWI 
limit for arsenic (range 0.44-427 mg/week) (Figure 2) and the proposed dose levels of 26 of these would result in 
intakes above the VWA action limit for arsenic of 0.510 mg/week. Additionally, the proposed dose levels of 24 of 
these 29 THPs would also give rise to mercury or lead intakes in excess of the TWI limits selected for these 
metals.  
 nd 0 TWI 10 102  103  104 
 Weekly intake of metal or metalloid (mg/wk) 
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Table 8 shows for lead, mercury and arsenic separately, the number of Ayurvedic, Chinese THPs and 
Tibetan THPs for which use at their proposed dose levels would result in intakes above TWI limits for each of 
these elements.  
 
Table 8 Number of Ayurvedic, Chinese and Tibetan THPs where use at the proposed dose levels results in lead, 
mercury or arsenic intakes above TWI limits 
  No. of Ayurvedic THPs No. of Chinese THPs No. of Tibetan THPs 
Total of THP in study  242 42 8 
Lead intake above TWI 10 na na 
Mercury intake above TWI 46 5 4 
Arsenic intake above TWI 22 3 4 
Total of THPs with at least one element 
above TWI 
50 5 4 
na: not applicable 
 
In addition to the TWI limits applied above, we also compared our estimated intake data to other relevant safety 
limits for mercury, arsenic and lead as well as to the maximum levels for lead and mercury in food supplements 
recently established by the European Commission [64]. Table 9 shows the number of THPs where use according 
to recommendations would result in intakes of mercury, arsenic and lead above these other safety limits [9, 54-
61, 64]. When the newly defined European maximum levels for lead and mercury were applied, the highest 
number of exceedances was seen: 101 (82%) of 123 of THPs positive for lead and 130 (99%) of 131 of the 
products containing mercury were above these limits (Table 9).  
 
 
Discussion 
 
Mercury, lead and arsenic were detected in 186 (64%) of 292 THPs used in Ayurveda, TCM and TTM 
sampled in the Netherlands. Use at the proposed dose levels of 59 (20%) of these 292 THPs would result in 
estimated mercury, arsenic and lead intakes significantly above established safety limits. Furthermore, 82% of the 
THPs with lead and 99% of the THPs containing mercury exceeded the recently established European maximum 
product levels for food supplements (Table 9) [64]. Our results are in good agreement with several studies on 
mercury, arsenic and lead contents of Asian THPs sampled in Western and Asian countries. Saper et al. reported 
in 2004, mercury, arsenic or lead in 20% of 70 Ayurvedic THPs collected in Boston and the estimated intakes of 
these elements at proposed use levels were all above selected safety limits [9]. Lead was found in 13 THPs 
(19%), mercury and arsenic both in 6 preparations (9%). Saper et al. used a US Pharmacopoeia specification as 
a safety limit for lead that was considerably more conservative than the JECFA PTWI for lead [54] used in our 
study which would explain why we found a lower percentage of THPs with estimated lead intakes above the TWI 
limit (Tables 5, 8 and 9).  
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Table 9 Lead, mercury and arsenic intakes with THPs compared to various safety limits for these elements and 
EU maximum product levels for lead and mercury 
Element No. of THPs 
positive for 
element 
No. of THPs with estimated 
element intakes or element 
level above limit (a) 
Risk assessment or risk management 
body responsible for limit and type of 
limit 
Limit recently applied 
for Asian THPs in: 
Lead 123 10 JECFA-PTWI (b) this study; [43] 
  99 US Pharmacopoeia-specification (c) [9] 
  101 
 
EU-maximum level (d) this study 
Mercury 131 55 RIVM-TDI (e)/ IPCS-TDI (f) this study 
  68 JECFA-PTWI (g) [43] 
  91 US EPA-RfD (h) [9] 
  130 
 
EU- maximum level (d) this study 
Arsenic 105 29 RIVM-TDI (e) this study 
  17 ANZFA-TDI (i) [43] 
  21 JECFA-PTWI (j) [10] 
  39 US EPA- RfD (k) [9] 
a)  Calculated either by comparing the estimated intake of a element resulting from the recommended use of the THP with the 
safety limit referred to in the next column calculated for a 60 kg adult or by comparing a maximum product level to the 
element concentration. 
References: b) [54]; c) [9]; d) [64]; e) [58]; f) [57]; g) [56]; h) [55]; i) [61]; j) [60]; k) [59] 
 
Relative to the results obtained by Saper et al. [9], the subset of Ayurvedic THPs in our study included 
more THPs (46 (19%) of 242) with estimated mercury intakes above the TWI, which also exceeded the number of 
THPs with estimated arsenic or lead intakes above the TWI (22 (9%) and 10 (4%), respectively) (Table 8). A 
similar distribution of mercury, arsenic and lead among Ayurvedic THPs is found in the official Ayurvedic 
formulary, which includes more formulas with mercury (23%) than arsenic (7,3%) or lead (2,5%) [34, 35]. In 2008, 
Saper et al. [65] published a study on mercury, arsenic and lead in Ayurvedic THPs purchased via the Internet in 
2005. Lead, mercury and arsenic were found in 40 (20.7%) of 193 Ayurvedic THPs manufactured in the US and 
India. The intake estimates for mercury, arsenic and lead for all THPs that contained these elements, exceeded 
selected standards [65]. McElvaine et al. [66] studied metal and metalloid contents of 22 East Indian THPs 
sampled in India. Arsenic was found in 9 (41%) of the THPs, lead and mercury were each detected in 14 (64%) of 
the samples and high cadmium levels were shown in 2 products. Maximum and median arsenic and mercury 
concentrations, considerably exceeded values found in our study but intake estimates were not provided. Garvey 
et al. [67] sampled 54 Chinese and Southeast Asian THPs in Vietnam, Hong Kong and the US and found in 36 
(67%) THPs levels of arsenic, lead and mercury that would result in intake estimates above safety limits that were 
similar to limits selected for our study. In a study from 2007 by Cooper et al. [43], at least 160 (65%) of 247 
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Chinese THPs sampled on the Australian market were contaminated with mercury, lead or arsenic. Background 
exposure to mercury, arsenic or lead from other foods was subtracted from the TDI, thereby reducing room for 
mercury, arsenic or lead intake from THPs, and a conservative JECFA PTWI for total mercury [68] was applied. In 
total 3% of the Chinese THPs contained mercury, arsenic or lead levels resulting in intakes at the recommended 
dose that would exceed the selected TDI estimates by 20-fold to up to 2750-fold [43]. In our study 5 (12%) of 42 
Chinese THPs could result in estimated mercury, arsenic or lead intakes exceeding safety limits in a range of 1.1-
fold to more than 2000-fold (Tables 7 and 8).  
In order to identify THPs possibly high in mercury, arsenic or lead beforehand, we screened the labeling 
for traditional names for Asian THPs or traditional names for ingredients as listed in Tables 1-3, which can contain 
arsenic, lead or mercury. Of the 59 THPs in our study that would result in mercury, arsenic or lead intakes 
significantly above TWI limits, the labeling of 25 (42%) carried indications from Tables 1-3, which could suggest 
high levels of these elements (Table 7). Our sampling protocol, which includes Tables 1-3, was therefore helpful 
in identifying products with significant mercury, arsenic or lead levels, which carried traditional product names or 
ingredients on the labeling. However, it proved not to be effective in identifying high-risk THPs with incomplete 
ingredient lists or modern product names. Our data suggests that consumers cannot rely on the labeling for 
avoiding Asian THPs with high amounts of mercury, arsenic or lead and that there is a significant risk of 
inadvertent exposure to these elements from Asian THPs. 
In order to estimate the risks associated with exposure to mercury, arsenic or lead from Asian THPs 
appropriate safety limits have to be selected. Table 9 shows that the selection of a safety limit considerably 
influences the outcome of the study, which should be considered when interpreting results of studies into 
mercury, arsenic or lead in THPs. It is pertinent that the differences in toxicity of the various species of an element 
are taken into account [39]. Reports on the speciation of mercury, arsenic or lead in Asian THPs are scarce. 
Establishing the speciation of elements is less straightforward for Ayurvedic THPs then for Chinese THPs 
because Ayurvedic THPs are subjected to more rigorous processing steps that include heat treatments. The 
ultimate mercury, arsenic or lead species in Ayurvedic THPs are therefore more likely to differ from the initial 
species in the starting materials.  
Mercury from Ayurvedic THPs requires special consideration. Purified mercury (parada) is used as the 
starting material for most mercury containing Ayurvedic THPs. Elemental mercury shows a low oral toxicity when 
compared to organic and inorganic mercury compounds [57, 69]. To test if Ayurvedic THPs contained any 
residual elemental mercury we performed a study on 23 Ayurvedic THPs in which we had shown mercury to be 
present. No elemental mercury was detected in these products (the results of this study are presented and 
discussed in Chapter 6 of this thesis), which indicates that all mercury detected relates to either inorganic or 
organic mercury. For the preparation of Ayurvedic THPs, mercury is mixed with sulfur until kajjali (black mercuric 
sulfide, HgS) is formed [34-36, 41]. Mercury reacts with sulfur, which forms HgS [70, 71]. The presence of HgS in 
Ayurvedic THPs was analytically confirmed for the important Ayurvedic mercury preparation Makaradhwaja [38], 
which is based on kajjali [36]. The preparation was shown to contain 85.3% mercury and 14.2% sulfur matching 
the stoichiometry of HgS [38]. Use of mercuric sulfide in an Indian ethnic remedy in a daily dose of 180-252 mg 
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during 4 weeks resulted in adverse effects consistent with a mercury poisoning [17]. Inorganic mercury 
poisonings from oral use of Chinese THPs with calomel (mercurous chloride, Hg2Cl2) [16] and cinnabar (used 
long-term) have been recorded [72]. Studies on rats and guinea pigs have shown that mercuric sulfide and its 
natural form cinnabar are bioavailable and neurotoxic [32, 73, 74]. Because methylmercury is primarily formed 
through methylation by microorganisms [57, 75] and because methylmercury is not used in traditional medicines 
[72] we considered the presence of this compound in toxicological relevant quantities to be unlikely. The JECFA 
PTWI for total mercury used by Cooper et al. [43] is mainly applicable to diets with high consumption of fish with 
high levels in methylmercury [56] and does not necessarily apply to foods high in inorganic mercury [68]. 
Therefore, a TDI for inorganic mercury [57, 58] was selected for the risk assessment of mercury from Asian 
THPs. Although this TDI is based on a NOAEL for inorganic mercuric chloride it also applies to other inorganic 
mercury compounds such as mercuric sulfide [57, 58]. 
Arsenic is used in Chinese THPs in inorganic form [10, 40, 42, 43]. In the Ayurvedic Formulary, 7% of 
the formulas contain realgar (manahsila, As4S4) and orpiment (talaka, As2S3) [34, 35]. From talaka a bhasma is 
made. Talaka bhasma was reported to contain As2S3 [38]. Furthermore, arsenic trioxide (As2O3) was found in two 
kushtas from India and Pakistan [45]. Arsenic trioxide is significantly more toxic than orpiment and realgar [44]. 
Inorganic arsenic compounds are more toxic than several organic arsenic compounds, notably those compounds 
(e.g. arsenobetaine) which can be found in seafood in considerable quantities and which are not of major 
toxicological concern [76]. Cases of arsenic poisoning involving Indian preparations have been reported in Italy 
[77] and in the UK [17]. The case in the UK involved arsenic intakes with the Indian preparations of up to 210 mg 
As2O3 per day for more than 4 months, causing symptoms consistent with inorganic arsenic poisoning [17]. An 
Indian case of arsenic poisoning showed keratosis after 6 months of use of several Ayurvedic preparations with 
significant arsenic levels and after 18 months of use non-cirrhotic portal hypertension was diagnosed [31]. 
Several chronic arsenic poisonings with Chinese THPs have been reported, which resulted in cutaneous 
manifestations such as malignancies and kerotic plaques [29, 78-80]. We selected a TDI for inorganic arsenic set 
by RIVM for the risk assessment of arsenic from Asian THPs. The TDI is based on the JECFA PTWI for inorganic 
arsenic [60] to which an extra uncertainty factor of 2 was applied for observation errors in epidemiological studies 
[58].  
Lead in Ayurvedic and Chinese THPs is mostly found in inorganic form. Reported forms are PbS and 
PbO, which can cause intoxications [37, 52, 53, 81]. A large number of lead poisonings with Ayurvedic THPs has 
been reported [15, 17, 19, 20, 24, 27, 28, 30, 46, 82-84]. These reports contradict the claim that lead in Ayurvedic 
THPs is detoxified. A case of lead poisoning with a Chinese THP has been recorded in Hong Kong [25]. The US 
Environmental Protection Agency (US EPA) did not establish an oral reference dose (RfD) for lead nor was the 
Agency for Toxic Substances and Disease Registry (ATSDR) able to derive a minimal risk level (MRL) for lead, 
because both agencies could not define a clear threshold for some of the health effects linked to exposure to lead  
[85, 86]. RIVM set a TDI for lead and lead compounds [58], which is directly derived from the JECFA PTWI for 
lead from all sources [54]. We selected therefore the PTWI set by JECFA [54] for the risk assessment of lead 
from Asian THPs.   
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Our study shows that the mercury, arsenic and lead contents of Asian THPs are still a cause for concern 
and that Asian THPs should routinely be tested for metals and metalloids. The VWA will continue to monitor 
metals and metalloids in Asian THPs on the Dutch market and enforce the safety of these products. 
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Abstract 
 
Traditional herbal preparations (THPs) play an important role in Ayurveda and other Indian traditional 
medicine systems. Ingredients high in metals or metalloids are intentionally added to several Ayurvedic and other 
Indian THPs. The Dutch Food and Consumer Product Safety Authority (VWA) recently reported that 19% of 242 
Ayurvedic THPs analyzed between 2004 and 2008 would result in mercury intakes above a toxicological safety 
limit for inorganic mercury when used at the recommended dose level (Chapter 5). The present study is aimed at 
investigating whether (part of) the mercury detected in these Ayurvedic THPs is present as elemental mercury 
(Hg(0)), which shows a low oral toxicity, providing an argument to reconsider the safety assessment using limits 
for inorganic mercury. To test this, we developed a method that enabled detection of Hg(0) in these Ayurvedic 
THPs and subsequently performed a study on the presence of Hg(0) in 19 Ayurvedic THPs of which our previous 
study showed that mercury intakes with the recommended daily dose exceeded the safety limit for inorganic 
mercury. The results obtained reveal that in 11 of the 19 THPs analyzed all mercury detected could be accounted 
for by other forms than Hg(0). Extraction of the other 8 THPs with 7M HNO3, a method demonstrated to efficiently 
extract Hg(0), revealed that most of the mercury present in these samples (i.e. 69-99%) could not be extracted by 
7M HNO3, pointing at other forms than Hg(0) being present. It is concluded that in all THPs mercury is not mainly 
present in its relatively non-toxic elemental form, that the mercury detected in Ayurvedic THPs is likely to be 
present in the inorganic form and that therefore risk assessment based on the safety limits for inorganic mercury 
are justified.   
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Introduction 
 
The main Indian traditional medicine systems are Ayurveda, Unani-Tibb and Siddha of which Ayurveda 
is best known in Western countries [1, 2]. Traditional herbal preparations (THPs) used in these systems can 
contain significant amounts of mercury, lead and arsenic [1, 3, 4]. We conducted a survey between 2004 and 
2008 into the presence of metals and metalloids in Ayurvedic and other Asian THPs (Chapter 5 of this thesis). In 
the survey presented in Chapter 5, mercury was detected in 117 out of 242 Ayurvedic THPs and use at the 
recommended dose level of 46 of these would result in total mercury intakes above a toxicological safety limit for 
inorganic mercury [5]. In Ayurveda, therapeutic qualities are attributed to mercury and this element is added to 
several Ayurvedic THPs in the form of preparations called “bhasmas” [6-10]. Metals and metalloids in bhasmas 
and kushtas, comparable preparations used in Unani-Tibb, are claimed to be detoxified by rigorous processing [4, 
6, 8-12].  
The chemical species in which a metal or metalloid exists can significantly affect its toxicity [13]. The 
main types of mercury species are elemental mercury (Hg(0)), inorganic and organic mercury compounds. 
Mercury is present in inorganic mercury compounds as monovalent or divalent mercury (expressed as Hg (I) and 
Hg (II) or Hg1+ and Hg2+). Organic mercury results from the combination of carbon and mercury [14]. Inorganic 
mercury is nephrotoxic and neurotoxic and long-term use of preparations with inorganic mercury compounds has 
resulted in poisonings worldwide [5]. Methylmercury (CH3Hg+) can be formed by aquatic microorganisms and this 
highly toxic organic mercury species can diffuse through phospholipid membranes [13, 14]. In contrast, Hg(0) 
shows a low oral toxicity when compared to organic and inorganic mercury compounds [5, 15, 16]. Therefore, 
detoxification of mercury should in theory imply conversion of inorganic and organic forms of mercury into Hg(0). 
The speciation of mercury in Ayurvedic and other Indian THPs is not well known but available reports point mainly 
to mercuric sulfide (HgS) [12, 17, 18]. A case of human mercury poisoning linked to the use of an Indian remedy 
with HgS has been reported [17].  
Parada or purified mercury (most likely present as Hg(0)) is used in 20% of the 634 formulas for 
Ayurvedic THPs in the official Ayurvedic Formulary of India, and 4% include hingula (cinnabar - HgS) [9, 10]. 
When used in THPs, parada is first ground with equal parts of sulfur with mortar and pestle until it is completely 
transformed into a very fine black powder called kajjali [19]. Kajjali consists of HgS [18]. Makaradhwaja, an 
important Ayurvedic mercury preparation based on kajjali [19], was shown to contain HgS [12, 20]. It is not well 
known whether Hg(0) is completely transformed into mercury compounds during the preparation of Ayurvedic 
THPs. Hg(0) and sulfur can form HgS at low temperatures. In an experiment, both elements were thoroughly 
mixed in a shaker in an S/Hg molar ratio of 1.5 at room temperature and low humidity. After 37 months of storage 
under the same conditions, 20% of the mixture consisted of mercuric sulfide [21]. In another experiment [22], 
equal weights of Hg(0) and sulfur (S/Hg molar ratio of 6) were mixed for several hours under anaerobic conditions 
at approximately 40 ºC with quartz cobbles to enhance agitation. The mercury completely reacted, yielding black 
mercuric sulfide. A molar excess of sulfur to Hg(0) facilitates a faster reaction [22]. During mixing of both elements 
under aerobic conditions, mercury oxide or mercury salts may form, but these compounds may also be already 
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present in the Hg(0) [22]. Because the preparation of kajjali, which also includes ample agitation and a sixfold 
molar excess of sulfur to mercury, resembles the production process of HgS in the last experiment, it is likely that 
kajjali also consists of HgS. But because kajjali is prepared under aerobic conditions other mercury compounds 
may also be formed.  
An important aspect in the risk assessment of mercury from the Ayurvedic THPs was whether mercury in 
these THPs was present as Hg(0), which shows a low oral toxicity. A relative high Hg(0) level would therefore 
require another type of safety limits than the safety limits for inorganic mercury [5] previously used in the risk 
assessment presented in Chapter 5 of this thesis. The objective of the current study was therefore to determine 
whether mercury found in Ayurvedic THPs was present as the non-toxic Hg(0) or not, in order to facilitate and 
further support the selection of established toxicological safety limits to be used for risk assessment providing the 
basis for subsequent market interventions. To this end a method enabling detection of Hg(0) in the Ayurvedic 
THPs was established followed by detection of the possible presence of Hg(0) in a series of 19 THPs which were 
previously shown to contain significant levels of mercury in the survey presented in Chapter 5. 
 
 
Material and methods 
  
Sampling 
For this study 19 Ayurvedic THPs that were previously shown to contain significant levels of mercury 
were selected as well as 2 Ayurvedic THPs that were previously shown to contain relatively low levels of mercury 
(Chapter 5 of this thesis). The THPs were sampled from 2 suppliers in the Netherlands and produced in Nepal 
and India. The labeling of most of these products carried the names of classical formulations described in official 
Ayurvedic handbooks and traditional ingredients [9, 10]. We therefore concluded that these products could serve 
as models for establishing whether elemental mercury (Hg(0)) was present in these Ayurvedic THPs. Of each 
THP, at least 20 g of material was sampled.  
 
ICP-MS determination of total mercury (Hg (T)) following microwave-assisted extraction 
The analytical method used by the VWA to determine total mercury (Hg(T)) in the 19 Ayurvedic THPs 
selected for the current study, has been described previously in our report on lead, mercury and arsenic in Asian 
THPs (Chapter 5 of this thesis). The method can be summarized as follows. In a quartz vessel, 3 ml nitric acid 
(HNO3, 65%) and 1 ml hydrogen peroxide (H2O2, 30%) were added to 20 mg of powdered sample. In order to test 
if each destruction vessel was clean prior to use, test runs were performed on each vessel with only 3 ml HNO3 
(65%) and 1 ml H2O2 (30%) before each series of samples. This was repeated after each series in order to 
confirm that the vessels did not contain any residual mercury. The vessels were placed in high-pressure digestion 
vessels, which were then closed. Next a microwave-assisted extraction was performed in a microwave oven 
(Ethos Plus Microwave Labstation, Milestone) equipped with temperature and pressure feedback control. In the 
microwave oven, the samples were brought in 15 minutes from room temperature to 200ºC and were then treated 
for 25 minutes at that temperature after which the samples were allowed to cool to room temperature. The 
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translucent solution produced in the microwave-assisted extraction process was then quantitatively transferred 
with de-ionized water from the extraction vessel to a 50 ml volumetric flask. Before filling the flask to the 50 ml 
mark with de-ionized water, 500 µl aureumchloride (AuCl, 100 mg/L) solution was added to prevent a build-up of 
persistent mercury residues in the ICP-MS system (Thermo Electron PQ Excell) used to determine the mercury 
levels in the samples (Chapter 5 of this thesis). Throughout the analysis Milli-Q grade de-ionized water was used. 
The sample solutions were diluted (up to 10,000 times) when necessary to fit within the calibration curve. ICP-MS 
measurement was performed using the ‘Collision Cell Technology mode’ (CCT-mode) with a helium/hydrogen 
flow (95/5 %). The accuracy of the method was determined by analysis of a Certified Reference Material 
(CRM)(IRMM; BCR 482: trace elements in Lichen). For mercury the accuracy of the method is about 100% and 
the RSDr was found to be 9.5%. The LOD of mercury was 0.03 mg/kg, the LOQ was 0.06 mg/kg and the 
expanded measurement uncertainty was 0.047 mg/kg.  
  
Extraction with 6M HCl and 7M HNO3 to determine the absence or presence of Hg(0) in THPs  
After the determination of the Hg(T) content of the THPs using ICP-MS as described above, it was 
investigated whether a significant part of the Hg(T) detected would be present as Hg(0). To this end a method 
was developed in which i) 7M HNO3 was shown to extract mercury present in Ayurvedic THPs including Hg(0) 
and in which ii) 6M hydrochloric acid (HCl) was shown to extract mercury present in Ayurvedic THPs excluding 
Hg(0). The two extraction methods together will then provide insight in the possible presence of Hg(0) in 
Ayurvedic THP samples.  
To test the specificity of the method for determining the absence or presence of Hg(0) in Ayurvedic 
THPs, Hg(0) or mercuric(II)chloride (HgCl2) were added to two different Ayurvedic THP samples with relatively 
low endogenous mercury levels (Ayu-Digeste and Ayu-Geripower) after which the recovery of these mercury 
species with the two extraction methods was determined. In general, the extraction procedures consisted of 
extracting 0.5 g of test sample with either 25 ml 6M HCl or 25 ml 7M HNO3 both at 100 °C for 60 minutes. After 
extraction the extract solution was quantitatively transferred with de-ionized water (Milli-Q) to a 50 ml volumetric 
flask.  
The sample preparation was as follows. From one THP sample (Ayu-Digeste), two groups of test 
samples were prepared in triplicate. To the first group of test samples from this THP Hg(0) was added (60-130 
g/kg) and then each sample was split. One part was extracted with 6M HCl and the other part with 7M HNO3 as 
described above. HgCl2 was added to the second group of test samples (13-40 g/kg). Each of the test samples to 
which HgCl2 was added, was then split in two and one part was extracted with 6M HCl and a second part with 7M 
HNO3. The addition of Hg(0) was repeated in test samples prepared from a second THP sample (Ayu-Geripower). 
To this test sample 30 g/kg Hg(0) was added and the test sample was split in two. One part was extracted with 
6M HCl and the other part with 7M HNO3 as described above. The mercury contents of the various extractions 
were subsequently analyzed using ICP-MS. 
When the specificity of the method to detect the absence or presence of Hg(0) in THPs was 
demonstrated the 19 THPs shown before to contain significant levels of mercury were analyzed for the absence 
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or presence of Hg(0). To this end, a part (0.5 g) of the sample was extracted with 6M HCl and a second part (0.5 
g) with 7M HNO3. Subsequently, the mercury contents of both extraction solutions were analyzed by ICP-MS.  
Each sample was extracted twice with each of the three extraction methods, i.e. the microwave assisted 
extraction method for Hg(T), and the 6M HCl and 7M HNO3 based extraction procedures. The reported values for 
each extraction method are the mean of two extractions. The standard deviation of paired measurements was 
calculated using the equation s = √ [(Σ d2)/ 2k] where ‘d’ is the difference of duplicate measurements and ‘k’ is the 
number of sets of duplicate measurements. The relative standard deviation (RSD) was calculated for each 
extraction method by dividing the standard deviation of paired measurements by the mean of all results obtained 
with the extraction method. 
 
 
Results 
 
Specifity of the method to determine the absence or presence of Hg(0) in THPs  
The specificity of the acid extraction method to detect either the presence or absence of Hg(0) was 
tested by addition of Hg(0) to two THP samples with relatively low mercury contents (Ayu-Digeste and Ayu-
Geripower) containing respectively 0.04 and 0.01 g/kg of mercury when analyzed by the method for determination 
of Hg(T). From each of these samples, test samples were prepared and Hg(0) was added to these two groups of 
test samples and the test samples thus obtained were split in two and were extracted with either 6M HCl or 7M 
HNO3 as described in the methods section. Mercury levels in these extracts were then measured by ICP-MS.  
 
Table 1 Mercury levels detected in extracts from THP samples spiked with HgCl2 or Hg(0) and extracted with 
either 6M HCl or 7M HNO3 ; values presented are the mean +/- SD of N = 2 or 3 independent analyses 
   HCl 6M (a)  HNO3 7M (b) 
THP Addition N Hg 
(g/kg) 
SD Hg extractability 
(%) 
SD  Hg 
(g/kg) 
SD Hg extractability 
(%) 
SD 
Ayu-Digeste - 3 0.040 0.001   0.043 0.001   
 Hg(0) 3   0 0   99 3.4 
 HgCl2 3   99 1.3   97 1.4 
Ayu-Geripower - 2 0.003 0.002   0.001 0.002   
 Hg(0) 2   0.1 0.2   97 1.5 
a) Extraction of 0.5 g sample with 25 ml of 6M HCl at 100 °C for 60 minutes   
b) Extraction of 0.5 g sample with 25 ml of 7M HNO3 at 100 °C for 60 minutes 
 
Table 1 presents the recovery (%) of Hg(0) added to these test samples prepared from Ayu-Digeste and 
Ayu-Geripower. In the first sample (Ayu-Digeste) Hg(0) was almost absent (0-0.03%) in the 6M HCl-extract, but 
fully extracted by 7M HNO3 (96-103%). For the second sample (Ayu-Geripower) similar results were obtained. In 
this sample Hg(0) was also almost absent (0-0.3%) in the 6M HCl-extract but fully extracted by 7M HNO3 (96-
98%). Subsequently, HgCl2 was added to Ayu-Digeste. This mixture was then extracted with 6M HCl and 7M 
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HNO3 as described in the methods section, followed by determination of the mercury levels of the extracts by 
ICP-MS. This was repeated twice. Table 1 presents the results obtained, and reveals that the recovery of HgCl2 
upon 6M HCl and 7M HNO3 extraction amounted to almost 100% for both extraction solvents.  
Together these data illustrate that 6M HCl could not extract Hg(0) whereas 7M HNO3 effectively extracts 
Hg(0) from THPs. This confirmed that the methods can be used to detect the presence of Hg(0), because the 
absence of Hg(0) can be derived from i) the situation where the 6M HCl extraction results in Hg levels similar to 
those detected by the method for quantification of Hg(T) and ii) the absence of significant Hg levels in extraction 
with 7M HNO3. With respect to the latter situation it is important to stress that although the experiments presented 
in Table 1 indicate that like Hg(0) also HgCl2 can be efficiently extracted by 7M HNO3, it has been demonstrated 
before that extraction by HCl or HNO3 of HgS, the form of mercury most likely to be present in Ayurvedic THPs, is 
highly variable and depending on the matrix, extraction conditions and the sample extracted [23]. 
 
Determination of the absence or presence of Hg(0) in selected Ayurvedic THPs 
Before the 19 commercial Ayurvedic THPs were analyzed for the presence of Hg(0) by acid extraction 
with 6M HCl and 7M HNO3, the total mercury (Hg(T)) levels in these samples were determined. Hg(T) was 
extracted by microwave-assisted extraction with 3:1 (v/v) HNO3 (65%) and H2O2 (30%) for 25 minutes at 200ºC 
and analyzed by ICP-MS (Table 2). The first column of Table 2 presents the Hg(T) levels of the 19 THPs obtained 
by the microwave-assisted extraction method. Each value is a mean of two independent extractions of the same 
sample by different analysts. The RSD of paired Hg(T) measurements was 24%. Next, parts of each sample were 
separately extracted with 6M HCl and 7M HNO3, after which the mercury levels of these extracts were determined 
by ICP-MS. The results obtained by both extraction procedures are presented in Table 2 as well. The values 
presented in this table for mercury levels obtained by HCl and HNO3 extractions, represent a mean of two 
independent extractions. The RSD of paired measurements of 6M HCl extracts was 9% and the RSD of paired 
measurements of 7M HNO3 extracts was 16%. 
The results of the Hg(T) microwave-assisted HNO3/H2O2 extraction procedure and the extraction with 6M 
HCL were comparable (Table 2). Paired sample T-test for mercury levels found with the Hg(T) extraction 
procedure and the HCl extraction procedure showed no significant difference (P>0.05). The mean of the mercury 
contents obtained by the Hg(T) extraction procedure (65 g/kg) was higher than the mean mercury level in the 
HNO3 extracts (17 g/kg). Paired sample T-test for mercury levels found with the Hg(T) extraction procedure and 
the HNO3 extraction method showed a significant difference in results of both extraction methods (P<0.05). The 
mean mercury contents of HCl extracts (57 g/kg) was higher than the mean mercury level found in the HNO3 
extracts (17 g/kg). Paired sample T-test for mercury levels found in the HCl extracts and the HNO3 extracts 
showed a significant difference in results of both extraction methods (P<0.05). 
Closer comparison of the data obtained by the Hg(T) extraction procedure with the mercury levels 
detected upon extraction with 6M HCl, a method shown unable to extract Hg(0) from THPs, reveals that for 11 of 
the 19 samples the mercury levels detected upon 6M HCl extraction are equal to, or even higher than the levels 
detected upon determination of Hg(T) (sample No. 1 up to and including No. 11 of Table 2). This reflects that in 
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these 11 samples all mercury present and detected by the Hg(T) method can be accounted for by mercury forms 
other than Hg(0) thus supporting the absence of Hg(0) in these 11 samples. 
 
 Table 2 Mercury levels in different extraction solutions obtained by treating Ayurvedic THPs with different 
extraction techniques 
Mercury level (g/kg) (a) Ayurvedic THP 
Microwave-assisted Hg(T) 
extraction with 3:1 HNO3:H2O2 (b) 
Hg in 6M HCl extraction 
solution (c) 
Hg in 7M HNO3  
extraction solution (d) 
1. Kamachudamani Ras 25 50 7 
2. Gandhadi Yog 4 6 3 
3. Ghandramsu Ras 45 69 2 
4. Agni Vati 7 11 9 
5. Makar Wazra 126 159 163 
6. Jeevani Vati 29 36 26 
7. Mahabatbiddhonsan Ras 39 46 10 
8. Shingorabrak 26 29 5 
9. Ras Yog 124 131 2 
10. Triyog Misran 13 13 7 
11. Heartina 47 47 3 
12. Arogya Vardhini Vati 26 24 8 
13. Yogendra Ras 194 167 25 
14. Sworna Yog 26 19 5 
15. Vasant Yog 37 25 3 
16. Bat Chintamani 150 84 35 
17. Amrit Ras 149 83 1 
18. Hridaya Chintamani 98 53 4 
19. Swashanti Yog 73 31 3 
a) Each value in the table is a mean of two extractions.  
b) Microwave-assisted Hg(T) extraction of 20 mg sample in 3 ml HNO3 (65%) and 1 ml H2O2 (30%) for 25 minutes at 
200ºC. The RSD of paired Hg(T) measurements was 24%. 
c) Extraction of 0.5 g sample with 25 ml of 6M HCl at 100 °C for 60 minutes. The RSD of paired measurements of 6M HCl 
extracts was 9%.  
d) Extraction with 0.5 g sample with 25 ml of 7M HNO3 at 100 °C for 60 minutes. The RSD of paired measurements of 7M 
HNO3 extracts was 16%. 
 
For the remaining 8 samples (sample No. 12 up to and including No. 19 of Table 2: Arogya Vardhini Vati, 
Yogendra Ras, Swoma Yog, Vasant Yog, Bat Chintamani, Amrit Ras, Hridaya Chintamani and Swashanti Yog) 
the mercury levels detected by the 6M HCl method were 42-92% of their respective Hg(T) levels thus leaving the 
possibility for the presence of Hg(0). However, for these 8 samples the results of the 7M HNO3 method 
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demonstrated the absence of significant levels of Hg(0), because upon extraction with 7M HNO3, a method shown 
to effectively extract Hg(0) from THPs, 69-99% of the Hg(T) mercury detected was not extracted. For these 
remaining 8 THPs the mercury levels detected by the 7M HNO3 method amounted to only 1-31% of the Hg(T) 
levels, indicating that also in these samples the mercury is mainly present in other forms than Hg(0).  
 
 
Discussion 
 
To test if Ayurvedic THPs contain elemental mercury (Hg(0)), we performed a study on 19 Ayurvedic 
THPs in which we previously found mercury by ICP-MS combined with a microwave-assisted extraction step 
(Chapter 5 of this thesis). The speciation of mercury in these THPs is pertinent for risk assessment because in 
contrast to inorganic or organic mercury species, Hg(0) via the oral route shows a low toxicity. In the current study 
the presence of elemental mercury was determined by performing additional acid extractions of mercury with 6M 
HCl and 7M HNO3. The mercury content of the extracts was subsequently analyzed with ICP-MS. It was shown 
that 6M HCl does not extract Hg(0) whereas 7M HNO3 effectively extracts Hg(0) from THPs. This demonstrated 
that the methods, combined with quantification of Hg(T) upon microwave assisted HNO3/H2O2 extraction, could be 
used to establish the absence or presence of Hg(0). Extraction of 19 Ayurvedic THPs previously shown to contain 
significant levels of mercury, with 6M HCl and 7M HNO3 showed that for 11 of the 19 samples the mercury levels 
detected by the 6M HCl extraction method were equal to or even higher than the total mercury contents (Hg(T)) 
quantified by microwave-assisted extraction. This indicates that these samples did not contain significant levels of 
Hg(0). For the remaining 8 THPs the mercury levels detected by the 7M HNO3 method did not reveal high levels 
of Hg(0) since the amount of mercury detected amounted to only 1-31% of the Hg(T), indicating that also in these 
samples the mercury is mainly present in other forms than Hg(0).   
The fact that for most of the 19 samples the overall level of mercury detected upon extraction with 7M 
HNO3 was low compared to the Hg(T) levels could be explained by i) the absence of Hg(0) as the major mercury 
species present and ii) the preferential presence of for example HgS, the form of mercury most likely to be 
present in Ayurvedic THPs and reported to be soluble in HCl and HNO3 to a varying extent depending on the 
matrix characteristics and extraction conditions [23-25]. However, the variation found between the individual 
measurements of each sample was relatively high for each of the three extraction methods. Due to the very high 
mercury levels found in the samples (up to 194 g/kg) the test solutions had to be diluted several times to prevent 
persistent mercury residues in the ICP-MS system. The high dilution factors required to prevent build-up of these 
residues were a possible source of the observed variation. Furthermore, inhomogeneity of the samples also 
represented a potential source of variation in this study. This was especially the case for the Hg(T) method 
because the sample weight used for Hg(T) analysis was relatively low (20 mg). The differences between the 
mercury levels found for each sample with the three extraction methods can therefore also be explained to some 
degree by the variation between the individual measurements of each sample. 
Fernández-Martinez and Rucandio [23] determined the solubility of a number of mercury species both in 
50% v/v HCl (37.5%) and in 50% v/v HNO3 (65%), equivalent to respectively 6M HCl and 7M HNO3. They 
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reported that most mercury species, including HgCl2, were quantitatively dissolved in both acids with the 
exception of HgS. This is in line with our finding that both acids could completely extract HgCl2 from a herbal 
preparation matrix to which this species was added. Moreover, additional findings of Fernández-Martinez and 
Rucandio [23] pointing to an influence of matrix characteristics and extraction conditions on HgS solubility would 
support the assumption that a high proportion of Hg(T) in our samples is HgS which in turn would explain the low 
and variable extraction efficiencies with 7M HNO3 relative to 6M HCl obtained in our study. Literature information 
on the speciation of mercury in Ayurvedic THPs also points to the presence of mainly HgS in Ayurvedic 
preparations with high Hg(T) levels (as discussed in the introduction and in Chapter 5 of this thesis). While neither 
pure HgS nor its mineral form cinnabar were found to be soluble in 50% v/v HNO3 (65%) or in 50% v/v HCl 
(37.5%) by Fernández-Martinez and Rucandio [23] they showed that the solubility of HgS in each solution was 
significantly higher, but to different degrees, in the presence of certain other compounds and at a relatively high 
extraction temperature (70 ºC). Relative to the HNO3 extraction method, the extractability of mercury was 
promoted by more compounds in the HCl extraction method [23]. In the 50% v/v HCl (37.5%) solution, KI, MNO2 
and NaNO3 drastically promoted the solubility of HgS at room temperature, almost leading to quantitative 
recoveries. At high temperature (70 ºC) all individually tested reagents (KI, KCl, FeCl3, Fe2O3, CuSO4, FeSO4, 
MNO2, NaNO3) were able to promote the solubility of HgS in an HCl solution to a significant degree. In 50% v/v 
HNO3 (65%), quantitative recoveries of HgS were only obtained in the presence of chloride ions both at room 
temperature and at high temperature. At room temperature no other of the reagents tested could increase the 
solubility of HgS in 50% v/v HNO3 (65%). Raising the extraction temperature to 70 ºC resulted only in partial 
dissolution of HgS in 50% v/v HNO3 (65%) in the presence of KI while the rest of the reagents resulted in a low 
(FeSO4) or no notable increase in the solubility at high temperature. This would suggest that the effect of higher 
extraction temperatures on the extraction efficiency with 50% v/v HNO3 (65%) is modest. Furthermore the 
Fernández-Martinez and Rucandio study [23] explored the effect of the matrix on the extractability of HgS by 
testing the extractability of HgS in soil at room temperature. The effect of the matrix on the extractability of HgS 
was much more pronounced in 50% v/v HCl (37.5%) than in 50% v/v HNO3 (65%). Only when the soil sample 
was spiked with halide compounds, the solubility of HgS in 50% v/v HNO3 (65%) was increased to partial 
dissolution [23].  
It is plausible that in our study the low and variable extraction efficiencies found at 100 ºC with 7M HNO3 
compared to 6M HCl were caused by differences in the composition of the THPs tested. However, Hg levels in 
HNO3 extracts of a few samples approached (Agni Vati and Jeevani Vati) or were equal (Makar Wazra) to Hg 
levels in their respective HCl extracts which could have been caused by relatively high levels of compounds such 
as halides in the THP matrix that could increase the solubility of Hg in HNO3 if this Hg would be mainly present as 
HgS as suggested by literature. The other samples in our study showed low ratios of Hg in HNO3 to Hg in HCl 
extracts which were equal to or lower than 50% in 16 THPs, suggesting that these THPs contained lower levels of 
compounds that could increase the solubility of HgS in 7M HNO3.  
Iron, chloride and manganese were reported to be present in significant amounts in several bhasmas in 
a study on the chemical composition of these Ayurvedic metallic-herbal preparations used in many Ayurvedic 
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THPs [12]. Fernández-Martinez and Rucandio [23] showed that iron, chloride and manganese compounds could 
promote the solubility of HgS in HCl and HNO3, but each to a different degree dependent on the extraction 
solution and extraction conditions. The levels of these compounds could vary considerably between different 
types of bhasmas. The iron, chloride and manganese levels in bhasmas ranged from not detected up to 4 g/kg for 
chloride, 11 mg/kg for manganese and 570 g/kg for iron in an iron-based bhasma [12]. Finally, it is also important 
to note that organic mercury, including for example methylmercury (CH3Hg+), is not reported to be used as a 
mercury source in traditional medicine and is mainly formed by aquatic microorganisms through methylation, 
under conditions not likely to occur during preparation of traditional medicines (discussed in Chapter 5 of this 
thesis). 
In summary, the high extractability of Hg from Ayurvedic THPs in 6M HCl found in our study would be in 
line with the results obtained by Fernández-Martinez and Rucandio [23] when the Hg in Ayurvedic THPs is mainly 
present as HgS. These authors showed that at high extraction temperatures a broader range of compounds could 
increase the solubility of HgS to a higher degree in 6M HCl than in 7M HNO3, which could explain that in our 
study the mercury levels in the HCl extracts were comparable to the Hg(T) levels obtained by the microwave 
assisted extraction method. Altogether, it is concluded that in all THPs mercury is not mainly present in its 
relatively non-toxic elemental form Hg(0) and that the mercury detected in Ayurvedic THPs is most likely present 
in an inorganic form and that therefore risk assessment based on the safety limits for inorganic mercury are 
justified.   
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Abstract  
 
Food supplements can contain polycyclic aromatic hydrocarbons (PAH). The European Food Safety 
Authority (EFSA) has defined 16 priority PAH that are both genotoxic and carcinogenic and identified 8 priority 
PAH (PAH8) or 4 of these (PAH4) as good indicators of the toxicity and occurrence of PAH in food. The current 
study aims to determine benzo[a]pyrene and other EFSA priority PAH in different categories of food supplements 
containing botanicals and other ingredients. In 2003 up to 2008, benzo[a]pyrene exceeded the limit of 
quantification (LOQ) in 553 (44%) of 1258 supplements with a lower bound mean of 3.37 µg/kg. In 2008 and 
2009, benzo[a]pyrene and 12 other EFSA priority PAH were determined in 333 food supplements. 
Benzo[a]pyrene exceeded the LOQ in 210 (63%) food supplements with a lower bound mean of 5.26 µg/kg. 
Lower bound mean levels for PAH4 and PAH8 (-indeno[1,2,3-cd]pyrene) were 33.5 µg/kg and 40.5 µg/kg, 
respectively. Supplements containing resveratrol, Ginkgo biloba, St. John’s wort and propolis showed relatively 
high PAH levels in 2008 and 2009. Before 2008, supplements with these ingredients and also dong quai, green 
tea or valerian contained relatively high benzo[a]pyrene levels. On average, PAH intake resulting from food 
supplement use will be at the lower end of the range of contributions of main food groups to PAH exposure, 
although individual food supplements can contribute significantly to PAH exposure. Regular control of PAH levels 
in food supplements may prove a way forward to further reduce the intake of PAH from food. 
 
 
 
 
 
 
 
 CHAPTER 7  |  163 163 
Introduction 
 
Polycyclic aromatic hydrocarbons (PAH) can be formed during incomplete combustion or pyrolysis of 
organic matter and during industrial processes [1-3]. PAH found in food are either derived from the environment 
or are directly formed during industrial food processing or domestic food preparation [2]. Several PAH such as 
benzo[a]pyrene are both genotoxic and carcinogenic. Lists of priority PAH were put forward on the basis of their 
individual genotoxic and carcinogenic properties by the US Environmental Protection Agency (EPA), the Scientific 
Committee on Food (SCF) of the European Union (EU) and the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) [1, 2, 4, 5]. The SCF identified a priority group of 15 PAH in the risk assessment of PAH in 
food and concluded that benzo[a]pyrene could be used as a marker for the occurrence and effect of carcinogenic 
PAH in food [1]. JECFA focused on 13 of these PAH, which were identified to be genotoxic and carcinogenic [2]. 
Additionally, JECFA noted that besides these 13 PAH, benzo[c]fluorene was also genotoxic and carcinogenic but 
the Committee did not include this substance in their evaluation because of a lack of data on its occurrence in 
food [2].  
 
Table 1 Overview of lists of priority PAH put forward by SCF, JECFA and EFSA and the priority PAH 
proposed by EFSA as indicators for the occurrence and toxicity of PAH in food 
 Priority PAH  EFSA indicator groups (c) PAH 
 SCF (a) JECFA (b) EFSA (c)  PAH2 PAH4 PAH8 
1. Benz[a]anthracene BaA  x x x   x x 
2. Benzo[b]fluoranthene BbF  x x x   x x 
3. Benzo[j]fluoranthene BjF  x x x     
4. Benzo[k]fluoranthene BkF  x x x    x 
5. Benzo[ghi]perylene BgP  x - x    x 
6. Benzo[a]pyrene BaP  x x x  x x x 
7. Chrysene CHR  x x x  x x x 
8. Cyclopenta[cd]pyrene CPP  x - x     
9. Dibenz[a,h]anthracene DhA  x x x    x 
10. Dibenzo[a,e]pyrene DeP  x x x     
11. Dibenzo[a,h]pyrene DhP  x x x     
12. Dibenzo[a,i]pyrene DiP  x x x     
13. Dibenzo[a,l]pyrene DlP  x x x     
14. Indeno[1,2,3-cd]pyrene IcP  x x x    x 
15. 5-methylchrysene 5MC  x x x     
16. Benzo[c]fluorene BcL  - + 1 x     
References: a) [1]; b) [2]; c) [3] 
 
The European Commission requested Member States in Recommendation 2005/108/EC to monitor in 
certain foods the occurrence of the 15 priority PAH identified by the SCF. These surveys were to cover foods 
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such as oils and fats, infant formulae and baby foods, meat and marine products for which maximum levels of 
benzo[a]pyrene are specified in Regulation (EC) No. 1881/2006 and other foods that can contain high levels of 
PAH, such as dried fruits and food supplements for which no limits yet exist in this Regulation [6, 7]. The data 
obtained would be used for future review of the suitability of maintaining benzo[a]pyrene as a marker [6]. In 2008 
the European Food Safety Authority (EFSA) [3], which continued the work of the SCF, reviewed the available 
data on occurrence and toxicity of 16 priority PAH, 15 of which were identified by SCF and one, benzo[c]fluorene, 
by JECFA. Table 1 shows the priority PAH identified by SCF, JECFA and EFSA [1-3]. EFSA concluded that 8 of 
these 16 ‘EFSA priority PAH’ for which oral carcinogenicity data are available (PAH8) could be used as indicator - 
either individually or in combination - of the carcinogenic potency of PAH in food (Table 1). However, EFSA 
established that benzo[a]pyrene alone was not a suitable indicator of the occurrence of PAH in food. EFSA 
concluded that in its place the most suitable indicators of PAH in food with regards to both occurrence and toxicity 
were currently PAH4 or PAH8 (Table 1), with PAH8 not providing much added value compared to PAH4 [3].  
The Dutch Commodities Act includes since January 2006 a maximum level of 10 µg/kg benzo[a]pyrene 
for food supplements with botanical ingredients and a maximum of 2 µg/kg benzo[a]pyrene for supplements 
without these ingredients [8]. These limits were introduced as a result of an ongoing survey by the Voedsel en 
Waren Autoriteit (VWA - the Dutch Food and Consumer Product Safety Authority) into the presence of 
benzo[a]pyrene in food supplements [8]. In 2006 we published the analytical method for quantification of 
benzo[a]pyrene and also benzo[a]pyrene levels in a series of food supplements, mainly supplements containing 
botanical and fat soluble vitamin ingredients, sampled since 2003 (n=950), and of other food samples (n=400) [5]. 
More than 30% of the food supplements contained benzo[a]pyrene above 1.2 µg/kg up to 135 µg/kg. Nearly half 
of 60 samples of raw materials for food supplements (mostly d-alpha tocopherol - natural vitamin E), contained 
benzo[a]pyrene above 1.2 µg/kg up to 275 µg/kg. Differences in PAH levels between categories of food 
supplements were not explored in this publication. The primary data suggested however that supplements with 
natural vitamin E and certain botanical ingredients frequently contained relatively high benzo[a]pyrene levels. In 
2005, the UK Food Standards Agency (FSA) determined the 15 SCF priority PAH in 200 food supplements [9]. 
EFSA published data on the 16 EFSA priority PAH in nearly 300 food supplements that also included the FSA 
data [3, 4, 9, 10]. In these and in other studies relatively high PAH levels were found in various individual food 
supplements containing botanical ingredients or bee products such as propolis [4, 11, 12]. However, differences 
in PAH levels between categories of food supplements were not analyzed further in these reports either.  
More detailed data on the variation in PAH levels between supplement categories would aid the setting 
of European limits for PAH in food supplements. Moreover, this information would also help to focus surveys on 
PAH in food supplements at those products with potentially high PAH levels. In this respect especially botanical 
food supplements represent a category of interest. Therefore, the objective of the present study was to collect 
data on the occurrence of PAH in different categories of food supplements, with special emphasis on botanical 
food supplements. Furthermore, the analytical method was expanded to include more of the 16 EFSA priority 
PAH in addition to benzo[a]pyrene.  
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Material and Methods 
 
Sampling 
For this survey food supplements were sampled on the Dutch market by inspectors of the VWA. From 
2003 up to and including 2007, 1258 samples of food supplements were collected for benzo[a]pyrene analysis. In 
2008 and 2009, 333 food supplements were collected for the determination of benzo[a]pyrene and other EFSA 
priority PAH. The supplements were collected using a standardized sampling protocol twice yearly. In order to 
identify groups of food supplements with relatively high PAH levels, the sampling protocol was adjusted each time 
to include more of those types of supplements that previously showed high PAH levels. Of each sample the name 
of the manufacturer or distributor, the product name, the date of minimum durability, and the production lot code 
were routinely entered in the VWA inspection database.  
The supplements sampled for this study contained vitamins, botanical ingredients including fatty acids or 
oils, phytochemicals extracted from plants, fatty acids or oils from animal origin, and other ingredients derived 
from animals such as glucosamine, chitosan, green lipped mussel extract, and others. EFSA defines the term 
‘botanical’ as all botanical materials such as whole, fragmented or cut plants, plant parts, algae, fungi, and 
lichens. The term ‘botanical preparations’ is used by EFSA to refer to all preparations obtained from botanicals by 
various processes (e.g. pressing, squeezing, extraction, fractionation, distillation, concentration, drying up, and 
fermentation)[13]. Unless otherwise specified, the term ‘botanical’ can refer in the current study both to a 
botanical (or botanical material) or a botanical preparation as defined by EFSA. In 2003 and 2004 the majority of 
the sampled food supplements were various types of supplements with d-alpha tocopherol (natural vitamin E) and 
botanical supplements. In the ensuing years (2005-2009) the sampling protocols targeted mainly botanical 
supplements. 
 
Grouping of supplements 
In order to identify whether certain ingredients of food supplements were contaminated with PAH to a 
higher extent and more frequently than others, sampling was preferentially aimed at supplements with only one 
main or ‘active’ ingredient. The ‘active’ ingredient refers to the ingredient that is clearly regarded by the 
manufacturer or distributor to show nutritional or physiological activity. The food supplements that were sampled 
belonged to three main categories: i) essential fatty acids, ii) botanicals, and iii) other substances. Within each 
main category, subcategories were created on the basis of the active ingredients. Supplements from a 
subcategory identified by an ingredient name such as Ginkgo biloba, contained in principle no other active 
ingredients. In cases where supplements could be grouped in more than one category these products were 
placed in the category that best defined the nature of these products. Plant oils could for instance be listed as 
botanical preparations but were categorized instead as ‘essential fatty acids’.  
Most types of mono-ingredient supplements of which less than 5 products were sampled, were placed in 
several general ‘mono-ingredient’ subcategories. However, some specific subcategories consisting of less than 5 
samples were created for mono-ingredient supplements that were of interest due to relatively high or 
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unanticipated low PAH levels. In only a few cases, botanical supplements with two active ingredients were 
included in the group of mono-ingredient botanical supplements, but only when the botanical ingredient was 
accompanied by one other active ingredient (vitamin C, for example) that was not found to contain significant 
PAH levels in this study. In case PAH were found in those supplements, it was concluded that these PAH were 
derived from the botanical ingredient.  
Food additives, substances added for technical purposes such as bulking and glazing agents, or other 
‘inactive’ ingredients that do not characterize the supplement, were not used to categorize the supplements. 
Ingredients of food supplements collected in 2008 and 2009 were recorded from the containers of food 
supplements. Containers of food supplements collected before 2008 were not available, and ingredients of these 
supplements were identified by searching the Internet by using the product name and the name of the 
manufacturer of distributor. 
 
Experimental 
The analytical method used to determine benzo[a]pyrene in supplements sampled from 2003 up to and 
including 2007 has been described previously by us [5]. This method was also able to quantify some other EPA 
PAH. It was based on an online donor acceptor complex chromatography (DACC) cleanup prior to reversed-
phase high performance liquid chromatography with fluorescence detection [14]. In 2008 the method was altered 
to meet the requirements for the analysis of the 16 EFSA priority PAH. This expanded method can be described 
as follows. The sample was homogenized and 1 g of sample was then transferred to a 20 ml volumetric flask and 
brought up to mark with 2-propanol. After shaking for 20 minutes at 120 strokes/minute in order to extract the 
PAH, the extract was filtered by means of a 0.45 µm syringe filter and injected on a DACC column (Chromspher 
Pi, 80 x 0,3 mm) using 2-propanol as mobile phase. After removal of matrix components using 2-propanol as the 
eluent, the PAH were stripped from the DACC column by means of ethylacetate – acetonitril (70/30 v/v) and 
subjected to 2 reversed phase analytical columns in series (Lichrocart 250-4 Lichrospher PAH RP-18 5 µm) prior 
to quantification of the PAH by variable wavelength fluorescence detection.  
Cyclopenta[cd]pyrene and benzo[j]fluoranthene were not included in the method because of low 
fluorescence intensities. Moreover, indeno[1,2,3-cd]pyrene could also not be included. The analysis of 
indeno[1,2,3-cd]pyrene would require different wavelength settings but these could not be implemented because 
of insufficient resolution of this PAH and dibenzo[a,e]pyrene. Use of a multi-channel fluorescence detector 
combined with a photo diode array detector would have allowed for the determination of these remaining three 
PAH, but our routine method was not equipped with these features at that time. The main alterations to the 
method described by us in 2006 [5] were in the mobile phase gradient and the fluorescence wavelength settings 
and these are presented in Tables 2 and 3, respectively. 
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Table 2 HPLC Quaternary pump gradient for the analysis of 13 PAH  
Time (min) H2O (%) Acetonitril (%) Ethylacetate (%) Flow (ml/min) 
  0.00 15 85 0 0.40 
15.00 15 85 0 1.00 
26.00 15 85 0 1.00 
35.00 5 90 5 1.00 
45.00 5 80 15 1.00 
50.00 5 80 15 1.00 
55.00 0 30 70 1.00 
70.00 0 30 70 1.00 
73.00 15 85 0 1.00 
75.00 15 85 0 1.00 
80.00 15 85 0 0.40 
 
 
Table 3 Variable wavelength settings for the analysis of 13 PAH 
Time (min) λexc (nm) λem (nm) PAH 
0 - 32.0 240 355 benzo[c]fluorene 
32.0 - 40.0 260 390 benz[a]anthracene 
chrysene 
5-methylchrysene 
40.0 - 56.8 290 430 benzo[b]fluoranthene 
benzo[k]fluoranthene 
benzo[a]pyrene 
dibenzo[a,l]pyrene 
dibenz[a,h]anthracene 
benzo[ghi]perylene 
56.8 - 62.0 296 405 dibenzo[a,e]pyrene 
benzo[b]chrysene 
62.0 - 66.5 292 435 dibenzo[a,i]pyrene 
66.5 - 84 300 450 dibenzo[a,h]pyrene 
 
The method of analysis was in-house validated according to ISO 17025 guidelines. The limit of detection 
(LOD) was determined based on the signal to noise ratio. The LOD was defined as the concentration at which the 
peak height corresponds with 3 times the bandwidth of the noise. The limit of quantification (LOQ) was defined as 
2 times the limit of detection. During the validation study, performance criteria such as precision under 
repeatability and reproducibility conditions, trueness, recovery and measurement uncertainty were established 
(Table 4). During the analyses measurement quality was assured by means of random analysis of standard 
control samples of food supplements, which were monitored in time by Shewhart control charts.  
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Table 4 Validation data on the method for the determination PAH in botanical materials 
PAH LOD 
(µg/kg) 
LOQ  
(µg/kg) 
Rec. 
(%) 
True. 
(%) 
RSDr 
(%) 
RL  
(µg/kg) 
U 
(%) 
Benz[a]anthracene  1.76 3.53 102 100 8 1.4 10 
Benzo[b]fluoranthene  0.76 1.53 99 99 2 0.9 7 
Benzo[j]fluoranthene  - - - - - - - 
Benzo[k]fluoranthene  0.26 0.53 107 100 9 2.5 18 
Benzo[ghi]perylene  0.95 1.90 109 104 2 0.7 10 
Benzo[a]pyrene  0.26 0.52 111 111 2 0.5 23 
Chrysene  0.39 0.79 100 102 6 0.9 8 
Cyclopenta[cd]pyrene - - - - - - - 
Dibenz[a,h]anthracene  1.00 2.01 100 96 3 0.5 10 
Dibenzo[a,e]pyrene  0.67 1.34 100 103 4 2.1 17 
Dibenzo[a,h]pyrene  0.52 1.04 98 121 27 2.9 47 
Dibenzo[a,i]pyrene  0.33 0.65 114 102 3 1.2 9 
Dibenzo[a,l]pyrene  0.40 0.79 112 113 2 1.2 27 
Indeno[1,2,3-cd]pyrene  - - - - - - - 
5-methylchrysene  0.35 0.69 96 98 8 1.5 12 
Benzo[c]fluorene  0.58 1.16 110 114 2 2.4 32 
LOD:  Limit of Detection  
LOQ:  Limit of Quantification  
Rec.:  Recovery 
True.:  Trueness 
RSDr:  Relative standard deviation calculated from results generated under repeatability conditions 
RL:  Reproducibility, within laboratory 
U:  Expanded uncertainty 
 
Intake estimates and statistics 
Intakes of benzo[a]pyrene, PAH2, PAH4 and PAH8 with a supplement when used at the maximum dose 
level were estimated for several supplements in which relatively high concentrations of benzo[a]pyrene were 
found. The daily intake of these PAH with a supplement was calculated from the weight of one unit (determined 
by preferably weighing 10 or more units), the analytically determined PAH level and the maximum recommended 
daily use level stated on the label. When a supplement consisted of capsules or soft gels, only PAH levels of its 
contents were reported and where the weight of a capsule or soft gel was needed for calculations the weight of its 
contents was taken.  
In this study all values lower than the limit of detection (LOD) or limit of quantification (LOQ) were 
replaced by 0 (lower bound) in order to calculate the descriptive statistics. To aid the comparison of our data with 
data on PAH in food supplements on the European market published in a report of the EFSA Unit of Data 
Collection and Exposure in 2007 and the revised and updated report published in 2008, the descriptive statistics 
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for the benzo[a]pyrene data obtained before 2008 included the calculation of the mean, the median, the 90th and 
the 95th percentiles (P90 and P95, respectively) and the maximum [10]. Percentiles were only calculated when 
sample numbers exceeded 10. For each food supplement category sampled in the 2008 and 2009 survey, mean 
levels of each of the 13 EFSA priority PAH were calculated and also the mean levels of benzo[a]pyrene, PAH2, 
PAH4 and PAH8. The data from the whole study period were compared to the maximum levels for 
benzo[a]pyrene defined in Dutch food law (10 µg/kg for botanical and 2 µg/kg for regular food supplements) and, 
following the approach of EFSA, to all maximum levels for this PAH existing in Regulation (EC) No. 1881/2006, 
also because supplements are not yet regulated by this Regulation in this respect [7, 8]. Existing maximum levels 
for benzo[a]pyrene in Regulation (EC) No. 1881/2006 are: 1 µg/kg for baby foods, infant formulae, follow on 
formulae and other infant foods; 2 µg/kg for oils, fats and fish; 5 µg/kg for smoked meat and fish and some 
marine products and 10 µg/kg for bivalve mollusks [7]. 
FSA reported in 2005 levels of 15 SCF priority PAH in 207 individual food supplements from different 
supplement categories. Levels of 15 SCF priority PAH above the LOD were reported for each individual sample 
separately [9]. The FSA report did not include descriptive statistics that would aid the comparison of our results to 
the FSA data. We therefore calculated from the FSA data the overall lower bound mean of the benzo[a]pyrene, 
PAH2, PAH4 and PAH8 levels, for which we replaced each value below the LOD by 0. These parameters were 
also calculated for each food supplement category as defined by the FSA. We divided the category of ‘Ginkgo/ 
Echinacaea’ in two, resulting in a separate category for each of these botanicals. 
 
 
Results 
 
Results in 2003 up to and including 2007 
The food supplements included in the study were grouped into main categories and subcategories 
based on the active ingredient or a combination of active ingredients. Table 5 shows for each subcategory the 
lower bound mean, median, P90, P95 and maximum benzo[a]pyrene levels obtained in 2003 up to and including 
2007. Also shown for each category in this table is the percentage of samples with benzo[a]pyrene levels that 
exceeded the LOQ and limits that currently apply to benzo[a]pyrene in various foods in European and Dutch food 
law. Based on the Dutch limit for benzo[a]pyrene in botanical food supplements of 10 µg/kg, benzo[a]pyrene 
levels in a food supplement category were considered high in the current study when the P90 of benzo[a]pyrene 
levels in a category exceeded 10 µg/kg. In total, 553 (44%) of 1258 supplements contained benzo[a]pyrene 
levels above the LOQ and the mean benzo[a]pyrene level was 3.37 µg/kg. For several supplements with 
relatively high benzo[a]pyrene concentrations, estimated intake levels of this PAH were calculated by using the 
manufacturers’ maximum recommended use level (Table 6).  
Benzo[a]pyrene levels in all samples in the category of mono-ingredient botanical food supplements, 
which included botanicals such as Boswellia serrata and kelp, were below 5 µg/kg (Table 5). A multivitamin 
supplement with several botanicals contained 43.4 µg/kg benzo[a]pyrene which would amount to a daily intake of 
229 ng of benzo[a]pyrene when used according to the maximum recommended use levels. The parameters used 
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for the calculation of this intake estimate are shown in Table 6 under No. 7. Supplements with green tea extracts 
showed the highest mean and median benzo[a]pyrene concentrations in botanicals between 2003 and 2007 
(Table 5). A supplement with green tea (Camellia sinensis) with the highest benzo[a]pyrene level found in this 
period of 145 µg/kg, would provide 225 ng of benzo[a]pyrene per day when used at the maximum recommended 
use level. The parameters used for the calculation of this intake estimate are shown in Table 6 under No. 4. 
Furthermore, supplements with a tea variety called ‘pu erh’, which is claimed to aid in weight loss, also showed 
relatively high benzo[a]pyrene levels. Moreover, benzo[a]pyrene levels were relatively high in the botanicals dong 
quai (Angelica sinensis), Ginkgo biloba, St. John’s wort (Hypericum perforatum) and valerian (Valeriana 
officinalis) and outside the botanical category, in propolis and pollen supplements, and natural vitamin E (d-alfa 
tocopherol) supplements with expiry dates before 2007. Vitamin E samples with later expiry dates displayed lower 
benzo[a]pyrene levels with a P90 lower than the LOQ. 
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Table 6 Examples of daily intake levels of benzo[a]pyrene (BaP) with supplements, when used according to the 
recommended use level as stated on the label, sampled in 2003 up to and including 2007 
Supplement type BaP (µg/kg) Year of analysis Maximum dose 
(No. of units) 
Unit weight (g) Intake BaP  
(ng/day)  
1. Bee propolis 18.9 2003 4 0.504  38.1 
2. Ginkgo biloba 64.4 2003 1 0.235 15.1 
3. Green tea 29.5 2004 4 0.385 45.4 
4. Green tea 145 2004 4 0.388 225 
5. Green tea  39.3 2003 2 0.426 33.5 
6. Multi-ingredient botanical  23 2003 2 1.21 55.6 
7. Multivitamin with botanicals 43.4 2003 3 1.76 229 
8. Natural vitamin E 63.4 2004 2 0.511  64.8 
9. Natural vitamin E 74.6 2003 6 0.827 370 
10. St John’s wort 28.9 2003 2 0.571  33.0 
11. St John’s wort 90 2003 1 0.278 25.0 
12. Valerian 17.1 2003 6 0.300 30.8 
13. Valerian 21.4 2003 3 0.479  30.8 
14. Valerian 29.8 2004 4 0.225  26.8 
 
 
Results from 2008 up to and including 2009 
In 2008 the method for benzo[a]pyrene was expanded to include more of the 16 EFSA priority PAH. Of 
these priority PAH, cyclopenta[cd]pyrene, benzo[j]fluoranthene and indeno[1,2,3-cd]pyrene (IcP) could not be 
quantified. Because indeno[1,2,3-cd]pyrene could not be determined, the PAH8 level reported in this survey lacks 
the levels for this PAH and was consequently referred to as PAH8(-IcP). The remaining 13 EFSA priority PAH 
were analyzed in 333 supplements sampled in 2008 and 2009 and the lower bound estimates for the mean 
benzo[a]pyrene, PAH2, PAH4 and PAH8(-IcP) levels were 5.33 µg/kg, 20.8 µg/kg, 33.8 µg/kg and 40.9 µg/kg, 
respectively. Table 7 shows for each EFSA priority PAH quantified in these 333 supplements the descriptive 
statistics including the lower bound mean and the percentage of the samples exceeding the LOQ and limits that 
currently apply to benzo[a]pyrene in various foods in European and Dutch food law. Benzo[a]pyrene levels were 
above the LOQ in 210 (63%) of the 333 samples. The priority PAH with the highest lower bound mean level was 
chrysene with a value of 15.5 µg/kg and the maximum level found for this PAH was 368 µg/kg. The priority PAH 
with the highest maximum level was benzo[c]fluorene with 503 µg/kg (Table 7). 
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Table 7 Lower bound PAH levels in food supplements (N=333) sampled in 2008 and 2009 and percentage 
of supplements with PAH levels exceeding the LOQ, 1, 2, 5 or 10 µg/kg 
PAH Product (%) above limit (µg/kg)  Concentration (µg/kg) 
 >LOQ >1 >2 >5 >10  Median Mean P90 P95 Max 
Benz[a]anthracene 29 29 29 20 11  0 5.18 11.0 24.2 188 
Benzo[a]pyrene 63 52 39 23 11  1.10 5.33 10.4 17.5 150 
Benzo[b]fluoranthene 57 57 45 27 15  1.60 7.80 16.2 28.0 314 
Benzo[j]fluoranthene - - - - -  - - - - - 
Benzo[k]fluoranthene 65 41 29 13 7  0.80 2.93 5.90 13.2 69.1 
Benzo[ghi]perylene 35 35 34 19 8  0 3.37 8.02 15.1 109 
Chrysene 50 48 44 36 27  0 15.5 32.8 91.2 368 
Cyclopenta[cd]pyrene - - - - -  - - - - - 
Dibenz[ah]anthracene 19 14 9 4 2  0 0.77 1.58 3.04 30.7 
Dibenzo[a,e]pyrene 8 8 5 4 2  0 1.01 0 2.08 200 
Dibenzo[a,h]pyrene 6 4 2 0 0  0 0.22 0 0.90 36.4 
Dibenzo[a,i]pyrene 7 6 4 2 1  0 0.29 0 1.40 13.7 
Dibenzo[a,l]pyrene 22 20 16 8 3  0 1.70 4.10 7.32 70.1 
Indeno[1,2,3-cd]pyrene - - - - -  - - - - - 
5-methylchrysene 24 22 17 10 7  0 3.22 4.58 22.5 94.8 
Benzo[c]fluorene 21 19 16 8 7  0 5.08 3.58 12.6 503 
 
 
For each subcategory of supplements sampled in 2008 and 2009, mean benzo[a]pyrene, PAH2, PAH4 
and PAH8(-IcP) levels were computed including the percentage of samples with benzo[a]pyrene levels that 
exceeded the LOQ and limits for benzo[a]pyrene in Dutch and European food law (Table 8). 
 The results obtained in 2008 and 2009 will be discussed by focusing on the PAH4 levels. Figure 1 
presents the minimum, median and maximum PAH4 levels of the different food supplement categories 
determined in the 2008 and 2009 survey. High PAH4 levels were defined for the purpose of the current study as a 
mean above 40 µg/kg of PAH4. This definition was based on the Dutch limit of 10 µg/kg for benzo[a]pyrene, 
which is one of the PAH4, in botanical food supplements. For several individual supplements of interest, 
reference is made in the text to specific entries in Table 9. This table presents for a total of 20 supplements 
sampled in 2008 and 2009 with relatively high PAH levels, the estimated daily intake levels of benzo[a]pyrene, 
PAH2, PAH4 and PAH8(-IcP), when used at the manufacturers’ maximum recommended dose level. 
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Figure 1Minimum, median (♦) and maximum levels of PAH4 (µg/kg) in different categories of food supplements sampled in 
2008 and 2009 
 
Mono-ingredient botanical supplements including botanicals such as cat’s claw (Uncaria tomentosa), 
Eleutherococcus senticosus, Echinacaea or red clover, showed relatively low PAH4 levels except for a 
supplement with brown marine algae with a PAH4 level of 84 µg/kg (Table 8). PAH4 levels of 17 multi-ingredient 
botanical supplements (n=111) were higher than 40 µg/kg. Estimated daily PAH4 intakes for four of these 
supplements when used at the maximum dose level recommended by the manufacturer, ranged from 69 to 170 
ng per day. Intake estimates for other PAH indicators and the parameters used to calculate these, are shown in 
Table 9 under Nos. 7, 8, 9 and 10. A multivitamin supplement with several botanicals such as valerian, golden 
root and St. John’s wort was found to contain 125 µg/kg PAH4 and 23 µg/kg benzo[a]pyrene. According to the 
producer the high PAH levels were caused by the use of a batch of St. John’s wort containing 94 µg/kg 
benzo[a]pyrene. Use of this supplement at the highest recommended dose level would result in a PAH4 exposure 
of 99 ng per day. Additional PAH exposure estimates and the parameters used to calculate these for this 
supplement are shown in Table 9 under No. 16.  
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In Chinese multi-ingredient botanical supplements, the mean PAH4 level of 38 µg/kg resulted mainly 
from a sample with 340 µg/kg of PAH4, while the median PAH4 level was below the LOQ (Figure 1, Table 8). In 
mono-ingredient botanical supplements with black cohosh (Actaea racemosa), dong quai, green tea, ginseng 
(Panax ginseng) or valerian, mean benzo[a]pyrene levels were lower in the 2008 and 2009 survey than in the 
survey from 2003 up to and including 2007 (Table 5 and 8). Furthermore, mean PAH4 levels in these categories 
from 2008 and 2009 remained below 40 µg/kg (Table 8). 
 
Table 9 Examples of daily intake levels of benzo[a]pyrene (BaP), PAH2, PAH4, PAH8 (-IcP) (a) with supplements 
when used according to the recommended use level as stated on the label; samples from 2008 and 2009 
Intake (ng/day) Food supplement sample Maximum dose  
(No. of units) 
Unit weight (g) 
BaP PAH2 PAH4 PAH8 
(-IcP) 
1. Chitosan and vitamin C 2 0.657 22 57 82 127 
2. Ginkgo biloba 3 0.341 14 258 394 436 
3. Ginkgo biloba  1 0.413 24 112 178 211 
4. Ginkgo biloba leaf extract and herb, 
taurine   
1 0.492 5 41 64 74 
5. Hypericum perforatum extract 1 0.369 4 21 38 51 
6. Hypericum perforatum extract 2 0.268 8 24 44 57 
7. Multi-ingredient botanical 4 0.521 31 68 130 174 
8. Multi-ingredient botanical 4 0.610 47 130 170 229 
9. Multi-ingredient botanical 1 0.622 15 40 69 91 
10. Multi-ingredient botanical 1 0.409 4 120 152 169 
11. Multi-ingredient botanical with resveratrol 
from Polygonum cuspidatum  
2 0.504 39 39 56 93 
12. Multi-ingredient botanical with resveratrol 
from Polygonum cuspidatum  
1 0.56 40 156 192 237 
13. Multi-ingredient botanical with resveratrol 3 0.633 171 400 705 934 
14. Multi-ingredient botanical with resveratrol 2 0.28 38 242 283 329 
15. Multivitamin with botanicals 2 1.31 43 282 405 480 
16. Multivitamin with botanicals 2 0.397 18 48 99 130 
17. Multivitamin with resveratrol from 
Polygonum cuspidatum 
1 0.396 23 51 95 131 
18. Polygonum cuspidatum (with resveratrol) 1 0.394 59 176 320 398 
19. Polygonum cuspidatum root extract  
(with resveratrol) 
4 1.011 76 211 265 378 
20. Polygonum cuspidatum root extract  
(with resveratrol) 
3 0.724 146 146 278 346 
a) (-IcP): indeno[1,2,3-cd]pyrene not analyzed 
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The mean PAH4 level in Ginkgo biloba supplements analyzed in 2008 and 2009 (n=22) was relatively 
high (47 µg/kg) but the median PAH4 level (1.1 µg/kg) was considerably lower (Figure 1, Table 8). The high 
mean PAH4 level mainly resulted from 5 Ginkgo biloba supplements with PAH4 levels above 40 µg/kg and 4 of 
these contained more than 100 µg/kg PAH4. Use of the Ginkgo biloba supplement with the highest PAH4 level of 
430 µg/kg at the maximum recommended dose level would result in a PAH4 intake of 178 ng per day. Additional 
intake estimates for other PAH indicators and the parameters used to calculate these are shown in Table 9 under 
No. 3. St. John’s wort (Hypericum perforatum) samples from 2008 and 2009 contained relatively high PAH levels 
(Table 8). Compared to the Ginkgo biloba supplements sampled in 2008 and 2009, PAH contamination of St. 
John’s wort samples from the same period was more evenly distributed over the samples and the mean PAH4 
level of 40.4 µg/kg was close to the median PAH4 level of 43.7 µg/kg (Figure 1, Table 8).  
Mono-ingredient supplements with resveratrol showed the highest mean PAH4 level in 2008 and 2009. A 
supplement only containing resveratrol from Polygonum cuspidatum root showed the highest benzo[a]pyrene 
level (150 µg/kg), PAH4 level (812 µg/kg) and PAH8(-IcP) level (1009 µg/kg) found during the whole study period 
from 2003 up to and including 2009. In addition, the benzo[c]fluorene level (117 µg/kg) was also high. Use at the 
maximum recommended dose level of this supplement would result in a PAH4 intake of 320 ng per day. Intake 
estimates for other PAHs and the parameters used to calculate these for this supplement are presented in Table 
9 under No. 18. A multi-ingredient supplement with resveratrol, wine grape extract and quercetin contained 474 
µg/kg benzo[c]fluorene and another resveratrol supplement from the same distributor, which also included wine 
grape extract (OPC), green tea polyphenols and rutin, contained 503 µg/kg benzo[c]fluorene. These 
benzo[c]fluorene levels were the highest levels found for any PAH in this survey and were comparable to the 
PAH8(-IcP) levels in these supplements (423 and 593 µg/kg, respectively). PAH4 exposure estimates for these 
supplements at the maximum recommended dose level were 192 ng and 283 ng per day, respectively. 
Additionally, benzo[a]pyrene, PAH2 and PAH8 intake estimates for these supplements and the parameters used 
to calculate these, are shown in Table 9 under Nos. 12 and 14, respectively. Another multi-ingredient botanical 
with resveratrol contained 371 µg/kg PAH4 and use of this product at the highest proposed dose level would 
result in a PAH4 intake level of 705 ng per day. Additional PAH intake estimates and the parameters used to 
calculate these for this supplement are presented in Table 9 under No. 13.  
PAH levels in the category of miscellaneous supplements without botanicals shown in Table 8 were low. 
However, a supplement with chitosan and vitamin C from this category contained 63 µg/kg PAH4. Use of this 
supplement would result in 82 ng PAH4 per day when used at the maximum recommended dose level. Additional 
PAH intake estimates and the parameters used to calculate these for this supplement are presented in Table 9 
under No. 1. Furthermore, PAH4 levels in propolis supplements were overall relatively high (Figure 1).  
Table 10 shows for each of the 13 EFSA priority PAH determined in this survey the mean PAH level in 
each subcategory of food supplements sampled in 2008 and 2009. Supplements with resveratrol (alone or in 
combination with other botanicals) showed for 11 of these PAH the highest mean levels. The highest mean 
dibenzo[ae]pyrene and dibenzo[ah]pyrene levels were found in Chinese botanical supplements. 
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Table 11 Lower bound mean BaP, PAH2, PAH4 and PAH8 levels in food supplements calculated from results 
reported by the FSA in 2005 (a)  
Supplement characteristics   Mean concentration (µg/kg) 
Main category  FSA category (b) Matching VWA category (c) N BaP PAH2 PAH4 PAH8 (d) 
Fatty acids Animal oils - 3 0.28 0.66 1.67 2.58 
 Fish oil Fish oil 9 0.08 0.23 0.37 0.59 
 Combination fish oil Multi-ingredient 8 0.16 1.0 1.6 1.9 
 Plant oils (e) Mono-ingredient  15 0.21 1.12 1.75 2.22 
Botanical Plant extracts (f) Mono-ingredient  26 6.27 26.5 48.1 61.0 
 Garlic Allium sativum 10 0.47 7.03 12.1 13.6 
 Echinacea Echinacea spp.  7 0.31 2.41 3.44 4.27 
 Ginkgo Ginkgo biloba 8 4.55 37.9 57.3 66.9 
 Ginseng Panax ginseng, Eleutherococcus 
senticosus 
15 3.96 11.4 21.2 29.3 
 Other aquatic 
products 
Spirulina; miscellaneous, without 
botanicals 
8 6.51 55.0 91.4 112 
Other Antioxidant Miscellaneous, without botanicals 10 0.28 2.2 3.5 4.3 
 Single vitamin Mono-ingredient without botanicals, 
vitamin C or E 
7 0.05 0.58 0.95 1.10 
 Multivitamin Miscellaneous, without botanicals 9 0.57 1.39 2.38 3.37 
 Multivitamin – child Miscellaneous, without botanicals 10 0 0.05 0.05 0.05 
 Minerals Mono-ingredient, without botanicals 17 0 0.10 0.16 0.20 
 Calcium Mono-ingredient, without botanicals 8 0.04 0.16 0.25 0.38 
 Iron Mono-ingredient, without botanicals 10 0.04 0.19 0.30 0.40 
 Zinc Mono-ingredient, without botanicals 7 0.33 1.66 2.77 3.42 
 Bee products Propolis, pollen, royal jelly 12 4.74 42.0 61.8 73.8 
 Glucosamine Mono-ingredient, without botanicals 8 0.04 0.33 0.51 0.65 
a) Lower bound estimates for the mean BaP, PAH2, PAH4 and PAH8 levels were calculated from results of the FSA survey 
on PAHs in Dietary supplements from 2005 [9]. The lower bound estimate was calculated by replacing values reported as 
lower than the LOD or LOQ, by 0. 
b) The FSA subcategories were taken from the FSA report [9], the FSA category Ginkgo/ Echinacea was separated into one 
for each botanical however. 
c)  Matching categories found in tables 5, 8 and 10 
d) Including indeno[1,2,3-cd]pyrene  
e) Including samples with Borago officinalis, Linum usitatissimum and Oenothera biennis seed oil, CLA and others. 
f) Including samples with Actaea racemosa, Aloe vera, Angelica sinensis, Camellia sinensis, Glycine max, Hypericum 
perforatum, Silybum marianum, Uncaria tomentosa, Vaccinum spp., Valeriana officinalis and others 
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We calculated from FSA data on 15 SCF priority PAH in 207 individual food supplements [9] the lower 
bound mean benzo[a]pyrene, PAH2, PAH4 and PAH8 levels which amounted to respectively, 1.90, 11.0, 18.3, 
and 22.7 µg/kg. These parameters were also calculated for each category of food supplements used by the FSA 
(Table 11). The relatively high PAH levels in the FSA category ‘plant extracts’ resulted mainly from individual 
supplements with spirulina, soy isoflavones, green tea, black cohosh, dong quai, St. John’s wort and red clover. 
The mean benzo[a]pyrene level of ginseng supplements (Table 11) matched best our findings for this botanical 
from 2003 up to and including 2007 (Table 5). A spirulina supplement with a PAH4 level of 660 µg/kg and a PAH8 
level of 789 µg/kg contributed considerably to he relatively high mean PAH level in the FSA category ‘other 
aquatic products’ (Table 11). From the maximum recommended dose level reported by the FSA we calculated a 
daily PAH8 intake level of 4120 ng/day for this supplement. 
 
 
Discussion 
 
Chapter 7 of this thesis presents the levels of benzo[a]pyrene and several of the priority PAH defined in 
2008 by EFSA in food supplements containing botanicals and other ingredients on the Dutch market. From 2003 
up to and including 2007, benzo[a]pyrene was present above the LOQ in 553 (44%) of 1258 supplements and the 
mean benzo[a]pyrene level was 3.37 µg/kg. In the 2008 and 2009 survey, 210 (63%) of 333 food supplements 
showed benzo[a]pyrene levels above the LOQ and the lower bound mean benzo[a]pyrene level was 5.33 µg/kg. 
In 2008 and 2009, besides benzo[a]pyrene 12 other EFSA priority PAH were also determined and the lower 
bound mean PAH2, PAH4 and PAH8 (minus indeno[1, 2, 3-cd]pyrene; IcP) levels were 20.8, 33.8 µg/kg and 40.9 
µg/kg, respectively. In this period, mono-ingredient supplements with resveratrol, St. John’s wort, Ginkgo biloba 
and propolis showed the highest mean PAH levels. Prior to 2008, the highest mean benzo[a]pyrene levels were 
found in mono-ingredient supplements with dong quai, green tea, Ginkgo biloba, St. John’s wort, valerian, 
propolis and pollen, and in natural vitamin E supplements with expiry dates before 2007.  
PAH levels in natural vitamin E supplements with expiry dates after 2007 were markedly lower in natural 
vitamin E supplements with earlier expiry dates (Table 5). In addition, PAH levels in supplements with green tea, 
dong quai, green tea, valerian and ginseng were lower in 2008 and 2009 relative to the previous period. These 
findings might reflect frequent monitoring of PAH levels in food supplements by the VWA in combination with 
increased awareness of manufacturers. However, PAH levels in supplements with St. John’s wort, Ginkgo biloba 
and propolis remained high and supplements with resveratrol appeared as a new category with relatively high 
PAH levels. High PAH levels in propolis have also been reported in several European Member States [9, 11, 12]. 
High PAH levels in natural vitamin E of the three major manufacturers in the world were described in a US patent 
from 1994 [15]. The reported benzo[a]pyrene levels in the patent of 28, 30 and 106 µg/kg were in line with our 
results for vitamin E food supplements with expiry dates before 2007 (Table 5) and our previous results [5]. 
Higher benzo[a]pyrene levels were reported for 2 different natural vitamin E products (mixed tocopherols) from 2 
Chinese manufacturers, which were 469.5 ± 36.8 µg/kg and 315.0 ± 9.5 µg/kg [16]. PAH8 levels in these two 
products were 2700 and 1500 µg/kg (rounded of to the nearest 100), respectively.  
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Our results were in agreement with a report of the FSA of 15 SCF priority PAH in a wide range of food 
supplements (n=207) sampled in 2004 [9]. The FSA data also showed relatively high mean PAH levels in Ginkgo 
biloba supplements and bee products (high levels were limited to propolis supplements). The lower bound mean 
benzo[a]pyrene, PAH2, PAH4, PAH8 levels (1.90, 11.0, 18.3, and 22.7 µg/kg, respectively) calculated from the 
FSA data were lower than our findings, which might be explained by differences in sampling strategies. With 
respect to benzo[a]pyrene, the levels reported by the FSA fitted best the data obtained by us from 2003 up to and 
including 2007 (Table 5). Danyi et al. determined the 16 EFSA priority PAH in 20 botanical mono-ingredient food 
supplements of which St. John’s wort showed the highest PAH levels. Benzo[c]fluorene was found in two 
supplements [4]. The results were within the range found in our survey but the number of samples was too low for 
a meaningful comparison. Danyi et al. also briefly addressed possible mechanisms by which botanical materials 
could become contaminated with PAH which included direct atmospheric deposition on plant surfaces, absorption 
from soil and drying practices during manufacturing [4]. JECFA recommended that contact of food with 
combustion gases should be minimized [2, 17]. Direct drying procedures that use combustion gasses as the 
drying gas that comes in contact with the foods increased PAH contamination by 3- to 10-fold, dependent on the 
fuel used [17]. The Codex Alimentarius code of practice for the reduction of contamination of food with PAH from 
smoking and direct drying processes advised therefore against the use of diesel oil, rubber, tyres or waste oil as 
fuel [17].  
EFSA reported in 2008 in an Opinion of the Panel on Contaminants in the Food Chain on PAH in food, 
lower and upper bound mean benzo[a]pyrene, PAH2, PAH4, PAH8 levels derived from data of 283 food 
supplements submitted to EFSA by five European countries including the UK [10]. The lower bound mean levels 
for these parameters were 2.78, 12.8, 23.7 and 30.0 µg/kg respectively [3]. We found in 2008 and 2009 higher 
values for these parameters, which amounted to respectively 5.33, 20.8, 33.8 and 40.9 µg/kg. Our sampling 
protocol was targeted at supplements with relatively high PAH levels whereas the data submitted to EFSA were 
obtained by both targeted and random sampling. Mean PAH8 levels in food supplements came second in the 
EFSA Opinion after levels in dried tea samples with a lower bound mean of 61.0 µg/kg PAH8 [3]. The highest 
individual PAH level reported for foods tested for all 15 SCF priority PAH was 1064 µg/kg benz[a]anthracene in 
tinned sprats. According to EFSA this value was possibly an aberration, however. The second and third highest 
individual PAH level (690 µg/kg of benzo[b]fluoranthene and 590 µg/kg of chrysene, respectively) were found in 
food supplements [3]. In the category of supplements, a black tea supplement showed the highest combined PAH 
concentrations and a supplement with spirulina and one with propolis extract showed the second and third 
highest concentrations, respectively [10]. In our study, the highest and second highest individual PAH levels were 
found in food supplements with resveratrol amounting to 503 and 474 µg/kg benzo[c]fluorene, respectively. EFSA 
received data on benzo[c]fluorene in only 24 food supplements and 9 (37.5%) of these contained this PAH with a 
maximum of 9.6 µg/kg [3]. We tested 333 supplements for benzo[c]fluorene and 70 (21%) contained this PAH 
with a maximum of 503 µg/kg (Table 7).  
With respect to using lower or upper bound PAH levels, EFSA concluded that overall there was a very 
limited impact of using the lower or the upper bound, but the choice for the upper bound would represent a small 
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but real overestimation [3]. In the current study we chose to report the lower bound PAH levels in order to avoid 
overestimation. EFSA calculated the lower bound by replacing values below the LOD by 0. However, conflicting 
information was provided by EFSA in the Opinion on PAH in food on how values reported by Member States to 
be below the LOQ were treated. The first method provided was replacing values below the LOQ by 0, and a 
second was replacing values below the LOQ by the value for the LOD for each individual PAH [3]. In the current 
study we calculated the lower bound PAH levels by replacing both the values below the LOD and the LOQ by 0. 
This approach is therefore likely to result in an underestimation of actual PAH levels in food supplements. 
EFSA calculated in their Opinion on PAH in food margins of exposure (MOEs) for benzo[a]pyrene, 
PAH2, PAH4 and PAH8 by dividing the lowest Benchmark Dose Lower Confidence Limit associated with an extra 
10% cancer risk relative to background incidence (BMDL10) by the estimated mean exposure to these PAH in the 
European Union (EU) [3]. From the estimated mean dietary exposure to PAH8 in the EU of 28.8 ng per kg body 
weight per day (ng/kg bw/day) and the lowest BMDL10 for PAH8 identified by EFSA of 0.49 mg/kg bw/day, an 
MOE of 17,000 applicable to average consumers was calculated [3]. Similarly, for the 97.5th percentile of the 
estimated dietary exposure to PAH8 in the EU of 51.3 ng/kg bw/day, an MOE of 9600 applicable to high level 
consumers was derived [3]. EFSA concluded that the MOEs calculated for average consumers indicated a low 
concern for consumer health but that the MOEs for high level consumers are close to or less than 10,000 which 
indicates a potential concern for consumer health and a possible need for risk management action [3, 18].  
In the current study, the highest estimated daily exposure to PAH8(-IcP) of 934 ng was calculated for a 
multi-ingredient botanical food supplement with resveratrol (No. 13 from Table 9). Assuming a body weight of 60 
kg, the exposure to PAH8(-IcP) with this supplement used at the maximum recommended dose level would 
amount to 15.6 ng/kg bw/day. From this value and the lowest BMDL10 value for PAH8 identified as acceptable by 
EFSA of 0.49 mg/kg bw/day [3], an MOE of 31,500 (rounded of to the nearest 100) was calculated. Similarly, 
MOEs calculated for the daily exposure to benzo[a]pyrene, PAH2 and PAH4 from this supplement at the 
recommended dose level by using BMDL10 values of respectively 0.07, 0.17 and 0.34 mg/kg bw/day [3], were 
24,600; 25,500 and 28,900, respectively. Although these MOEs were higher than 10,000, the estimated daily 
benzo[a]pyrene intake of 2.85 ng/kg bw/day with this supplement at the recommended dose level exceeded the 
virtual safe dose (VSD) for all dietary PAH expressed as 0.5 ng/kg bw/day of benzo[a]pyrene established in 2001 
by the Dutch National Institute for Public Health and the Environment (RIVM) using benzo[a]pyrene as an 
indicator for the occurrence and carcinogenic potency of dietary PAH. The VSD was based on a rat study with 
coal tar mixture administered by oral gavage [19]. The estimated PAH8 intake from this particular supplement 
would amount to more than 50% of the estimated mean dietary exposure to PAH8 in the European Union 
calculated by EFSA and 30% of the 97.5th percentile of estimated dietary exposure to PAH8 in the European 
Union derived by EFSA [3].  
Relatively high estimated PAH intakes with individual food supplements containing high PAH levels have 
been reported in other studies as well [9, 11]. In the FSA study [9], a spirulina supplement used at the maximum 
recommended dose level would provide 68.7 ng/kg bw/day of PAH8, which would result in an MOE of 7100 
calculated by using a BMDL10 for PAH8 of 0.49 mg/kg bw/day. In a study on PAH in propolis on the Italian 
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market, high estimated PAH8 intakes were derived for several propolis products [11]. For a sample of raw 
propolis, a daily PAH8 intake of 46.7 ng/kg bw/day was estimated for a 60 kg adult by assuming a daily dosage of 
200 mg [11]. From this estimated PAH8 intake an MOE of 10,500 could be calculated. However, the daily dosage 
used to estimate the PAH8 exposure was rather low. Our study included a propolis supplement with a maximum 
recommended dose level of 2 g per day (No. 1 of Table 6). Recommended dosages of 3 g propolis per day were 
also found on the Internet [11]. When a recommended dose level of 2 g would be assumed for this particular raw 
propolis sample, the MOE would be tenfold lower thus resulting in an MOE below 10,000 [11]. 
EFSA also presented data on the contributions of individual food categories to PAH exposure of 
consumers of these foods. These contributions were calculated by first collecting for each food category the mean 
consumption of consumers only in each Member State and then by multiplying the median of these by the mean 
contamination [3]. The contributions thus obtained ranged from 30 ng PAH8 per day for cheese up to 421 ng per 
day for seafood and seafood products [3]. In our 2008 and 2009 survey, the range of the estimated daily PAH8(-
IcP) intakes at the recommended dose level of 20 supplements with relatively high PAH levels was 51 up to 934 
ng per day (Table 9). Use at the recommended dose level of three of these supplements would result in PAH8(-
IcP) exposure exceeding the highest contribution of a food category to PAH8 exposure of consumers [3]. This 
shows that individual food supplements can contribute significantly to the daily PAH exposure of consumers. 
Collectively, the PAH intake from food supplements will be less substantial however. From the mean PAH8(-IcP) 
level of 40.9 µg/kg found in our 2008 and 2009 survey and an assumed daily dosage of 1 g, a daily PAH8(-IcP) 
intake of 41 ng per day, equivalent to 0.7 ng/kg bw/day for a 60 kg adult, could be estimated. This intake estimate 
of PAH8(-IcP) would amount to 2.4% of the mean level dietary exposure to PAH8 in the EU and 1.3% of the high 
level dietary exposure [3]. Furthermore, the PAH8(-IcP) intake of 41 ng per day estimated above for food 
supplements (mainly with botanical ingredients) was comparable to contributions from cheese (30 ng PAH8 per 
day) and sugar and sugar products including chocolate (39 ng PAH8 per day) to PAH exposure of consumers [3].  
Maximum levels for contaminants in European Food law should be set at a level, which is as low as 
reasonably achievable (ALARA) when these contaminants are considered to be genotoxic carcinogens [7]. It was 
interesting to note that overall in 192 (58%) of the supplements in the 2008 and 2009 survey (n=333), PAH4 
levels were lower than 10 µg/kg and in 99 (30% of the total) of these PAH4 levels were below the LOQ. 
Furthermore, in all subcategories of food supplements identified in this survey there were supplements that 
contained no quantifiable or relatively low levels (here defined as PAH4 level below 10 µg/kg) of PAH. This 
suggests that contamination of food supplements with PAHs is avoidable.  
In summary, it can be concluded that use at maximum recommended dose levels of individual food 
supplements, especially those with botanicals or propolis, can contribute significantly to PAH exposure, whereas 
collectively, PAH intake resulting from food supplement use will be at the lower end of the range of contributions 
of main food groups to PAH exposure of consumers of these foods. Efforts aiming at regular control and reduction 
of PAH levels in food supplements may prove a way forward to further reduce the intake of these genotoxic 
carcinogens from food. 
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Background 
 
In the last two decades it became increasingly recognized that the availability and use of botanicals 
outside the regulatory framework for medicinal products was increasing in the Netherlands and in other Member 
States of the European Union and that also certain acutely toxic herbs and herbs with delayed toxic effects were 
being brought on the market [1, 2]. In 2004, the European Food Safety Authority (EFSA) considered in a position 
paper on this topic that, because food supplements with botanical materials and preparations were gaining in 
popularity, safety concerns linked to these products also became more prominent. The safety concerns linked to 
botanicals and botanical preparations essentially relate to i) the presence of naturally occurring toxic substances 
in plants, ii) the intentional addition or accidental occurrence of toxic contaminants and iii) interactions of botanical 
ingredients with active ingredients from medicinal products (herbal food-drug interactions) [2].  
The presence of naturally occurring toxic substances in botanicals and botanical preparations is an 
important reason for safety concerns and several of these concerns have been addressed in the Netherlands by 
the Commodities Act Decree ‘Herbal preparations’. The Decree entered into force in 2001 and applies to the use 
of plants and fungi in food and non-food commodities. Herbal preparations are defined by this Decree as ‘herbal 
substances, subjected to treatment or not, including herbal extracts, which are intended to be used by humans’. 
In addition, ‘herbal substances’ are defined as ‘substances that are composed of plant material’. The Decree 
limits the presence of several naturally occurring toxic substances, such as for example aristolochic acids, in 
herbal preparations and it bans the use of certain toxic plants and fungi in herbal preparations [1]. Outside the 
regulatory context, the terms ‘herbal preparation’ and ‘botanical preparation’ or ‘botanical’ can be used 
interchangeably.  
A second reason for concerns about the safety of botanicals and botanical preparations relates to the 
intentional addition or accidental occurrence of a wide range of toxic contaminants. Contamination with lead, 
mercury and arsenic of herbal preparations has been described to occur in several Asian traditional medicine 
systems resulting in poisonings worldwide [3]. In the Indian traditional medicine system Ayurveda, Traditional 
Tibetan Medicine (TTM) and in Traditional Chinese Medicine (TCM), the metals mercury and lead and the 
metalloid arsenic are deliberately added to herbal preparations for therapeutic reasons. Metals and metalloids 
such as mercury and arsenic can exist in different defined chemical species and the toxicity of these species can 
vary significantly. In order to estimate the risks related to exposure to metals and metalloids from food it is 
important to take into account the chemical species in which these metals and metalloids exist. Furthermore, 
contamination of herbal preparations with polycyclic aromatic hydrocarbons (PAH) occurs. This may be the result 
of inadequate processing procedures such as drying practices where raw plant material comes in direct contact 
with combustion gasses. Contamination may also result from environmental deposition and these environmental 
PAH may be concentrated by the extraction steps applied in the production process of the botanical preparation, 
resulting in the past in for instance natural vitamin E samples that were highly PAH contaminated [4-6]. Several 
PAH such as benzo[a]pyrene, are genotoxic and carcinogenic. PAH were evaluated by several risk assessment 
bodies including EFSA, which identified 16 priority PAH. EFSA concluded that 8 of these 16 EFSA priority PAH 
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for which oral carcinogenicity data are available (PAH8) could be used as indicator of the carcinogenic potency of 
PAH in food. According to EFSA, the most suitable indicators of PAH in food with regards to both occurrence and 
toxicity are currently a combination of 4 compounds of the PAH8 (referred to as PAH4) or PAH8 itself [7].  
Finally, toxicological concern is raised by the potential of certain botanicals and botanical preparations to 
interact with conventional medicines leading to serious adverse effects. St. John’s wort is a well-known example 
of a herb for which serious herb-drug interactions have been described and the mechanism of action is discussed 
in some detail in Chapter 3 of this thesis. Risks of herb-drug interactions were however not discussed further in 
this thesis.  
The aim of the present thesis was to review the toxicity of selected herbal preparations, to investigate 
the presence and actual levels of selected contaminants and naturally-occurring toxic substances in herbal 
preparations on the Dutch market and to estimate the associated risks.  
 
 
Summary 
 
After an introduction to the topic of interest (Chapter 1) the thesis started with an overview of the present 
state-of-the-art in regulation and legislation of botanicals and botanical preparations used in food (Chapter 2). The 
need for adequate regulation and legislation is generally well recognized nowadays, especially given the rapid 
increase in consumer use, the over-the counter availability of botanicals and botanical preparations and the 
existence of serious safety concerns. In the Netherlands, regulation and legislation of botanicals and botanical 
preparations used in food covers naturally-occurring toxic compounds and contaminants present in these 
products, but it does not include provisions to counter the risk of interactions between certain botanical 
ingredients of foods and conventional drugs.  
The Dutch Commodities Act Decree ‘Herbal preparations’ regulates the use of toxic plants and fungi in 
herbal preparations. It includes limits for three types of phytotoxins in herbal preparations, which are toxic 
pyrrolizidine alkaloids, aristolochic acids and yohimbe alkaloids. Furthermore, the Decree currently prohibits the 
use in herbal preparations of 46 plants and fungi that are too toxic to be used in food or in other commodities. The 
constituents responsible for the toxic effects of these 46 plants are also found in plants not specifically regulated 
by the Decree. Within Europe, EFSA developed a new methodology for the safety assessment of botanicals used 
in food supplements and published a Compendium of botanicals that raise toxicological concern to be used as 
input for risk assessments [8, 9]. European and Dutch risk assessment bodies concluded that several botanicals 
pose health risks. Chapter 2 presents an overview of the Dutch and European regulatory framework for selected 
food commodities with botanical ingredients as well as an overview of health concerns defined by risk assessors 
related to botanicals not specifically covered by these food safety laws. It is concluded that the current regulation 
and legislation in the Netherlands and Europe needs to be updated to address health risks relating to botanicals 
and botanical preparations that are identified to be of concern.   
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Naturally-occurring toxic compounds in botanicals 
Given that one of the safety concerns over botanicals and botanical ingredients relates to natural toxins 
being present in these preparations, Chapter 3 presents an overview of the nature and mechanism of action of 
several toxic botanical ingredients that are, or will probably be, specifically covered by Dutch or European 
legislation and that are presently receiving increased attention in the field of food toxicology. This relates to 
compounds including aristolochic acids, pyrrolizidine alkaloids, beta-carotene, coumarin, the alkenylbenzenes 
safrole, methyleugenol and estragole, ephedrine alkaloids and synephrine, kavalactones, anisatin, St. John’s wort 
ingredients, cyanogenic glycosides, solanine and chaconine, thujone, and glycyrrhizinic acid. It can be concluded 
that several of these phytotoxins cause concern, because of their bioactivation to reactive alkylating intermediates 
that are able to react with cellular macromolecules causing cellular toxicity, and, upon their reaction with DNA, 
genotoxicity resulting in tumors. Another group of the phytotoxins presented is active without the requirement for 
bioactivation and, in most cases, these compounds appear to act as neurotoxins interacting with one of the 
neurotransmitter systems. Altogether, the examples presented in Chapter 3 clearly illustrate that natural does not 
equal safe and that in modern society adverse health effects, upon either acute or chronic exposure to 
phytochemicals, can occur as a result of use of plant- or herb-based foods, teas, or other extracts. 
Chapter 4 of this thesis subsequently reports data on the actual occurrence of a group of natural toxic 
botanical constituents of concern, namely aristolochic acids, in selected types of herbal preparations on the Dutch 
market. The occurrence of aristolochic acids I and II was monitored in traditional herbal preparations (THPs) used 
in Traditional Chinese Medicine (TCM). As discussed in Chapter 3, herbs with aristolochic acids and derivatives 
are nephrotoxic, genotoxic and carcinogenic. Several species from the family of the Aristolochiaceae that are 
used in TCM contain aristolochic acids. After aristolochic acid related nephropathy (AAN) and urothelial cancer 
were described in Belgium in female patients who had been exposed to aristolochic acids through contaminated 
herbal preparations, herbs with aristolochic acids were prohibited worldwide. Confusing nomenclature can result 
in contamination of certain Chinese THPs with aristolochic acids. The presence of aristolochic acids in THPs 
sampled on the Dutch market was analyzed using an LC-MS method. From 2002 up to and including 2006, 190 
Chinese THPs were sampled using recent information on Chinese THPs potentially containing aristolochic acids. 
Aristolochic acid I was found in 25 samples up to a concentration of 1676 mg/kg. Aristolochic acid II was also 
found in 13 of these samples up to 444 mg/kg. All 25 positive samples including Mu Tong, Fang Ji, Tian Xian 
Teng and Xi Xin were part of a group of 68 THPs identified as possibly containing aristolochic acids. In a worst-
case scenario, use of a sample of Mu Tong with the highest aristolochic acid content over a 7-day period would 
result in intake levels of aristolochic acids similar to the intake levels, which significantly raised the cancer risk in 
the Belgian AAN cases. Our results show that contaminated THPs still can be found on the market even after 
worldwide publicity. Therefore, it can be concluded that testing of possible aristolochic acid contamination of 
THPs is still essential.  
EFSA noted that misidentification of plants harvested from the wild is a continuing problem causing the 
accidental use of toxic herbal species [2]. In addition to misidentification of plants in the wild, confusing 
nomenclature used for botanicals on the market can also result in misidentification and subsequent contamination 
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of food commodities with toxic plants of which we found evidence in our survey into aristolochic acids in Chinese 
THPs. From 2002 up to and including 2006 we sampled 14 preparations labeled as ‘Mu Tong’ of which relatively 
many (n=7) contained aristolochic acids (Chapter 4). The name Mu Tong refers to the stem of Aristolochia 
manshuriensis but it can also be used for the stem of 2 Clematis spp. and 2 Akebia spp. Of the 7 Mu Tong 
samples with aristolochic acids, 4 were indicated to contain exclusively the stem of Akebia quinata or Akebia 
trifoliata. Because Akebia quinata or Akebia trifoliata do not contain aristolochic acids, it was concluded that 
Aristolochia spp. were partially or completely substituting for these plants. Furthermore, one of these samples 
labeled to contain the stem of these two Akebia plants contained the highest amount of aristolochic acids found in 
the survey. This shows that misidentification or substitution of plants used in Chinese THPs is a risk that should 
be taken into account by producers or distributors of these products in the Netherlands.  
The European Medicine Agency (EMA; previously the acronym EMEA was used) assessed in 2005 the 
evidence concerning Mu Tong and Fang Ji (the root of Aristolochia fangchi or 3 other herbs) substitutions and 
advised that in absence of appropriate quality control procedures the prohibition of species at risk of being 
confused with Aristolochia spp. should be considered. The plants posing a risk because of confusion with and 
substitution of Aristolochia spp. for these unrelated plants, include Akebia quinata, Akebia trifoliata, Clematis 
armandii, Clematis montana, Cocculus orbiculatus, Cocculus laurifolius, Cocculus trilobus and Stephania 
tetrandra [10]. Because Stephania tetrandra (Fang Ji or Han Fang Ji) is not toxic the Dutch Ministry of Health 
removed this botanical from the list of plants and fungi banned for use in herbal preparations in the Decree 
‘Herbal preparations’ in 2005 [11]. RIVM and VWA advised however to maintain Stephania tetrandra on the list 
due to the potential for substitution with Aristolochia spp. [12, 13]. Currently, none of the herbs posing a risk 
because of confusion and substitution with Aristolochia spp. are banned in the Netherlands. Moreover, EMA 
advised to consider controlling other plant species of the Aristolochiaceae family, especially Asarum spp. that 
may contain aristolochic acids [10]. THPs with ‘Xi Xin’ (Asarum sieboldii herba) included in our study presented in 
Chapter 4, frequently contained aristolochic acids. Of 12 products with Xi Xin, 11 contained relatively low levels of 
aristolochic acid I. Possible implications of these findings are discussed further on in this Chapter in the section 
on future perspectives. 
 
Contamination of herbal preparations 
In addition to toxicological concerns over naturally occurring toxic compounds in botanicals, the safety of 
food commodities with botanical ingredients can also become compromised through contamination, intentionally 
or by accident, with a multitude of substances, including, for example, polycyclic aromatic hydrocarbons (PAH) or 
metals such as lead. In traditional medicine especially botanicals are frequently used, although animal parts 
and/or minerals are also applied [14]. In several Asian traditional medicine systems such as Ayurveda, Unani-
Tibb, Siddha, TCM and Traditional Tibetan Medicine (TTM), ingredients that contain significant amounts of 
mercury, arsenic or lead are deliberately added to certain herbal preparations for therapeutic purposes. Although 
these ingredients are widely considered to be safe in these traditional medicine systems, they have caused 
intoxications worldwide. The aim of the study presented in Chapter 5 of this thesis was therefore to determine 
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mercury, arsenic and lead levels in Asian THPs on the Dutch market. 292 THPs used in Ayurveda, TCM and TTM 
were sampled between 2004 and 2007. Samples were mostly multi ingredient THPs containing herbs and 
minerals. The labeling of less than 20% of the THPs suggested the presence of mercury, arsenic or lead. These 
elements were shown by ICP-MS to be present in 186 (64%) of 292 THPs. Estimated weekly mercury, arsenic 
and lead intake levels were calculated for each THP from the analytically determined concentrations and the 
recommended dose. 59 THPs (20%) were likely to result in intakes of these elements significantly exceeding 
safety limits. Of these 59 THPs, intake estimates for 50 THPs significantly exceeded the safety limit for mercury 
(range 1.4-1747 mg/week); intake estimates for 26 THPs significantly exceeded the safety limit for arsenic (range 
0.53-427 mg/week) and intake estimates for 8 THPs were significantly above the safety limit for lead (range 2.6-
192 mg/week). It was concluded that the mercury, arsenic and lead contents of THPs used in Ayurveda, TCM 
and TTM remain a cause for concern and require strict control.  
The survey into lead, mercury and arsenic in Asian THPs presented in Chapter 5 was continued in 2008. 
The results of the 2008 survey do not indicate that the safety of these products has improved significantly that 
year compared to the results obtained in the previous years. We found in 2008, mercury, lead and arsenic in 60 
(77%) of 78 Asian THPs. When used at the recommended dose level, four of these THPs would result in arsenic 
or mercury intakes above the safety limits selected in Chapter 5. Mercury levels of 27 THPs exceeded the 
recently established EU limit for mercury in food supplements of 0.1 mg/kg on a total of 28 THPs in which 
mercury was found. Lead levels of 36 THPs were above the new EU limit for lead in food supplements of 3.0 
mg/kg on a total of 56 THPs in which lead was found [15].  
Recently, EFSA assessed the risks of lead and arsenic intakes from food and from these risk 
assessments it can be concluded that current levels of exposure to lead and arsenic from food are of more 
concern than previously considered. This also affects the risks linked to Asian THPs with lead or arsenic as 
estimated in Chapter 5. The EFSA Panel on Contaminants in the Food Chain (CONTAM) concluded in its 
Scientific Opinion on Arsenic in Food of October 2009 that the provisional tolerable weekly intake (PTWI) of 15 
µg/kg bw established by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) is no longer 
appropriate. The CONTAM Panel identified a range of values for the 95% lower confidence limit of the benchmark 
dose of 1% extra risk (BMDL01), for use in the risk characterization for inorganic arsenic. The BMDL01 values for 
the relevant health endpoints, i.e. skin lesions, cancers of the skin, urinary bladder and lung, ranged from 0.3 to 8 
µg/kg bw/day [16]. In our study on arsenic, lead and mercury in Asian THPs sampled before 2008 presented in 
Chapter 5, we used a TDI of 1.0 µg/kg bw/day established by RIVM. This TDI was based on the JECFA PTWI to 
which an extra uncertainty factor of 2 was applied for observation errors in epidemiological studies [17]. The TDI 
established by RIVM for inorganic arsenic lies at the lower end of the range of BMDL01 values defined by the 
CONTAM Panel. In our study presented in Chapter 5, 26 of 292 Asian THPs analyzed showed arsenic levels that 
when used at recommended dose levels, would result in intakes significantly above the RIVM TDI. Furthermore, 
another 77 of the total also contained arsenic but at levels that would result in exposure levels that do not exceed 
the TDI of 1.0 µg/kg bw/day significantly when used according recommendations on the label. For the majority of 
samples in this group a margin of safety of one or two orders of magnitude exists between estimated arsenic 
 CHAPTER 8  |  193 193 
intake levels for these samples at the recommended dose levels and the RIVM TDI. Since the TDI lies in the 
range of BMDL01 values identified by the CONTAM Panel, this margin can also be considered representative for 
the range of BMDL01 values identified by the CONTAM Panel.  
Because no maximum level for arsenic applies to food supplements in European or Dutch food law, the 
VWA has to proof that a supplement with relatively high arsenic levels is injurious to health or unfit for human 
consumption before management actions can be taken. The placing on the market of products, which are 
injurious to health or unfit for human consumption, is prohibited by the General Food Law (European Regulation 
(EC) No 178/2002) which provisions directly apply in the Netherlands [18]. In view of the CONTAM Panel Opinion 
on Arsenic in Food it should be considered whether it is still appropriate to use the RIVM TDI for inorganic arsenic 
to assess if a food supplement with a relatively high arsenic level can be used safely. The setting of maximum 
limits for arsenic in food supplements would help the enforcement of the safety of these products and should 
therefore be considered.  
Furthermore, the CONTAM Panel also noted that food supplements based on algae were among the 
food commodities in which the highest total arsenic levels were measured. This is especially relevant for several 
algae such as hijiki (Hizikia fusiforme) that can contain high total arsenic levels of which up to 60% consists of 
inorganic arsenic besides organic arsenic compounds that are of lower toxicological concern [16, 19]. In other 
algae inorganic arsenic makes up only a small percentage of total arsenic levels [19]. The CONTAM Panel also 
stressed the need for data on arsenic speciation in different food commodities in order to refine risk assessments 
[16].  
The CONTAM Panel published in April 2010 an Opinion on the risk assessment for lead in food. The 
Panel concluded in its Scientific Opinion on lead in food that the PTWI of 25 µg/kg bw established by JECFA is 
not appropriate anymore. Because there was no evidence for a threshold for a number of critical endpoints 
including developmental neurotoxicity and nephrotoxicity in adults, the Panel considered it to be not appropriate 
to derive a PTWI. It was concluded that there is potential concern at current levels of exposure to lead for effects 
on neurodevelopment in infants, children and pregnant women. Measures taken to protect children and women of 
child-bearing age against the potential risk of neurodevelopmental effects will also protect against all other 
adverse effects of lead, in the population as a whole. The Panel derived a BMDL01 intake level of 0.50 µg/kg bw 
per day for neurodevelopmental effects [20]. In our study on arsenic, lead and mercury in Asian THPs (Chapter 5) 
we used a TDI of 3.6 µg/kg bw/day established by RIVM which was directly based on the JECFA PTWI for lead 
[17]. Because EFSA does no longer consider the JECFA PTWI for lead to be appropriate, the use by the VWA of 
the corresponding TDI adopted by RIVM for food commodities to which no legal maximum limits applies, should 
also be reconsidered.  
The mercury detected in Ayurvedic THPs, as reported in Chapter 5, may result from the fact that in 
Ayurveda, mercury is deliberately added to several THPs in the form of preparations called ‘bhasmas’. Metals or 
metalloids in bhasmas are claimed to be detoxified by rigorous processing. The toxicity of mercury depends on 
the chemical form in which it exists [21, 22]. Mercury in its elemental state, referred to as Hg(0), shows a low oral 
toxicity while inorganic and organic mercury forms are significantly more toxic [22, 23]. As shown in Chapter 5 we 
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determined mercury in 242 Ayurvedic THPs and use of 19% of these preparations at the recommended dose 
level would result in mercury intakes above a toxicological safety limit for inorganic mercury. The study presented 
in Chapter 6 is aimed at investigating whether (part of) the mercury detected in these Ayurvedic THPs is present 
as Hg(0), which would provide an argument to reconsider the safety assessment using limits for inorganic 
mercury. To test this we developed a method that enabled detection of Hg(0) in these Ayurvedic THPs and 
subsequently performed a study on the presence of Hg(0) in 19 Ayurvedic THPs of which the study in Chapter 5 
showed that mercury intakes with the recommended daily dose exceeded the safety limit for inorganic mercury. 
The results obtained reveal that in 11 of the 19 THPs analyzed all mercury detected could be accounted for by 
other forms than Hg(0). Extraction of the other 8 THPs with 7M HNO3, a method demonstrated to efficiently 
extract Hg(0), revealed that most of the mercury present in these samples (i.e. 69-99%) could not be extracted by 
7M HNO3, pointing at other forms than Hg(0) being present. It was concluded that in all THPs the main part of the 
mercury content is not present in its relatively non-toxic elemental form, that the mercury detected in Ayurvedic 
THPs is likely to be present in the inorganic form and that therefore the estimation of the related risks based on 
the safety limits for inorganic mercury would be justified. Finally, no additional risk assessments of inorganic 
mercury by national or international expert committees have been identified to date.   
The metals and metalloids encountered in Asian THPs are most likely the result of intentional addition 
and differ in that respect from contaminants such as polycyclic aromatic hydrocarbons (PAH) that can occur in 
food through several processes. PAH are also found in food supplements and the Dutch Commodities Act 
includes since January 2006 a maximum level of 10 µg/kg benzo[a]pyrene for botanical food supplements and a 
limit of 2 µg/kg for supplements without botanical ingredients [24]. EFSA has defined 16 priority PAH that are 
both genotoxic and carcinogenic and identified 8 priority PAH (PAH8) or 4 of these (PAH4) as good indicators of 
the toxicity and occurrence of PAH in food. The study described in Chapter 7 aims to determine benzo[a]pyrene 
and other EFSA priority PAH in different categories of food supplements containing botanicals and other 
ingredients. In 2003 up to 2008, benzo[a]pyrene exceeded the limit of quantification (LOQ) in 553 (44%) of 1258 
supplements with a lower bound mean of 3.37 µg/kg. In 2008 and 2009, benzo[a]pyrene and 12 other EFSA 
priority PAH were determined in 333 food supplements. Benzo[a]pyrene exceeded the LOQ in 210 (63%) food 
supplements with a lower bound mean of 5.26 µg/kg. Lower bound mean levels for PAH4 and PAH8 (-
indeno[1,2,3-cd]pyrene) were 33.5 µg/kg and 40.5 µg/kg, respectively. Supplements containing resveratrol, 
Ginkgo biloba, St. John’s wort and propolis showed relatively high PAH levels in 2008 and 2009. Before 2008, 
supplements with these ingredients and also dong quai, green tea or valerian contained relatively high 
benzo[a]pyrene levels. On average, PAH intake resulting from food supplement use will be at the lower end of the 
range of contributions of main food groups to PAH exposure, although individual food supplements can contribute 
significantly to PAH exposure. Regular control of PAH levels in food supplements may prove a way forward to 
further reduce the intake of PAH from food. It was interesting to note that overall in 192 (58%) of the supplements 
in the 2008 and 2009 survey (n=333), PAH4 levels were lower than 10 µg/kg and in 99 (30% of the total) of these 
PAH4 levels were below the LOQ. Furthermore, in all subcategories of food supplements identified in this survey 
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there were supplements that contained no quantifiable or relatively low levels of PAH. This suggests that 
contamination of food supplements with PAHs is avoidable.   
Overall, on the basis of the surveys on contamination of herbal preparations on the Dutch market with 
aristolochic acids, lead, mercury, arsenic and PAH of which the analytical data are presented in this PhD thesis it 
can be concluded that contamination of herbal preparations with PAH is most widespread, followed by 
contamination with mercury, arsenic or lead, and with aristolochic acids in the last place. The toxicity of these 
different substances cannot easily be compared. When however for each of these contaminants the effects of 
exposure at the high end of the range of estimated intake levels identified in this thesis during a certain amount of 
time would be compared, the effects found for aristolochic acids would likely be most detrimental to health, 
followed by the toxic effects of lead, arsenic, mercury and PAH, in that particular order. However, the facts that 
aristolochic acids were only found in a small segment of the products sold in TCM outlets in the Netherlands, and 
that considerably more Asian THPs were found on the market that contained lead, arsenic or mercury, would 
suggest that Asian THPs with relatively high levels of lead, arsenic or mercury are currently more likely to cause 
adverse effects in the Netherlands. Estimated exposure levels to PAH from food supplements identified in 
Chapter 7 are within the range of exposure levels to PAH from food identified in the European Union and the 
associated health effects are therefore of a lower order than the effects of aristolochic acids, lead, mercury and 
arsenic. However, because several PAH are genotoxic and carcinogenic and exposure to PAH from food is of 
potential concern for high level consumers, efforts should be made to reduce exposure to PAH from food 
supplements to further decrease the exposure from food.  
 
 
Future perspectives 
  
The European Commission concluded in 2008 that laying down specific European rules for substances 
other than vitamins and minerals for use in food supplements is not justified [25]. This means that it is not likely 
that in the foreseeable future a European counterpart to the Dutch Commodities Act Decree ‘Herbal preparations’ 
will be established. Regulation (EC) No 1925/2006 establishes a procedure in article 8 to be used in cases where 
a substance other than vitamins or minerals (e.g. a botanical) might represent a potential risk to consumers. The 
Commission may take, based on an EFSA safety assessment or information provided by the Member States, the 
decision to prohibit or restrict the use of this substance in food. The safety of botanical ingredients can be 
assessed using the EFSA approach for the safety assessment of botanicals and botanical preparations in 
combination with the EFSA Compendium of botanicals reported to contain toxic, addictive, psychotropic, or other 
substances of concern. No decisions have yet been taken using this procedure. It is yet not clear whether the 
Commission will make much use of the procedure in article 8 of Regulation (EC) No 1925/2006 to restrict or 
prohibit certain botanicals for use in foods.  
EFSA already pointed out in 2004 that the use of botanicals and botanical preparations in food is 
increasing [2]. Safety concerns related to botanicals will therefore increase in significance as well. Because new 
European legislation for botanicals and botanical preparations intended to be used in food supplements is not 
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likely to be established in the near future, it would be prudent to keep legislation such as the Decree ‘Herbal 
preparations’ up to date in order to protect Dutch consumers from serious risks resulting from use of herbal 
preparations. When an update of the Decree ‘Herbal preparations’ is initiated, this update should take into 
account risk assessments and recommendations on botanical products by national and European risk 
assessment agencies such as RIVM, EMA and EFSA.  
Several risk assessment bodies have advocated label warnings for a number of botanicals. For example, 
EMA defined warnings related to interactions of herbal medicinal products with St. John’s wort with other 
medicinal products [26]. Because St. John’s wort is also used in botanical food supplements and other herbal 
preparations, these warnings might be of significance for all St. John’s wort-containing products for oral use on 
the market. In addition, a number of risk assessors recommended that preparations with black cohosh (Actaea 
racemosa or Cimicifuga racemosa) should carry warnings regarding the potential of this herb to cause liver 
dysfunction [27]. It should be considered to include in the Decree ‘Herbal preparations’ compulsory label warnings 
for certain herbal preparations for which health concerns exist, but which could be used safely when consumers 
are informed how specific adverse health effects from this product can be avoided. However, it would then be 
advisable to establish for which types of adverse effects this approach is appropriate. Although it is not customary 
in the Netherlands for foods to carry label warnings, compulsory label warnings have been established for foods 
with certain levels of glycyrrhizinic acid. Currently, the rule does not apply to herbal preparations such as 
botanical food supplements. However, it should be considered to extend the label warning to herbal preparations 
in which Glycyrrhiza species are used that contain glycyrrhizinic acid.  
Furthermore, it is important to note that the introduction of label warnings on a product that is linked to 
certain adverse health effects does not guarantee that these health problems will cease to occur. This is 
illustrated by differences in approaches worldwide to protect consumers against kava kava toxicity. Use of this 
botanical is linked to liver problems and kava kava was banned in herbal preparations for this reason in the 
Netherlands in 2003. In the USA, kava kava remained on the market. The US herbal industry incorporated 
warnings about possible liver problems into their labeling and the US Food and Drug Administration (FDA) issued 
warnings as well. Despite these measures, reports of hepatotoxicity continued to be received by the FDA. 
Australia also introduced label warnings about rare cases of liver problems upon intake of kava kava but reports 
of hepatotoxicity continued to be received there as well [28].  
EFSA concluded in 2004 that the growing volume of sales in the European Union with products obtained 
from suppliers based in Asia or elsewhere and the move towards widespread outlets for the products of traditional 
medicine call for more formal pre-marketing assessment and more stringent controls than the occasional random 
checks and analyses often carried out by individual national or local authorities on what is already out in the 
market [2]. At present the Dutch or European regulatory framework for food commodities with botanical 
ingredients presented in Chapter 2 does not include provisions that enable stringent pre-marketing assessments 
for all products that are brought on the market. It is however possible to increase the frequency of surveys into 
naturally-occurring toxic constituents of botanicals and contaminants in food supplements that are already on the 
market. This approach can result in improvements of the safety of these products, although this may prove to be 
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a lengthy process. For instance, there are signs that enforcement actions by the VWA have caused a decrease in 
the number of THPs with aristolochic acids on offer in retail channels. In 2008, the VWA sampled 77 Chinese 
THPs for analysis of aristolochic acids and in one THP traces of aristolochic acids were detected [15]. In contrast, 
aristolochic acids were found in 25 of 190 Chinese THPs that were sampled from 2002 up to and including 2006 
(Chapter 4 of this thesis). But conclusions on a potential reduction in the risk of contamination of herbal 
preparations with aristolochic acids in Dutch retail channels should be based on results of several more years of 
market surveys. On the basis of future results it can then be assessed whether Asarum species and the plants at 
risk of substitution with Aristolochia species should be prohibited from use in herbal preparations. Another reason 
to assess the safety of the use of Asarum species in herbal preparations on the market is the possible presence 
of alpha-asarone, which is a mammalian carcinogen [29]. It should also be noted that consumers might come into 
contact with products containing aristolochic acids via channels such as Internet, which complicates official 
controls. Additionally, it is imperative that food business operators who bring THPs on the market, which in theory 
could contain aristolochic acids either directly because of the intended presence of plants from the 
Aristolochiaceae family, or unintentionally through confusion of intended botanical ingredients with Aristolochia 
spp., include measures in their quality control (Hazard Analysis Critical Control Points - HACCP) procedures in 
order to prevent this hazard. 
The CONTAM Panel Opinions on arsenic and lead [16, 20] are of significance for the enforcement of the 
safety of herbal preparations and other food supplements. It should be considered if it is still appropriate to use 
the RIVM TDI for inorganic arsenic and the RIVM TDI for lead to assess whether a food supplement with a 
relatively high arsenic or a relatively high lead level can be used safely. The setting of maximum levels for arsenic 
in food supplements would help the enforcement of the safety of these products and should therefore be 
considered. Also data on arsenic and mercury speciation in different food commodities is needed in order to 
refine risk assessments [16].  
Regarding the future setting of maximum levels for PAH in food supplements in European food safety 
law it should be noted that in our survey on PAH in food supplements presented in Chapter 7 in nearly 60% of the 
supplements in the 2008 and 2009 survey PAH4 levels were lower than 10 µg/kg. Furthermore, there were 
supplements present in all subcategories of food supplements that contained no quantifiable or relatively low 
levels of PAH present. This suggests that contamination of food supplements with PAHs is avoidable. These 
findings may be of significance for the setting of European maximum levels for PAH in food supplements, which 
may prove a way forward to further reduce the intake of PAH from food. 
 
 
Conclusions 
 
From the work described in this thesis it can be concluded that for herbal preparations ‘natural’ does not 
equal ‘safe’. Especially the results presented in Chapters 4 and 5 show that the mere fact that a herbal 
preparation has been brought on the Dutch market is not a guarantee that the product is safe and that it may not 
cause adverse health effects. Work done by national and European risk assessment agencies such as RIVM, 
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EMA and EFSA and reports in literature as discussed in Chapters 2 and 3 shows that certain herbal preparations 
other than those that are at present specifically covered by Dutch food safety law, raise toxicological concern as 
well. Furthermore, consumers should be aware that the risk of adverse health effects increases when herbal 
preparations are purchased outside regular retail channels, as is the case when preparations are acquired via 
Internet, traditional medicine outlets, smartshops or similar types of outlets. While food inspection authorities 
direct considerable effort to enforce food safety in the food supplement field, the primary legal responsibility for 
the safety of the food products is on the business operators who place these products on the market. It is 
imperative that food business operators who bring herbal preparations on the market acquire in-depth information 
on the hazards relevant to these products and include measures in their quality control (HACCP) procedures that 
aim to prevent, eliminate or reduce all significant hazards to acceptable levels. The fact that a food inspection 
authority has not yet analyzed products from a food business operator for the presence of certain constituents 
that raise toxicological concern or examined whether the operator has implemented measures aimed at 
preventing, eliminating or reducing these hazards to acceptable levels, does not mean that these hazards do not 
require action by the food operator. Finally, the European Commission concluded that new European legislation 
for botanicals and botanical preparations intended to be used in food supplements is not necessary and that 
existing legislation could be used to restrict or prohibit the use in food of certain toxic substances such as certain 
botanicals. Because it is yet not clear whether the European Commission will make much use of these 
possibilities it would be prudent to keep the Dutch Decree ‘Herbal preparations’ and other national legislation up 
to date in order to protect consumers from serious risks resulting from use of botanicals in food products such as 
herbal preparations. 
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SAMENVATTING EN DISCUSSIE 
 
Inleiding 
 
Gedurende de laatste twintig jaar is het in toenemende mate duidelijk geworden dat de beschikbaarheid 
en het gebruik van kruidenpreparaten buiten het geneesmiddelencircuit in Nederland en in andere Lidstaten van 
de Europese Unie aan het groeien was. Er kwam in deze periode ook meer aandacht voor kruiden op de markt 
die acuut toxisch zijn of die een schadelijke werking hebben op de lange termijn [1, 2]. In 2004 onderkende 
tevens de Europese Autoriteit voor voedselveiligheid (the European Food Safety Authority - EFSA) dat met de 
groeiende populariteit van voedingssupplementen die kruidenpreparaten bevatten eveneens de gevaren 
toenamen. De gevaarseigenschappen van kruiden en kruidenpreparaten houden verband met i) het voorkomen 
van natuurlijke toxinen in planten, ii) de opzettelijke toevoeging of toevallige aanwezigheid van toxische 
contaminanten of iii) interacties van kruideningrediënten met werkzame ingrediënten uit geneesmiddelen [2]. 
De aanwezigheid van toxische stoffen in kruidenpreparaten die van nature voorkomen in de planten die 
in de preparaten verwerkt zijn, is een belangrijke reden tot zorg. Het Warenwetbesluit Kruidenpreparaten stelt 
daarom regels aan de aanwezigheid van specifieke toxische stoffen zoals aristolochiazuren in kruidenpreparaten. 
Dit ‘Kruidenbesluit’ trad in werking in 2001 en is van toepassing op het gebruik van planten en schimmels in 
levensmiddelen en andere waren. Kruidenpreparaten worden door het Kruidenbesluit gedefinieerd als 
kruidensubstanties, al dan niet bewerkt, die bestemd zijn om te worden gebruikt door de mens, daaronder 
begrepen kruidenextracten. Daarbij zijn kruidensubstanties gedefinieerd als substanties bestaande uit 
plantenmateriaal. In aanvulling op regels die de aanwezigheid van meerdere giftige stoffen in kruidenpreparaten 
beperken, verbiedt het besluit tevens het gebruik van bepaalde giftige kruiden en schimmels in kruidenpreparaten 
[1]. De begrippen ‘kruidensubstanties’ en ‘kruidenpreparaten’ zijn buiten de wettelijke context min of meer 
synoniem aan respectievelijk de begrippen ‘botanicals’ en ‘botanical preparations’ die door EFSA worden 
gebruikt. 
Een tweede reden voor bezorgdheid over de veiligheid van kruidenpreparaten is de opzettelijke 
toevoeging of onbedoelde aanwezigheid van een reeks aan contaminanten. Vervuiling met lood, arseen en kwik 
is beschreven voor kruidenpreparaten uit verschillende Aziatische traditionele geneeswijzen en gebruik van 
dergelijke vervuilde kruidenpreparaten heeft wereldwijd tot vergiftigingen geleid [3]. In de traditionele Indiase 
geneeswijze Ayurveda, de traditionele Tibetaanse geneeswijze en in de traditionele Chinese geneeswijze worden 
voor therapeutische doeleinden de metalen kwik en lood en het metalloïde arseen opzettelijk toegevoegd aan 
kruidenpreparaten. Metalen en metalloïden zoals kwik en arseen kunnen voorkomen in verschillende chemische 
vormen die in toxiciteit aanmerkelijk van elkaar kunnen verschillen. Voor het schatten van de risico’s van metalen 
en metalloïden in voeding is informatie over de chemische vorm waarin deze stoffen aanwezig zijn van belang. 
Andere contaminanten die in kruidenpreparaten gevonden kunnen worden zijn polycyclische aromatische 
koolwaterstoffen (PAK’s). Vervuiling met PAK’s kan het resultaat zijn van het toepassen op levensmiddelen van 
daarvoor ongeschikte productieprocessen zoals het direct drogen van plantenmateriaal met verbrandingsgassen. 
Contaminatie kan ook plaatsvinden doordat PAK’s uit het milieu neerslaan op gewassen. In bepaalde 
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productieprocessen toegepaste extractiestappen kunnen deze PAK’s vervolgens concentreren wat in het 
verleden heeft geleid tot contaminatie van natuurlijk vitamine E met hoge concentraties aan PAK’s [4-6]. 
Meerdere PAK’s zoals benzo[a]pyreen zijn genotoxisch en carcinogeen. Verschillende expertcomités hebben 
risicobeoordelingen van PAK’s uitgevoerd. Een panel van EFSA heeft 16 PAK’s aangewezen die prioriteit moeten 
krijgen in het onderzoek. EFSA concludeerde dat 8 van deze 16 prioriteits-PAK’s waarvoor gegevens over 
carcinogeniteit beschikbaar zijn (de PAK8) gebruikt kunnen worden als indicator van de carcinogene 
eigenschappen van PAK’s in de voeding. De meest geschikte indicator voor PAK’s voor wat betreft de toxiciteit 
en het voorkomen in voeding, is op dit moment een combinatie van 4 van de individuele verbindingen uit de 
PAK8 (de PAK4) of de PAK8 zelf [7].  
Tenslotte geeft het optreden van interacties tussen bepaalde kruiden en conventionele geneesmiddelen 
aanleiding tot zorg. Deze interacties kunnen de gezondheid ernstig schaden. Sint-janskruid is een bekend 
voorbeeld van een kruid waarvan het gelijktijdig gebruik met bepaalde geneesmiddelen kan leiden tot ernstige 
interacties. Het mechanisme achter de interacties tussen sint-janskruid en deze geneesmiddelen wordt in 
Hoofdstuk 3 van dit proefschrift besproken. Interacties tussen andere kruiden en geneesmiddelen worden verder 
niet behandeld in dit proefschrift.  
Het doel van dit proefschrift was het beschrijven van de toxiciteit van bepaalde kruidenpreparaten, het 
vaststellen van de aanwezigheid en concentraties van bepaalde contaminanten en natuurlijke toxinen in 
kruidenpreparaten op de Nederlandse markt en het schatten van de geassocieerde risico’s. 
 
 
Samenvatting 
 
Nadat in Hoofdstuk 1 het onderzoeksonderwerp is geïntroduceerd, wordt in Hoofdstuk 2 een overzicht 
gegeven van de huidige wet- en regelgeving voor kruidenpreparaten die als levensmiddel toegepast worden. 
Door de snelle toename in het gebruik van kruidenpreparaten, de brede beschikbaarheid van deze producten en 
de kans op ernstige bijwerkingen wordt de noodzaak tot adequate wet- en regelgeving voor deze producten 
tegenwoordig breed erkend. In Nederland zijn in de levensmiddelenwetgeving normen opgenomen voor 
natuurlijke toxinen en contaminanten in kruidenpreparaten maar er ontbreken in deze wetgeving bepalingen die 
gericht zijn op het verminderen van de kans op interacties tussen bepaalde kruidenpreparaten en reguliere 
geneesmiddelen. Het Nederlandse Warenwetwetbesluit Kruidenpreparaten (ook wel het Kruidenbesluit) reguleert 
het gebruik van giftige planten en schimmels in kruidenpreparaten. Het Kruidenbesluit bevat normen voor drie 
plantentoxinen in kruidenpreparaten: toxische pyrrolizidine alkaloïden, aristolochiazuren en yohimbe alkaloïden. 
Daarnaast verbiedt het Kruidenbesluit op dit moment het gebruik in kruidenpreparaten van 46 planten en 
schimmels die te giftig zijn om in levensmiddelen of in bepaalde andere waren te gebruiken. De verbindingen die 
verantwoordelijk zijn voor de giftige effecten van deze 46 planten en schimmels worden ook gevonden in andere 
planten of schimmels die niet in het Kruidenbesluit zijn opgenomen. Op Europees niveau ontwikkelde EFSA een 
nieuwe methodologie voor de veiligheidsbeoordeling van kruidenpreparaten die in voedingssupplementen 
gebruikt worden. EFSA publiceerde tevens een Compendium van kruiden waarvan de veiligheid ter discussie 
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staat. Informatie uit het Compendium kan vervolgens als beginpunt voor risicoschattingen dienen [8, 9]. Europese 
en Nederlandse risicobeoordelaars concludeerden dat verschillende kruidenpreparaten een risico voor de 
gezondheid kunnen zijn. Hoofdstuk 2 geeft een overzicht van de Nederlandse en Europese wettelijke bepalingen 
voor levensmiddelen met kruidenbestanddelen. Tevens worden in dit hoofdstuk risicoschattingen besproken van 
meerdere kruiden waarvoor geen specifieke wettelijke maatregelen zijn genomen. Geconcludeerd kan worden 
dat de huidige wettelijke bepalingen in Nederland en Europa moeten worden aangepast om te voorkomen dat 
kruidenpreparaten die aanleiding tot zorg geven de gezondheid van gebruikers kunnen schaden. 
 
Natuurlijke toxinen in kruiden  
Omdat de aanwezigheid van natuurlijke toxinen in kruidenpreparaten een belangrijke reden tot zorg is, 
richt Hoofdstuk 3 zich op het werkingsmechanisme en de aard van verschillende toxische kruidensubstanties die 
op dit moment extra in de belangstelling staan in de levensmiddelentoxicologie en waarvoor specifieke 
maatregelen in de Nederlandse of Europese wetgeving genomen zijn of - waarschijnlijk - genomen zullen 
worden. Dit betreft kruidenbestanddelen zoals aristolochiazuren, pyrrolizidine alkaloïden, bèta-caroteen, 
coumarine, de alkenylbenzeensubstanties safrol, methyleugenol en estragol, efedrine alkaloïden en synefrine, 
kavalactonen, anisatine, sint-janskruidbestanddelen, cyanogene glycosiden, solanine en chaconine, thujon en 
glycyrrhizinezuur. Geconcludeerd kan worden dat meerdere van deze fytotoxinen aanleiding tot zorg geven door 
bioactivatie tot reactieve alkylerende metabolieten die kunnen reageren met cellulaire macromoleculen leidend tot 
cellulaire toxiciteit en, in geval van een reactie met DNA, genotoxiciteit en tumoren. Een andere groep van de 
besproken fytotoxinen is toxisch zonder bioactivatie en deze stoffen zijn in de meeste gevallen neurotoxinen die 
op neurotransmittersystemen inwerken. Alles samengenomen illustreren de in Hoofdstuk 3 besproken 
voorbeelden duidelijk dat het begrip ‘natuurlijk’ niet gelijk staat aan ‘veilig’ en dat in de huidige maatschappij 
schadelijke gezondheidseffecten kunnen optreden door acute of chronische blootstelling aan fytotoxinen als 
gevolg van het gebruik van levensmiddelen op basis van kruiden of ander plantenmateriaal, kruidenthees of 
andere kruidenextracten. 
Hoofdstuk 4 van dit proefschrift beschrijft vervolgens de resultaten van onderzoek naar het 
daadwerkelijke voorkomen van een groep van natuurlijke toxische bestanddelen van kruiden die vanuit 
toxicologisch oogpunt reden tot zorg vormen. In het hoofdstuk wordt het voorkomen onderzocht van 
aristolochiazuren I en II in specifieke typen kruidenpreparaten op de Nederlandse markt, namelijk traditionele 
kruidenpreparaten (TKP’s) die worden toegepast in de Traditionele Chinese Geneeswijze (TCG). Zoals reeds 
besproken in Hoofdstuk 3 zijn kruiden met aristolochiazuren en derivaten daarvan nefrotoxisch, genotoxisch en 
carcinogeen. Meerdere soorten uit de familie van de Aristolochiaceae die gebruikt worden in TCG bevatten 
aristolochiazuren. Nadat aristolochiazuurgerelateerde nierschade (aristolochic acid related nephropathy - AAN) 
en kanker aan de urinewegen beschreven was in België bij vrouwelijke patiënten die waren blootgesteld aan 
aristolochiazuren uit gecontamineerde kruidenpreparaten, werden kruiden met aristolochiazuren wereldwijd 
verboden. Verwarrende nomenclatuur kan tot gevolg hebben dat bepaalde Chinese TKP’s verontreinigd raken 
met aristolochiazuren. De aanwezigheid van aristolochiazuren in TKP’s op de Nederlandse markt werd 
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geanalyseerd met een LC-MS methode. Vanaf 2002 tot en met 2006 werden 190 Chinese TKP’s bemonsterd op 
basis van recente informatie over Chinese TKP’s die mogelijk aristolochiazuren bevatten. Aristolochiazuur I werd 
in 25 monsters gevonden tot een concentratie van 1676 mg/kg. Tevens werd aristolochiazuur II in 13 van deze 
monsters gevonden tot een concentratie van 444 mg/kg. Alle 25 positieve monsters waaronder Mu Tong, Fang Ji, 
Tian Xian Teng en Xi Xin maakten deel uit van een groep van 68 THPs die geïdentificeerd waren als mogelijk 
gecontamineerd met aristolochiazuren. In een worstcase scenario zou het gebruik van het monster Mu Tong met 
het hoogste aristolochiazuurgehalte in de studie gedurende een periode van 7 dagen resulteren in een 
blootstelling aan aristolochiazuren vergelijkbaar met de blootstellingsniveaus die in de Belgische AAN-casussen 
geassocieerd waren met een verhoogd kankerrisico. Onze resultaten tonen aan dat zelfs na wereldwijde 
publiciteit gecontamineerde TKP’s nog steeds op de markt gevonden kunnen worden. Het kan daarom 
geconcludeerd worden dat het testen op mogelijke contaminatie van TKP’s met aristolochiazuren nog steeds 
noodzakelijk is. 
EFSA is van mening dat misidentificatie van in het wild geoogste planten een blijvend probleem is dat 
kan leiden tot het onbedoelde gebruik van toxische plantensoorten [2]. In aanvulling op misidentificatie in het wild 
kan het gebruik van verwarrende nomenclatuur voor kruidenpreparaten op de markt leiden tot misidentificatie en 
daarop volgend tot contaminatie van levensmiddelen met toxische planten. Een voorbeeld hiervan vonden we in 
ons onderzoek naar aristolochiazuren in Chinese TKP’s. Vanaf 2002 tot en met 2006 bemonsterden we 14 
preparaten met de aanduiding ‘Mu Tong’ waarvan relatief veel (n=7) aristolochiazuren bevatten (Hoofdstuk 4). De 
naam Mu Tong duidt op de stengel van Aristolochia manshuriensis maar het kan ook gebruikt worden voor de 
stengel van 2 Clematis spp. en 2 Akebia spp. Van de 7 Mu Tong monsters met aristolochiazuren waren 4 zo 
aangeduid dat deze preparaten alleen de stengel van Akebia quinata of Akebia trifoliata zouden bevatten. Omdat 
Akebia quinata en Akebia trifoliata geen aristolochiazuren bevatten, werd geconcludeerd dat deze preparaten 
gedeeltelijk of volledig door Aristolochia spp. gesubstitueerd waren. Daarbij werd in één van de monsters 
waarvan uit de aanduiding bleek dat alleen de stengel van deze twee soorten Akebia planten aanwezig zou zijn, 
de hoogste hoeveelheid aan aristolochiazuren uit het onderzoek gevonden. Dit toont aan dat misidentificatie of 
substitutie van kruiden in Chinese TKP’s een risico is waarmee rekening gehouden moet worden door 
producenten en distributeurs van dergelijke producten in Nederland.  
De Europese Geneesmiddelen Autoriteit (European Medicine Agency - EMA; eerder werd de afkorting 
EMEA gebruikt) onderzocht in 2005 het bewijs voor substitutie van Mu Tong en Fang Ji (de wortel van 
Aristolochia fangchi of van 3 andere kruiden) en adviseerde daarbij dat in de afwezigheid van geschikte 
kwaliteitscontroleprocedures een verbod op de plantensoorten die verward zouden kunnen worden met 
Aristolochia spp. zou moeten worden overwogen. De niet aan Aristolochia spp. verwante planten die bewust of 
onbewust verwisseld kunnen worden met Aristolochia spp. en zo een risico vormen zijn Akebia quinata, Akebia 
trifoliata, Clematis armandii, Clematis montana, Cocculus orbiculatus, Cocculus laurifolius, Cocculus trilobus en 
Stephania tetrandra [10]. Omdat Stephania tetrandra (Fang Ji of Han Fang Ji) niet toxisch is, verwijderde het 
Nederlandse Ministerie van Volksgezondheid in 2005 dit kruid van de lijst uit het Warenwetbesluit 
Kruidenpreparaten met planten en schimmels die niet in kruidenpreparaten gebruikt mogen worden [11]. Het 
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RIVM en de VWA adviseerden echter om Stephania tetrandra op de lijst te handhaven vanwege de kans op 
substitutie met Aristolochia spp. [12, 13]. Op dit moment is geen van de kruiden die een risico vormen voor 
verwarring en substitutie met Aristolochia spp. in Nederland verboden. EMA adviseerde eveneens om andere 
soorten uit de familie van de Aristolochiaceae te reguleren, in het bijzonder Asarum spp. die ook 
aristolochiazuren kunnen bevatten [10]. TKP’s met ‘Xi Xin’ (Asarum sieboldii herba) in ons onderzoek dat in 
Hoofdstuk 4 is gepresenteerd, bevatten in meerdere gevallen aristolochiazuren. Van de 12 producten met Xi Xin 
bevatten 11 relatief lage concentraties aristolochiazuur I. Mogelijke implicaties van deze resultaten worden 
verderop in dit hoofdstuk besproken in de sectie over toekomstperspectieven. 
 
Contaminatie van kruidenpreparaten 
Naast de aanwezigheid van toxische stoffen in kruidenpreparaten die van nature in de gebruikte 
kruideningrediënten van deze preparaten voorkomen, is contaminatie van kruidenpreparaten eveneens een 
reden tot zorg. De veiligheid van levensmiddelen met kruideningrediënten kan in gevaar gebracht worden door 
opzettelijke of toevallige contaminatie met een reeks aan stoffen waaronder bijvoorbeeld polycyclische 
aromatische koolwaterstoffen (PAK’s) en metalen zoals lood. In traditionele geneeswijzen worden met name 
kruidenpreparaten toegepast, hoewel dierlijke producten en mineralen ook worden gebruikt [14]. In meerdere 
traditionele geneeswijzen uit Azië zoals Ayurveda, Unani-Tibb, Siddha, TCG en de Traditionele Tibetaanse 
Geneeswijze (TTG) worden voor therapeutische doeleinden in kruidenpreparaten opzettelijk ingrediënten gebruikt 
die significante hoeveelheden kwik, arseen of lood bevatten. Hoewel deze ingrediënten algemeen als veilig 
beschouwd worden in deze traditionele geneeswijzen hebben ze wereldwijd vergiftigingen veroorzaakt. Het doel 
van het onderzoek dat in Hoofdstuk 5 van dit proefschrift besproken wordt, was daarom het bepalen van de 
gehalten aan kwik, arseen en lood in Aziatische TKP’s op de Nederlandse markt. In totaal werden tussen 2004 
en 2007, 292 TKP’s bemonsterd die worden toegepast in Ayurveda, TCG and TTG. De monsters waren met 
name TKP’s met meerdere ingrediënten zoals kruiden en mineralen. Uit de etikettering van minder dan 20% van 
de TKP’s kon worden opgemaakt dat kwik, arseen of lood aanwezig zou kunnen zijn. Deze elementen werden 
aangetoond met een ICP-MS-methode in 186 (64%) van 292 TKP’s. Voor elke TKP werd de geschatte wekelijkse 
innamehoeveelheid aan kwik, arseen en lood berekend op basis van de analytisch bepaalde concentratie en de 
aanbevolen gebruikshoeveelheid van het product. Gebruik van 59 TKP’s (20%) zou waarschijnlijk resulteren in 
innameniveaus van deze elementen die significant hoger waren dan veiligheidslimieten. Van deze 59 TKP’s 
overschreden innameschattingen voor 50 TKP’s op significante wijze veiligheidslimieten (range 1,4-1747 
mg/week); innameschattingen voor 26 TKP’s overschreden significant de veiligheidslimiet voor arseen (range 
0,53-427 mg/week) en innameschattingen voor 8 TKP’s waren significant hoger dan de veiligheidslimiet voor lood 
(range 2,6-192 mg/week). Geconcludeerd kan worden dat de gehalten aan kwik, arseen en lood in TKP’s die in 
Ayurveda, TCG en TTG worden toegepast redenen tot zorg blijven die strikte controle vereisen.  
Het onderzoek naar lood, kwik en arseen in Aziatische TKP’s gepresenteerd in Hoofdstuk 5 werd in 
2008 voortgezet. De resultaten van die studie wezen niet uit dat de veiligheid van deze producten in dat jaar in 
aanzienlijke mate was toegenomen ten opzichte van de resultaten uit voorgaande jaren. In 2008 werd kwik, 
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arseen en lood in 60 (77%) van 78 Aziatische TKP’s gevonden. Vier van deze preparaten zouden bij gebruik 
volgens de gebruiksaanwijzing leiden tot kwik of loodinnames boven de veiligheidslimieten die in Hoofdstuk 5 zijn 
geselecteerd. Op een totaal van 28 TKP’s waarin kwik was gevonden, overschreed het kwikgehalte van 27 TKP’s 
de recent voor voedingssupplementen vastgestelde Europese maximumgehalte aan kwik van 0,1 mg/kg. Het 
loodgehalte van 36 TKP’s lag boven het nieuwe Europese maximumgehalte aan lood in voedingssupplementen 
van 3,0 mg/kg op een totaal van 56 TKP’s waarin lood was aangetroffen [15].  
Recent heeft EFSA het risico van de blootstelling aan lood en arseen uit de voeding beoordeeld en uit 
deze risicobeoordelingen bleek dat lood en arseen op de huidige blootstellingsniveaus uit de voeding 
zorgwekkender zijn dan eerder was vastgesteld. Deze vaststelling heeft ook gevolgen voor de risico’s van 
Aziatische TKP’s met lood of arseen zoals deze in Hoofdstuk 5 zijn ingeschat. Het EFSA Panel voor 
contaminanten in de voedselketen (Panel on Contaminants in the Food Chain - CONTAM) concludeerde in zijn 
Wetenschappelijke Opinie over arseen in de voeding van oktober 2009 dat de voorlopige grenswaarde voor de 
toelaatbare wekelijkse inname van arseen van 15 µg per kg lichaamsgewicht (µg/kg lg) vastgesteld door het 
expertcomité voor levensmiddelenadditieven van de FAO/WHO (Joint FAO/WHO Expert Committee on Food 
Additives - JECFA) niet langer meer voldoet. Het CONTAM Panel identificeerde een reeks waarden voor de 95% 
betrouwbaarheidsondergrens van de ‘benchmark dose’ voor 1% extra risico (BMDL01) voor gebruik bij de 
karakterisatie van de risico’s van anorganisch arseen. De BMDL01-waarden voor de relevante 
gezondheidseffecten (huidlaesies, huid-, blaas- en longkanker) varieerden van 0,3 tot en met 8 µg/kg lg/dag [16]. 
In onze studie naar arseen, lood en kwik in Aziatische TKP’s die voor 2008 zijn bemonsterd (Hoofdstuk 5) 
hebben we een TDI van 1,0 µg/kg lg/dag gebruikt die is vastgesteld door het RIVM. Deze TDI is gebaseerd op de 
JECFA PTWI waarop een veiligheidsfactor van 2 was toegepast om te corrigeren voor observatiefouten in 
epidemiologische studies [17]. De TDI die door het RIVM voor anorganisch arseen was vastgesteld, bevindt zich 
tussen de lagere waarden van de reeks van BMDL01-waarden die door het CONTAM panel zijn geïdentificeerd. 
In onze studie die in Hoofdstuk 5 is besproken, werden in 26 van 292 Aziatische TKP’s arseenconcentraties 
gevonden die bij aanbevolen gebruik zouden leiden tot innamen die significant boven de TDI van het RIVM 
zouden liggen. Daarnaast werd in 77 andere van de 292 TKP’s ook arseen gevonden maar in concentraties die 
bij het op het etiket aanbevolen gebruik niet zouden leiden tot innamen die significant boven de TDI van 1,0 
µg/kg lg/dag zouden liggen. Voor het merendeel van de monsters in deze groep bestaat een veiligheidsmarge 
(margin of safety) van een orde van grootte van 1 of 2 tussen de geschatte arseeninnameniveaus voor deze 
monsters en de RIVM TDI. Omdat de TDI in de reeks ligt van BMDL01-waarden die geïdentificeerd zijn door het 
CONTAM panel kan deze marge eveneens als representatief beschouwd worden voor de reeks van BMDL01-
waarden die door het CONTAM Panel zijn geïdentificeerd. 
Doordat in de Europese of Nederlandse levensmiddelenwetgeving maximumgehalten aan arseen in 
voedingssupplementen ontbreken, moet de VWA bewijzen dat een supplement met een relatief hoog 
arseengehalte schadelijk is voor de gezondheid of ongeschikt voor menselijke consumptie voordat 
handhavingsmaatregelen kunnen worden genomen. Het in de handel brengen van producten die schadelijk zijn 
voor de gezondheid of die ongeschikt zijn voor menselijke consumptie is verboden in de Algemene 
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Levensmiddelenverordening (Europese Verordening (EG) Nr. 178/2002) [18]. De eisen uit deze verordening zijn 
direct van toepassing in Nederland. Naar aanleiding van de Opinie over arseen in de voeding van het CONTAM 
Panel moet overwogen worden of de TDI voor anorganisch arseen die door het RIVM is vastgesteld nog gebruikt 
kan worden om te toetsen of een voedingssupplement met een relatief hoog arseengehalte nog veilig gebruikt 
kan worden. Om de handhaafbaarheid van de voedselveiligheid van voedingssupplementen te verbeteren moet 
het vaststellen van maximumgehalten aan arseen in deze producten overwogen worden. 
Daarnaast gaf het CONTAM Panel aan dat voedingssupplementen met zeewier behoren tot de groep 
van levensmiddelen waarin de hoogste totaal-arseengehalten gemeten waren. Dit is met name relevant voor 
verschillende zeewiersoorten zoals hijiki (Hizikia fusiforme) dat hoge totaal-arseengehalten kan bevatten waarvan 
tot 60% uit anorganisch arseen bestaat naast de eveneens aanwezige organische arseenverbindingen die 
toxicologisch gezien minder zorgwekkend zijn [16, 19]. In andere zeewiersoorten bestaat maar een gering deel 
van het totaal-arseengehalte uit anorganisch arseen [19]. Het CONTAM Panel beklemtoonde tevens dat er 
behoefte is aan gegevens over de speciatie van arseen in verschillende levensmiddelen zodat risicoschattingen 
daarmee verfijnd kunnen worden [16]. 
Het CONTAM Panel publiceerde in april 2010 een Opinie over de risicoschatting van lood in voeding. 
Het Panel concludeerde in zijn Wetenschappelijke Opinie over lood in voeding dat de PTWI van 25 µg/kg lg 
vastgesteld door JECFA niet meer voldoet. Omdat er geen bewijs was voor het bestaan van een drempelwaarde 
bij het optreden van een aantal effecten zoals neurotoxiciteit tijdens de ontwikkeling en nefrotoxiciteit bij 
volwassenen, was het Panel van mening dat het niet juist is om een PTWI vast te stellen. Geconcludeerd werd 
dat voor lood de huidige blootstellingsniveaus aanleiding tot zorg kunnen geven met betrekking tot effecten op de 
ontwikkeling van het zenuwstelsel bij zuigelingen, kinderen en zwangere vrouwen. Maatregelen om kinderen en 
vrouwen in de vruchtbare leeftijd te beschermen tegen een potentieel risico van effecten op de ontwikkeling van 
het zenuwstelsel zal tevens bescherming bieden tegen alle andere schadelijke effecten van lood in de totale 
populatie. Het Panel leidde een BMDL01-innameniveau af van 0,50 µg/kg lg/dag voor effecten op de 
ontwikkeling van het zenuwstelsel [20]. In ons onderzoek naar arseen, lood en kwik in Aziatische TKP’s 
(Hoofdstuk 5) hebben we een TDI van 3,6 µg/kg lg/dag gebruikt die was vastgesteld door het RIVM en die direct 
gebaseerd was op de JECFA PTWI voor lood [17]. Omdat EFSA niet langer van mening is dat de JECFA PTWI 
voor lood voldoet, is het raadzaam dat het gebruik van de daaraan gelijkwaardige RIVM TDI door de VWA voor 
de beoordeling van levensmiddelen waarvoor nog geen wettelijke maximumniveaus bestaan, wordt 
heroverwogen. 
Het kwik dat in Ayurvedische TKP’s werd aangetroffen zoals gerapporteerd in Hoofdstuk 5 kan het 
gevolg zijn van de opzettelijke toevoeging van kwik in Ayurveda aan verschillende TKP’s in de vorm van 
preparaten die bhasma’s genoemd worden. Gesteld wordt dat metalen of metalloïden in bhasma’s ontgift zijn 
door intensieve behandelingen. De toxiciteit van kwik hangt af van de chemische vorm waarin het zich bevindt 
[21, 22]. De giftigheid van elementair kwik, aangeduid als Hg(0), is bij orale blootstelling gering terwijl 
anorganische en organische kwikverbindingen bij orale blootstelling aanmerkelijk giftiger zijn [22, 23]. Zoals 
beschreven in Hoofdstuk 5 hebben we 242 Ayurvedische TKP’s op kwik onderzocht en het bleek daarbij dat het 
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gebruik van 19% van deze preparaten volgens het doseringsadvies zou leiden tot blootstellingsniveaus voor kwik 
boven de toxicologische veiligheidslimiet voor anorganisch kwik. Het doel van het onderzoek dat in Hoofdstuk 6 
wordt besproken, is het vaststellen of het kwik in deze Ayurvedische preparaten (gedeeltelijk) aanwezig is als 
Hg(0), wat in dat geval een argument zou zijn om de risicoschatting waarin limieten voor anorganisch kwik zijn 
gebruikt te heroverwegen. Voor dit onderzoek hebben we een methode ontwikkeld die de detectie van Hg(0) in 
deze Ayurvedische TKP’s mogelijk maakt. Daarop hebben we onderzoek gedaan naar de aanwezigheid van 
Hg(0) in 19 Aziatische TKP’s waarvan het onderzoek in Hoofdstuk 5 uitwees dat de inname van kwik bij het 
voorgeschreven gebruik de veiligheidslimiet voor anorganisch kwik zou overschrijden. Uit de resultaten kan 
worden opgemaakt dat in 11 van de onderzochte 19 TKP’s al het aangetroffen kwik afkomstig is van andere 
vormen dan Hg(0). Extractie van de andere 8 TKP’s met 7M HNO3 liet zien dat het meeste kwik uit deze 
monsters (69-99%) niet geëxtraheerd kon worden met 7M HNO3. Omdat was aangetoond dat Hg(0) efficiënt 
geëxtraheerd kan worden met 7M HNO3 wijst dit resultaat er op dat kwik in andere vormen dan Hg(0) aanwezig 
is. Geconcludeerd werd dat in alle TKP’s het merendeel van het kwik niet aanwezig is in de elementaire vorm 
waarvan de giftigheid relatief laag is. Tevens werd geconcludeerd dat het kwik in Ayurvedische TKP’s 
waarschijnlijk aanwezig is in anorganische vorm en dat daarom het schatten van de gerelateerde risico’s op basis 
van veiligheidslimieten voor anorganische vorm gerechtvaardigd is. Tenslotte werden geen additionele 
risicobeoordelingen van anorganisch kwik door nationale of internationale expert comités gevonden. 
De metalen en metalloïden die in Aziatische TKP’s werden aangetroffen, zijn hoogstwaarschijnlijk het 
gevolg van de opzettelijke toevoeging en dit opzicht verschillen deze stoffen hier van contaminanten zoals 
polycyclische aromatische koolwaterstoffen (PAK’s) die onbedoeld voedsel kunnen vervuilen als gevolg van 
verschillende processen. PAK’s kunnen tevens voorkomen in voedingssupplementen en de Nederlandse 
Warenwet bevat sinds januari 2006 een maximumniveau van 10 µg/kg benzo[a]pyreen voor kruidenpreparaten 
en een maximumniveau van 2 µg/kg voor supplementen zonder kruideningrediënten [24]. 
EFSA heeft 16 prioriteits-PAK’s geïdentificeerd die genotoxisch en carcinogeen zijn waarvan 8 
prioriteits-PAK’s (PAK8) of 4 van deze (PAK4) goede indicators zijn voor de toxiciteit en het voorkomen van 
PAK’s in de voeding. Het onderzoek dat in Hoofdstuk 7 is beschreven, heeft het bepalen van benzo[a]pyreen en 
andere EFSA prioriteits-PAK’s in verschillende categorieën van voedingssupplementen met kruidenpreparaten en 
andere ingrediënten ten doel. In 2003 tot en met 2007 overschreed benzo[a]pyreen de bepaalbaarheidsgrens in 
553 (44%) van 1258 supplementen met een ‘lower bound’ gemiddelde van 3,37 µg/kg. In 2008 en 2009 werden 
benzo[a]pyreen en 12 andere EFSA prioriteits-PAK’s bepaald in 333 voedingssupplementen. Het 
benzo[a]pyreengehalte overschreed de bepaalbaarheidsgrens in 210 (63%) van de voedingssupplementen met 
een lower bound gemiddelde van 5,26 µg/kg. Lower bound gemiddelden van PAK4 en PAK8 (-indeno[1,2,3-
cd]pyreen) waren 33,5 µg/kg en 40,5 µg/kg, respectievelijk. Supplementen met resveratrol, Ginkgo biloba, sint-
janskruid en propolis vertoonden relatief hoge PAK’s-niveaus in 2008 en 2009. Vóór 2008 bevatten 
supplementen met deze ingrediënten en ook die met dong quai, groene thee of valeriaan eveneens relatief hoge 
gehalten aan benzo[a]pyreen. Gemiddeld genomen zal de inname van PAK’s door het gebruik van 
voedingssupplementen zich aan de onderkant bevinden van een reeks van bijdragen van hoofdcategorieën van 
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levensmiddelen aan de blootstelling aan PAK’s, hoewel de bijdrage van individuele voedingssupplementen aan 
de blootstelling aan PAK’s significant kan zijn. Regelmatige controle van de gehalten aan PAK’s in 
voedingssupplementen kan een geschikt instrument zijn om de inname van PAK’s uit voeding verder te verlagen. 
Het was interessant dat in totaal bij 192 (58%) van de supplementen uit het onderzoek in 2008 en 2009 (n=333) 
de PAK4 gehalten lager lagen dan 10 µg/kg en dat in 99 (30% van het totaal) van deze 192 supplementen de 
PAK4 gehalten onder de bepalingsgrens lagen. Daarnaast werden in elke subcategorie van 
voedingssupplementen uit het onderzoek supplementen gevonden zonder PAK’s of met relatief lage gehalten 
aan PAK’s. 
 Alles samengenomen kan gesteld worden op basis van de onderzoeken naar contaminatie van 
kruidenpreparaten op de Nederlandse markt met aristolochiazuren, lood, kwik, arseen en PAK’s waarvan de 
analytische data in dit proefschrift zijn gepresenteerd dat contaminatie van kruidenpreparaten met PAK’s het 
meest voorkomt, gevolgd door contaminatie met kwik, arseen of lood, en met aristolochiazuren op de laatste 
plaats. De toxiciteit van deze verschillende substanties kan niet makkelijk met elkaar vergeleken worden. 
Wanneer echter voor elk van deze contaminanten de effecten van blootstelling aan de bovenkant van de in dit 
proefschrift geschatte blootstellingsniveaus gedurende een bepaalde tijdsduur vergeleken zouden worden, dan 
zouden aristolochiazuren waarschijnlijk het meest schadelijk zijn voor de gezondheid, gevolgd door de toxische 
effecten van lood, arseen, kwik en PAK’s, in die volgorde. Echter, het feit dat aristolochiazuren alleen werden 
aangetroffen in een klein segment van het aanbod van TCG-winkels en dat aanzienlijk meer Aziatische TKP’s op 
de markt gevonden werden die lood, arseen of kwik bevatten, doet vermoeden dat in Nederland op dit moment 
de kans op schadelijke effecten groter is bij Aziatische TKP’s met relatief hoge gehalten aan lood, arseen of kwik. 
Doordat de in Hoofdstuk 7 geschatte innameniveaus van PAK’s uit voedingssupplementen in dezelfde orde van 
grootte liggen als de blootstellingniveaus aan PAK’s uit levensmiddelen die voor de Europese Unie zijn 
vastgesteld, zijn de geassocieerde effecten op de gezondheid van een lagere orde dan de effecten van 
aristolochiazuren, lood, kwik en arseen. Evenwel, omdat verschillende PAK’s genotoxisch en carcinogeen zijn en 
blootstelling aan PAK’s uit de voeding voor consumenten met hoge blootstellingsniveaus een mogelijke reden tot 
zorg is, zouden inspanningen verricht moeten worden om de blootstelling aan PAK’s uit voedingssupplementen 
te verlagen en zo een verdere daling van de blootstelling uit de voeding te kunnen bewerkstelligen. 
 
  
Toekomstperspectieven  
  
De Europese Commissie concludeerde in 2008 dat het vaststellen van specifieke Europese regels voor 
andere stoffen dan vitaminen en mineralen voor gebruik in voedingssupplementen niet gerechtvaardigd is [25]. 
Dit betekent dat het niet waarschijnlijk is dat er in de nabije toekomst een Europese pendant van het Nederlandse 
Warenwetbesluit Kruidenpreparaten zal komen. Verordening (EG) Nr. 1925/2006 stelt in artikel 8 een procedure 
vast die gebruikt dient te worden voor gevallen waarin een andere stof dan vitaminen of mineralen (bijvoorbeeld 
een kruidenpreparaat) een potentieel risico voor de consument zou kunnen vormen. De Commissie kan op basis 
van een risicobeoordeling van EFSA of informatie van een Lidstaat het besluit nemen om het gebruik van de stof 
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in levensmiddelen te beperken of te verbieden. De veiligheid van kruideningrediënten kan beoordeeld worden 
met de methode die EFSA ontwikkeld heeft voor de risicobeoordeling van kruidensubstanties en 
kruidenpreparaten in combinatie met het EFSA Compendium van kruidensubstanties waarvan gerapporteerd is 
dat ze toxische, verslavende of psychotrope stoffen bevatten of andere stoffen die aanleiding voor bezorgdheid 
geven. Er zijn nog geen besluiten genomen op basis van deze procedure. Het is nog niet duidelijk in welke mate 
de Commissie gebruik zal maken van de procedure in artikel 8 van Verordening (EG) Nr. 1925/2006 om het 
gebruik van bepaalde kruidenpreparaten in levensmiddelen te beperken of te verbieden. 
EFSA wees er reeds in 2004 op dat het gebruik van kruidensubstanties en kruidenpreparaten in 
levensmiddelen aan het toenemen was [2]. De potentiële risico’s van kruidenpreparaten zullen daarom ook in 
betekenis toenemen. Omdat het niet waarschijnlijk is dat binnen afzienbare tijd nieuwe Europese regelgeving 
voor het gebruik van kruidensubstanties en kruidenpreparaten in voedingssupplementen wordt vastgesteld, is het 
verstandig om regelgeving zoals het Warenwetbesluit Kruidenpreparaten bij te blijven werken om Nederlandse 
consumenten te beschermen tegen ernstige risico’s van het gebruik van kruidenpreparaten. Wanneer een 
aanpassing van het Kruidenbesluit in gang wordt gezet is het aanbevelenswaardig dat hierbij risicobeoordelingen 
en aanbevelingen over kruidenpreparaten door nationale en Europese risicobeoordelaars zoals het RIVM, EMA 
en EFSA in aanmerking worden genomen. 
Verschillende risicobeoordelingsorganen hebben voor bepaalde kruidenpreparaten aanbevelingen 
gedaan om waarschuwingsteksten op de etikettering te plaatsen. EMA heeft bijvoorbeeld waarschuwingsteksten 
vastgesteld voor interacties tussen kruidengeneesmiddelen met sint-janskruid en andere geneesmiddelen [26]. 
Omdat sint-janskruid ook in voedingssupplementen toegepast wordt, kunnen deze waarschuwingsteksten van 
belang zijn voor alle sint-janskruidproducten voor oraal gebruik die op de markt worden aangeboden. Daarnaast 
heeft een aantal risicobeoordelaars aanbevolen om op preparaten met zilverkaars (Actaea racemosa of 
Cimicifuga racemosa) een waarschuwingstekst te plaatsen over het vermogen van het kruid om leverschade te 
veroorzaken [27]. Overwogen moet worden om in het Warenwetbesluit Kruidenpreparaten een verplichting op te 
nemen om waarschuwingsteksten te plaatsen op de etikettering van bepaalde kruidenpreparaten die aanleiding 
tot zorg geven maar die veilig gebruikt zouden kunnen worden als de consument geïnformeerd wordt over hoe 
specifieke gezondheidseffecten vermeden kunnen worden. Het zou echter raadzaam zijn om vast te stellen voor 
welke gezondheidseffecten deze aanpak geschikt is. Hoewel het ongebruikelijk is in Nederland dat op de 
etikettering van levensmiddelen waarschuwingen staan, zijn er verplichte waarschuwingsteksten vastgesteld voor 
levensmiddelen met bepaalde gehalten aan glycyrrhizinezuur. Op dit moment geldt deze verplichting niet voor 
kruidenpreparaten zoals voedingssupplementen met kruideningrediënten. Evenwel zou overwogen moeten 
worden om deze verplichting ook te laten gelden voor kruidenpreparaten met Glycyrrhiza-soorten die 
glycyrrhizinezuur bevatten.  
Daarnaast is het belangrijk om op te merken dat het plaatsen van een waarschuwingstekst op de 
etikettering van een product dat in verband is gebracht met bepaalde schadelijke gezondheidseffecten geen 
garantie is voor het uitblijven van verdere gevallen van gezondheidsschade. Dit wordt geïllustreerd door de 
verschillen in resultaten van diverse methoden waarmee wereldwijd getracht wordt om consumenten te 
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beschermen tegen schadelijke effecten van kava kava. Nadat het gebruik van dit kruid in verband werd gebracht 
met leverschade werden kruidenpreparaten met kava kava in 2003 verboden in Nederland. In de Verenigde 
Staten werd kava kava niet van de markt gehaald. De fabrikanten van kruidenpreparaten in de Verenigde Staten 
plaatsten daarentegen waarschuwingsteksten over mogelijke leverschade op de etikettering van deze preparaten 
en de Food and Drug Administration (FDA) publiceerde tevens waarschuwingen over dit kruid. In weerwil van 
deze maatregelen bleef de FDA rapportages van levertoxiciteit ontvangen. Australië voerde eveneens 
waarschuwingsteksten in die wezen op het verband tussen kava kava en het in zeldzame gevallen optreden van 
leverschade, maar ook hier bleven de rapportages van levertoxiciteit aanhouden [28]. 
EFSA concludeerde in 2004 dat zowel de groei in de verkoopvolumes in de Europese Unie van 
producten uit Azië of andere gebieden als de toenemende verspreiding van verkooplocaties van producten die 
gebruikt worden in traditionele geneeswijzen vragen om een meer formele beoordeling van die producten voordat 
ze op de markt gebracht worden. Daarnaast vragen deze ontwikkelingen volgens EFSA ook om strengere 
controles dan de sporadische keuringen en analyses van producten die al op de markt zijn en die meestal 
uitgevoerd worden door individuele nationale en lokale autoriteiten [2]. In de huidige Nederlandse en Europese 
wet- en regelgeving voor levensmiddelen met kruideningrediënten zoals besproken in Hoofdstuk 2 zijn geen 
bepalingen opgenomen die het mogelijk maken om alle producten die op de markt gebracht worden, 
voorafgaande aan de marktintroductie aan een strenge beoordeling te onderwerpen. Het is echter wel mogelijk 
om de frequentie te verhogen van het onderzoek naar natuurlijke gifstoffen uit kruiden en contaminanten in 
voedingssupplementen die al op de markt zijn. Deze benadering kan leiden tot een verbetering van de veiligheid 
van deze producten, hoewel dit een langdurig proces kan zijn. Er zijn bijvoorbeeld aanwijzingen dat de 
handhavingsacties van de VWA hebben geleid tot een afname in het aantal TKP’s met aristolochiazuren die in 
het winkelkanaal worden aangeboden. In 2008 bemonsterde de VWA 77 Chinese TKP’s voor onderzoek op 
aristolochiazuren en in één TKP werden sporen van aristolochiazuren gevonden [15]. Daarentegen werden in 25 
van 190 Chinese TKP’s die vanaf 2002 tot en met 2006 waren bemonsterd aristolochiazuren gevonden 
(Hoofdstuk 4 van dit proefschrift). Conclusies over een mogelijke verlaging van de kans op contaminatie met 
aristolochiazuren van kruidenpreparaten die in Nederland in het winkelkanaal worden aangeboden kunnen echter 
alleen getrokken worden op basis van de resultaten van meerdere jaren van aanvullend marktonderzoek. Op 
basis van de toekomstige resultaten kan dan beoordeeld worden of een verbod op het gebruik in 
kruidenpreparaten van Asarum-soorten en de planten die mogelijk verwisseld kunnen worden met Aristolochia-
soorten noodzakelijk is. Een andere reden om de veiligheid van het gebruik van Asarum-soorten in 
kruidenpreparaten op de markt te beoordelen, is de mogelijke aanwezigheid van alfa-asaron, een stof die bij 
zoogdieren kankerverwekkend is [29]. Tevens moet in aanmerking genomen worden dat consumenten in 
aanraking kunnen komen met producten met aristolochiazuren via kanalen zoals het internet wat het toezicht 
door de overheid kan bemoeilijken. Alles samengenomen is het essentieel dat een exploitant van een 
levensmiddelenbedrĳf dat TKP’s op de markt brengt die in theorie aristolochiazuren zouden kunnen bevatten 
door het opzettelijk toepassen van planten uit de familie van de Aristolochiaceae of door verwisseling van de 
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bedoelde kruideningrediënten met Aristolochia spp., beheersmaatregelen opneemt in zijn kwaliteitssysteem 
(Hazard Analysis Critical Control Points - HACCP) om dit gevaar te borgen. 
De Opinies van het CONTAM Panel over arseen en lood [16, 20] zijn van belang voor de handhaving 
van de veiligheid van kruidenpreparaten en andere voedingssupplementen. Vastgesteld moet worden of de TDI 
van het RIVM voor anorganisch arseen en die voor lood nog geschikt zijn voor de beoordeling of een 
voedingssupplement met een relatief hoog gehalte aan arseen of lood veilig gebruikt kan worden. Omdat 
maximumgehalten aan arseen in voedingsupplementen zouden kunnen helpen bij de handhaving van de 
veiligheid van deze producten, zou het vaststellen van dergelijke maximumgehalten overwogen moeten worden. 
Tevens is data over de speciatie van arseen en kwik in verschillende levensmiddelen nodig om 
risicobeoordelingen verder te kunnen verfijnen [16].  
Enkele resultaten van ons onderzoek naar PAK’s in voedingssupplementen (Hoofdstuk 7 van dit 
proefschrift) kunnen van betekenis zijn voor de geplande vaststelling van maximumgehalten aan PAK’s in 
voedingssupplementen in de Europese voedselveiligheidswetgeving. Zo waren de PAK4-waarden in bijna 60% 
van de supplementen uit het onderzoek in 2008 en 2009 lager dan 10 µg/kg. Daarnaast werden in alle 
subcategorieën van voedingssupplementen in het onderzoek supplementen gevonden met gehalten aan PAK’s 
die niet bepaalbaar of relatief laag waren. Dit doet vermoeden dat contaminatie van voedingssupplementen met 
PAK’s vermijdbaar is.  
 
 
Conclusie 
 
Op basis van het onderzoek dat in dit proefschrift is beschreven, kan geconcludeerd worden dat bij 
kruidenpreparaten niet geldt dat ‘natuurlijk’ hetzelfde is als ‘veilig’. Met name de onderzoeksresultaten die in 
Hoofdstukken 4 en 5 zijn besproken, tonen aan dat slechts het feit dat een kruidenpreparaat op de Nederlandse 
markt verkrijgbaar is, niet garandeert dat het product veilig is en dat het geen schadelijke effecten op de 
gezondheid zal hebben. Rapportages van nationale en Europese risicobeoordelingsorganen zoals het RIVM, 
EMA en EFSA en andere bronnen uit de literatuur die in Hoofdstukken 2 en 3 zijn besproken, tonen aan dat 
andere kruidenpreparaten dan de preparaten waarvoor op dit moment specifieke bepalingen zijn opgenomen in 
de Nederlandse voedselveiligheidswetgeving eveneens op toxicologische gronden reden tot zorg vormen. Het is 
van belang dat consumenten zich realiseren dat het risico van bijwerkingen toeneemt wanneer kruidenpreparaten 
buiten de reguliere winkelkanalen om worden aangeschaft, zoals het geval is wanneer preparaten gekocht 
worden via het internet of bij winkels met producten uit traditionele geneeswijzen, smartshops of bij vergelijkbare 
winkeltypen. Hoewel levensmiddeleninspectiediensten relatief veel capaciteit inzetten op de handhaving van de 
voedselveiligheid in de voedingssupplementenbranche, ligt de primaire verantwoordelijkheid voor de veiligheid 
van voedingssupplementen bij de exploitanten van bedrijven die deze levensmiddelen op de markt brengen. Het 
is van essentieel belang dat ondernemers die kruidenpreparaten op de markt hebben gedetailleerde kennis 
hebben van de gevaren die deze producten met zich meebrengen. Tevens moeten ondernemers in 
kwaliteitssystemen (HACCP) beheersmaatregelen opnemen waarmee alle relevante gevaren voorkomen, 
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geëlimineerd, dan wel tot een aanvaardbaar niveau gereduceerd kunnen worden. Het feit dat een 
levensmiddeleninspectiedienst nog geen producten van een exploitant van een levensmiddelenbedrijf heeft 
onderzocht op de aanwezigheid van bepaalde stoffen die schadelijk kunnen zijn, of heeft beoordeeld of de 
ondernemer maatregelen heeft genomen om deze gevaren te voorkomen, elimineren, dan wel tot een 
aanvaardbaar niveau te reduceren, betekent niet dat deze gevaren geen maatregelen vereisen. Tenslotte moet in 
aanmerking worden genomen dat de Europese Commissie geconcludeerd heeft dat nieuwe Europese wetgeving 
voor kruidensubstanties en kruidenpreparaten die in voedingsupplementen gebruikt worden niet nodig is en dat 
de huidige wetgeving volstaat om het gebruik in levensmiddelen van specifieke toxische substanties zoals 
bepaalde kruidenpreparaten te beperken of te verbieden. Omdat het nog niet duidelijk is in welke mate de 
Europese Commissie gebruik zal maken van deze mogelijkheden is het verstandig om het Nederlandse 
Warenwetbesluit Kruidenpreparaten en andere nationale wetgeving bij te blijven werken om Nederlandse 
consumenten te beschermen tegen ernstige risico’s van het gebruik van kruiden in levensmiddelen zoals 
kruidenpreparaten. 
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DANKWOORD 
 
Met het schrijven van dit dankwoord ben ik bijna aan het einde gekomen van mijn promotieonderzoek. 
Het dankwoord is daarmee ook één van de weinige onderdelen van dit proefschrift waar ik als enige aan gewerkt 
heb. Heel wat mensen hebben met veel enthousiasme aan het onderzoek bijgedragen en ik wil graag iedereen 
die me steeds een stukje of zelfs hele stukken verder heeft geholpen bedanken voor die hulp.  
In het bijzonder wil ik mijn promotor Ivonne Rietjens bedanken voor de enthousiaste en constructieve 
begeleiding waarmee ze me vanaf de eerste discussies over mogelijke onderzoeksonderwerpen tot aan de 
eindstreep gestimuleerd heeft om een mooi proefschrift te schrijven. Ik heb veel geleerd van haar positieve 
feedback en suggesties bij de artikelen die ik haar heb voorgelegd. Het was erg fijn dat ze nieuwe versies steeds 
binnen korte tijd van commentaar kon voorzien. Daarnaast had ik het geluk om een jaar mee te kunnen draaien 
in een door Ivonne voorgezeten EFSA-werkgroep over de veiligheid van kruidenpreparaten waardoor ik een hoop 
heb kunnen leren over het uitvoeren van risicobeoordelingen.  
Bij de Keuringsdienst van Waren (KvW) en later de Voedsel en Waren Autoriteit (VWA) hebben veel 
collega’s een bijdrage geleverd aan het onderzoek. Enkele van hen wil ik in het bijzonder noemen. Bij de KvW 
stimuleerde Paul Beljaars mij om me te blijven ontwikkelen en hij heeft me zo aan het denken gezet over 
promoveren. Van Wendy Verdonk en Hans Beelen heb ik veel geleerd over het handhavingsvak. Bij het 
onderzoek naar de veiligheid van kruidenpreparaten kon ik verder bouwen op de fundamenten die Wendy gelegd 
heeft. De nauwe betrokkenheid van Hugo de Sitter en later Yvonne Huigen was erg belangrijk voor de goede 
voortgang van het onderzoek. Bij de VWA hebben enkele mensen waaronder Henk de Groot zich sterk gemaakt 
voor het opstarten van mijn promotieonderzoek. Henk gaf me ook het laatste zetje door me een keer indringend 
te vragen welke redenen ik dan zou hebben om niet te gaan promoveren. Ik ben de VWA en in het bijzonder 
Henk de Groot en Theo Appelhof dankbaar dat ik de onderzoeksdata van de VWA kon gebruiken én dat ik 
daarnaast ook de Postdoctorale Opleiding Toxicologie kon volgen.  
Nu ik al die data klaar had liggen hoefde ik er alleen nog artikelen van te maken. Hoe moeilijk kon dat 
nou zijn? Het bleek dat het opschrijven van alles waarvan ik dacht dat het van belang kon zijn, niet 
noodzakelijkerwijs een leesbaar artikel oplevert. Ivonne Rietjens heeft die eerste versies van mijn eerste artikel 
met veel geduld becommentarieerd. Op een bepaald moment vroeg mijn collega Erik Konings of ik mee wilde 
schrijven aan een ander artikel dat binnen een maand af moest zijn om in een themanummer van een 
wetenschappelijk blad geplaatst te kunnen worden. Ik heb van die maand schrijven en de subtiele coaching van 
Erik een hoop geleerd, onder andere dat een artikel er behoorlijk van opknapt als je je tot de hoofdboodschap 
beperkt. Ik was erg blij dat Erik me verder wilde helpen bij mijn promotie als co-promotor.  
Ik heb veel hulp gekregen van de collega’s van het Chemische lab in Eindhoven. Ze namen altijd de tijd 
om me analytische begrippen uit te leggen. Daarnaast vulden ze enorme Excel-sheets met monstergegevens die 
anders niet uit de systemen te halen zouden zijn. Zonder zulke behulpzame en sympathieke collega’s als Leo 
van de Laak, Elly Tissen, Eddy van der Male, Henk Koopmans, Monique van de Graaf, Gertie Lucassen-Thielen, 
Paul in ‘t Veld en Peter Verheijen was ik niet ver gekomen. In het bijzonder wil ik Jacqueline van der Wielen, 
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Walther Klerx en Michiel Grutters bedanken voor hun essentiële aandeel in dit proefschrift door de analytische 
onderzoeksmethoden op te zetten en te beschrijven, de analytische data te controleren en mee te denken over 
de studieopzet. Daarnaast was Edith de Haan van TNO bijzonder belangrijk voor het onderzoek beschreven in 
hoofdstuk 6 door in korte tijd een nieuwe analytische methode op te zetten om daarmee een dringende 
onderzoeksvraag te beantwoorden. 
Maar voordat het lab aan de slag kan met het analytische onderzoek moeten er eerst de juiste 
kruidenpreparaten verzameld worden. Juist bij het in dit proefschrift beschreven onderzoek is de monstername 
bijzonder complex. Het vergt veel kennis van de markt en de producten om uit dat aanbod juist die 
kruidenpreparaten te selecteren die een gevaar zouden kunnen zijn. Zonder de ervaring en kunde van de 
controleurs van de Vakgroep Bijzondere eet- en drinkwaren zou het niet mogelijk zijn geweest om een, naar mijn 
idee, realistisch beeld te geven van de gevaren van specifieke groepen kruidenpreparaten die op de Nederlandse 
markt te vinden zijn. Ik wil daarom mijn collega’s Ellen Albers, Jan van de Loo, Liesbeth Huisman, Jan Homma, 
Bram Walther, Yvonne van Naarden-van Zanten, Gerry Lange, Ineke Kraaijenbrink, Heiko van den Berg, Gert-
Jan Post, Hennie van Lokven en Monique van Beers voor de fijne samenwerking bedanken.  
En dan niet  te vergeten het warme nest van de oude afdeling Signalering. Graag wil ik alle collega’s van 
de oude groep bedanken voor hun humor, interesse, fijne gesprekken, steun en adviezen en de indrukwekkende 
aanvoer van drop en ander snoep. Jammer genoeg is de afdeling nu verdeeld over twee divisies. In het bijzonder 
wil ik Martin Kooijman en Joke Sens bedanken voor de leuke en fijne samenwerking van de afgelopen jaren. Het 
is erg prettig om met collega’s te werken die aan een half woord genoeg hebben. 
Tot slot wil ik mijn vrienden en familie bedanken voor hun steun bij mijn promotieonderzoek. Vooral het 
laatste jaar was behoorlijk intensief en ik ben bang dat ik heel wat van hen schromelijk verwaarloosd heb. Ik kijk 
uit naar de weekenden waarin ik mijn tijd weer vrijelijk kan besteden en die achterstand kan inlopen. Het was fijn 
dat Henk en René zo betrokken waren bij mijn promotie. Ik ben Henk erg dankbaar voor de prachtige grafische 
vormgeving van het boekje, waaronder de mooie omslag. Ik heb ook veel gehad aan de praktische adviezen van 
de ervaringsdeskundigen Michel en Martijn en ik was blij dat ze me als paranimfen verder wilden helpen. 
Gedurende het hele onderzoek was de interesse en steun van mijn ouders en mijn zus Marieke erg belangrijk 
voor mij en het was erg fijn om samen met hen naar de promotiedatum toe te leven.  
 
 
ANNEX  |  221 219 
CURRICULUM VITAE 
 
Martijn Johan Martena was born on 13th of April 1975 in Nieuwleusen, The Netherlands. In 1999, he 
obtained his MSc degree in Human Nutrition at Wageningen Agricultural University, specializing in nutrition and 
health. As part of this study he conducted research projects on the uptake of beta-carotene in mixed lipid-bile salt 
micelles and the determination of selected phytochemicals. The latter was conducted at the Institute for Biological 
Chemistry and Nutrition of the University of Hohenheim in Stuttgart. Owing to these research projects he 
developed a lasting interest in the effects of active substances in plants on health. After obtaining his degree, he 
worked in 2000 at two Internet startup companies selling food supplements, where he was responsible for the 
scientific content of the companies’ websites. Early 2001, he left e-commerce to work for his current employer, 
the Dutch Food and Consumer Product Safety Authority (VWA). His activities at the VWA are aimed at the safety 
of food supplements, herbal preparations and other health foods, food safety law, the health claims legislation 
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